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Abstract 
 
The clinical success of cisplatin and its derivatives for the treatment of different cancers has 
had a profound effect on the use of metal-containing agents in medicine. Despite the 
successes, the drawbacks of platinum-based therapy, such as drug resistance, toxicity and the 
emergence of unwanted side effects, have bred a need for effective and novel anticancer 
agents. Hence, the design and study of bioorganometallic complexes as potential therapeutic 
agents may eventually lead to the identification of new drug candidates. The purpose of this 
study was to synthesize and characterize a series of polynuclear transition-metal-containing 
complexes based on a (poly)propyleneimine dendritic scaffold, and investigate the in vitro 
antiproliferative activity of these complexes. 
 
A series of new neutral and cationic N,O-ruthenium-arene, N,N- and N,O-osmium-arene 
metallodendrimers were successfully synthesized and characterized. This was achieved via 
the reaction of salicylaldehyde with the peripheral amine end-groups of first-, second-, third-
and fourth-generation 1,4-diaminobutane poly(propylene) dendritic scaffolds, to afford 
polyvalent Schiff base dendritic ligands bearing salicylaldiminato functionalities on the 
surface. Complexation with metal-precursors [M(η6-arene)Cl2]2 (where M = Ru or Os and 
arene = p-cymene or hexamethylbenzene) afforded the metallodendrimers in good yield.  
 
A second series of new cationic N,O- and N,N- ferrocenyl-derived ruthenium-arene 
metallodendrimers were prepared from new ferrocenyl-derived conjugates. The first step 
required preparation of the ferrocenyl-derived conjugates, and was achieved by reacting vinyl 
ferrocene with 4-bromo-2-hydroxybenzaldehyde or 5-bromo-2-pyridinecarboxaldehyde via a 
Heck coupling reaction. Schiff base condensation of first- and second-generation 1,4-
diaminobutane poly(propylene) dendritic scaffolds with the ferrocenyl-conjugates afforded 
ferrocenyl-derived dendritic ligands. Complexation of the ferrocenyl-derived dendritic ligands 
with [Ru(η6-p-cymene)Cl2]2 produced heterometallic ferrocenyl-derived ruthenium-arene 
metallodendrimers. There is a direct correlation between the electron transfer capacity and 
anticancer activity of ferrocenyl-derived anticancer agents. The mode of action of these 
compounds is suggested to follow a series of redox processes which eventually results in the 
generation of reactive oxygen species. Consequently, electrochemical studies revealed that the 
N,O- ferrocenyl-derived ruthenium-arene metallodendrimers result in two irreversible redox 
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processes (oxidation of Fe
II
 and Ru
II
), whilst the N,N- ferrocenyl-derived ruthenium-arene 
metallodendrimers display one reversible wave (i.e. Fe
II
/Fe
III
- couple) in the positive region. 
Hence, these systems favor the production of reactive oxygen species which in turn enhance 
these systems antitumor properties. 
 
All of the metallodendrimers were isolated as air- and moisture-stable solids, which are 
soluble in only a handful of solvents. The mononuclear analogs were synthesized as models 
of the larger metallodendrimers. Single crystal X-ray diffraction, for a select number of model 
mononuclear complexes, confirmed the proposed molecular structure and pseudo-tetrahedral 
geometry around the metal ion. All dendritic ligands and complexes were fully characterized 
using an array of spectroscopic (
1
H, 
13
C{
1
H} and 
31
P{
1
H} NMR, FT-IR and UV-Vis 
spectroscopy) and analytical (electrochemical, elemental analysis and mass spectrometry) 
methods.  
 
As potential antitumor agents, the in vitro biological activity of all the complexes were 
evaluated against A2780 (cisplatin sensitive) and A2780cisR (cisplatin resistant) human 
ovarian carcinoma cell lines. In nanomedicine the concept of multinuclearity is used to 
improve the potency of therapeutic drugs, with respect to metallodendrimers, this concept is 
known as the dendritic effect and can be exploited by preparing dendrimer analogs of 
increasing dendrimer generation. Consequently, all metallodendrimers demonstrated 
moderate to high cytotoxic effects, with an increase in cytotoxicity observed upon increasing 
dendrimer generation. In particular, the fourth-generation N,O-ruthenium-arene 
metallodendrimers display potent activity (IC50 = 2 - 3 μM, A2780). The mononuclear 
derivatives have no significant cytotoxic effect (IC50 > 50 μM, A2780). Furthermore, 
introduction of the 1,3,5-triaza-7-phosphaadamantane ligand into the ruthenium coordination 
sphere displayed a vast improvement in the antitumor activity of these complexes. However, 
no improvement in cytotoxicity was observed when replacing ruthenium with osmium. The 
mode of action of platinum-based therapeutic drugs involves binding to DNA and hence, 
preliminary DNA binding studies in the form of NMR and gel electrophoresis experiments 
were performed and suggest DNA is a possible drug target. 
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Preliminary in vitro cell viability studies of the homometallic ferrocenyl-derived ligands and 
their heterometallic complexes revealed that both systems are moderately active against 
A2780 and A2780cisR human ovarian cancer cells at the 5 μM dose concentration. More 
specifically, four of the twelve compounds evaluated displayed enhanced activity. 
Furthermore, the data suggests introduction of the second metal, in the form of the ruthenium-
arene moiety, does improve the activity in at least two of the heterometallic 
metallodendrimers compared to their homometallic dendritic ligands. 
 
A third series of metallodendrimers bearing functionalized tricarbonylmanganese(I) CO-
releasing moieties on the periphery were successfully prepared. This required preparation of 
bipyridylimine dendritic ligands, via a Schiff base condensation reaction, between first- and 
second-generation 1,4-diaminobutane poly(propylene) dendritic scaffolds and 4’-methyl-2,2’-
bipyridine-4-carboxaldehyde. Chelation of the new bipyridylimine dendritic ligands with 
[Mn(CO)5Br] afforded new polynuclear tricarbonylmanganese(I) metallodendrimers. In 
addition, a mononuclear model complex was prepared and comprehensively studied. All 
complexes are air-stable solids and stable in solution for up to 16 h in the absence of light. 
The CO-release properties of these complexes were investigated using the myoglobin assay, 
and show photoactivated CO-release at 410 nm. Regardless of the generation number, the 
complexes released ~65 % of the total number of CO ligands per molecule, with no scaling 
effects observed. These CO-releasing metallodendrimers afford new ways for the targeted 
delivery of large amounts of carbon monoxide to cellular systems. 
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5’GMP guanosine 5’-monophosphate 
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ATR attenuated total reflectance 
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bpy bipyridyl 
 
13
C{
1
H} proton decoupled carbon-13 
calc calculated 
CBA cytometric bead array 
CH3CN acetonitrile 
cisR cisplatin-resistant
 
CO carbon monoxide 
CORMs CO-releasing molecules 
COSY correlation spectroscopy 
Cp cyclopentadienyl  
Cp* pentamethylcyclopentadienyl 
cye cymene 
 
d doublet 
dd doublet-doublet 
D2O deuterated water 
DAB 1,4-diaminobutane 
DCM dichloromethane 
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dendr dendrimer 
deoxy-Mb deoxy-myoglobin 
DMSO dimethylsulfoxide 
DMF dimethylformamide 
DNA deoxyribonucleic acid 
 
EA elemental analysis 
en ethylenediamine 
Epa anodic potential 
Epc cathodic potential  
EPR enhanced permeability and retention 
Eqn. equation 
ESI electrospray ionization 
EtOAc ethyl acetate 
EtOH ethanol 
Et3N triethylamine 
Et3NH
+
Cl
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triethylamine ammonium chloride 
Et2O diethyl ether 
 
FAB-MS fast atom bombardment - mass spectrometry 
Fc ferrocene 
FT-IR fourier transform infrared spectroscopy 
 
g gram(s) 
 
h hour(s) 
HMB hexamethylbenzene 
HPLC high performance liquid chromatography 
HR high-resolution 
HSQC heteronuclear single quantum correlation 
Hz hertz 
 
IC50 50 % inhibitory concentration  
IR infrared 
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LED light-emitting diode 
Lit. literature 
 
m multiplet (NMR); medium intensity (IR) 
MALDI-TOF matrix-assisted desorption/ionization - time of flight 
Mb myoglobin 
Mb-CO carboxy- myoglobin 
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MeOH methanol 
MHz megahertz 
min minute(s) 
mL millilitre(s) 
mol mole(s) 
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MP melting point 
MS mass spectrometry 
m/z mass to charge ratio 
 
NFP N-formylpiperidine 
NMR nuclear magnetic resonance 
 
OC open circular 
ORTEP Oak Ridge Thermal Ellipsoid Plot 
 
p para 
31
P{
1
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PBS phosphate buffer solution 
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Ph phenyl 
PhotoCORMs Photo-activated CORMs 
PPh3 triphenylphosphine 
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Pr
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isopropyl 
pta (PTA) 1,3,5-triaza-7-phosphaadamantane 
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q quartet 
qn quintet 
 
RAPTA ruthenium-arene PTA 
RP-HPLC reverse phase-HPLC 
RT room temperature 
 
s singlet (NMR); strong intensity (IR)  
SC supercoiled 
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t triplet 
THF tetrahydrofuran  
TFA trifluoroacetic acid 
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tR retention time 
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UV/Vis Ultraviolet-visible 
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Chapter 1 
Introduction and Literature Review:  
From Metallodrugs to Metallodendrimers for Therapy 
 
This chapter forms part of the following publication: 
Preshendren Govender, B. Therrien and G. S. Smith, Bio-Metallodendrimers – Emerging Strategies in 
Metal-Based Drug Design, European Journal of Inorganic Chemistry, 2012, 2853-2862. 
 
1.1 Cancer: An Introduction 
 
Cancer is a class of disease characterized by uncontrolled cell proliferation (i.e. undergoing 
cell division beyond the normal limits) and the ability of these cells to invade adjacent tissue, 
and sometimes spreading to other locations of the body via blood or lymph. The main types of 
cancers (based on mortality rate) are lung, stomach, colorectal, liver and breast cancer. These 
cancers can be treated by several methods such as surgery, radiotherapy and most importantly 
chemotherapy, which is the main treatment of this disease. Chemotherapy is the treatment of 
cancer with anticancer drugs that target and destroy cancer cells. In the last decade, a 
revolution in cancer treatment has been presented by organometallic chemists.
1, 2
 
 
1.2 The Use of Metals as Therapeutic Agents 
 
For the last 25 years medicinal inorganic chemistry was a new and unexplored field. 
However, research has flourished following the success of platinum-based anticancer agents.
3
 
In addition to metal-based therapies, the efficacy of organic drugs can be improved by 
combining them with metals.
3
  
 
1.2.1 Platinum Anticancer Agents  
The therapeutic properties of cis-diamminedichloridoplatinum(II) (cis-[Pt(NH3)2Cl2], 
cisplatin) (Figure 1.1) was accidently discovered by Barnett Rosenberg,
4, 5
 in the late 1960s, 
whilst he was investigating the influence of an electric field on the growth of Escherichia coli 
bacteria. Cisplatin was in fact first synthesized by Michele Peyrone
6
 in 1844 and was known 
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as Peyrone’s chloride. More than a century later it became the first metal-containing 
anticancer drug. 
 
 
Figure 1.1 Cisplatin the first metal-based anticancer complex discovered by Rosenberg.
4
 
 
Today, cisplatin is FDA approved, and is used in the treatment of a wide range of tumors,
7
 in 
particular ovarian
8, 9
 and testicular cancers.
10, 11
 Cisplatin is also used in combination therapy 
of many other solid tumors, such as head, neck, bladder and small cell lung cancers.
12
 
Analogs of cisplatin (i.e. carboplatin and oxaliplatin, Figure 1.2), have shown great 
effectiveness as second-generation drugs.
13
 Oxaliplatin is currently a ‘billion-dollar’ drug, 
primarily used to treat colorectal cancer.
14
 
 
 
Figure 1.2 Structures of 2
nd
 generation Pt-based anticancer agents, carboplatin (left) and 
oxaliplatin (right).
13
 
 
Farrell and co-workers synthesized a Pt-based trinuclear complex with the general formula 
[trans, trans, trans-(NH3)2-Pt(Cl)(CH2)6NH2Pt(NH3)2NH2(CH2)6NH2Pt-(NH3)2(Cl)][NO3]4 
(BBR3464, Figure 1.3) which showed potent in vitro toxicity over cisplatin and its 
mononuclear analog.
15
 BBR3464 was claimed as the first platinum-based drug with a DNA 
binding mode different to cisplatin.
16
 Though Phase II trials of BBR3464 were not pursued 
further,
16
 the concept of multinuclearity may assist in the improvement of the activity of 
potential therapeutic agents. 
 
 
Figure 1.3 Structure of the trinuclear Pt-based anticancer agent, BBR3464.
15
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The clinical successes of platinum-based therapies tend to be overlooked due to the severe 
toxic side-effects and drug-resistance of these complexes.
12, 17
 To overcome these limitations 
researchers have moved their attention to compounds incorporating other metals.
3
 
 
1.2.2 Titanium Anticancer Agents 
There have been two Ti
IV 
complexes explored as anticancer agents, both entered clinical trials 
in the 1990s. The first, is a tris-acetylacetonate derivative called Budotitane (Figure 1.4)
18
 and 
the second, titanocene dichloride [(η5-C5H5)2TiCl2] (Figure 1.4).
19
 Both complexes are similar 
in structure to cisplatin, with both containing two labile chlorido ligands. Though the rate 
hydrolysis of these Ti-complexes is much faster than cisplatin, it did however lead to 
complications. Bound water is more acidic, which lead to the formation of hydroxo-bridged 
species, which in turn lead to toxic TiO2 and hence did not complete Phase I clinical trials.
20, 
21
 Titanocene dichloride had more success than Budotitane, with the completion of Phase I 
and II clinical trials; however it was abandoned.
22
 Titanocene dichloride was not approved for 
clinical use since it did not show significant advantages over current drugs on the market. The 
poor water solubility and low hydrolytic stability hampered its development.
20, 21
 
 
 
Figure 1.4 Structures of Ti-based anticancer agents: Budotitane (left) and titanocene dichloride 
(right).
18, 19
  
 
To aid in stability of the Ti-based complexes, ansa derivatives of titanocene dichloride were 
developed (Figure 1.5)
23
 and some complexes were active against 36 human tumor cell 
lines.
24
 However, the hydrolytic stability of the complexes remained a problem, hence an 
alternative approach was taken. The dichlorido ligands of the ansa derivatives were replaced 
with an oxalate ligand, generating bis[(p-methoxybenzyl)cyclopentadienyl]-titanium(IV) 
oxalate (oxali-titanocene Y, Figure 1.5) which was found to be twice as potent as cisplatin 
towards pig kidney epithelial (LLC-PK) cells
25
 and demonstrated favorable pharmacokinetic 
properties. 
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Figure 1.5 Structures of dichloride titanocene derivative (left) and oxali-titanocene Y (right).
23, 25
 
 
1.2.3 Gallium Anticancer Agents 
There are only a handful of gallium-based complexes used as anticancer agents,
26
 namely 
Ganite
® 
(gallium nitrate complex),
26
 KP46 ([tris(8-quinlinolato)gallium(III)]
27
 and GaM 
(gallium maltolate, tris(3-hydroxy-2-methyl-4H-pyran-4onato)gallium)
28
 (Figure 1.6). 
Ganite
®
 is FDA approved, and used to treat cancer-related hypercalcemia, however the drug 
has poor bioavailability.
26
 KP46 is an orally bioavailable drug, which has been through Phase 
I clinical trials for the treatment of solid tumors via S-phase cell cycle and apoptosis.
27
 
Though not redox active under biological conditions, Ga
III
 has similar chemistry to Fe
III 
and 
can be transported to cells via the Fe
III
 transport system (bound to serum protein transferrin).
29
 
 
 
Figure 1.6 Structures of KP46 (left) and GaM (right).
27, 28
 
 
1.2.4 Tin Anticancer Agents 
Sn
IV
 complexes have become very attractive as therapeutic agents because of their attractive 
properties such as, increased water solubility, lower general toxicity than Pt-based drugs, 
better body clearance, fewer side-effects
30
 and most importantly does not develop drug 
resistance.
31,
 
32
 Recently, a tributyl complex tri-n-butyltin(IV)lupinylsulfide hydrogen 
flumarate (IST-FE 35, Figure 1.7), displayed inhibition of the implanted tumors (p388 
myelomonocytic leukemia and B16-F10 melanoma) in BDF1 mice.
33, 34
 Following a single 
dose of the drug, IST-FE 35 reduced the tumor volume by 96 % at day 11.
33, 34
 
Chapter 1. Introduction and Literature Review 
 
 
 
5 
 
 
 
Figure 1.7 Structure of Sn
IV
 anticancer complex, IST-FS 35.
33, 34
 
 
Other examples of a Sn-based antitumor agents, are the trigonal-bipyrimidal anionic tin(IV) 
complexes recently synthesized by Kaluderovic,
35
 namely, triphenyltin(IV) chlorides 
containing N-phthaloyl-L-glycine (P-Gly), N-phthaloyl-L-alanine (P-AlaH), and 1,2,4-
benzenetricarboxylic 1,2-anhydride (BTCH), were tested against a series of cancer cell lines. 
The Sn-based complexes displayed high activity in the cancer cell lines, with some of the 
complexes displaying IC50 values lower than cisplatin. The most active complex of the series 
(50 times more potent than cisplatin) was the organotin complex, triethylammonium 
(N-phthaloylglycinato)triphenyltin(IV) chloride [SnPh3(P-Gly)Cl]
 
(Figure 1.8), and was found 
to induce apoptosis via extrinsic pathways on DLD-1 cancer cells.
35
 
 
 
Figure 1.8 Organotin complex [SnPh3(P-Gly)Cl]
-
 (where P-Gly = N-phthaloylglycinato), 50 
times more potent than cisplatin and induces apoptosis.
35
 
 
Other metals have been used in the pursuit of potential therapeutic agents, such as gold,
36
 
arsenic,
37
 copper,
38
 zinc,
39
 bismuth,
40
 molybdenum.
41
 However, ruthenium-based complexes 
have shown the most promise as anticancer agents.
42
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1.2.5 Ruthenium(III) Anticancer Agents 
Soon after the discovery of the cytotoxic effects of platinum-based drugs, ruthenium 
compounds were investigated as potential therapeutic agents. As an alternative to platinum, 
ruthenium has shown favorable properties and conditions to form the basis for anticancer drug 
design.
13
 Moreover, ruthenium is less toxic than platinum, with its biological activity 
attributed to its ability to mimic the behavior of iron, and bind to biomolecules, such as 
human serum albumin and transferrin.
43
 Two inorganic Ru
III
 complexes, [ImH][trans-
Ru(DMSO)(Im)Cl4] (NAMI-A, where Im = imidazole)
44-46
 and [IndH][trans-Ru(Ind)2Cl4] 
(KP1019, where Ind = indazole)
47-49
 (Figure 1.9) are currently undergoing Phase II clinical 
trials. 
 
Figure 1.9 Ru(III)-anticancer compounds, NAMI-A (left) and KP1019 (right), currently 
undergoing clinical trials. 
 
NAMI-A, synthesized by Gianni Sava, is a tetrachlorido imidazole/DMSO-Ru
III
 compound, 
and was the first of the two Ru
III
 complexes to enter clinical trials. NAMI-A, was found to be 
inactive during initial in vitro testing. However, in vivo testing showed that the drug inhibits 
matrix metalloproteinases and prevents metastases (tumor growth),
46
 with little impact on 
primary tumors in animal models.
45
 
 
KP1019, developed by Bernhard Keppler, is administered intravenously and hence binds 
initially to proteins in the blood stream. In fact, following cellular uptake of KP1019, it was 
primarily found bound to proteins (i.e. albumin and transferrin) and on DNA in peripheral 
leukocytes.
48
 The side-effects seen with platinum-based anticancer agents were related to their 
binding to serum proteins, while KP1019 binds to transferrin, an important step in its mode of 
action, as it aids in the transport into the cell via the transition pathway.
47, 50, 51
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In recent years the focus on Ru
III
 complexes has shifted towards the development of Ru
II
 
complexes, as in both cases (i.e. NAMI-A and KP1019) the active drug is considered a Ru
II
 
species. Moreover, the Ru
III
 agents are ‘activated’ upon entering the cancerous cell, by 
reduction to the Ru
II
 species which coordinate more rapidly to biomolecules. 
52, 53
 
1.3 Ruthenium(II) Compounds as Anticancer Agents 
 
Ru
III
-based anticancer drugs such as NAMI-A, KP1019 and their derivatives, pioneered as 
alternatives to Pt-based therapeutic agents. However, with the +2 oxidation state proposed as 
the active ruthenium species, several investigations into the development of Ru
II
 compounds 
as anticancer agents have been pursued.
54-56
 
 
1.3.1 Organometallic Ruthenium-Based Antitumor Compounds 
In organometallic complexes, it is the metal-carbon bond which endows these coordination 
complexes with their unique properties. The lability of the metal-ligand bond can greatly be 
influenced by the presence of metal-carbon bonds, as these complexes have high trans-effects 
and trans-influences. Moreover, the π-bonded arene and cyclopentadienyl (Cp) ligands can 
act as both electron donors and π-acceptors. 
 
Similarly to Ru
III
 complexes, Ru
II
 complexes have been extensively studied as anticancer 
agents.
54-56
 The most widely studied organoruthenium compounds are the ruthenium-arene 
and ruthenium-cyclopentadienyl half-sandwich compounds, also referred to as ‘piano-stool’ 
complexes.
57
 The term ‘piano-stool’ is derived from the orientation of the coordinating 
ligands around the metal centre. All these pseudo-octahedral complexes have either a Cp (η5) 
or arene (η6) ring (i.e. the ‘seat’ of the ‘piano-stool’), and coordinating ligands (i.e. the ‘legs’ 
of the ‘piano-stool’). There are three forms of binding in which the coordinating ligands can 
coordinate around the d
6
 metal (Ru
II
, Os
II
, Ir
III
 or Rh
III
) (Figure 1.10). 
 
 
Figure 1.10 General structures of ruthenium- and osmium-arene (left), and iridium- and rhodium-
cyclopentadienyl half-sandwich (right) complexes. 
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Depending on the nature of the ligand, binding can occur in a monodentate (Z), bidentate  
(X-Y) or tridentate (X-Y-Z) manner, in-turn generating neutral or charged (isolated as salts) 
complexes. The different types of coordinating ligands (X, Y, Z and arene/Cp) dictate the 
reactivity (labile or inert) of the complexes. The π-donor ability of the arene/Cp ligand 
protects the metal centre from oxidation.
1
 The first half-sandwich organoruthenium antitumor 
agent was 1-β-hydroxyethyl-2-methyl-5-nitro-imidazole (metronidazole) coordinated to a 
ruthenium(II)-benzene dichlorido moiety (Figure 1.11).
58
 The Ru-complex is more active in 
vitro than its base-ligand, metronidazole.
58
 
 
 
Figure 1.11  The first organoruthenium antitumor agent.
58
 
 
There are two main classes of ruthenium-arene complexes developed for cytotoxicity against 
cancer cells. The first class was pioneered by Peter Sadler, with general formula [(η6-
arene)Ru(XY)Z]
n+
 (XY are bidentate chelating ligands (NN, NO, OO, SO) and Z is a 
monodentate ligand (most likely a chlorido)).
3, 59-64
 The second class with general formula 
[(η6-arene)Ru(PTA)Cl2] (RAPTA) (where PTA = 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane) was pioneered by Paul Dyson.
53, 65-70
 
 
Sadler prepared RM175, with formula [(C6H5Ph)Ru(en)Cl][PF6] (en = ethylenediamine)
71
 
(Figure 1.12), which showed good biological activity against primary cell lines. The activity 
of RM175 is comparable to cisplatin against A2780 human ovarian cancer cells and displays 
activity against a cisplatin-resistant cell line.
72
  
 
Figure 1.12 Molecular structure of RM175. 
Chapter 1. Introduction and Literature Review 
 
 
 
9 
 
Sadler then replaced the ruthenium with osmium (affording AFAP51, Figure 1.13) and 
following a series of experiments, the authors reported ruthenium plays a key role in anti-
metastatic activity.
73
 AFAP-51 shows six times more potency against breast cancer cells 
(MCF-7) than RM175. However, the Ru
II
 derivative shows in vivo activity against mammary 
carcinoma and reduces metastasis, where AFAP-51 did not.
73
 A series of structure-activity-
relationship studies (SARs) were performed, replacement of the arene ring, from simple to 
extended arene systems (e.g. benzene, biphenyl or tetrahydroanthracene), afforded 
improvement in biological activity. Moreover, introducing other bidentate ligands (e.g. N, N, 
N’, N’ tetramethylethylenediamine, TMEDA), reduces activity of the complex.74  
 
 
Figure 1.13 Molecular structure of AFAP51.
73
 
 
Dyson prepared RAPTA-C, with formula [(η6-p-cymene)Ru(PTA)Cl2] (Figure 1.14), which 
has a similar structure to RM175. Similarly seen with NAMI-A, RAPTA-C was inactive in 
vitro, however in vivo experiments displayed the true potential of these drugs, as the complex 
showed activity against lung metastasis in CBA mice.
68
 Another attractive feature of RAPTA-
C, is its low toxicity compared to its Ru
III
 counterparts, hence the drug can be administered in 
higher dosage.
75
 A study was performed where the authors replaced the ruthenium of 
RAPTA-C with osmium, generating the isostructural complex (Figure 1.14), and investigated 
the enzyme inhibition properties of the complexes.
76
 The study included the Cp derivatives 
(CpIr
III
 & CpRh
III
) of RAPTA-C (Figure 1.14). 
 
 
Figure 1.14 RAPTA-C (far left) and derivatives of RAPTA-C (Os
II
, Ir
III
, Rh
III
).
76
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RAPTA-C and the Os
II
 derivative both displayed similar activity to their Ru
III
 counterparts 
with cytotoxicity in the lower micromolar range. However, the Cp
*
Rh
III
 and Cp
*
Ir
III
 
derivatives were inactive. The authors attributed the poor activity of the Cp
*
 derivatives to the 
formation of weak metal-sulfur (M-S) bonds at the cathespin B active site, whilst the active-
arene derivatives displayed formation of thermodynamically favoured strong M-S bonds.
76
 
 
Following intracellular uptake, some ‘piano-stool’ complexes can be ‘activated’ via ligand 
substitution or via redox reaction, affording a more reactive species and can be called ‘pro-
drugs’.43 
 
1.3.2 Proposed Mode of Cytotoxic Action of Ruthenium-Arene Compounds: With focus 
on RAPTA Compounds 
Alessio and co-workers addressed whether or not the aromatic fragment (arene or Cp
*
) is 
important in bringing about the biological activity of organoruthenium complexes.
77
 The 
authors prepared half-sandwich ruthenium(II)-(1,4,7-trithiocyclononane) complexes 
functionalized with PTA (Figure 1.15) and compared these derivatives with known RAPTA 
analogs.
77
 
 
 
Figure 1.15 RAPTA-C (left) and the Ru
II
[9]aneS3 derivative (right).
77
 
 
The results showed the arene ring is in fact not an essential feature in the biological activity of 
the RAPTA complexes, as the Ru
II
[9]aneS3 derivatives showed similar activity to the RAPTA 
analogs. Hence, the arene/Cp ligand can be replaced by a face-capping 6-electron ligand, 
without influence on the biological activity.
77
 However, Bratsos et al. suggest the 
coordinating ligands must have low steric demand and low hydrophobic activity.
78
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These results were somewhat surprising, hence researchers focussed on investigating the 
mode of action of the RAPTA analogs. Unlike the classic Pt-based anticancer agents, the 
mechanism of action proved to be complex, involving both extra- and intra-cellular processes. 
Nevertheless, since metal drugs are usually prodrugs, and are activated via aquation following 
uptake into the cell, the aquation of the complexes were investigated (Scheme 1.1).
79, 80
 
 
 
Scheme 1.1 Hydrolysis of RAPTA-C in pure water at 1 or 2 μM concentration.79, 80 
 
RAPTA complexes have two kinetically labile chlorido ligands which undergo rapid solvent 
exchange. With the use of UV/Vis and 
31
P{
1
H} NMR spectroscopy, aquation studies of 
RAPTA-C were carried out.
79, 80
 In 100 mM NaCl solution (simulating high chloride 
concentration in the blood) aquation was suppressed, and at 4 mM NaCl solution (simulation 
low intracellular chloride concentration) aquation occurs, to yield major and minor products 
(Scheme 1.1) of RAPTA-C.  
 
These findings show aquation occurs once the drug is taken up by the cell, but is aquation 
necessary to bring about a biological response? Hence, the two chlorido ligands in RAPTA-C 
were replaced with bidentate oxalate and 1,1-cyclobutanedicarboxylate ligands, affording 
derivatives with formula [(η6-p-cymene)Ru(PTA)(C2O4)] (oxaliRAPTA) and [(η
6
-p-
cymene)Ru(PTA)(C6H6O4)] (carboRAPTA) respectively (Figure 1.16).
67
 
 
 
Figure 1.16 OxaliRAPTA (left) and carboRAPTA (right).
67
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The results were as expected, with oxaliRAPTA remaining un-aquated in pure water, whilst 
carboRAPTA only formed <5 % of aquation products, compared to RAPTA-C.
67
 Binding to 
bimolecular targets were also investigated, with all three complexes showing similar binding 
and similar cytotoxicities against several cell lines. The authors suggest, although aquation 
takes place following cell uptake, it is not essential for reactions with biomolecules.
67
 
 
There has been growing interest in tethering RAPTA-type complexes to proteins, which 
significantly increases the cytotoxicity of the complexes (Scheme 1.2).
70, 81
 
 
 
Scheme 1.2 Strategy in tethering a RAPTA moiety to human serum albumin (HSA).
81
 
 
The RAPTA-like moiety was coordinated to a linker which in turn was conjugated to the 
carrier protein (human serum albumin, HSA) via hydrazone bond formation. The protein 
conjugate showed potent cytotoxicity (IC50 = 11 μM) compared to RAPTA-C (IC50 >300 μM) 
in the same cell line (A2780).
81
 
 
Consequently, there has been growing interest in multinuclear Ru
II 
complexes as potential 
therapeutic agents.
53, 82
 
 
1.3.3 Multinuclear Ruthenium-Arene Compounds as Anticancer Agents 
The trinuclear Pt-based anticancer agent, BBR3464, is 2-6 orders of magnitude more active 
than cisplatin in cisplatin-resistant cell lines.
83
 Hence, the use of multinuclear complexes as 
potential therapeutic agents has since been considered. 
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In order to improve the activity of the ruthenium-arene complexes, Keppler and co-workers, 
synthesized water-soluble dinuclear ruthenium-arene complexes, based on 3-hydroxy-2-
methyl-pyridinone, with varied alkyl spacers (Figure 1.17).
64, 84
 The dinuclear ruthenium-
arene complexes were compared against Pt-based antitumor agents (i.e. cisplatin, carboplatin 
and oxaliplatin), in a series of human tumor cell lines.
64, 84
 In particular, one of the dinuclear 
complexes has similar activity to oxaliplatin, with the mononuclear derivative (Figure 1.17) 
inactive in the same cell line.  
 
 
Figure 1.17 Mononuclear (left) and dinuclear (with varying spacer lengths, right) ruthenium-
arene antitumor complexes.
64, 84
  
 
Following initial screening of the dinuclear complexes, the authors investigated the DNA 
interaction using biochemical and biophysical methods.
85
 Using a DNA model (in the absence 
of proteins), the dinuclear complexes formed intrastrand and interstrand cross-links with 
DNA. In some cases, the complexes cross-link two DNA duplexes and/or proteins to DNA, 
which has not yet been observed with other ruthenium-arene complexes. This concept of 
interhelical and DNA-protein cross-linking of these dinuclear complexes could exhibit a 
variety of biological effects and be useful in nucleic acid research.
85
 
 
Gras and co-workers prepared a series of cationic thiophenolato-bridged diruthenium 
complexes with general formula [(arene)2Ru2(SPh)3]
+
 (where arene = benzene, p-cymene, 
hexamethylbenzene, C6H5R (where R = (CH2)nOC(O)C6H4-p-O(CH2)6CH3 or 
(CH2)nOC(CO)CH=CHC6H4-p-OCH3 and n = 2 or 4)) (Figure 1.18).
86
 The thiophenolato-
bridged dinuclear complexes were highly toxic against human ovarian cancer cells (A2780) 
and cisplatin-resistant cells (A2780cisR), with a few of the complexes in the nanomolar 
range.
86
 
Chapter 1. Introduction and Literature Review 
 
 
 
14 
 
 
Figure 1.18 Thiophenolato-bridged dinuclear ruthenium complexes, the functionalized arene 
derivative (left) and p-cymene derivative (right).
86
 
 
The authors attributed the activity of the diruthenium complexes to the phenyl or tolyl 
substituents on the three thiolato bridges, as analogous trishydroxythiophenolato complexes 
[(η6-arene)2Ru2(S-p-C6H4OH)3]Cl (IC50 values around 100 μM) are much less toxic towards 
cancer cells.
87
 
 
Stringer et al. prepared a series of mononuclear and dinuclear ruthenium-arene complexes 
based on a benzaldehyde thiosemicarbazone (Figure 1.19).
88
 The thiosemicarbazone moiety is 
known for its potent enzyme inhibition (in particular ribonucleotide reductase) and is capable 
of interrupting DNA replication.
89
 The dinuclear complex showed enhanced biological 
activity (IC50 = 8.96 μM) in the oesophageal cancer cell line (WHCO1), over its mononuclear 
derivative (IC50 >200 μM, WHCO1).
88
  
 
Figure 1.19 Ruthenium-arene thiosemicarbazone-based antitumor agents, mononuclear (left) and 
dinuclear (right).
88
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A tetranuclear ruthenium-arene complex with general formula [(p-cymene)4Ru4(R1)Cl6]Cl2 
(where R1 = 1,2-bis(di-N-methylimidazol-2-ylphosphine)ethane) was prepared by Noffke and 
co-workers (Figure 1.20).
90
 However, the cytotoxicity of the complexes are poor in several 
cancer cell lines (Hct116, Huh7, H411E and A2780 cells). 
 
 
Figure 1.20 A novel tetranuclear ruthenium-arene complex synthesized by Noffke et al.
90
 
 
Therrien and co-workers synthesized tetranuclear metalla-rectangles (or metalla-cycles), with 
moderate to excellent cytotoxicity towards human ovarian cancer cells (A2780 and 
A2780cisR).
91, 92
 In particular, the biological activity of the tetranuclear ruthenium-arene 
metalla-cycles of general formula [(η6-arene)4Ru4(00∩00)2(N∩N)2]
4+
 (arene = p-cymene, 
hexamethylbenzene; 00∩00 and N∩N are linkers) (Figure 1.21), can be fine-tuned, as the size 
of the linker used as well as the type of arene-ligand greatly influences the activity. 
 
 
Figure 1.21 Highly cytotoxic metalla-rectangles synthesized by Therrien et al.
91
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Besides the ruthenium-arene tetranuclear metalla-cycles,
93
 hexanuclear metalla-prisms
94
 and 
octanuclear metalla-boxes
95, 96
 have been synthesized. The hexanuclear metalla-prisms 
(Figure 1.22) do not show encapsulation of guest molecules, however, the complexes showed 
good DNA interaction and cytotoxicity in cancer cells (A2780).
97
 
 
 
Figure 1.22 Hexanuclear ruthenium-arene metalla-prisms (left) and octanuclear ruthenium-arene 
metalla-boxes.
96, 97
 
 
The octanuclear metalla-boxes were prepared using tetra(pyridyl)porphyrin panels, which 
resulted in octacationic ruthenium-arene complexes (Figure 1.22).
96
 The complexes interact 
well with duplex and quadruplex DNA, with good cytotoxicity against human ovarian cells 
(A2780 and A2780cisR). More, recently these cage-like structures have been investigated as 
potential drug-delivery systems.
98, 99
 
 
Synthesis of multinuclear ruthenium-arene systems is an additional strategy used to modify 
the mechanism of action of metal-based drugs. Another strategy to develop potent therapeutic 
systems is to develop heteronuclear systems, which is the incorporation of two or more 
different metals into one system. 
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1.4 Ferrocene in Cancer Research  
 
Ferrocene was first discovered in 1951,
100, 101
 however the structure was elucidated afterwards 
(Figure 1.23) independently by Wilkinson, Fischer and Pfab.
102, 103
 The benzene inspired 
name ‘ferrocene’ was coined by Woodword and co-workers in 1952.104 Scientists wasted no 
time in developing new strategies in synthesizing ferrocene and its derivatives.
105
 Owing to its 
ease of functionalization and favorable electronic properties, a wide range of applications for 
these sandwich complexes were explored.
106
 Stability of ferrocene in aqueous and aerobic 
media, the large variety of derivatives and the favorable electronic properties made ferrocene 
and its derivatives attractive as potential biological agents.
107, 108
 
 
 
Figure 1.23 The molecular structure of ferrocene. 
 
1.4.1 Ferrocene in Medicine: With Focus on Ferrocenyl-Based Derivatives as 
Therapeutic Agents 
Many ferrocenyl compounds display good in vivo or in vitro activity as antitumor,
109, 110
 
antimalarial,
111
 antifungal
112
 and antiretroviral (ARV)
113
 agents, and show DNA-cleavage 
activity.
114
 Brynes et al. reported the first ferrocene-based anticancer complex in the late 
1970s, with the compounds bearing amine or amide groups (Figure 1.24) tested against 
leukemia P-388 cells.
115
 The ferrocenyl-derived compounds were administered to mice and 
the activity of these complexes were low but showed an improvement compared to the 
starting ligand.
115
 This report clearly suggests, the incorporation of ferrocene into an 
appropriate biomolecule or carrier molecule, could provide the compound with enhanced 
anticancer activity. 
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Figure 1.24 The structure of a ferrocenyl-derived compound tested against leukemia P-388 
cells.
115
 
 
Jaouen and co-workers developed a series of ferrocenyl derivatives and studied their activity 
in cancer cells.
116
 The ferrocenyl derivatives, called ferrocifens (Figure 1.25), were derived 
from the anticancer drug tamoxifen (Figure 1.25), where one of the phenyl rings was replaced 
with ferrocene moiety. Derivatives of the active metabolite, hydroxytamoxifen (Figure 1.25) 
were also synthesized and the antiproliferative activity of these ferrocenyl derivatives 
investigated against breast cancer cells (MCF-7, hormone independent and MDA-MB231, 
hormone dependent).
117
 The ferrocifens exhibited strong biological activity in both cell lines, 
though some were comparable to hydroxytamoxifen, others were slightly better. The authors 
attribute the activity to the greater lipophilicity of ferrocifens and the cytotoxicity induced by 
the redox-active ferrocene moiety. Furthermore, these results show that ferrocifens are the 
first molecules to show activity in both hormone-dependent and hormone-independent human 
breast cancer lines.
118
 
 
Figure 1.25 Structures of parent drugs tamoxifen and hydroxytamoxifen (left), and the ferrocenyl-
based derivatives, ferrocifens (right).
117, 118
 
 
The extended π-system plays an important role on the mode of action of the ferrocenyl-
derived anticancer agents, with authors reporting a correlation between cytotoxicity and 
electron transfer capacity of these complexes.
119
 The mode of action is said to originate from 
a series of redox processes on the ferrocenyl moiety, which results in the generation of 
reactive oxygen species (ROS).
119
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It has been shown that tethering the ferrocenyl moiety onto biologically active compounds 
increases their potency. The increase in activity has been attributed to the combined action of 
the organic drug and the Fenton chemistry of the Fe centre.
120
 
 
1.4.2 Heterometallic and Multinuclear Ferrocenyl-Derived Anticancer Agents 
Ferrocene has been linked to both platinum,
121-124
 gold
125
 and ruthenium
126, 127
 in an effort to 
achieve a synergistic effect between the two biologically active centres. Nieto and co-workers 
synthesized a series of heterometallic Pt(II) compounds with β-aminoethylferrocenes. The 
compounds were tested against four cancer cell lines (HBL-100 (breast), HeLa (cervix), 
SW1573 (lung), WiDr (colon)). One of the β-aminoethylferrocenes-Pt(II) compounds (Figure 
1.26) displayed good cytotoxicity in all four cell lines (IC50 = 1.7 - 2.3 μM), with activity in 
the colon cancer cell line better than the benchmark drug (cisplatin). 
 
 
Figure 1.26 Structure of heterometallic Pt(II)-compound with β-aminoethylferrocenes.123 
 
Recently, Dyson and co-workers prepared heterometallic phosphinoferrocene amino 
conjugates, incorporating the biologically active ruthenium-arene moiety (Figure 1.27).
126
 
These systems show moderate to good in vitro antitumor activity towards both the sensitive 
and cisplatin-resistant human ovarian cancer cell lines (A2780, IC50 = 4.1 μM; A2780cisR, 
IC50 = 6.9 μM).
126
 
 
Figure 1.27 Structure of heterometallic ruthenium-arene phosphinoferrocene amino conjugate.
126
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As a result of the electrochemical properties and chemical stability of ferrocene, multinuclear 
ferrocenyl-derived polymers have been prepared and extensively investigated as prototypes 
for molecular electronic devices.
128, 129
 Using a fast four-step synthesis, Astruc and co-
workers reported the synthesis of the 54-ferrocene dendrimer (Figure 1.28).
130
 The dendrimer 
is reversibly oxidized in dimethylformamide in a single 54-electron wave or by chemical 
means with NO
+
, illustrating that access to precise redox-active nanoscopic molecules is 
possible. The resulting compound was used to modify a platinum electrode and the authors 
report such materials may have the potential to find uses as sensors or as molecular 
batteries.
130
 
 
 
Figure 1.28 Structure of 54-ferrocene dendrimer.
130
 
 
These multinuclear systems show promise as sensors and as molecular batteries, however 
there is a need for developing such macromolecular systems as potential anticancer agents, as 
there are few if not any reported.
131
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1.5 CO-Releasing Molecules: A Therapeutic Approach 
 
For decades, the odorless, tasteless and colorless gas carbon monoxide (CO) has been viewed 
as highly toxic on the human oxygen transport system in the blood.
132
 However, small 
molecules such as nitric oxide and hydrogen sulfide have shown to be important signalling 
molecules in human biology.
133, 134 
This is also true for CO, with the major source of 
endogenously produced CO (86 %) in the human body obtained from the catalyzed oxidation 
of heme. The remaining 14 % of CO is generated from other physiological processes like 
photo-oxidation, lipid peroxidation, xenobiotics and bacteria. Heme oxygenase (HO) 
catalyzes the regiospecific conversion of heme (iron(III) protoporphyrin IX) to α-biliverdin, 
CO and free Fe
3+
, via a multistep mechanism (Scheme 1.3).
135, 136
 
 
 
Scheme1.3 The formation of biliverdin and CO from heme by heme oxygenase.
135
 
 
The first step, of the three step dioxygen activation pathway, is the regiospecific 
hydroxylation of heme at the α-meso carbon atom. The second step involves the conversion of 
α-meso-hydroxyheme to verdoheme, which occurs by the deprotonation of α-meso-
hydroxyheme followed by binding oxygen to give a ferrous peroxy radical. The final step 
involves oxygen activation which cleaves the heme macrocycle to afford biliverdin and free 
ferrous iron.
137
 The biliverdin (a green pigment) is subsequently reduced to bilirubin (a yellow 
pigment). This is one of the most visible enzyme reactions as it occurs during the 
development of bruises.  
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Some of the physiological effects of CO include anti-inflammatory activity, whereby it 
reduces allergic inflammation, protects against hyperoxia, decreases perfusion pressure in 
isolated human placenta and some beneficial cytoprotective activity.
138-140
 The concept of 
delivering low concentrations of CO gas to palliate disease was a remarkable step
141
 and was 
in line with the idea that carbon monoxide (derived from HO) endogenously contributes to 
important intracellular functions. Moreover, it is known that the prolonged inhalation of CO 
may lead to toxic side-effects imposed by the gas on the transport and delivery of oxygen
142
 
and rendering this approach of limited use in a therapeutic context. Thus, from a 
pharmacological perspective and to develop novel pharmaceutical agents suitable for 
therapeutic applications, it was further envisaged that this problem could be overcome by 
storing CO in a “stable chemical form‟, with the CO groups carried and supplied to cells or 
tissues in a more convenient fashion.
143
 Indeed, the search led to transition metal carbonyl 
complexes of manganese, iron, or cobalt as promising lead structures. 
 
1.5.1 Transition Metal Carbonyl Complexes as Novel CO-Releasing Molecules 
(CORMs) 
One of the promising features of transition metal carbonyl complexes are that certain 
compounds are sensitive to light and under certain optimized conditions, such as the 
photoexcitation of metal-carbonyl complexes which leads to the dissociative loss of CO.
144
 
The initial experiments by Roberto Motterlini using in vitro and ex vivo systems showed that 
carbon monoxide liberated by Mn2(CO)10 led to the mitigation of coronary 
vasoconstriction.
145
 These results provided evidence that CO can be liberated from transition 
metal carbonyls and delivered to cells. Thus, the term “CO-releasing molecules‟ (CORMs) 
was coined to classify the bioactive CO carriers. To study the cellular mode of action of 
carbon monoxide for potential therapeutic applications, interests in the use of CORMs are 
steadily increasing.
146
 
 
The first CORMs to be identified were by Motterlini and co-workers, who have pioneered the 
development of CORMs, with the use of manganese decacarbonyl [Mn2(CO)10] (CORM-1)
144, 
145
 and the synthesis of tricarbonyldichlororuthenium(II) dimer [Ru(CO)3Cl2]2 (CORM-2)
147
 
(Figure 1.29). It has been reported that [Mn2(CO)10] is sensitive to light and upon photo-
excitation, the metal-carbonyl bond is cleaved leading to the dissociative loss of CO.
148
 Due 
to its limited solubility in water, dimethylsulfoxide was used for investigating the CO-release 
behavior.
143
 Motterlini et al. reported that in aqueous solutions [Mn2(CO)10] liberated CO 
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upon stimulation with light in a 1:1 ratio, as quantified spectrophotometrically, by measuring 
the conversion of deoxymyoglobin (deoxyMb) to carboxymyoglobin (MbCO).
145
 More 
interestingly, extenuation of coronary vasoconstriction was achieved by [Mn2CO10] upon 
stimulation with light to release CO which was not the case when the experiment was 
conducted in dark.
147
 
 
 
Figure 1.29 The first CORMs identified by Motterlini and co-workers [Mn2(CO)10] (CORM-1, left) 
and [Ru(CO)3Cl2]2 (CORM-2, right).
145, 147
 
 
Ruthenium-based carbonyl complexes were explored as CORMs, as there is a wide range of 
coordinating ligands for this metal in aqueous solution.
149
 In addition, ruthenium-based 
compounds have already been developed for the treatment of cancer and inflamation.
56, 150
 
Hence, the synthesis of CORM-2, which reacts reversibly with dimethylsulfoxide, leading to 
the loss of a CO group.
147
 In a dimethylsulfoxide solution, CORM-2 results in a mixture of 
fac-[Ru(CO)3(DMSO)Cl2] and cis, cis, trans-[Ru(CO)2(DMSO)2Cl2], identified as the 
tricarbonyl and dicarbonyl monomers respectively.
147
 The [Ru(CO)3(DMSO)Cl2] species 
rapidly releases CO to myoglobin and showed vasoactive properties in which the metal 
carbonyl compound significantly prevented the increase in arterial pressure in a rat model of 
acute hypertension.
143
 The chemical structures, properties and carbon monoxide release 
profiles of some CORMs are shown in Table 1.1.
143
 
 
Good water solubility of compounds is advantageous in the process of drug discovery and 
designing new therapeutic agents. As mentioned, both CORM-1 and CORM-2 are only 
soluble in a few organic solvents, e.g. dimethylsulfoxide and ethanol. The versatile chemistry 
of transition metals enables them to be effectively modified by coordinating biological ligands 
to the metal centre, in order to render the molecule more water-soluble and eventually less 
toxic. These key features led to the discovery of fac-tricarbonylchloro(glycinato)ruthenium(II) 
[fac-Ru(CO)3(glycinate)Cl] complex (Figure 1.30), as the first water-soluble CORM.
151
 [fac-
Ru(CO)3(glycinate)Cl] was termed CORM-3 and rapidly releases a CO group to myoglobin 
with t½ <2 min and is stable in pure water with t½ >24 h.
151
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Table 1.1 Chemical structures, properties and CO-release profiles of some important CORMs. 
Compound Chemical Structure Solubility 
CO-release 
(in PBS, PH 7.4) 
Year of 
Identification 
CORM-1 
[Mn2(CO)10] 
 
DMSO, 
EtOH 
Light dependent 
Fast (t1/2 <1 min) 
2002
145
 
CORM-2 
[Ru(CO)3Cl2]2 
 
DMSO, 
EtOH 
Solvent-assisted 
Fast (t1/2 ~ 1 min) 
2002
147
 
CORM-3 
[fac-Ru 
(CO)3(glycinate)Cl] 
 
H2O  
(stable at 
acidic pH) 
Solvent-assisted 
Fast (t1/2 ~ 1 min) 
2003
151
 
CORM-A1 
[Na2H3BCO2] 
 
H2O  
(stable at 
basic pH) 
pH-dependent 
Slow (t1/2 ~ 21 min) 
2004
152
 
CORM-F3 
[C9H5BrFeO5] 
 
DMSO, 
EtOH 
Induced by metal 
oxidation 
Slow (t1/2 ~ 55 min) 
2006
153
 
 
 
 
Figure 1.30 The first water-soluble CORM identified by Motterlini and co-workers  
[Ru(CO)3(glycinate)Cl] (CORM-3).
151
 
CORM-3 has a diverse solution chemistry, with hydroxide attacking one carbonyl at pH 3 
giving [Ru(CO)2(CO2H)(glycinate)Cl]
-
 and its isomers, which then undergo another pH-
dependent reaction to give [Ru(CO)2(CO2)(glycinate)Cl]
2-
 or 
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[Ru(CO)2(CO2H)(OH)(glycinate)]
-
 at physiological pH, both as a mixture of isomers, 
(Scheme 1.4).
154
 
 
Scheme 1.4 The pH dependence of CORM-3 in an aqueous medium. 
 
A detailed study showed that substituted 2-pyrones are capable of inhibiting the human 
ovarian cancer (A2780) and human chronic myelogenous leukemia (K562) cell lines, with 
IC50 values at sub-micromolar levels.
155
 The 2-pyrone behaves as a pro-drug, where a 
carbonyl ring-opening reaction leads to the bioactive form.
155
 Thus, the complexation of 2-
pyrone in an η4-diene-like fashion to an iron tricarbonyl unit, lead to the activation of the 2-
pyrone ring-system, in-turn opening the way for the synthesis of several novel η4-2-pyrone 
functionalized iron-containing carbonyl complexes. One such complex, the first iron-
containing CORMs [(η4-2-pyrone)Fe(CO)3] (CORM-F3), which undergoes solvent-assisted 
CO-release, with a CO-release rate of approximately 0.19 μM/min (Figure 1.31).153 
 
 
Figure 1.31 The first iron-containing CORM [(η4-2-pyrone)Fe(CO)3] (CORM-F3).
153
 
 
Furthermore, the IC10 value for CORM-F3 (132 μM) indicated the concentration used for 
vasorelaxation (100 μM) is non-toxic and its pharmacological effect is due to the CO-
release.
153
 Also, it was found that CORM-F3 did not affect the cell viability of RAW246.7 
murine macrophages at a concentration of 100 μM.153 The substitution of bromine with 
chlorine (CORM-F8) results in a considerable loss of CO-release activity. Additionally, 
substitution at the 4- or 6-position with methyl groups (CORM-F11) further decreases the 
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ability of the compound to release CO.
156
 More recently, Romão et al. synthesized a series of 
Mo(CO)3-based complexes with a wide range of biomedical applications, focussing on 
inflammation, infection, and vasorelaxation, with a recent review detailing the requirements 
of CORMs for clinical applications.
157
 
 
In addition to compounds where CO-release is induced by ligand exchange (i.e. with solvent 
or other dissolved species), enzyme-triggered CO-releasing molecules (ET-CORMs) have 
been developed by Schmalz and co-workers.
158-160
 The concept of ET-CORMs was first 
introduced in 2011, with the synthesis acyloxybutadiene-irontricarbonyl complexes (Figure 
1.32),
158
 which are activated by enzymatic cleavage of the ester functionality. 
 
 
Figure 1.32 Acyloxydiene-Fe(CO)3 complexes used as ET-CORMs.
158
 
 
Moreover, the acyloxydiene-Fe(CO)3 complexes are sufficiently stable under physiological 
conditions but are readily converted to the “active” species by means of enzymatic hydrolysis. 
The authors propose that once the acyloxydiene-Fe(CO)3 complex enters the cell, cleavage of 
the ester function via enzymatic hydrolysis (usually by an intracellular esterase), triggers CO-
release and generates the labile enol complex (Scheme 1.5).
159
 Which is followed by 
oxidative decomposition (via a 16 electron species), in-turn leading to release of three 
molecules of CO, the enone ligand and the free metal ion.
159
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Scheme 1.5 Proposed mechanism of action of ET-CORMs.
159
 
 
Other than solvent-assisted or enzyme trigger CO-release, recently photoactivation has 
become another important tool to induce CO-release of carbonyl-based complexes.
161
 
 
1.5.2 Photoinduced CO-Releasing Molecules (PhotoCORMs) 
Photoactivation has become an attractive tool and has gained much importance to induce 
biological activity of pro-drugs. Metal-carbonyl complexes are the obvious candidate as they 
have been known for years to release CO.
162
 One such approach is photodynamic therapy 
(PDT), a clinical technique employing the combination of light, oxygen and a sensitizing 
agent to induce the photochemical degradation of unwanted cells within the body.
163-167
 
Medicinal PDT deals with the reactions which pharmaceuticals (drugs or diagnostic agents) 
undergo when exposed to UV/Visible light. The basic concept of PDT is not new, with the 
healing aspects of light described by the Greek historian Herodotus in the 5
th
 Century BC, and 
the first use of a combination of light and a photosensitizer (eosin) to treat skin cancer took 
place in 1903 (Figure 1.33).
168 
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Figure 1.33 Molecular structure of photoactivated eosin used to treat skin cancer.
168
 
 
Developed by Ford, Schatzschneider and others,
146, 161, 169-171
 photoactivation of CORMs has 
become an important technique to induce CO-release (Eqn. 1.1). Photoactivation of CO-
releasing molecules (PhotoCORMs) follows the selective enrichment of a dark-stable CORM 
prodrug, at a biological target (e.g. cancer site), from which carbon monoxide is only released 
upon irradiation. This is an attractive approach which allows for precise spatial and temporal 
control of the biological action of CO.
140
 
 
Equation 1.1: 
        
  
                 
(where x and y are integers) 
 
Westerhausen et al. report the synthesis of a iron-based water-soluble CORM, cis, trans-
dicarbonylbis(cysteamine)-iron, called CORM-S1 (Figure 1.34).
172
 With the use of the 
spectrophotometric myoglobin assay, CORM-S1 was stable in the dark for a period of time, 
before CO-release was photoactively initiated with 470 nm light. The authors reported the 
slow release (t1/2 = 43.9 min) of CO, with two molecules of CO-released per molecule of 
CORM-S1. It has previously been shown that the potassium channels found in the cell 
membrane can be stimulated by CO.
173
 Hence, CO-release was investigated utilizing the 
membrane patch experiment.
174
 An immediate increase in current was observed when 
compared to the dark control.
172
 This data confirmed that particular PhotoCORMs can initiate 
biological responses and are well suited for the use in biological systems. 
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Figure 1.34 The novel water-soluble PhotoCORM identified by Westerhausen and co-workers 
[Fe(cysteamine)2(CO)2] (CORM-S1).
172
 
 
Schatzschneider and co-workers reported the CO-release of a tris(pyrazolyl)methane (tpm) 
manganese tricarbonyl complex, [Mn(CO)3(tpm)]PF6 (Figure 1.35).
175
 In which a 
manganese(I) tricarbonyl unit is coordinated by a tridentate facial tpm co-ligand. The CO-
release properties of [Mn(CO)3(tpm)]PF6 was investigated using the spectrophotometric 
myoglobin assay, on the basis of changes in the Q-band region. These changes in the Q-band 
region are due to the formation of MbCO from deoxyMb. This CORM exhibited 
photoinduced release of two carbonyl ligands upon excitation at 365 nm and is also efficiently 
internalized by HT-29 human colon carcinoma cells. The primary photophysical process is a 
metal-ligand charge transfer (MLCT) transition from manganese t2g-type orbitals to 
unoccupied orbitals with mixed metal-CO character. [Mn(CO)3(tpm)]PF6 is the parent 
compound of a family of metal-tricarbonyl complexes with functionalized tpm ligands, and 
was found to be inactive in the dark up to 100 μM.175 
 
 
Figure 1.35 Tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex, [Mn(CO)3(tpm)]PF6, 
synthesized by Schatzschneider et al.
175
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Furthermore, the bioavailability of [Mn(CO)3(tpm)]PF6 was quantified by measuring the 
cellular Mn uptake by HT-29 human colon cancer cells with atomic absorption spectroscopy 
(AAS).
175
 In these studies, it was found that the cellular Mn content increased linearly with 
increasing incubation concentration, indicating a passive diffusion rather than active transport 
across the cell membrane.
175
 The most important property of this novel CORM 
([Mn(CO)3(tpm)]PF6), was the efficient reduction of cell biomass after photoactivation, 
comparable to that induced by established anticancer agent 5-fluorouracil (5-FU) which is in 
clinical use for many years. For a targeted delivery of PhotoCORMs, researchers envisaged 
functionalization of PhotoCORMs to biomolecules in an attempt to enable specific uptake 
into cancer cells.  
 
1.5.3 PhotoCORMs as Bio-Conjugates 
A common drawback of CORMs, regardless of how CO-release is brought about (i.e. solvent-
assisted, enzyme-triggered or photoactivated), is the formation of the metal-co-ligand 
fragment following release of the CO ligand(s), which might possess a biological activity of 
its own. One strategy is thought to functionalize macromolecular systems with CORMs, thus 
following CO-release, the metal-co-ligand fragment remains bound to the “carrier” and 
eventually metabolized.  
 
The promising results of PhotoCORM [Mn(CO)3(tpm)]PF6 (mentioned above), prompted the 
authors to investigate the biocompatibility and the targeted ability of this CORM.
176
 
Photoactive cytotoxic peptide bioconjugates (Figure 1.36) were prepared with the use of Pd-
catalyzed Sonogashira cross-coupling and “click” reactions.176 One notable feature is the 
functionalization of the tpm ligand allowed for the preparation of water-soluble 
bioconjugates. Furthermore, it was demonstrated that the CO-release behavior of the 
[Mn(CO)3(tpm)]
+
 moiety as compared to the parent CORM [Mn(CO)3(tpm)]PF6 remains 
unaffected after peptide conjugation. 
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Figure 1.36 Photoactive [Mn(CO)3(tpm)]
+ 
functionalized bioconjugates prepared by 
Schatzschneider et al.
176
 
 
Kunz and co-workers reported the synthesis and CO-release of a novel PhotoCORM delivery 
vehicle, a biologically compatible polymeric carrier (2-hydroxypropyl methylacrylamide 
(HPMA)).
177
 Here, the authors functionalized HPMA or, a biodegradable linker, 
bis(pyridylmethyl)ethanolamine (HPMA-PLA), with bis(pyridylmethyl)amine manganese 
tricarbonyl complexes (Figure 1.37).
177
 Once again, the myoglobin assay was used to 
determine CO-release, with the polymer free complexes releasing ~ 2 CO ligands per 
complex following irradiation (t1/2 = 20 min). The CO-release of the polymer conjugates was 
not quantifiable, although qualitatively CO-release was observed following irradiation. 
 
 
Figure 1.37 Photoactive bis(pyridylmethyl)amine manganese tricarbonyl functionalized HPMA 
(left) and HPMA-PLA (right).
177
 
 
Furthermore, the authors investigated the in vitro cytotoxicity of the free complexes and 
polymer conjugates against human colon carcinoma (Hct116) and human heptanoma (HepG2) 
cell lines. Only the HPMA-PLA polymer conjugate and free styrene complex showed activity. 
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However, the cytotoxic effect was not brought about due to CO-release, as the free styrene 
complex and the HPMA-PLA polymer conjugate showed toxicity before irradiation (in the 
dark) and following irradiation. 
 
Many different mononuclear CORMs systems have been reported in the literature, however, 
there are few if not any examples of multinuclear CORMs reported. Hence there is scope in 
the preparation of such multinuclear systems. 
 
1.6 Metallodendrimers: Metal Decorated Dendrimers for Oncology 
 
The term metallodendrimers is derived from the name given to metal functionalized highly 
branched macromolecules known as dendrimers. The term dendrimer is built from the Greek 
words “dendros” meaning tree, and “meros” meaning part. These complex macromolecules 
have well defined shape, are highly branched and are built from a central core.
178
 compared to 
linear polymers, dendrimers can be synthesized reproducibly with low polydispersity, which 
is a highly discernible feature for drug delivery agents. A wide range of functionalities can be 
included throughout the dendritic framework (on the periphery, at the core or interspersed), 
which give them a wide range of applications in medicinal chemistry,
179, 180
 host-guest 
chemistry
181, 182
 and catalysis.
183-186
 
 
1.6.1 General Design and Synthesis of Dendrimers 
A dendritic scaffold has four main regions (Figure 1.38):
187
 
i. the core scaffold (initiator), 
ii. repeating branching units attached to the core  
(generation, Gn, where n can be 0 to 12), 
iii. terminal groups, found on the periphery, attached to the outmost generation, 
iv. void spaces (for encapsulation of small molecules). 
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Figure 1.38 A general schematic of the dendritic scaffold.
187
 
 
There are two general methods/routes in synthesizing dendrimers, namely the divergent route 
(building ‘outwards’ from a central core) and the convergent route (synthesis of dendritic-like 
wedges (dendrons), followed by a final coupling reaction) (Figure 1.39).
188
 
 
 
Figure 1.39 General methods in synthesizing dendrimers, the divergent route (top) and 
convergent route (bottom).
188
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The divergent synthesis can be explained by the synthesis of poly(amidoamine) (PAMAM) 
dendrimers, which were the first commercially available dendrimers of the dendrimer family 
(Scheme 1.6).
189
 PAMAM synthesis is initiated by using and alkyl diamine core, such as 
ethylene diamine (EDA) which reacts via a Michael addition with methyl acrylate monomers 
to produce a branch intermediate. The branch intermediate is reacted with excess EDA to 
produce G0 with four NH2 surface groups, or reacted with ethanolamine to produce G0 with 
four OH surface groups.
190
 Synthesis of the higher generations is achieved by sequential 
Michael addition of methyl acrylate monomers followed by an extensive amidation reaction 
with EDA.  
 
 
Scheme 1.6 Synthesis of PAMAM dendrimers using the divergent synthesis.
190
 
 
This synthesis produced highly branched, highly ordered and monodispersed polymers. 
However, dendrimer growth reaches a critical point due to steric crowding of the dendritic 
arms, which limits development into higher generations, and results in a number of structural 
defects known as de Gennes dense packing effect.
191
 The effect is only observed from 
generation 7 to generation 10, where the yields become insignificant and is attributed to steric 
factors.
192
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Hence, an alternate route was devised to address the deficiencies of the divergent method, 
namely the convergent approach. As mentioned, convergent synthesis involved building from 
the periphery toward a central focal point, by coupling surface units to building blocks to 
form the branching structure (dendron). Following the synthesis of the dendrons, each 
dendron is conjugated to a multifunctional core to complete the dendrimer. The convergent 
approach has fewer structural defects and the purification of the dendrons are simpler 
compared to an entire dendrimer. 
 
Hawker and Frechet reported the synthesis of polyether dendrimers using the convergent 
approach (Scheme 1.7).
193
 The polyether dendrimers were based on 3,5-dihydroxylbenzyl 
alcohol units coupled to a activated benzyl bromide, affording successive dendrons.
193
 
 
Scheme 1.7 Synthesis of polyether dendrimers using the convergent synthesis, by Hawker and 
Frechet.
193
 
 
Early research in dendrimers mainly focussed on synthesis and characterization,
194, 195
 more 
recently researchers have directed their focus towards functionality and applications of these 
macromolecules. 
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1.6.2 Applications of Metallodendrimers: With Focus on Nanomedicine 
The well-defined and ordered molecular structure of dendrimers and their unique properties 
such as the high density and highly flexible design, the reactivity of the functional groups on 
the periphery, as well as the possible aqueous solubility and low toxicity offers dendrimers 
applications in a variety of fields. These fields include catalysis,
183-185
 biosensors,
196, 197
 
adhesives,
198
 magnetic resonance imaging,
199
 and nanomedicine.
179, 180
 Moreover in catalysis, 
the catalytically-active complex can be located throughout the dendritic framework (Figure 
1.40).
178
 The multinuclearity approach affords greater activity and efficiency of the 
metallodendrimers over their mononuclear analogs.
184, 200, 201
 
 
 
Figure 1.40 Catalytically active transition-metals can be attached, (a) to the periphery, (b) to the 
core, (c) to the focal point of a dendron or (d) on the periphery of a dendron.
178
 
 
The concept of multinuclearity could lead to improved activity of metallodrugs. Hence, 
another application of metallodendrimers is the delivery of drugs. Several approaches have 
been used (Figure 1.38):
187
 
i. physical encapsulation of the drugs into the void spaces  
(drawbacks, fast and uncontrolled delivery of drugs)
202
 
ii. electrostatic binding between the ionic peripheral groups of the dendrimer and the 
drug 
iii. hydrogen bonding between the peripheral functional groups and the drug 
iv. and covalent linkage of the drug to the dendritic periphery or surface 
 (known as the pro-drug approach) 
 
Notably, in nanomedicine, the concept of multinuclearity can be applied to improve the 
potency of chemotherapeutic drugs. By exploiting the enhanced permeability and retention 
effect (EPR effect) dendrimers can be used to selectively target drug-targets. 
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The EPR effect is a phenomenon in which macromolecules (such as metallodendrimers), can 
exploit the physiological patterns of solid tumors (Figure 1.41). Metallodendrimers can 
accumulate at the tumor site due to an increase in blood vessel permeability (porous 
endothelial layer) within the cancerous cells over healthy tissues.
203, 204
 The healthy 
endothelial layer surrounding blood vessels, restricts the size of molecules that can diffuse 
from the blood stream into the cells. In contrast, the endothelial layer of cancerous tissues is 
more porous, providing access to the surrounding tissue. Furthermore, diseased tissues have 
an impaired lymphatic drainage system, thus once macromolecules have entered the 
cancerous site they are retained for longer periods (increase in bio-availability). A 
tetraruthenium cluster is highly active against the polio virus, without effecting healthy 
cells.
83
 
 
 
Figure 1.41 Illustration showing the diffusion of metallodendrimers into the tumor site, explained 
by the phenomenon known as the EPR effect.
203, 204
 
 
The use of dendrimers in the field of medicine is highly developed, with a number of 
dendrimer conjugates reported.
205-207
 However, the use of metallodrugs conjugated to 
dendritic frameworks is sparse, with only a handful of reports as antitumor agents 
180, 187
 or 
antimalarial agents.
208
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1.6.3 Metallodendrimers as Anticancer Agents 
Following the successes of cisplatin and its analogs,
13
 in particular the trinuclear Pt-based 
complex (BBR3464) mentioned earlier.
15
 Researchers have pursued the idea of 
functionalizing metallodrugs onto dendritic scaffolds in an effort to improve the activity of 
the metallodrug. There are only a handful of metallodendrimers specifically developed to 
target cancerous cells and are highlighted in a recent review.
180
 
 
It should come to no surprise that the first metallodendrimer synthesized to target cancer cells, 
was a tetranuclear Pt-based compound (Figure 1.42).
209
 The platinum-functionalized 
metallodendrimer DAB(PA-tPt-Cl)4 (where DAB = diaminobutane, PA = polyamine) is based 
on the first-generation poly(propylene) (PPI) dendritic scaffold. The Pt-metallodendrimer was 
synthesized to overcome problems associated with cisplatin-resistance in cancer cells: 
i. deactivation of the Pt-species by intracellular thiolates and 
ii. improved repair of crosslinks with DNA. 
 
 
Figure 1.42 Structure if G1 tetranuclear Pt-functionalized metallodendrimer,  
DAB(PA-tPt-Cl)4.
209
 
 
The four-armed molecule is expected to form crosslinks with DNA, which are very different 
from the adduct(s) formed by cisplatin. The tetranuclear complex was able to bind to four 
molecules of the model nucleobase, guanine-5’-monophosphate (GMP) at the N7 position, 
similarly seen with BBR3464. The complex showed moderate cytotoxicity against mouse 
leukemia cells (L1210/0, IC50 = 12.4 μM),
209
 and was investigated against seven human cell 
lines (IC50 >9 μM).
209
 The authors attribute the low activity to high charge and branching of 
the metallodendrimer, which would in turn impede the movement of the complex into the 
active site (i.e. crossing the cell membrane). 
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With the severe side-effects of platinum-based drugs,
17
 researchers shifted their attention to 
other metals. Hence, Zhao and co-workers synthesized tetranuclear (Pt-based) and 
hexanuclear (Cu-based) PAMAM metallodendrimers (Figure 1.43), with the biological 
activity of these complexes investigated (in cisplatin-sensitive, MOLT-4, and cisplatin-
resistant, MCF-7, breast cancer cells).
210
  
 
 
Figure 1.43 Structure of G1 tetranuclear Pt- (left) and Cu-functionalized (right) 
metallodendrimers.
210
 
 
The ligands showed no activity against the cancer cells, whilst the multinuclear complexes 
showed enhanced activity over their mononuclear derivatives. Moreover, the copper analogs 
displayed greater activity to their platinum analogs, with the authors attributing the low 
toxicity of the Pt-complexes to poor solubility in the testing medium and ability of the 
complexes to self-assemble (seen through SEM experiments).
210
 
 
Stability of anticancer agents in solution is a key aspect before consideration for biological 
and clinical applications. Rodrigues and co-workers monitored the degradation and stability 
of low generation ruthenium-based poly(alkylideneamine)-nitrile metallodendrimers (Figure 
1.44) by 
31
P-NMR spectroscopy. The metallodendrimers containing the [Ru(Cp)(PPh3)2]
+
 
moiety was unstable at physiological temperature, as there is a release of the Ru half-
sandwich. However, the metallodendrimer containing the [Ru(dppe)2Cl]
+
 is stable over 4 h in 
solution, revealing the potential of the complexes for biological applications. 
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Figure 1.44 Structure of poly(alkylideneamine)-nitrile metallodendrimers functionalized with 
[Ru(dppe)2Cl]
+
 or [Ru(Cp)(PPh3)2]
+
.
211
 
 
Metallodendrimers have also shown promise as potential photodynamic therapy (PDT) 
agents, with the synthesis of a 32-armed ruthenium-polypyridyl functionalized PAMAM 
metallodendrimer, by Velders and co-workers.
212
 The positively charged derivative shows 
promise as a PDT agent, whilst the negatively charged derivative shows promise for 
diagnostic fluorescence assays. 
 
 
Figure 1.45 A positively and negatively charged PAMAM polypyridyl ruthenium 
metallodendrimer.
212
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Recently, a series of neutral and cationic first- and second-generation monodentate (N- donor) 
and chelating (N,N- and N,O-) ruthenium-arene metallodendrimers were prepared.
213, 214
 
These peripherally functionalized metallodendrimers were based on a poly(propyleneimine) 
dendritic scaffold and displayed increasing cytotoxicity upon increasing dendrimer 
generation. Furthermore, the improved activity gives good reason for the preparation of 
higher generation metallodendrimers, which may lead to potent antitumor compounds. The 
coupling of metallodrugs to dendritic scaffolds to afford bio-metallodendrimers is novel, but 
in recent years it has been explored, revealing a new field of metal-based biomolecules.  
 
1.7 Closing Remarks 
 
With the number of cases reported each year increasing exponentially, cancer is a serious 
threat. The severe toxicity and acquired drug resistance of current chemotherapeutics has led 
to an urgent need for alternative drugs. Bioorganometallic molecules have emerged as 
alternative compounds to address the problems presented by commercially available drugs.  
 
Whilst there are few reports on the use of multinuclear metallodendrimers as anticancer 
agents, the promising results observed for mononuclear complexes, provides motivation for 
the investigation of their multinuclear derivatives. 
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1.8 Aims and Objectives of the Thesis 
 
1.8.1 General Aims 
In the light of past and recent developments, there is precedence for the development of new 
bioorganometallic metallodendrimers. Therefore, the aims of the project were: 
 The design and synthesis of new multimeric dendritic ligands. 
 The coordination of these dendritic ligands to metals (Ru, Os, Mn) to afford 
multinuclear metallodendrimers. 
 Evaluation of these metallodendrimers for their activity as therapeutic agents. 
 
1.8.2 Specific Objectives 
1.8.2.1 Synthesis 
This project dealt with the preparation of new multinuclear metallodendrimers containing 
ruthenium, osmium, iron or manganese via peripheral functionalization of a 
poly(propyleneimine) dendritic scaffold. The complexes were characterized using an array of 
spectroscopic and analytical techniques. Furthermore, to compare the biological activity of 
the metallodendrimers, their mononuclear analogs were also prepared. The complexes can be 
divided into three sub-categories, which involve the preparation of three types of ligands 
systems, all which were complexed with metallodrugs and their biological activity 
investigated. 
 
I. The preparation of first-, second-, third- and fourth-generation metallodendrimers, 
where the dendritic ligand coordinates in a chelating bidentate manner to the 
biologically active ruthenium- or osmium-arene metal centre (Figure 1.46). 
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Figure 1.46 General structures of ruthenium- and osmium-arene metallodendrimers prepared in 
this study. 
 
II. The preparation of first- and second-generation metallodendrimers, where ferrocene 
has been incorporated into the dendritic scaffold, to possibly influence the lipophilic 
nature of the complexes (Figure 1.47). 
 
 
Figure 1.47 General structure illustrating the incorporation of the ferrocene moeity onto the 
dendritic scaffold.  
 
III. The preparation of first- and second-generation metallodendrimers, where the 
polypyridyl dendritic ligand coordinates in a chelating bidentate manner to a CO-
releasing Mn(I) precursor (Figure 1.48). 
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Figure 1.48 General structures of CO-releasing polypyridyl Mn(II) metallodendrimers prepared. 
 
All complexes have been characterized using a variety of analytical and spectroscopic 
techniques, which include NMR, IR and UV-Vis spectroscopy, elemental analysis and mass 
spectrometry.  
 
1.8.2.2 Biological Investigation 
Following preparation of the metallodendrimers, it was necessary to investigate the in vitro 
antitumor activity of the complexes in human ovarian cancer cells (A2780 & A2780cisR). 
Furthermore, stability studies and DNA binding experiments were performed on the most 
active complexes. Eventually, structure-activity relationships were established and reported. 
 
The CO-release properties of the manganese-based metallodendrimers were investigated. The 
CO-release was assessed using the myoglobin assay and complemented with investigations 
using infrared and UV/Vis spectroscopy during the photolysis of the complexes.  
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Chapter 2 
Synthesis and Characterization of Neutral and Cationic 
Ruthenium(II)- and Osmium(II)-Arene Complexes  
Based on Poly(propyleneimine) Dendritic Scaffolds 
 
This chapter forms part of the following publications: 
Preshendren Govender, L. C. Sudding, C. M. Clavel, P. J. Dyson, B. Therrien and G. S. Smith, The Influence 
of RAPTA Moieties on the Antiproliferative Activity of Peripheral-Functionalized Poly(salicylaldiminato) 
Metallodendrimers, Dalton Transactions, 2013, 42, 1267-1277. 
 
Preshendren Govender, F. Edafe, B. C. E. Makhubela, P. J. Dyson, B. Therrien and G. S. Smith, Neutral and 
Cationic Osmium(II)-Arene Metallodendrimers: Synthesis, Characterization and Anticancer Activity, 
Inorganica Chimica Acta, 2014, 409, 112-120. 
 
2.1 Introduction 
 
Despite the successes of cisplatin and other platinum-based derivatives, the drawbacks of 
platinum-based chemotherapeutics, such as drug resistance, side-effects and toxicity, have 
motivated investigations towards the preparation of complexes based on other metals as 
effective anticancer agents.
1, 2
 Most noteworthy and relevant to this study, is the development 
of half-sandwich organometallic ruthenium-arene complexes with potent anticancer activity, 
of general formula [(η6-arene) Ru(X)(Y)(Z)], where X and Y are bidentate chelating groups 
(NN, NO, OO or SO), or two monodentate ligands, and Z a monodentate moiety, often a 
leaving group.
3-6
 A host of derivatives have been synthesized, which include incorporation of 
paullones,
7, 8
 pyr(id)ones,
9
 ethylenediamine (en),
3, 10
 or 1,3,5-triaza-7-phosphatricyclo-
[3.3.1.1.]decane (PTA),
11, 12
 to the ruthenium coordination ion.  
 
Metallodendrimers have been investigated as potential therapeutic agents,
13
 as their 
multivalency may lead to increased interactions between a dendrimer-drug conjugate and a 
target bearing multiple receptors. A series of monodentate (N- donor) and chelating (N,N- and 
N,O-) ruthenium-arene (where arene = p-cymene or hexamethylbenzene) first- and second-
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generation metallodendrimers, based on a poly(propyleneimine) dendritic scaffold have 
previously been reported (Figure 2.1).
14, 15
 The chelating ruthenium-arene metallodendrimers 
5 - 12 show superior in vitro antitumor activity over the monodentate ruthenium-arene 
metallodendrimers 1 - 4, with the second-generation cationic N,N-ruthenium-
hexamethylbenzene metallodendrimer 8 displaying the greatest activity. A clear correlation 
between the size dependency of the metallodendrimer and cytotoxicity was also observed. For 
this reason, it was envisaged that investigation into the synthesis of higher generations of 
ruthenium-arene metallodendrimers may lead to more potent antitumor agents. Furthermore, 
half-sandwich rhodium- and iridium-analogs 13 - 20, of the mentioned ruthenium-arene 
metallodendrimers 5 - 12, were reported recently, and displayed moderate to good activity in 
vitro (Figure 2.1).
16 
 
 
Figure 2.1  A series of neutral and cationic half-sandwich ruthenium-arene, rhodium-Cp* and 
iridium-Cp* (where Cp* = pentamethylcyclopentadienyl) metallodendrimers 1 - 20.. 
 
Eventually, the design and synthesis of these various metallodendrimers will form an 
important structure-activity study, which will give valuable insights into the mode of action of 
these potential therapeutic agents. 
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In this chapter, the synthesis and characterization of novel ruthenium- and osmium-arene 
metallodendrimers is described. A rationale for the synthesis of this class of compounds and 
the use of a series of dendritic scaffolds is discussed. Several spectroscopic and analytical 
techniques were employed to confirm and elucidate the proposed structures, and are 
described. The biological activity of these metallodendrimers and their mononuclear analogs 
is discussed in Chapter 4. 
 
2.2 Synthesis and Characterization of N,O-Salicylaldiminato Ligands  
 
First- and second-generation N,O-salicylaldiminato dendritic ligands, DAB-G1-PPI-
(C7H5NOH)4 (21) and DAB-G2-PPI-(C7H5NOH)8 (22), were synthesized using known 
methods.
17
 As an extended study the third- and fourth-generation N,O-salicylaldiminato 
dendritic ligands 23 and 24 are new compounds and hence are discussed below. 
 
N,O-salicylaldiminato dendritic ligands 23 and 24 were prepared by reacting salicylaldehyde 
with the appropriate dendritic scaffold (DAB-G3-PPI-(NH2)8 for 23 or DAB-G4-PPI-(NH2)32 
for 24) (Scheme 2.1) via a Schiff base condensation reaction (Scheme 2.2, general 
mechanism) using modified literature reported methodologies.
17
 
 
 
Scheme 2.1 Synthesis of N,O-salicylaldiminato dendritic ligands 21 - 24. 
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Scheme 2.2 Mechanistic outline of a general Schiff base condensation reaction. 
 
The reactants were stirred for 48 h in toluene, at room temperature, in the presence of 
anhydrous MgSO4, which is used as a drying agent to remove water formed as a by-product in 
the reaction. Following filtration and removal of the solvent, a liquid-liquid 
(water/dichloromethane) extraction was employed to remove unreacted starting material. The 
dendritic ligands 23 and 24 were isolated as yellow-orange oils, in moderate to low yields 
(Table 2.1). The oils are soluble in most organic solvents such as dichloromethane, methanol, 
toluene, diethyl ether and dimethylsulfoxide. Spectroscopic (
1
H NMR, 
13
C{
1
H} NMR and IR 
spectroscopy) and analytical data (elemental analysis and mass spectrometry) confirmed the 
proposed structures. 
 
Table 2.1 Physical appearance and percentage yield for dendritic ligands 23 and 24. 
Compound Physical Appearance 
Yield  
[%] 
23 Orange-yellow oil 71 
24 Orange oil 40 
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2.2.1 
1
H and 
13
C{
1
H} NMR Spectroscopy  
The 
1
H and 
13
C{
1
H} NMR spectra of 23 and 24 were recorded in deuterated chloroform 
(CDCl3) and are consistent with literature reported values for the first- and second-generation 
N,O-salicylaldiminato analogs,
17
 in as far as a reasonable comparison could be made. 
 
The 
1
H NMR spectra of 23 (Figure 2.2) and 24 show a distinct downfield shift in the signal 
assigned to aliphatic CH2 protons adjacent to the imine nitrogen, observed at 3.56 ppm for 23 
and 3.53 ppm for 24. The downfield shift is attributed to the electron withdrawing effects 
imposed by the imine moiety. The aliphatic protons at the core and on the branches of the 
dendritic ligands appear between 1.30 ppm and 3.60 ppm.  
 
Figure 2.2 
1
H NMR spectrum of fourth-generation N,O-dendritic ligand 23 in CDCl3. 
 
Dendritic ligands 23 and 24 show complex 
1
H NMR spectra, with peak broadening and 
overlapping of signals in the aliphatic region, and is attributed to the multi-functionality of the 
dendrimers and to the sensitivity of the NMR machine. The dendritic arms have many degrees 
of freedom and hence the 
1
H NMR spectrum displays broadened peaks. Low temperature 
1
H 
NMR is an alternate method to improve the quality and/or resolution of the 
1
H NMR spectra 
of 23 and 24, but these experiments were not performed. The aromatic protons resonate in a 
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similar range to the monomeric ligand CH3CH2CH2(C7H5NOH) (discussed in Section 2.5),
18
 
between 6.8 ppm and 7.3 ppm for both 23 and 24. The imine and hydroxyl protons of 23 and 
24 are assigned to the singlet and broad singlet at ~8.3 ppm and ~13.5 ppm respectively 
(Table 2.2).  
 
Table 2.2 Selected spectroscopic and analytical data for dendritic ligands 23 and 24. 
Compound 
1
H NMR  
(imine, OH) [ppm]
a
 
13
C{
1
H} NMR 
(imine) [ppm]
a
 
IR  
(imine) [cm
-1
]
b
 
MS  
([M]
+
) [m/z]
c
 
23 8.27, 13.50 164.9 1634 3354 
24 8.27, 13.48 164.8 1634 6844 
a 
Recorded in CDCl3,  
b 
Recorded in NaCl solution cells in CH2Cl2, 
c 
MALDI-TOF-MS 
 
The 
13
C{
1
H} NMR spectra of 23 and 24 displayed the expected carbon peaks for each 
compound. No significant changes were observed in the chemical shifts of the signals when 
moving from the third-generation 23 to the fourth-generation 24. Signals for the aliphatic 
carbons are seen between 24 - 57 ppm and for the aromatic carbons between 117 - 161 ppm 
for both 23 and 24. The chemical shifts of the signals assigned to the aromatic and imine 
carbons of 23 and 24 (Table 2.2), are comparable to the chemical shifts reported for the first- 
and second- generation analogs.
17
 
 
2.2.2 Infrared Spectroscopy 
Along with 
1
H and 
13
C{
1
H} NMR spectroscopy, infrared spectroscopy was used to assist in 
identifying the C=N stretching vibration, indicative of a successful Schiff base condensation 
reaction. The dendritic ligands 23 and 24 were recorded in dichloromethane in NaCl solution 
cells. The appearance of a strong stretching vibration at 1634 cm
-1 
for 23 and 24 (Table 2.2) 
suggests successful condensation of the carbonyl and the amine functionalities. The stretching 
vibration at 1634 cm
-1
 is assigned to the (C=N)imine bond and is comparable to the first- and 
second- generation dendritic ligands 21 and 22.
17
 For 23 and 24, a broad band at ~2950 cm
-1
 
is observed and indicated the presence of the hydroxyl functionality. The absence of the 
carbonyl (~1700 cm
-1
) and amine (~3300 cm
-1
) stretching vibrations suggest tautomerism did 
not occur (Scheme 2.3).
19
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Scheme 2.3 Tautomerism of the hydroxyimine (left) to the keto-amine (right). 
 
2.2.3 Elemental Analysis and Mass Spectrometry 
The elemental analysis data for 23 and 24 was initially found outside acceptable limits and 
was ascribed to the inclusion of solvent(s). Following extensive drying under vacuum, the 
presence of solvent was consistently observed in the 
1
H NMR spectrum of 23 and 24. 
Recalculation of percentages with the inclusion of three molecules of water (for 23) and one 
molecule of toluene (for 24) brought the experimental data within acceptable limits. This 
phenomenon is observed with other poly(propyleneimine) dendrimers functionalized at the 
periphery with organic and inorganic moeities.
15, 20
  
 
Further evidence for the formation of 23 and 24 is supported by MALDI-TOF mass 
spectrometry data, which shows the parent molecular ion peak [M]
+
 in the spectrum of each 
ligand, at m/z = 3354 and m/z = 6844 for 23 and 24 (Figure 2.3) respectively (Table 2.2). 
 
 
Figure 2.3 MALDI-TOF mass spectrum of N,O-dendritic ligand 24.  
 
 
 
 
 
[M]
+
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2.3 Synthesis and Characterization of Neutral N,O-Ru(II)-Arene 
Metallodendrimers 
 
The synthesis of the first- and second- generation neutral N,O-ruthenium-arene 
metallodendrimers 9 - 12 were previously reported by our group (Figure 2.1).
15
 The same 
methodology was employed in the synthesis of the third- and fourth-generation analogs 25 - 
28, and is discussed below. 
 
The synthesis of the new neutral N,O-ruthenium-arene metallodendrimers 25 - 28 involved 
two reactions. The first reaction, was the preparation of the appropriate ruthenium dimer, 
([Ru(η6-p-PriC6H4Me)Cl2]2 & [Ru(η
6
-C6Me6)Cl2]2), following literature reported 
procedures.
21, 22
 The second reaction involved the bridge-splitting reaction of the dendritic 
ligands 23 and 24 with either the [Ru(η6-p-PriC6H4Me)Cl2]2 or [Ru(η
6
-C6Me6)Cl2]2 dimer, in 
the presence of a weak base, to afford dendritic complexes 25 - 28 (Scheme 2.4).  
 
 
Scheme 2.4 Synthesis of neutral N,O-Ru(II)-arene metallodendrimers 25 - 28. 
 
The bridge-splitting reaction was first attempted without the addition of a base, and following 
the workup of the reaction, only starting materials were observed. Consequently, prior to 
addition of the ruthenium dimer, a weak base (triethylamine) was added to deprotonate the 
hydroxyl group. The reactions were stirred in dichloromethane for 48 h at room temperature, 
filtered and the solvent removed resulting in a crude solid. The crude solids were purified by 
low temperature precipitation from dichloromethane, to afford the p-cymene derivatives (25 
and 26) as yellow-brown solids and hexamethylbenzene derivatives (27 and 28) as orange 
solids in 68 - 91 % yields (Table 2.3).  
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Table 2.3 Physical appearance and percentage yield for dendritic complexes 25 - 28. 
Compound Physical Appearance 
Yield  
[%] 
Melting Point 
[ºC] 
25 Yellow-brown solid 91 
a
62 
26 Yellow-brown solid 89 
a
81 
27 Orange solid 84 179 - 189 
28 Orange solid 68 
a
183 
a 
Decompose without melting 
 
Dendritic complexes 25 - 28 are non-hygroscopic, air-stable and soluble in dimethylsulfoxide, 
acetone, acetonitrile, tetrahydrofuran, dichloromethane, chloroform, toluene, methanol and 
insoluble in non-polar solvents. The hexamethylbenzene derivatives 27 and 28 are more 
thermally stable (melting points >150 ºC) compared to their p-cymene counterparts 25 and 26, 
which decompose without melting between 60 and 80 ºC (Table 2.3). 
 
2.3.1 
1
H and 
13
C{
1
H} NMR Spectroscopy  
The proposed chelation of the imine nitrogen and the phenolic oxygen to the ruthenium ion 
was confirmed by 
1
H NMR spectroscopy. The 
1
H NMR spectra of 25 - 28 were recorded in 
CDCl3 and display characteristic peaks for the coordination of the dendritic ligands 23 and 24 
to the ruthenium-arene (where arene = p-cymene or hexamethylbenzene) moiety. The 
1
H 
NMR spectra of 25 - 28 showed broadened peaks (similarly observed in the 
1
H NMR spectra 
of 23 and 24), with many of the peaks overlapping and/or coalescing, due to the 
multinuclearity of these dendritic systems. 
 
There are distinctive shifts in signals assigned to the imine proton and protons on the aromatic 
ring of 25 - 28, and is attributed to the electronic influences brought about by the chelation of 
the imine nitrogen and phenolic oxygen to the ruthenium ion. There is an upfield shift in the 
imine singlet from ~8.3 (in 23 and 24) to ~8.1 ppm for 25 - 28 (Table 2.4), and an absence in 
the broad peak (~13.5 ppm) assigned to the proton on the hydroxyl moiety (in 23 and 24). 
These two observations confirm deprotonation of the phenolic oxygen and coordination of the 
both the imine nitrogen and phenolic oxygen to the ruthenium ion. Coordination of 23 and 24, 
generates a chiral centre around the ruthenium ion, which is brought on by the four different 
groups on the ruthenium ion. The formation of the chiral centre explains the doubling of 
signals observed in the 
1
H NMR spectra of 25 - 28, and this in turn generates diastereotopic 
protons on the dendritic ‘arms’ of complexes 25 - 28. Diastereotopic protons on the carbon 
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adjacent to the imine nitrogen, display two sets of broad multiplets in the ranges 1.8 - 2.8 ppm 
and 4.0 - 4.5 ppm for 25 - 28. 
 
Table 2.4 Selected spectroscopic and analytical data for dendritic complexes 25 - 28. 
Compound 
1
H NMR  
(imine)  
[ppm]
a
 
13
C{
1
H} NMR 
(imine) 
[ppm]
a
 
IR (C=N)imine 
(complex, ligand) 
[cm
-1
]
b
 
MS  
(fragment, assignment) 
[m/z]
c
 
25 8.05 164.7 1621, 1634 845.1812 [M-9Cl]
9+
 
26 8.08 164.9 1621, 1634 580.9363 [M-26Cl]
26+
 
27 8.18 165.8 1617, 1634 
d
8080 [M-Cl]
+
 
28 8.16 166.0 1618, 1634 630.0355 [M+26H]
26+
 
a 
Recorded in CDCl3,  
b 
Recorded in NaCl solution cells in CH2Cl2,  
c 
HR-ESI-TOF-MS,  
d 
MALDI-TOF-MS 
 
1
H NMR spectra of p-cymene derivatives (25, 26) 
In the 
1
H NMR spectra of 25 and 26, the methyl protons on the isopropyl group (i.e. on the p-
cymene ring) exhibit one broad multiplet per methyl group. The two broad multiplets are 
observed at ~1.0 ppm and ~1.1 ppm and are assigned to the diastereotopic methyl groups of 
the isopropyl functionality, and attributed to the formation of the asymmetric centre. A 
broader multiplet for 25 and 26 is observed between 3.1 - 3.2 ppm and is assigned to the 
single proton on the isopropyl functionality. Two broad doublets for 25 and 26 are observed 
between 6.3 - 6.8 ppm and are assigned to the aromatic protons on the p-cymene ring. 
 
1
H NMR spectra of hexamethylbenzene derivatives (27, 28) 
The 
1
H NMR spectra of 27 and 28 show a singlet in the range of 1.8 - 3.8 ppm, and is 
assigned to the methyl protons on the hexamethylbenzene ring. 
 
13
C{
1
H} NMR spectra of 25 - 28 were recorded in CDCl3 and similar chemical shifts for 
signals assigned to aromatic carbons were observed. Extra signals were seen in the aliphatic 
region for the higher generation complexes 26 and 28, and were assigned to the aliphatic 
carbons on the dendritic ‘arms’. The 13C{1H} NMR spectra of 25 - 28 are similar to the 
spectra of 23 and 24, with expected shifts observed for the imine and pyridyl carbons (Table 
2.4) due to coordination to the ruthenium ion. 
13
C{
1
H} NMR spectra of 25 - 28 show signals 
for the aromatic carbons in the range of 114 - 135 ppm. The 
13
C{
1
H} NMR spectra of the p-
cymene derivatives 25 and 26 display a range of signals between 19 - 23 ppm and 31 - 100 
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ppm, and are assigned to the carbon atoms on the p-cymene moiety. The 
13
C{
1
H} NMR 
spectra of the hexamethylbenzene derivatives 27 and 28 show signals at 16 ppm and ~90 ppm 
for the sp
3
 carbon and sp
2
 carbon on the hexamethylbenzene ring respectively. 
 
2.3.2 Infrared Spectroscopy 
Further evidence for the coordination of the dendritic ligands 23 and 24 via the imine nitrogen 
to the ruthenium ion, is illustrated in the infrared spectra of 25 - 28. A distinct shift in the 
(C=N)imine stretching vibration from ~1634 cm
-1
 (for the ligand) to 1621 cm
-1
 for 25 and 26, 
and to ~1617 cm
-1
 for 27 and 28 is observed (Table 2.4 and Figure 2.4). Furthermore, the 
absence in the stretching vibration at ~2950 cm
-1
 (due to the (O-H)hydroxyl in the ligand) 
confirmed the absence of the hydroxyl proton and suggests formation of a σ-bond with the 
ruthenium ion, for 25 - 28. 
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Figure 2.4 Overlaid infrared spectra of dendritic ligand 23 (black) and metallodendrimer 25 
(red) recorded in NaCl solutions cells in dichloromethane. 
 
2.3.3 Elemental Analysis and Mass Spectrometry 
The synthesis of 25 - 28 involves deprotonation of the hydroxyl group, prior to coordination 
to the ruthenium moiety, which affords Et3NH
+
Cl
-
 as a by-product (also observed in the 
1
H 
NMR spectra). Thus, theoretical values were recalculated with the inclusion of solvent 
C=Nimine  
(ligand) 
C=Nimine  
(complex) 
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molecules and/or inorganic salts (i.e. Et3NH
+
Cl
-
). The re-calculated percentages correlate well 
with the experimental values. 
 
Positive-ion MALDI-TOF mass spectral data for metallodendrimers 25, 26 and 28 and HR-
ESI mass spectral data for metallodendrimer 27 were consistent with the proposed structures. 
The mass spectral data further supported elemental analysis data for 25 - 28, with the base-
peaks listed in Table 2.4. 
 
2.4 Synthesis and Characterization of Cationic N,O-Ru(II)-Arene-PTA 
Metallodendrimers 
 
A series of new first-, second-, third- and fourth-generation cationic N,O-Ru(II)-arene-PTA 
metallodendrimers [29][PF6]4 - [36][PF6]32 were prepared. The synthesis involved a one-pot 
reaction of the ruthenium dimer [Ru(η6-arene)Cl2]2 (arene = p-Pr
i
C6H4Me or C6Me6) and the 
appropriate salicylaldiminato dendritic ligand 21 - 24 (Scheme 2.5). Prior to addition of the 
ruthenium dimer, triethylamine was added to deprotonate the hydroxyl group. Following 
formation of the anion and splitting of the ruthenium dimer, the reaction mixture was filtered 
and the water-soluble ligand PTA (1,3,5-triaza-7-phosphatricyclo[3.3.1.1.] 
decane) was added.  
 
 
Scheme 2.5 Synthesis of cationic N,O-Ru(II)-arene-PTA metallodendrimers [29][PF6]4 - 
[36][PF6]32. 
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The PTA ligand displaced the chlorido ligand, which in turn generated a cationic species. 
Attempts to isolate 29 - 36 as chlorido derivatives were not successful. The chlorido products 
were hygroscopic and hence difficult to isolate. These products form an oily residue when 
exposed to air. Hence, 29 - 36 were stabilized as hexafluorophosphate salts. This was 
achieved via an anion exchange using NaPF6 and the products isolated as yellow, thermally 
stable, solids in high yields (Table 2.5). Metallodendrimers [29][PF6]4 - [36][PF6]32 are non-
hygroscopic, air-stable and soluble in dimethylsulfoxide, acetone and acetonitrile. 
 
Table 2.5 Physical appearance, percentage yield and melting point for dendritic complexes 
[29][PF6]4 - [36][PF6]32. 
Compound Physical Appearance 
Yield  
[%] 
Melting Point 
[ºC] 
[29][PF6]4 Yellow solid 94 
a
272 
[30][PF6]8 Mustard solid 90 
a
275 
[31][PF6]16 Mustard solid 88 259 - 281 
[32][PF6]32 Mustard solid 78 195 - 199 
[33][PF6]4 Yellow solid 91 
a
224 
[34][PF6]8 Yellow solid 93 
a
203 
[35][PF6]16 Yellow solid 88 
a
200 
[36][PF6]32 Yellow solid 78 
a
196 
a 
Decompose without melting 
 
Coordination of the ligand occurred via the imine nitrogen and the phenolic oxygen, and the 
proposed structures were confirmed by analytical and spectroscopic techniques. 
 
2.4.1 
1
H, 
31
P{
1
H} and 
13
C{
1
H} NMR Spectroscopy  
Compared to the neutral metallodendrimers 9 - 12 and 25 - 28,
15
 the 
1
H NMR spectra of the 
cationic metallodendrimers [29][PF6]4 - [36][PF6]32 show a general downfield shift in signals 
due to the cationic nature of these complexes. Broadened peaks are observed in the 
1
H NMR 
spectra of [29][PF6]4 - [36][PF6]32, with many of the peaks overlapping and/or coalescing, due 
to the multinuclear nature of the complexes (Figure 2.5). The broadening of peaks is more 
noticeable with the third- and fourth-generation derivatives. Chirality induced by the 
ruthenium ion is evident by the appearance of two broad multiplets assigned to the 
diastereotopic protons on the carbon adjacent to the imine nitrogen (between 3.0 - 4.0 ppm), 
of complexes [29][PF6]4 - [36][PF6]32. Two multiplets observed between 4.1 and 4.6 ppm in 
the 
1
H NMR spectra are assigned to the PTA ligand. A small upfield shift in the singlet 
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assigned to the imine proton from 8.27 ppm (in the ligand) to between 8.1 - 8.2 ppm, and the 
disappearance in the broad singlet at ~13.5 ppm (phenolic proton on the ligand) for [29][PF6]4 
- [36][PF6]32 is observed (Table 2.6). Furthermore, this evidence suggests coordination occurs 
via the imine nitrogen and phenolic oxygen.  
 
 
Figure 2.5 
1
H NMR spectrum of first-generation N,O-Ru(II)-hexamethylbenzene-PTA 
metallodendrimer [33][PF6]4 in (CD3)2CO. 
 
1
H NMR spectra of p-cymene derivatives ([29][PF6]4 - [32][PF6]32) 
Metallodendrimers [29][PF6]4 - [32][PF6]32 show a loss of two-fold symmetry of the p-
cymene moiety upon coordination of the bidentate N,O-dendritic ligand. This feature in turn 
results in the methyl protons of the isopropyl group exhibiting two broad multiplets in the 
range of 1.0 - 1.3 ppm, and a broad multiplet observed at ~3.5 ppm assigned to the single 
proton of the isopropyl group. The aromatic protons of the p-cymene ring display four broad 
multiplets in the range of 5.6 - 6.5 ppm.  
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1
H NMR spectra of hexamethylbenzene derivatives ([33][PF6]4 - [36][PF6]32) 
Metallodendrimers [33][PF6]4 - [36][PF6]32 exhibit a singlet at ~2.1 ppm assigned to the 
methyl protons of the hexamethylbenzene ring.  
 
The 
31
P{
1
H} NMR spectra of [29][PF6]4 - [36][PF6]32 attests to the purity of the complexes as 
a singlet in the range of -47 - -26 ppm is observed (Table 2.6), suggesting a single phosphine 
species is present. Furthermore, these chemical shifts are comparable to structurally similar 
mononuclear RAPTA complexes reported in the literature.
23
  
 
Table 2.6 Selected spectroscopic and analytical data for dendritic complexes [29][PF6]4 - 
[36][PF6]32. 
Compound 
1
H NMR 
(imine) 
[ppm]
a
 
13
C{
1
H} NMR 
(imine) 
[ppm]
a
 
31
P{
1
H} NMR 
 (PTA) 
[ppm]
a
 
MS  
(fragment, assignment) 
[m/z]
b
 
[29][PF6]4 8.20 166.9 -32.5 
575.6148 [M]
4+
  
(where M = [29][PF6]4 - 4PF6) 
[30][PF6]8 8.21 166.7 -32.3 
540.1608 [M+H]
9+
  
(where M = [30][PF6]8 - 8PF6) 
[31][PF6]16 8.21 167.0 -26.2 
617.1169 [M]
16+
  
(where M = [31][PF6]16 - 16PF6) 
[32][PF6]32 8.10 166.7 -26.6 
603.1587 [M]
32+
  
(where M = [32][PF6]32 - 32PF6) 
[33][PF6]4 8.02 165.5 -41.0 
603.7332 [M+2H]
4+
  
(where M = [33][PF6]4 - 4PF6) 
[34][PF6]8 8.02 165.4 -40.8 
451.1324 [M+3H]
11+  
(where M = [34][PF6]8 - 8PF6) 
[35][PF6]16 8.00 165.3 -40.6 
629.2938 [M]
16+  
(where M = [35][PF6]16 - 16PF6) 
[36][PF6]32 8.16 170.2 -40.4 
596.1664 [M+2H]
34+ 
(where M = [36][PF6]32 - 32PF6) 
a 
Recorded in (CD3)2CO 
b 
HR-ESI-TOF-MS 
 
13
C{
1
H} NMR spectra for metallodendrimers [29][PF6]4 - [36][PF6]32 showed the expected 
number of signals for the proposed structure. There is an increase in the number of signals 
observed as the generation number is increased. The increase in signals is attributed to the 
increase in the number aliphatic carbons (i.e. carbons found on the dendritic ‘arms’) as the 
generation number is increased. Signals assigned to the carbons at the dendritic ‘core’ and on 
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the dendritic ‘arms’ were observed in the range of 21 - 69 ppm. A singlet is observed for the 
imine carbon in the range of 165 - 170 ppm (Table 2.6). The CH2 groups of the PTA ligand is 
observed at ~51 ppm and ~72 ppm for the p-cymene derivatives [29][PF6]4 - [32][PF6]32, 
whilst signals for the hexamethylbenzene derivatives [33][PF6]4 - [36][PF6]32 were observed at 
~49 ppm and ~73 ppm in the 
13
C{
1
H} NMR spectra. 
 
2.4.2 Infrared Spectroscopy 
The infrared spectra of [29][PF6]4 - [36][PF6]32 display a shift in the (C=N)imine absorption 
band for the uncoordinated dendritic ligands (~1650 cm
-1
) to lower wavenumbers for the 
metal complex (~1618 cm
-1
), which further supports coordination of imine nitrogen to the 
ruthenium ion. These shifts can be explained by the synergic effect,
24
 where the (C=N)imine 
bond experiences electron-withdrawing effects from the coordinated ruthenium and the 
aromatic ring, which in turn weakens the (C=N)imine bond and pushes the stretching vibration 
to a lower wavenumber. The disappearance in the (O-H)hydroxyl stretching vibration suggests 
the dendritic ligands coordinate through the phenolic oxygen, similarly observed for the 
neutral metallodendrimers 9 - 12 and 25 - 28. 
 
2.4.3 Elemental Analysis and Mass Spectrometry 
Similarly observed with 25 - 28, the metallodendrimers [29][PF6]4 - [36][PF6]32 displayed 
elemental analysis percentages outside acceptable limits, and these were ascribed to possible 
solvent inclusion (even after extensive drying) and/or encapsulation of inorganic salts (i.e. 
Et3NH
+
Cl
-
), which is observed in the 
1
H NMR spectrum of these complexes. This is a result 
of the phenomenon whereby dendritic arms fold back onto one another, in turn trapping small 
molecules, and is also observed in other poly(propyleneimine) dendrimers functionalized at 
the periphery with organic groups.
20
 Synthesis of metallodendrimers [29][PF6]4 - [36][PF6]32 
involves deprotonation of the hydroxyl group, prior to coordination to the ruthenium moiety, 
which in turn yields Et3NH
+
Cl
-
 as a by-product (similarly observed with metallodendrimers 
25 - 28). Recalculation of the percentages with the inclusion of Et3NH
+
Cl
-
 and/or ethanol 
(reaction solvent) gave percentages within acceptable limits.  
 
The 
1
H, 
13
C{
1
H}, 
31
P{
1
H} NMR and IR spectral data was supported by HR-ESI-MS data, 
which showed [M]
16+
 as the highest molecular weight fragment for [31][PF6]16 and 
[35][PF6]16, whilst [M]
32+
 was observed for [32][PF6]32. The highest molecular weight 
fragments for the rest of the dendritic salts in this series are listed in Table 2.6. 
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2.5 Synthesis and Characterization of Cationic N,O-Ru(II)-Arene-PTA 
Mononuclear Complexes 
 
The new mononuclear complexes [38][PF6] and [39][PF6] were synthesized as models of the 
larger metallodendrimers [29][PF6]4 - [36][PF6]32 in order to compare size dependency on the 
antiproliferative activity (discussed in Chapter 4). The synthesis of the p-cymene [38][PF6] 
and hexamethylbenzene [39][PF6] derivatives involved a two-step process. The first step was 
synthesis of the monomeric ligand (E)-2-((propylimino)methyl)phenol 37, via a Schiff base 
condensation reaction, by following literature reported methods (Scheme 2.6).
18
 
 
Scheme 2.6 Synthesis of monomeric ligand (E)-2-((propylimino)methyl)phenol 37. 
 
The second step involved the bridge-splitting reaction of the appropriate ruthenium dimer 
with monomeric ligand 37. Complex 38 and 39 were isolated as hexafluorophosphate salts via 
a one-pot reaction of the [Ru(η6-arene)Cl2]2 (arene = p-Pr
i
C6H4Me or C6Me6) with the 
monomeric ligand 37, in the presence of triethylamine, followed by the addition of PTA and 
sodium hexafluorophosphate (Scheme 2.7).  
 
 
Scheme 2.7 Synthesis of cationic N,O-Ru(II)-arene-PTA mononuclear complexes [38][PF6] and 
[39][PF6]. 
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Complexes [38][PF6] and [39][PF6] were isolated as thermally stable yellow solids in 
relatively high yields and are soluble in dimethylsulfoxide, acetone, acetonitrile and 
chloroform.  
 
2.5.1 
1
H, 
31
P{
1
H} and 
13
C{
1
H} NMR Spectroscopy  
1
H NMR spectroscopy was used to assist in providing evidence for the coordination of the 
imine nitrogen and phenolic oxygen to the ruthenium ion. The 
1
H NMR spectra of complexes 
[38][PF6] and [39][PF6] was recorded in acetone-d6 and showed all the relevant peaks for the 
proposed structures. Following coordination of ligand 37 to the ruthenium ion, there is a 
absence in the broad singlet assigned to the hydroxyl proton (~13.5 ppm in the 
1
H NMR of 
37) and an upfield shift in the singlet assigned to the imine proton at 8.32 ppm (in 37) to 8.13 
ppm for both [38][PF6] and [39][PF6] (Table 2.7). 
 
Table 2.7 Selected spectroscopic and analytical data for mononuclear complexes [38][PF6] and 
[39][PF6]. 
Compound 
1
H NMR  
(imine)  
[ppm]
a
 
13
C{
1
H} NMR 
(imine) 
[ppm]
a
 
31
P{
1
H} NMR 
(PTA) 
[ppm]
a
 
IR (C=N)imine 
(complex, ligand) 
[cm
-1
]
b
 
MS (fragment, 
assignment) 
[m/z]
c
 
[38][PF6] 8.13 166.9 -33.0 1619, 1635 566 [M-CYE]
+
 
[39][PF6] 8.13 165.2 -41.6 1618, 1635 283 [M-PF6]
+
 
a 
Recorded in (CD3)2CO 
b 
Recorded as KBr pellet 
c 
ESI-MS 
 
Similarly seen with the cationic metallodendrimers [29][PF6]4 - [36][PF6]32, the protons on the 
propyl chain are diastereotopic and this is attributed to the chiral nature of the molecule. 
Hence, two multiplets (integrating for one proton per signal) in the range of 3.8 - 4.1 ppm for 
[38][PF6] (Figure 2.6) and in the range of 3.6 - 3.8 ppm for [39][PF6] (Figure 2.7), is 
observed. 
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Figure 2.6  
1
H NMR spectrum for the mononuclear N,O-Ru(II)-p-cymene-PTA complex [38][PF6] 
in (CD3)2CO. 
 
1
H NMR spectra of p-cymene derivative ([38][PF6]) 
The asymmetric nature of the ruthenium centre results in a loss of 2-fold symmetry around the 
arene ring. Hence the diastereotopic methyl groups on the isopropyl moiety are observed as 
two doublets. Furthermore, each doublet integrates for three protons, with a coupling constant 
of 
3
J = 3.7 Hz per doublet. The three doublets and one multiplet observed in the range of 5.6 - 
6.5 ppm corresponds to the aromatic protons of the p-cymene ring, with coupling constants 
around 
3
J = 5 Hz. A multiplet is observed at 2.6 ppm for [38][PF6] and is assigned to the 
single proton on the isopropyl functionality.  
 
1
H NMR spectra of hexamethylbenzene derivative ([39][PF6]) 
A singlet is observed at 2.06 ppm, integrates for 18 protons, and is assigned to the CH3 groups 
on the hexamethylbenzene ring. 
Chapter 2. Ruthenium and Osmium Metallodendrimers 
 
 
 
76 
 
 
Figure 2.7 
1
H NMR spectrum for the mononuclear N,O-Ru(II)-hexamethylbenzene-PTA complex 
[39][PF6] in (CD3)2CO. 
 
The 
1
H NMR spectra of [38][PF6] and [39][PF6] display two doublets and a singlet in the 
range of 4.2 - 4.5 ppm and is assigned to the two types of CH2 protons on the PTA moiety. 
The 6 protons of -P-CH2-N- are represented as a singlet at ~4.5 ppm (Figure 2.6 and Figure 
2.7). This signal is usually represented as a doublet in the free ligand, with P-H coupling (
2
JP-
H = 10.5 Hz). However, the JP-H coupling is reduced to a negligible value (with no coupling 
observed in the 
1
H NMR spectra) following coordination to the ruthenium ion, as observed in 
other PTA complexes.
25, 26
 Whilst the 6 protons of -N-CH2-N- display an AB spin system 
centred at ~4.2 ppm (Figure 2.6 and Figure 2.7), which is assigned to the N-CHax-N and N-
CHeq-N protons on the PTA ligand, and has previously been observed in other transition 
metal-PTA complexes.
27-29
 
 
The 
31
P{
1
H} NMR spectra shows a singlet at -33.0 ppm and 41.6 ppm for [38][PF6] and 
[39][PF6] respectively (Table 2.7). Furthermore, this suggests a single coordinated phosphine 
species is present (PTA) and also attests to the purity these complexes. 
 
Chapter 2. Ruthenium and Osmium Metallodendrimers 
 
 
 
77 
 
13
C{
1
H} NMR spectra for [38][PF6] and [39][PF6] gave the expected number of carbon 
signals for the proposed structure. There is a downfield shift in the singlet assigned to the 
imine carbon, and is observed at 164 ppm (in ligand 37) to 165 ppm for [38][PF6] and 167 
ppm for [39][PF6] The appearance of two singlets at ~50 ppm and ~73 ppm, confirms 
coordination of the PTA ligand to the ruthenium ion, for both [38][PF6] and [39][PF6]. 
 
2.5.2 Infrared Spectroscopy 
Complexes [38][PF6] and [39][PF6] display a shift in the C=Nimine stretching vibration to 
lower wavenumbers, form 1635 cm
-1
 (in the ligand 37) to ~1619 cm
-1
 (Table 2.7), similarly 
observed with metallodendrimers [29][PF6]4 - [36][PF6]32. 
 
2.5.3 Elemental Analysis and Mass Spectrometry 
The elemental analysis results are consistent with the proposed structures of [38][PF6] and 
[39][PF6]. ESI mass spectrometry data depicted molecular ion peaks with a loss of the p-
cymene moiety and the loss of the PF6 counter-ion for complexes [38][PF6] and [39][PF6] 
respectively (Table 2.7). In addition to spectroscopic and analytical data, single crystal X-ray 
diffraction analysis of [38][PF6] and [39][PF6] confirm the bidentate coordination of the 
ligand to the ruthenium ion. 
 
2.5.4 X-ray Crystallography 
Single-crystal X-ray diffraction of [38][PF6] and [39][PF6] confirms the expected pseudo-
tetrahedral or “piano-stool” geometry around the Ru(II) ion, and the coordination of the 
salicylaldiminato ligand 37 in a bidentate-chelating mode through its phenolic oxygen and 
imine nitrogen (Figure 2.8). In both these mononuclear complexes, the metal centre is 
stereogenic, however [38][PF6] and [39][PF6] are obtained as racemic mixtures. 
Crystallographic details can be found in Chapter 6, summarized in Table 6.1. 
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Figure 2.8 ORTEP representations of mononuclear cations [38][PF6] (left) and [39][PF6] 
(right). Thermal ellipsoids are drawn at the 50 % probability level. The PF6
-
 counter-
ion and hydrogen atoms have been omitted for clarity. 
 
The geometrical parameters of [38][PF6] and [39][PF6] are comparable to those observed in 
other N,O-ruthenium-arene complexes,
30, 31
 and selected geometrical parameters are listed in 
Table 2.8. The Ru-P distances in [38][PF6] and [39][PF6] are comparable to those observed in 
analogous ruthenium-arene-PTA compounds.
23, 32
 In [38][PF6], the ruthenium ion is situated 
~1.728 Å from the centroid of the p-cymene ligand and in [39][PF6] the distance is ~1.732 Å 
from the centroid of the hexamethylbenzene ligand. 
 
Table 2.8 Selected average bond lengths and bond angles in [38][PF6] and [39][PF6]. 
 [38][PF6] [39][PF6] 
 interatomic distances (Å) 
Ru1-N1 2.080(7) 2.063(6) 
Ru1-O1 2.074(6) 2.058(5) 
Ru1-P1 2.320(2) 2.325(2) 
C4-C5 1.448(13) 1.421(10) 
C4-N1 1.280(11) 1.272(9) 
N1-C3 1.499(11) 1.479(9) 
Rucentroid ~1.728 ~1.732 
 [38][PF6] [39][PF6] 
 angles () 
N1-Ru1-O1 87.0(3) 87.7(2) 
N1-Ru1-P1 86.7(2) 86.7(2) 
O1-Ru1-P1 79.8(2) 79.7(2) 
C5-C4-N1 126.8(8) 127.6(7) 
C4-N1-C3 113.5(8) 117.1(7) 
O1 
O1 
N1 
N1 Ru 
Ru 
P1 
P1 
C4 
C4 
C3 
C3 
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2.6 Synthesis and Characterization of Neutral and Cationic Os(II)-Arene 
Complexes 
 
In order to investigate whether the type of metal has influence on the biological activity, new 
osmium analogs of the ruthenium complexes were prepared. In the synthesis of the neutral 
and cationic Os(II)-arene complexes, only the p-cymene analogs were synthesized.  
 
The methodology employed in the synthesis of the neutral N,O-osmium-arene 
metallodendrimers (40, 41) and cationic N,O-osmium-arene-PTA metallodendrimers 
([42][PF6]4, [43][PF6]8) were similar to the methods employed in the synthesis of their 
ruthenium analogs mentioned. The neutral metallodendrimers 40 and 41 were synthesized by 
reacting the dendritic scaffolds 21 (for 40) or 22 (for 41) with [Os(η6-p-PriC6H4Me)Cl2]2 in 
dichloromethane (Scheme 2.8), in the presence of triethylamine. The neutral 
metallodendrimers 40 and 41 were afforded as yellow solids, in moderate to high yields 
(Table 2.9) and soluble in most polar organic solvents. 
 
 
Scheme 2.8 Synthesis of osmium metallodendrimers 40 - [43][PF6]8, [46][PF6]4 and [47][PF6]8. 
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Table 2.9 Physical appearance, percentage yield and melting point for osmium complexes 40 - 
[43][PF6]8, [46][PF6]4, [47][PF6]8, 48, [49][PF6] and [51][PF6]. 
Compound Physical Appearance 
Yield  
[%] 
Melting Point 
[ºC] 
40 Mustard-yellow solid 88 
a
151 
41 Mustard-yellow solid 52 
a
165 
48 Orange-yellow solid 48 226-231 
[42][PF6]4 Yellow solid 95 185-188 
[43][PF6]8 Yellow solid 54 179-182 
[49][PF6] Orange-yellow solid 54 226-231 
[46][PF6]4 Dark orange solid 72 
a
194 
[47][PF6]8 Yellow-brown solid 76 
a
193 
[51][PF6] Red solid 62 
a
181 
a 
Decompose without melting 
 
The cationic N,O-osmium-arene-PTA metallodendrimers [42][PF6]4 and [43][PF6]8 were 
synthesized by a one-pot reaction of the dendritic ligand 21 (for [42][PF6]4) or 22 (for 
[43][PF6]8) with [Os(η
6
-p-Pr
i
C6H4Me)Cl2]2, followed by the addition of PTA, and stabilized 
as the hexafluorophosphate salt via a cation-exchange reaction (Scheme 2.8). Cationic 
metallodendrimers [42][PF6]4 and [43][PF6]8 were isolated as thermally stable yellow solids, 
in moderate to high yields (Table 2.9) and are soluble in acetone, acetonitrile and 
dimethylsulfoxide. 
 
The synthesis of the cationic N,N-osmium dendritic complexes [46][PF6]4 and [47][PF6]8 
involved a two-step synthesis. The first step in the synthesis was the preparation of the first- 
and second-generation iminopyridyl dendritic ligands 44 and 45 via Schiff base condensation 
reaction described by Smith et al.
33, 34
 The second step in the synthesis afforded [46][PF6]4 
and [47][PF6]8 as hexafluorophosphate salts, by reacting the dendritic ligands 44 (for 
[46][PF6]4) or 45 (for [47][PF6]8) and [Os(η
6
-p-Pr
i
C6H4Me)Cl2]2, and followed by a 
metathesis reaction with NaPF6 (Scheme 2.8). The cationic metallodendrimers [46][PF6]4 and 
[47][PF6]8 were isolated as thermally stable orange-red solids, in moderate yields (Table 2.9) 
and are soluble in acetone, acetonitrile and dimethylsulfoxide. Attempts to synthesize the 
cationic N,N-osmium-p-cymene-PTA metallodendrimers proved futile, as abstraction of the 
chlorido ligand was difficult. 
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In order to compare size dependency on the biological activity (discussed in Chapter 4), 
mononuclear derivatives 48, [49][PF6] and [51][PF6] of the osmium metallodendrimers were 
synthesized. These were prepared in a similar manner to the mononuclear ruthenium analogs 
mentioned. The neutral and cationic mononuclear complexes 48, [49][PF6] and [51][PF6] 
were prepared from the known salicylaldiminato and iminopyridyl monomeric ligands 37 and 
50.
18, 35
 Cleavage of [Os(η6-p-PriC6H4Me)Cl2]2 dimer with the monomeric ligands 37 or 50 
afforded the neutral osmium complex 48 as a yellow solid, whilst the cationic complexes 
[49][PF6] and [51][PF6] were isolated as yellow and red hexafluorophosphate salts 
respectively (Scheme 2.9, Table 2.9). 
 
 
Scheme 2.9 Synthesis of mononuclear neutral and cationic osmium complexes 48, [49][PF6] and 
[51][PF6]. 
 
The neutral and cationic osmium complexes were characterized with a series of spectroscopic 
and analytical techniques. 
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2.6.1 
1
H, 
31
P{
1
H} and 
13
C{
1
H} NMR Spectroscopy 
1
H and 
13
C{
1
H} NMR spectra of N,O-Os(II)-arene complexes (40, 41, 48) 
The 
1
H NMR spectra of the neutral complexes 40, 41 and 48 confirm coordination of the N,O-
ligand to the osmium ion. Notable features include the disappearance of the broad singlet 
(~13.5 ppm) assigned to the hydroxyl proton of the N,O-ligand and an upfield shift in the 
imine signal from ~8.3 ppm (in the N,O-ligand) to ~7.8 ppm for complexes 40, 41 and 48. 
The aliphatic protons at the dendritic core and on the dendritic branches, for 40 and 41, 
display broadened resonance signals, with some of the signals coalescing. This was attributed 
to the high nuclearity of the dendritic complex and fluxionality of the dendritic arms. Peak 
broadening was also observed in the analogous ruthenium-p-cymene metallodendrimers 9 - 
12 (Figure 2.1).
15
 Signals observed in the 
1
H NMR spectrum of the mononuclear complex 48 
are more discernable and well-resolved. Similarly observed with the ruthenium-arene 
complexes described above, there is a loss of two-fold symmetry about the p-cymene moiety 
upon coordination of the bidentate N,O-salicylaldiminato ligand, and as a result, the methyl 
protons of the isopropyl group appear as two broad doublets (1.0 - 1.2 ppm). Hence, the 
diastereotopic protons on the aliphatic carbon (adjacent to the imine nitrogen) are assigned to 
two broad multiplets in the range of 4.0 - 4.4 ppm for metallodendrimers 40 and 41, with a 
similar resonance observed for the mononuclear derivative 48. 
13
C{
1
H} NMR spectral data 
display the expected number of signals for the proposed structure of neutral complexes 40, 41 
and 48. 
 
1
H, 
31
P{
1
H} and 
13
C{
1
H} NMR spectra of N,O-Os(II)-arene-PTA complexes ([42][PF6]4, 
[43][PF6]8, [49][PF6]) 
In comparison to the mentioned neutral complexes 40, 41 and 48, introduction of the PTA 
ligand to the osmium ion generates a positively charged species, which in turn results in an 
overall downfield shift in signals observed in the 
1
H NMR spectra of the cationic derivatives 
[42][PF6]4, [43][PF6]8 and [49][PF6]. Replacement of the chlorido ligand with the PTA ligand 
retains chirality at the osmium centre. Hence, the methyl protons of the p-cymene moiety 
appears as two distinct doublets (~1.1 ppm & ~1.3 ppm), and the diastereotopic protons on 
the aliphatic carbon (adjacent to the imine nitrogen) are observed as two multiplets (3.9 - 4.2 
ppm). The aromatic protons on the p-cymene moiety, of the neutral metallodendrimers 40 and 
41, are assigned to two broad multiplets (5.6 - 5.7 ppm) in the 
1
H NMR spectrum. However, 
this pattern was not observed with the cationic metallodendrimers [42][PF6]4 and [43][PF6]8, 
these protons on the p-cymene ring were assigned to four broad multiplets in the range 5.5 - 
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6.3 ppm, with signals for the mononuclear complex [49][PF6] appearing slightly more 
downfield. 
31
P{
1
H} NMR spectroscopy was used to further confirm purity of [42][PF6]4, 
[43][PF6]8 and [49][PF6], as only a singlet was observed at -71 ppm, with similar values 
reported for structurally related complexes.
36, 37
 The expected number of signals were 
observed in the 
13
C{
1
H} NMR spectra for the proposed structures of [42][PF6]4, [43][PF6]8 
and [49][PF6]. 
 
1
H and 
13
C{
1
H} NMR spectra of N,N-Os(II)-arene complexes ([46][PF6]4, [47][PF6]8, 
[51][PF6]) 
As expected, signals in the 
1
H NMR spectra for the cationic N,N-complexes [46][PF6]4, 
[47][PF6]8 and [51][PF6] are comparable to previously reported isostructural ruthenium 
analogs 5 - 8 (Figure 2.1), with some of the chemical shifts almost identical.
15
 The 
1
H NMR 
spectra of [46][PF6]4, [47][PF6]8 and [51][PF6] depict a loss of a 2-fold symmetry at the 
osmium ion, similarly observed with the above mentioned neutral (25 - 28) and cationic 
([29][PF6]4 - [36][PF6]32) ruthenium complexes, and hence a similar splitting pattern is 
observed. The 
13
C{
1
H} NMR spectra of [46][PF6]4, [47][PF6]8 and [41][PF6] display the 
expected number of signals. 
 
2.6.2 Infrared Spectroscopy 
The infrared spectra of neutral complexes 40, 41 and 48 depict a shift in the C=Nimine 
stretching vibration from ~1635 cm
-1
 (for the N,O-ligand) to lower wavenumbers at ~1618 
cm
-1
, further suggesting coordination of the imine nitrogen. Furthermore, a stretching 
vibration in the infrared spectra was observed at the same frequency (~1618 cm
-1
) for the 
N,N-osmium complexes [46][PF6]4, [47][PF6]8 and [51][PF6] and was also ascribed to the 
C=Nimine bond (Figure 2.9). Whilst the infrared spectra of the cationic N,O-osmium-PTA 
complexes [42][PF6]4, [43][PF6]8 and [49][PF6] depicted a stretching vibration at ~1613 cm
-1
 
and was assigned to the C=Nimine bond.  
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Figure 2.9 Infrared spectrum of cationic metallodendrimer [46][PF6]4 recorded as a KBr pellet. 
 
2.6.3 Elemental Analysis and Mass Spectrometry 
Similarly observed with the ruthenium metallodendrimers mentioned above, elemental 
analysis data for the osmium metallodendrimers were initially outside acceptable limits. 
Recalculation of the percentages with the inclusion of salts and/or solvent molecules gave 
percentages of the osmium metallodendrimers 40 - [43][PF6]8, [46][PF6]4 and [47][PF6]8 
within acceptable limits. HR-ESI-TOF mass spectrometry data confirmed the proposed 
structures of metallodendrimers 40 - [43][PF6]8, [46][PF6]4 and [47][PF6]8. Positive-ion mass 
(ESI-MS) spectral data was consistent with the proposed structures of the mononuclear 
complexes 48, [49][PF6] and [51][PF6].  
 
2.6.4 X-ray Crystallography 
The proposed structures of the mononuclear complexes 48, [49][PF6] and [51][PF6] were 
further confirmed by single-crystal X-ray diffraction on crystals grown by slow evaporation 
of a concentrated solution of 48 in dichloromethane, or from either slow diffusion of hexane 
into a dichloromethane solution of [49][PF6], or slow diffusion of diethyl ether into an 
acetone solution of [51][PF6]. Mononuclear complex 48 crystallized in the orthorhombic 
C=Nimine  
(complex) 
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space group Pbca as two independent structures (48A and 48B) in the asymmetric unit, and 
[49][PF6] and [51][PF6] crystallized in the triclinic space group P -1. ORTEP drawings of the 
molecular structures of 48, [49][PF6] and [51][PF6] are illustrated in Figures 2.10 and 2.11. 
The molecular structures of 48A, 48B, [49][PF6] and [51][PF6] display the characteristic 
‘piano-stool’ geometry and further confirms coordination of the bidentate-chelating 
salicylaldiminato (37) or iminopyridyl (50) ligands, through the imine nitrogen and phenolic 
oxygen or pyridyl nitrogen respectively. Crystallographic details can be found in the 
experimental Chapter 6, summarized in Table 6.2. 
 
Figure 2.10 ORTEP representations of mononuclear complexes 48 (two independent complexes 
48A (left) and 48B (right)). Thermal ellipsoids are drawn at the 50 % probability 
level. Hydrogen atoms have been omitted for clarity. 
 
Figure 2.11 ORTEP representations of mononuclear complexes [49][PF6] (left) and [51][PF6] 
(right). Thermal ellipsoids are drawn at the 50 % probability level. The PF6
-
 counter-
ion and hydrogen atoms have been omitted for clarity. 
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Selected geometrical parameters of complexes 48A, 48B and [51][PF6] are listed in Table 
2.10 and are comparable to those observed in other N,O- or N,N-osmium-arene complexes.
38-
40
 The Os-P bond distance in [49][PF6] is comparable to other structurally similar osmium-
arene-PTA complexes.
37
 Expected structural similarities between these Os-complexes and 
previously reported ruthenium analogs are observed, such that the Os-Cl bond distance of 
[51][PF6] (2.390 Å) is identical to the Ru-Cl bond distance (2.391 Å).
15
 This feature is seen 
with the Os-P bond distance of [49][PF6] and the Ru-P bond distance of the ruthenium-arene-
PTA complex [48][PF6] mentioned.  
 
Table 2.10 Selected average bond lengths and bond angles in 48A, 48B, [49][PF6] and 
[51][PF6]. 
 48A 48B [49][PF6] [51][PF6] 
 interatomic distances (Å) 
Os1-N1imine 2.097(4) 2.092(4) 2.104(4) 2.089(7) 
Os1-N2pyr - - - 2.075(8) 
Os1-O1 2.069(3) 2.063(3) 2.084(3) - 
Os1-P1 - - 2.326(1) - 
Os1-Cl1 2.428(1) 2.435(1) - 2.390(2) 
C7-N1imine 1.291(6) 1.286(6) 1.292(6) 1.319(12) 
C8-N1imine 1.430(7) 1.428(7) 1.490(6) 1.451(12) 
Oscentroid ~1.650 ~1.654 ~1.720 ~1.691 
 48A 48B [49][PF6] [51][PF6] 
 angles () 
N1imine-Os1-O1 88.3(1) 87.9(1) 86.4(1) - 
N1imine-Os1-P1 - - 86.8(1) - 
O1-Os1-P1 - - 79.6(1) - 
O1-Os1-Cl1 83.0(1) 83.9(1) - - 
N1imine-Os1-N2pyr - - - 76.9(3) 
N1imine-Os1-Cl1 85.2(1) 84.2(1) - 85.8(2) 
N2pyr-Os1-Cl1 - - - 84.7(2) 
C6-C7-N1imine 129.6(5) 129.1(5) 127.6(5) 118.3(8) 
C7-N1imine-C8 115.8(4) 115.2(4) 114.4(4) 123.9(8) 
 
A study of their in vitro antitumor activity has been undertaken and the results are discussed 
in Chapter 4. 
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2.7 Overall Summary 
A series of new neutral and cationic N,O-ruthenium-arene metallodendrimers have been 
successfully synthesized and characterized using a series a spectroscopic and analytical 
techniques, namely 
1
H, 
13
C{
1
H} NMR, infrared, mass spectrometry and elemental analysis. 
Their mononuclear analogs were prepared and characterized. Single crystal X-ray diffraction 
was utilized to further confirm the proposed structures and illustrate the mode of coordination 
is in-fact through the imine nitrogen and phenolic oxygen. 
 
A second series of new neutral and cationic N,N- and N,O-osmium-arene metallodendrimers 
have successfully been prepared, with spectroscopic and analytical methods used to 
corroborate proposed structures. Once again, mononuclear derivatives of the osmium-arene 
analogs were prepared and characterized, with single crystal X-ray diffraction on these 
complexes further confirming the proposed molecular structure. 
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Chapter 3 
Synthesis and Characterization of Heterometallic  
Ferrocenyl-Containing Ruthenium(II)-Arene Complexes  
Based on Poly(propyleneimine) Dendritic Scaffolds 
 
3.1 Introduction 
 
Apart from ruthenium-based anticancer agents, the introduction of a second metal in the 
preparation of heterometallic complexes as potential anticancer agents has flourished.
1-5
 One 
such metal is iron or more specifically the iron-based organometallic complex, ferrocene.
6
 
Ferrocene-based molecules have become very attractive in the field of medicinal chemistry 
and more specifically as promising anticancer agents,
7-9
 with the activity of these complexes 
attributed to their favorable electronic properties and ease of functionalization.
10, 11
 
Furthermore, simple derivatives of ferrocene display good activity in vitro, with inhibition of 
tumors observed in vivo.
12, 13
 In the pursuit for new tamoxifen-like drugs, Jaouen and co-
workers synthesized ferrocifens or 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenylbut-
1-ene) (Figure 3.1), which are highly active ferrocenyl-derivatives of the purely organic breast 
cancer drug tamoxifen.
14, 15
 The increase in activity is attributed to the dual action of the 
organic drug and the Fenton chemistry (i.e. formation of singlet oxygen) of the Fe centre.
16, 17
  
 
This effect is observed with a number of biologically active molecules.
18
 Such an example is 
ferroquine (Figure 3.1), the ferrocenyl-based derivative of chloroquine, which displays an 
increased efficacy towards chloroquine-resistant malaria strains.
19-22
 Furthermore, Edwards et 
al. reported the coupling of ferrocene to penicillin and cephalosporin which improved the 
antibacterial activity (Figure 3.1).
23-25
 
 
In an effort to develop cytotoxic anticancer agents, ferrocene derivatives have been coupled 
with gold,
26
 silver,
27
 palladium,
1
 rhodium
28
 and iridium
28
 in order to achieve a synergistic 
effect between the two active metals. The coupling of the two metals displayed cytotoxicities 
(in various cancer cell lines) comparable to the benchmark drug cisplatin. Bimetallic 
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ferrocenyl-derived gold(I)-phosphine complexes display activity against human ovarian 
cancer cells (A2780). The most potent ferrocenyl-derived gold complex (Figure 3.1) in the 
series displays better activity than cisplatin, with cytotoxicities in the nanomolar range.
26
  
 
 
Figure 3.1 Various ferrocenyl-derived anticancer compounds. 
 
As mentioned, ruthenium compounds are tolerated well in vivo and exhibit lower toxicity than 
their platinum counterparts.
29
 It is proposed that the activity of Ru(III) complexes is brought 
about by reduction of the complex to the more active Ru(II) species in vivo.
30
 This has, in 
part, triggered the development of half-sandwich organometallic ruthenium(II)-arene 
complexes as anticancer agents.
31-33
 However, there are only a handful of reports where 
ruthenium and iron are coupled within the same molecule and investigated for anticancer 
activity.
34-36
 The majority of ferrocenyl-derived ruthenium-arene derivatives display moderate 
activity compared to cisplatin. However, a heterobimetallic ruthenium-hexamethylbenzene 
phosphinoferrocene amino conjugate (Figure 3.1) displays activity in the low micromolar 
range (~4 μM in A2780),34 further providing motivation for this study.  
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The coupling of the ferrocene to biologically active molecules or the preparation of new 
ferrocenyl-based anticancer agents is clearly an attractive field. Furthermore, the stability of 
ferrocene in aqueous and aerobic media, the ability to prepare a large variety of derivatives, 
and its favorable electrochemical properties has become a promising molecule for biological 
applications.
37
  
 
In light of these findings, this chapter describes the synthesis and characterization of novel 
cationic ferrocenyl-derived ruthenium-arene metallodendrimers. The rationale for the 
synthesis of this class of compounds is to attempt to increase the lipophilic nature of these 
molecules, by coupling the ferrocenyl moiety to the ruthenium-arene metallodendrimers 
described in Chapter 2, in an effort to improve the antitumor activity of these complexes. 
Furthermore, Chapter 4 discusses the antitumor activity of the ruthenium-arene 
metallodendrimers reported in Chapter 2, with the cationic derivatives displaying the best 
activity in the series. Hence, only cationic ferrocenyl-derived ruthenium-arene 
metallodendrimers were prepared. Several spectroscopic and analytical techniques were 
employed to confirm and elucidate the proposed structure of the metallodendrimers and 
mononuclear analogs, and are described. The biological activity of these metallodendrimers 
and their mononuclear analogs is discussed in Chapter 4. 
 
3.2 Synthesis and Characterization of N,O- and N,N- Ferrocenyl-Derived 
Conjugates  
 
Synthesis of the ferrocenyl-derived conjugates required the preparation of vinyl ferrocene 53. 
Two efficient routes are known in the preparation of 53. The first route involves dehydration 
of 1-ferrocenylethanol using aluminium oxide,
38
 whilst the second route proceeds via a Wittig 
reaction from ferrocene carboxaldehyde 52 in tetrahydrofuran (Scheme 3.1).
39
 The second 
route, via a Wittig reaction, was chosen as this reported higher yields.
39, 40
 The phosphonium 
ylide was formed by treating methyltriphenylphosphonium iodide with n-BuLi, and treated 
with 52 to form vinyl ferrocene 53 in a yield of 86 % (Scheme 3.1). The 
1
H NMR spectrum of 
53, shows an absence in the singlet at ~10 ppm, usually assigned to the proton on aldehyde 
moiety of 52, and the appearance of three doublet-of-doublets (5.02, 5.33 & 6.45 ppm) which 
are assigned to the three protons on the alkene moiety of 53. Further confirmation for the 
presence of the alkene in 53 can be observed in the infrared spectrum with the appearance of 
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the stretching vibration at 1627 cm
-1
 (C=Calkene bond). The melting point of 53 (Mp: 48 - 49 
º
C) was obtained and attests to the purity of the compound as-well-as corresponds well with 
literature reports (Lit. Mp: 49 - 50 
º
C).
41
 
 
Scheme 3.1 Synthesis of N,O- and N,N-ferrocenyl-derived conjugates 53 - 55. 
 
The new ferrocenyl-derived conjugates (4E)-(4-ferrocenyl-vinyl)-2-hydroxy-benzaldehyde 54 
and (5E)-(5-ferrocenyl-vinyl)-2-pyridinecarboxaldehyde 55 were prepared via a Heck 
coupling reaction of 53 and the appropriate aryl-bromide (Scheme 3.1).  
 
The method followed was described by Reyes et al.,
42
 whereby 53 was coupled with 4-
bromobenzaldehyde 56 in dimethylformamide and triethylamine, with tri-o-tolylphosphine 
(POT) and palladium acetate as a catalyst, to afford (E)-(4-ferrocenyl-vinyl)benzaldehyde 57 
(Scheme 3.2).  
 
Scheme 3.2 Synthesis of (E)-(4-ferrocenyl-vinyl)benzaldehyde 57 reported by Reyes et al.
42
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However, to mimic the structure of previously synthesized metallodendrimers described in 
Chapter 2, a site for chelation of the ruthenium centre is required. Hence, coupling of 53 with 
4-bromo-2-hydroxybenzaldehyde or 5-bromo-2-pyridinecarboxaldehyde afforded 54 and 55 
respectively (Scheme 3.1). In the synthesis of 54 and 55, the method described by Reyes et al. 
was modified slightly, with 1,4-dioxane as the solvent, triphenylphosphine instead of POT, 
palladium acetate as the catalyst and a stoichiometric amount of triethylamine as the base 
 
The Heck reaction is an important reaction in both scientific (preparation of olefins, dienes 
and other unsaturated compounds)
43-47
 and industrial (preparation of dyes, UV screens and 
pharmaceuticals)
48, 49
 chemistry, as it is one of the key reactions used in C-C bond formation. 
Hence, it is also important to understand how these catalytic reactions take place. The Heck 
reaction (also known as the Mizoroki-Heck reaction) is typically carried out with a palladium 
catalyst, a catalytic amount of the tertiary phosphine and a stoichiometric amount of a weak 
base (Scheme 3.3).
50-54
 The Pd-catalyzed reaction is typically used to couple aryl- or vinyl-
halides and activated alkenes. 
 
Scheme 3.3 Catalytic cycle describing the interconversion of the oxidation sates during the course 
of the palladium catalyzed Heck C-C coupling reaction. 
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The first step in the Heck reaction (also known as the pre-activation step, Scheme 3.3), 
involves reduction of the Pd(II) catalyst into the Pd(0) active species I, via a multiple ligand 
exchange with the phosphine ligand. The second step, involves an oxidative addition reaction 
of the aryl-halide to the coordinatively unsaturated complex I, generating a σ-alkenyl- or σ-
aryl- palladium(II) complex II. The next step involves formation of the π-complex III, by 
rapid coordination of the alkene to the electrophilic Pd-coordination sphere. Alkene insertion 
or syn addition follows, whereby a new C-C bond is formed generating complex IV. β-
Hydride elimination is next and generates a new π-complex V. The final step (drawn as two 
steps), is a reductive elimination step, whereby the π-complex V liberates the desired alkene 
and a hydridopalladium halide complex VI, which, with the aid of a base, regenerates the 
Pd(0) active species I.
55
 
 
The Pd-catalyst, triphenylphosphine, triethylamine, 53 and the appropriate aldehyde were 
heated under reflux for 3 days, to afford 54 or 55 as purple solids in low yields (10 - 25 %). 
54 and 55 are soluble in most organic solvents such as dichloromethane, methanol, toluene, 
diethyl ether and dimethylsulfoxide. Spectroscopic (
1
H NMR, 
13
C{
1
H} NMR and IR 
spectroscopy) and analytical data (HPLC and mass spectrometry) confirmed the integrity of 
the new ferrocenyl-derived conjugates. 
 
3.2.1 
1
H and 
13
C{
1
H} NMR Spectroscopy  
The 
1
H and 
13
C{
1
H} NMR spectra of the new ferrocenyl-derived conjugates 54 and 55 were 
recorded in deuterated chloroform, and affirms the coupling of the two starting materials. The 
characteristic singlet for the presence of a highly deshielded proton on an aldehyde 
functionality is observed for both 54 (Figure 3.2) and 55 (Figure 3.3) at ~10 ppm. In the 
1
H 
NMR spectrum of 54, a singlet is observed at ~11.1 ppm and is assigned to the phenolic 
proton. The characteristic AA’BB’-type spin system for monosubstituted ferrocenyl-derived 
derivatives, which is a singlet (~4.2 ppm) integrating for five protons and two triplets (~4.4 
ppm & ~4.5 ppm) integrating for two protons each, is observed in the 
1
H NMR spectrum for 
both 54 and 55. Similar chemical shifts and coupling constants are consistent for structurally 
similar monosubstituted ferrocenyl-derived complexes.
56, 57
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Figure 3.2 
1
H NMR spectrum of (4E)-(4-ferrocenyl-vinyl)-2-hydroxy-benzaldehyde 54 in CDCl3. 
 
 
Figure 3.3 
1
H NMR spectrum of (5E)-(5-ferrocenyl-vinyl)-2-pyridinecarboxaldehyde 55 in 
CDCl3. 
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The disappearance of the three doublet-of-doublets (observed in the 
1
H NMR spectrum of 53) 
and the appearance of the two doublets (~6.7 ppm and ~7.1 ppm), are assigned to the two 
protons on the alkene moiety for both 54 and 55 and suggest C-C bond formation. The two 
doublets have a coupling constant of 
3
JHH = ~16 Hz each, suggesting that the alkene moieties 
of 54 and 55 adopt a trans confirmation rather than a cis confirmation, as typical coupling 
constants for a cis confirmation would be much lower (
3
JHH = ~9 Hz) (Figure 3.4).
58
 Hence, 
the E-isomer formed exclusively, as signals for the Z-isomer was not observed in the 
1
H NMR 
spectrum of 54 and 55. A similar coupling constant (i.e. 
3
JHH = 16 Hz) was reported by Yang 
et al., for the structurally similar compound (4E)-(4-ferrocenyl-vinyl)-pyridne.
56
  
 
 
Figure 3.4 E and Z forms of ferrocenyl-derived conjugates 54 and 55, with the cis isomer (right) 
not observed. 
 
The 
13
C{
1
H} NMR spectrum of the ferrocenyl-derived conjugates 54 and 55 are similar, with 
some of the signals displaying identical chemical shifts. The 2D-HSQC NMR spectrum of 54 
and 55 was utilized in the assignment of the signals in 
13
C{
1
H} spectrum. Three signals in the 
range of 65 - 70 ppm are observed for 54 and 55 and assigned to the carbons on both the 
substituted and unsubstituted Cp rings. 
 
3.2.2 Infrared Spectroscopy 
The infrared spectrum of 54 and 55 were recorded as pure solids using the ATR technique. A 
strong sharp stretching vibration is observed at 1614 cm
-1
 and 1575 cm
-1
 for 54 and 55 
respectively, and is assigned to the C=C bond of the alkene moiety. This observation confirms 
successful C-C bond formation via the Heck reaction. The stretching vibrations observed at 
1652 cm
-1
 and 1703 cm
-1
 are assigned to the C=O bond of 54 and 55 respectively. 
Furthermore, an extra stretching vibration is observed in the IR spectrum of 55, at 1629 cm
-1
, 
and is assigned to the C=N bond of the pyridyl ring. 
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3.2.3 Mass Spectrometry and HPLC 
HR-ESI mass spectrometry was also used to characterize 54 and 55 in the positive-ion mode. 
The mass spectrum of 54 and 55 gave a base peak for [M+H]
+
 ions at m/z = 333.0562 and m/z 
= 318.0580 respectively and are consistent with the proposed structures. 
 
Analytical-HPLC traces were obtained for 54 and 55, with single peaks observed at tR = 17 
min and tR = 16 min respectively and attests the purity of these compounds. 
 
3.3 Synthesis and Characterization of Ferrocenyl-Derived N,O-Salicylaldiminato 
and N,N-Pyridylimine Dendritic Ligands 
 
The third step in the synthesis involved preparation of two new ferrocenyl-derived N,O-
salicylaldiminato dendritic ligands 56 and 57 and two new ferrocenyl-derived N,N-
pyridylimine dendritic ligands 58 and 59. The dendritic ligands 56 - 59 were prepared via a 
Schiff base condensation of 54 (for 56 & 57) or 55 (for 58 & 59) with the amino groups of 
DAB-G1-(NH2)4 (for 56 & 58) or of DAB-G2-(NH2)8 (for 57 & 59) in dichloromethane 
overnight (Scheme 3.4), with purification involving precipitation from petroleum ether (40 - 
60 
º
C). The dendritic ligands 56 - 59, were isolated as orange solids in moderate yields (50 - 
65 %). 
 
 
Scheme 3.4 Synthesis of ferrocenyl-derived N,O-salicylaldiminato and N,N-pyridylimine dendritic 
ligands 56 - 59. 
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The ligands 56 - 59 are air- and moisture-stable, are soluble in a handful of solvents, such as 
dichloromethane, chloroform, acetonitrile and dimethylsulfoxide, and not soluble in protic 
and non-polar solvents. These compounds were characterized using 
1
H and 
13
C{
1
H} NMR 
spectroscopy, infrared spectroscopy, elemental analysis and mass spectrometry.  
 
3.3.1 
1
H and 
13
C{
1
H} NMR Spectroscopy  
The 
1
H and 
13
C{
1
H} NMR data of 56 - 59 were recorded in deuterated chloroform and display 
overlapping and broadening of signals, similarly observed with the dendritic ligands 
previously mentioned in Chapter 2. The 
1
H NMR spectrum of 56 - 59 (Figures 3.5 and 3.6) 
shows an absence of the singlet at ~10 ppm (CHO proton of 54 & 55) with an appearance of a 
broad singlet at ~8.2 ppm (for 56 & 57) and ~8.4 ppm (for 58 & 59), which is assigned to the 
proton on the newly formed imine bond. Typically, the signals for the aliphatic protons on the 
dendritic core and dendritic arms appear in the region between 1.4 - 3.7 ppm for 56 - 59. The 
two doublets at ~6.7 ppm and ~7.0 ppm, with coupling constants of 
3
JHH = ~16 Hz, are 
assigned to the protons on the alkene moiety of 56 - 59.  
 
 
Figure 3.5 
1
H NMR spectrum of first-generation ferrocenyl-derived N,O-salicylaldiminato 
dendritic ligand 56 in CDCl3. 
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Broad signals are observed in the region of 6.9 - 7.1 ppm (for 56 & 57) and 7.8 - 8.6 ppm (for 
58 & 59), and are assigned to the aromatic and pyridyl protons respectively. Unlike the N,O-
salicylaldiminato dendritic ligands 21 - 24 mentioned in Chapter 2, the 
1
H NMR spectrum of 
56 and 57 did not display a broad singlet (typically ~13.5 ppm), which is usually assigned to 
the phenolic proton. This was attributed to possible solvent exchanges, though usually 
expected in deuterated dimethylsulfoxide and deuterated acetone, and not in deuterated 
chloroform. 
 
The 
13
C{
1
H} spectrum for 56 - 59 display the expected number of signals in both the aromatic 
and aliphatic region. The singlet observed in the 
13
C{
1
H} spectrum for the ferrocenyl-derived 
conjugates 54 and 55, at ~195 ppm and ~193 ppm respectively (assigned to the carbonyl 
carbon) was not observed in the spectrum of 56 - 59. This observation confirms formation of 
the imine bond, as a singlet at ~164 ppm (for 56 & 57) and at ~162 ppm (for 58 & 59) is 
observed in the 
13
C{
1
H} NMR spectrum, and is assigned to the carbon atom of the imine 
bond. 
 
 
Figure 3.6 
1
H NMR spectrum of first-generation ferrocenyl-derived N,N-pyridylimine dendritic 
ligand 58 in CDCl3. 
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3.3.2 Infrared Spectroscopy 
The infrared spectra of 56 - 59 was recorded as pure solids using the ATR technique, with the 
results further confirming the formation of the imine bond. The infrared spectrum of dendritic 
ligands 56 and 55 display a strong broad stretching vibration at ~1610 cm
-1
 and is assigned to 
both the C=N and C=C bonds of the imine and alkene moieties respectively. However, 
dendritic ligands 58 and 59 display two bands of medium intensity, at ~1580 cm
-1
 and ~1640 
cm
-1
, and are assigned to the alkene and imine bonds respectively. Furthermore, 58 and 59 
display an extra stretching vibration at 1628 cm
-1
, and is assigned to the C=N bond of the 
pyridyl ring. 
 
3.3.3 Elemental Analysis and Mass Spectrometry 
Following extensive drying of 56 - 59, satisfactory elemental diffraction was not obtained, as 
percentages obtained were outside acceptable limits and is ascribed to possible solvent 
inclusions. The inclusion of small molecules has been observed with purely organic 
dendrimers, as the free rotation of the dendritic arms allows for folding onto one another in 
turn trapping small molecules.
59
 Recalculation of the C, H and N percentages obtained for 56 
- 59 with the inclusion of dichloromethane (reaction solvent, observed in the 
1
H NMR 
spectrum, ~ 5 mols of dichloromethane) gave percentages within acceptable limits. 
 
HR-ESI mass spectrometry was used to confirm the proposed structures of 56 - 59, and the 
molecular ion peaks are listed in (Table 3.1). All complexes exhibited a base peak 
corresponding to a charged complex, with both 56 and 58 displaying a triply charged complex 
[M+3H]
3+
 at m/z = 525.1727 and at m/z = 500.0750 respectively. 
 
Table 3.1 Mass spectral data for ferrocenyl-derived dendritic ligands 56 - 59. 
Compound 
MS  
(fragment, assignment) 
[m/z]
a
 
56 525.1727 [M+3H]
3+
 
57 822.8010 [M+4H]
4+
 
58 500.0750 [M+3H]
3+
 
59 633.1572 [M+5H]
5+
 
 a 
HR-ESI-TOF-MS 
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3.4 Synthesis and Characterization of Ferrocenyl-Derived N,O-Salicylaldiminato 
and N,N-Pyridylimine Monomeric Ligands 
 
The monomeric ligands 60 and 61 were synthesized in a similar manner to their dendritic 
derivatives 56 - 59, by reacting n-propylamine with 54 and 55 (Scheme 3.5), via a Schiff base 
condensation reaction. Following purification over a small pad of silica (2 cm in height), the 
new monomeric ligands 60 and 61 were isolated as orange-red solids in 56 % and 71 % yield 
respectively. 
 
 
Scheme 3.5 Synthesis of monomeric ligands (5E, 2E)-(5-ferrocenyl-vinyl)-2-
((propylimino)methyl)phenol 60 and (5E, 2E)-N-((5-ferrocenyl-vinyl-pyridin-2-
yl)methylene)propan-1-amine 61. 
 
3.4.1 
1
H and 
13
C{
1
H} NMR Spectroscopy  
The Schiff base reaction used in the synthesis of monomeric ligands 60 and 61 was confirmed 
by 
1
H and 
13
C{
1
H} NMR spectroscopy, recorded in deuterated chloroform. The 
1
H NMR 
spectrum of 60 (Figure 3.7) and 61 (Figure 3.8) exhibit a signal integrating for one proton, at 
8.3 ppm, and are assigned to the imine proton. The singlet (at 4.1 ppm) and the two doublets 
(at 4.3 ppm & 4.5 ppm), integrating for five and two protons (for each doublet) respectively, 
and are assigned to the protons on the ferrocenyl functionality for both 60 and 61. Signals for 
the aliphatic protons are observed at 1.0 ppm (triplet), 1.7 ppm (multiplet) and 3.6 ppm 
(multiplet). The signals for the aromatic protons (for 60) and pyridyl protons (for 61) are 
observed in the range of 6.9 - 7.2 ppm and 7.7 - 8.6 ppm respectively. Similarly observed for 
the dendritic ligands 56 and 55, no broad signal for the hydroxyl proton was observed for 60.  
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Figure 3.7 
1
H NMR spectrum of monomeric ligand (5E, 2E)-(5-ferrocenyl-vinyl)- 
2-((propylimino)methyl)phenol 60 in CDCl3. 
 
 
Figure 3.8 
1
H NMR spectrum of monomeric ligand (5E, 2E)-N-((5-ferrocenyl-vinyl-pyridin- 
2-yl)methylene)propan-1-amine 61 in CDCl3. 
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All the relevant signals for the carbon atoms are observed in the 
13
C{
1
H} NMR spectrum of 
60 and 61. In particular, signals for the imine carbon (~160 ppm) and two alkene carbons 
(~123 ppm & ~125 ppm) were observed. 
 
3.4.2 Infrared Spectroscopy 
Monomeric ligand 60 displays a broad stretching vibration at 1607 cm
-1
 and is assigned to the 
alkene and imine bonds. Whilst 61 displayed three stretching vibrations at 1579 cm
-1
, 1630 
cm
-1
 and 1643 cm
-1
, and are assigned to the alkene, pyridyl and imine bonds respectively. 
 
3.4.3 Mass Spectrometry and HPLC 
HR-ESI mass spectral data for 60 and 61 displays a base peak for a charged complex [M+H]
+ 
at m/z = 374.1206 and at m/z = 359.1208 respectively. This data further confirms the proposed 
structures of 60 and 61. 
 
In addition, the purity of the monomeric ligands 60 and 61 was determined using high 
performance liquid chromatography (HPLC), with single peaks observed at tR = ~18 min. 
 
3.5 Synthesis and Characterization of Cationic Ferrocenyl-Derived N,O-Ru(II)-
Arene-PTA and N,N-Ru(II)-Arene Metallodendrimers 
 
A similar approach, used in the synthesis of non-ferrocenyl-based metallodendrimers 
prepared in Chapter 2, was followed in the preparation of metallodendrimers [62][PF6]4 - 
[65][PF6]8. The appropriate dendritic ligand was initially reacted with [Ru(η
6
-p-
Pr
i
C6H4Me)Cl2]2 in ethanol at room temperature. However, this method proved to be 
unsuccessful for the synthesis of [62][PF6]4 - [65][PF6]8, most likely due to the poor solubility 
of the dendritic ligands 56 - 59 in ethanol.  
 
The metallodendrimers [62][PF6]4 - [65][PF6]8 were therefore synthesized by reacting the 
appropriate first- or second-generation dendritic ligand (56 - 59) with the ruthenium precursor 
[Ru(η6-p-PriC6H4Me)Cl2]2 in an ethanol:dichloromethane (50:50 % v/v) mixture at room 
temperature (Scheme 3.6).  
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Scheme 3.6 Synthesis of cationic ferrocenyl-derived N,O-Ru(II)-Arene-PTA and N,N-Ru(II)-Arene 
metallodendrimers [62][PF6]4 - [65][PF6]8. 
 
For the N,O-salicylaldiminato dendritic ligands 56 and 57, triethylamine was added to remove 
the phenolic proton, which was followed by complexation with [Ru(η6-p-PriC6H4Me)Cl2]2 in a 
one-pot in situ reaction. The water-soluble PTA ligand was added to displace the chlorido 
ligand, in turn generating a cationic species.  
Compounds 62 - 65 were isolated as hexafluorophosphate salts, via a metathesis reaction with 
NaPF6, to afford orange solids ([62][PF6]4 & [63][PF6]8) or dark purple solids ([64][PF6]4 & 
[65][PF6]8), in good yields (72 - 85 %). Compounds [62][PF6]4 - [65][PF6]8 are non-
hygroscopic, air- and moisture-stable solids, can be stored on the bench-top for more than five 
months and are soluble in dimethylsulfoxide, acetone and dimethylformamide, and partially 
soluble in acetonitrile. 
 
Chelation of the ligands to the metal centre, as well as purity of the metallodendrimers, were 
confirmed by spectroscopic (
1
H, 
13
C{
1
H} NMR and infrared spectroscopy) and analytical 
techniques (elemental analysis and mass spectrometry). 
 
3.5.1 
1
H, 
31
P{
1
H} and 
13
C{
1
H} NMR Spectroscopy  
The 
1
H NMR data of the metallodendrimers [62][PF6]4 - [65][PF6]8 was recorded in 
deuterated acetone. Comparison of the 
1
H NMR spectrum of [62][PF6]4 - [65][PF6]8 to its 
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corresponding dendritic ligand reveals an overall downfield shift in the broadened signals (in 
the range of 1.3 - 4.0 ppm) associated with the aliphatic protons of the dendritic core or on the 
dendritic arms. This downfield shift is attributed to the incorporation of the metal ion onto the 
ligand, which in turn generates a charged species further influencing the overall chemical shift 
of signals. Confirmation for the chelation of the dendritic ligand to the ruthenium ion is 
attributed to a slight downfield shift in the imine signal from ~8.0 ppm (for 56 & 57) and ~8.3 
ppm (for 58 & 59) to ~8.1 ppm (for [62][PF6]4 (Figure 3.9) & [63][PF6]8) and ~8.9 ppm (for 
[64][PF6]4 (Figure 3.10) & [65][PF6]8) respectively. Upon coordination of the dendritic ligand 
to the ruthenium ion, [62][PF6]4 - [65][PF6]8 results in a loss of two-fold symmetry of the p-
cymene moiety. This results in the methyl protons of the isopropyl group exhibiting two 
broad multiplets in the range of 1.1 - 1.3 ppm (for [62][PF6]4 - [65][PF6]8), with a broad 
multiplet observed at ~2.6 ppm assigned to the single proton on the isopropyl group. The 
protons on the substituted and un-substituted ferrocenyl functionality are assigned to the 
broad singlet and two broad doublets in the region 4.0 - 4.4 ppm for [62][PF6]4 - [65][PF6]8. 
The protons on the alkene moiety appear at ~6.7 ppm and 7.1 ppm for [62][PF6]4 and 
[63][PF6]8, whilst they appear at ~6.7 ppm and 7.6 ppm for [64][PF6]4 and [65][PF6]8. 
 
 
Figure 3.9 
1
H NMR spectrum for [DAB-G1-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA-(5-
ferrocenyl-vinyl)}4][PF6]4 ([62][PF6]4) in (CD3)2CO. 
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1
H NMR spectra of N,O-Ru(II)-arene-PTA metallodendrimers ([62][PF6]4 & [63][PF6]8) 
The 
1
H NMR spectrum of metallodendrimers [62][PF6]4 (Figure 3.9) and [63][PF6]8 show 
signals in the range of 5.5 - 7.2 ppm and are assigned to the aromatic protons. The signals for 
the protons on the PTA ligand (4.1 - 4.6 ppm) overlap with the broad signals assigned to the 
protons on the ferrocenyl functionality and the diastereotopic protons (as a result of chirality 
induced by the ruthenium ion) on the aliphatic carbon adjacent to the imine nitrogen. 
Furthermore, the signals for the PTA ligand display the typical splitting pattern for an AB 
spin system, and correlates well with splitting patterns observed with other PTA complexes in 
the iterature.
60, 61
 
 
Four multiplets observed at around 5.5, 5.8, 6.2 and 6.4 ppm, are assigned to the aromatic 
protons on the p-cymene ring. 
 
 
Figure 3.10 
1
H NMR spectrum for [DAB-G1-PPI-{(η
6
-p-cye)Ru((C6H5N2)-κ
2
-N,N)Cl-(5-ferrocenyl-
vinyl)}4][PF6]4 ([64][PF6]4) in (CD3)2CO. 
 
 
 
Chapter 3. Ferrocenyl-Derived Ruthenium and Osmium Metallodendrimers 
 
 
 
109 
 
1
H NMR spectra of N,N-Ru(II)-arene metallodendrimers ([64][PF6]4 & [65][PF6]8) 
Chirality induced by the ruthenium ion results in the appearance of two broad multiplets (4.4 - 
4.8 ppm) assigned to the diastereotopic protons on the aliphatic carbon adjacent to the imine 
nitrogen for [64][PF6]4 (Figure 3.10) and [65][PF6]8. These broad multiplets overlap with the 
two broad doublets assigned to the protons on the substituted ferrocenyl functionality, with 
the protons on the un-substituted ferrocenyl functionality appear as a singlet at 4.2 ppm. Three 
multiplets at around 8.1, 8.4 and 9.5 ppm are assigned to the protons on the pyridyl ring, with 
the signals for the aromatic protons on the p-cymene ring appearing at ~6.0 ppm and ~6.3 
ppm for [64][PF6]4 and [65][PF6]8. 
 
The 
31
P{
1
H} NMR spectrum of [62][PF6]4 and [63][PF6]8 display a singlet at ~-32 ppm, 
suggesting a single phosphine species and further attests to the purity of the complexes. In 
addition, a high-field septet ~-144.0 ppm, assigned to the phosphorus atom of the PF6 counter-
ion, which couples to the six fluorine atoms with 
1
JP-F = 711 Hz. Similar splitting pattern and 
coupling constant are reported for other hexafluorophosphate salts.
62, 63
 
 
The 
13
C{
1
H} NMR data for [62][PF6]4 - [65][PF6]8 were recorded in deuterated acetone with 
the expected number of signals for the carbon atoms observed. Furthermore, extra signals 
(due to the ruthenium-arene functionalization) for the carbon atoms of the p-cymene moiety 
are also observed for [62][PF6]4 - [65][PF6]8. In addition, metallodendrimers [62][PF6]4 and 
[63][PF6]8 display two singlets for the carbon atoms of the PTA ligand in the range of 51 - 72 
ppm, confirming coordination to the ruthenium ion and displacement of the chlorido ligand. 
 
3.5.2 Infrared Spectroscopy 
Infrared data of metallodendrimers [62][PF6]4 - [65][PF6]8 were obtained using the ATR 
technique. Upon coordination of the ligand to the ruthenium ion, a distinct shift in the 
C=Calkene and C=Nimine stretching vibration is observed from ~1613 cm
-1
 (for 56 & 57) to 
~1590 cm
-1
 (for [62][PF6]4 & [63][PF6]8). A similar shift to lower wavenumbers of the 
C=Nimine stretching vibration for metallodendrimers [64][PF6]4 and [65][PF6]8, from ~1640 
cm
-1
 (for 58 & 59) to ~1625 cm
-1
, is observed. 
 
3.5.3 Elemental Analysis and Mass Spectrometry 
Similarly observed for the dendritic ligands 56 - 59, satisfactory elemental analysis was not 
obtained for [62][PF6]4 - [65][PF6]8, as percentages obtained were outside acceptable limits. 
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However, recalculation of the C, H and N percentages obtained for [62][PF6]4 - [65][PF6]8 
with the inclusion of dichloromethane (reaction solvent, observed in the 
1
H NMR spectrum, 
between 3 - 9 moles) resulted in percentages within acceptable limits. 
 
In addition, HR-ESI mass spectrometry was also used to characterize metallodendrimers 
[62][PF6]4 - [65][PF6]8, with the spectral data listed in Table 3.2. The first-generation 
metallodendrimers [62][PF6]4 and [64][PF6]4 exhibited a base peak corresponding to a 6+ and 
5+ charged ions respectively. Whilst the second-generation derivatives [63][PF6]8 and 
[65][PF]8 depicted a multi-charged ion complex and a molecular ion peak in the mass 
spectrum respectively. 
 
Table 3.2 Mass spectral data for dendritic ligands [62][PF6]4 - [65][PF6]8. 
Compound 
MS  
(fragment, assignment) 
[m/z]
a
 
[62][PF6]4 628.1917 [M+2H]
6+
 (where M = [62][PF6]4 - 4PF6) 
[63][PF6]8 247.1670 [M+18H]
26+
 (where M = [63][PF6]8 - 8PF6) 
[64][PF6]4 649.1115 [M+H]
5+
 (where M = [64][PF6]4 - 4PF6) 
[65][PF6]8 667.4059 [M]
8+
 (where M = [65][PF6]8 - 8PF6) 
 a 
HR-ESI-TOF-MS 
 
3.5.4 Electrochemistry 
The different σ-donating and π-accepting capacities of the dendritic ligands 56 - 59 influence 
the oxidation potentials of the Ru
II
 centres. Furthermore, these potentials provide insight on 
the basic character of the ligands in the complexes. Previous reports suggest, ligands that 
favour oxidation of the ferrocenyl moiety can produce reactive oxygen species, which have 
the ability to disrupt lipid membranes and in turn influence the antitumor activity of the 
complexes.
64-66
 Hence, to investigate such possible correlations in the current systems and to 
provide further characterization of the complexes, the metallodendrimers [62][PF6]4 - 
[65][PF6]8 were studied by cyclic voltammetry at a Pt disc working electrode in acetonitrile, 
containing [n-Bu4N][ClO4] as the background electrolyte, a platinum wire auxiliary electrode 
and a Ag/Ag
+
 reference electrode. A comparison of the relevant electrochemical data is given 
in Table 3.3. 
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Table 3.3 Electrochemical data of metallodendrimers [62][PF6]4 - [65][PF6]8 and ferrocene 
(Fc). 
 Fe
II
 / Fe
III
  
Compound Epa [V] Epc [V] ΔEp [V]
a
 E1/2 [V]
b
 ΔE1/2 [V]
c
 ipa / ipc Epa (Ru) [V] 
[62][PF6]4 0.16 n.o. - - - - 0.98 
[63][PF6]8 0.17 n.o. - - - - 0.98 
[64][PF6]4 0.23 0.15 0.08 0.19 0.07 1.14 n.o. 
[65][PF6]8 0.22 0.15 0.07 0.19 0.07 1.46 n.o. 
Fc 0.17 0.07 0.10 0.12 0 0.99 - 
a ΔEp = Epa - Epc, where Epa and Epc are the anodic and cathodic peak potentials vs. Ag/AgCl respectively. 
b 
E1/2 = (Epa + Epc)/2 
c ΔE1/2 = E1/2(Fc-compound) - E1/2(Fc) 
Electrochemical studies were measured in CH3CN at a scan rate of 100 mVs
-1
 ([62][PF6]4 & [63][PF6]8) and  
50 mVs
-1
 ([64][PF6]4 & [65][PF6]8), and referenced to Ag/Ag
+
. 
The E1/2 potentials of [62][PF6]4 - [65][PF6]8 are quoted relative to ferrocene/ferrocenium couple of a sample 
containing only ferrocene. 
n.o. = clear peak not observed. 
[n-Bu4N][ClO4] was used as the background electrolyte. 
 
The free ferrocene standard exhibits a one-electron reversible wave with E1/2 = 0.12 V for 
Fc/Fc
+
 couple relative to the Ag/Ag
+
 reference electrode. First- and second-generation 
metallodendrimers display similar voltammetric behaviours in acetonitrile, and hence 
representative cyclic voltammograms are shown in Figure 3.11 and Figure 3.12 for the first-
generation N,O-ruthenium-arene-PTA metallodendrimer [62][PF6]4 and N,N-ruthenium-arene-
PTA metallodendrimer [64][PF6]4, respectively.  
 
Cyclic voltammograms of N,O-Ru(II)-arene-PTA metallodendrimers ([62][PF6]4 & 
[63][PF6]8) 
The redox potentials of [62][PF6]4 and [63][PF6]8 were measured at a scan rate of 100 mVs
-1
 
and ferrocene was used as the internal standard. Both [62][PF6]4 (Figure 3.11, bottom) and 
[63][PF6]8 exhibit similar voltammograms with two irreversible waves in the positive region. 
The ferrocene oxidation (Fe
II
 → FeIII) wave appears at Epa = 0.16 V and 0.17 V for [62][PF6]4 
and [63][PF6]8 respectively. In principle, the more electron-donating groups coordinated to 
the metal centre, the more facile the oxidation and vice versa. Hence, a second redox event for 
the oxidation of the ruthenium centre (Ru
II
 → RuIII) appears at 0.98 V for both [62][PF6]4 and 
[63][PF6]8,
67
 and is electrochemically irreversible, suggesting thermodynamic instability of 
the oxidation products.
68, 69
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Figure 3.11 Cyclic voltammogram of [62][PF6]4 showing a partial (top) and a full scan (bottom), 
as recorded in acetonitrile at a Pt disc-electrode (scan rate: 100 mVs
-1
). The partial 
voltammogram is shifted by +2 μA to avoid overlap. [n-Bu4N][ClO4] was used as the 
background electrolyte. 
 
When scanned with the switching potential set just after the first oxidation wave, the 
reversible one-electron ferrocene/ferrocenium redox potential is observed for both [62][PF6]4 
(Figure 3.11, top) and [63][PF6]8. Unlike other ruthenium-iron heterometallic systems,
34, 36, 68, 
70-72
 where an irreversible wave for the ruthenium centre and a reversible wave for the 
ferrocenyl moiety are common, here this is not observed. However, the electrochemical 
studies performed on the reported ruthenium-iron heterometallic systems found in the 
literature, were performed using different conditions (i.e. background electrolyte, reaction 
solvent and/or the compound counter-ion), and hence effect the oxidation/reduction processes 
compared. In the present study, the electrochemical data suggest oxidation of the ruthenium 
centre influences and prevents reduction of the ferrocenium species, resulting in two 
irreversible redox processes observed for [62][PF6]4 and [63][PF6]8. 
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Cyclic voltammograms of N,N-Ru(II)-arene metallodendrimers ([64][PF6]4 & [65][PF6]8) 
The redox potentials of [64][PF6]4 and [65][PF6]8 were measured at a scan rate of 50 mVs
-1
 
and are given versus the ferrocene couple. Due to the partial solubility of [64][PF6]4 and 
[65][PF6]8 in acetonitrile, a slower scan rate was chosen, as faster scan rates did not produce 
smooth cyclic voltammograms. The cyclic voltammogram for [64][PF6]4 (Figure 3.12) and 
[65][PF6]8 exhibit one reversible wave in the positive region and is assigned to the Fe
II
/Fe
III
 
couple.
36, 72
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Figure 3.12 Cyclic voltammogram of [64][PF6]4 showing a full scan, as recorded in acetonitrile at 
a Pt disc-electrode (scan rate: 50 mVs
-1
). [n-Bu4N][ClO4] was used as the background 
electrolyte. 
 
Furthermore, current ratios (ipa/ipc) are close to unity suggesting these are one-electron redox 
potentials. However, there was no oxidation of Ru
II
 observed and is attributed to the electron 
withdrawing nature of the chlorido ligand, thereby lowering the electron density at the 
ruthenium centre, making the Ru-oxidation more difficult. As expected the 
ferrocene/ferrocenium redox potential of the first- and second-generation metallodendrimers 
[64][PF6]4 and [65][PF6]8 are nearly identical Table 3.3. In comparison to free ferrocene (E1/2 
= 0.12 V), the ferrocenyl moiety of [64[PF6]4 and [65][PF6]8 is more difficult to oxidize (E1/2 
= 0.19 V), and is attributed to the electron-withdrawing effects from the alkene moiety, the 
ruthenium centre and the overall positive charge of the complexes. This was similarly 
demonstrated for monosubstituted ferrocenyl-derived complexes containing electron-
withdrawing groups bonded to the ferrocene ring.
73
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3.6 Synthesis and Characterization of Cationic Ferrocenyl-Derived N,O-Ru(II)-
Arene-PTA and N,N-Ru(II)-Arene Mononuclear Complexes 
 
In order to compare size dependency on the biological activity (discussed in Chapter 4), 
mononuclear derivatives [66][PF6] and [67][PF6] of the ferrocenyl-derived ruthenium-arene 
metallodendrimers were prepared. Two equivalents of the monomeric ligand 60 or 61 were 
reacted with one equivalent of the ruthenium-arene dimer [Ru(η6-p-PriC6H4Me)Cl2]2 by 
stirring at room temperature in an ethanol:dichloromethane (50:50 % v/v) (Scheme 3.7), in the 
presence of triethylamine (for preparation of [66][PF6]). PTA was added to the reaction 
mixture containing the N,O-salicylaldiminato ligand 60, which displaced the chlorido ligand 
and generated a cationic complex. The new mononuclear complexes [66][PF6] and [67][PF6] 
were isolated as orange and dark-purple hexafluorophosphate salts respectively, and have 
similar solubilities in polar solvents to their dendritic counterparts [62][PF6]4 - [65][PF6]8. 
 
Scheme 3.7  Synthesis of [CH3CH2CH2-(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA-(5-ferrocenyl-
vinyl)][PF6] [66][PF6] and [CH3CH2CH2-(η
6
-p-cye)Ru((C6H5N2)-κ
2
-N,N)Cl-(5-
ferrocenyl-vinyl)][PF6] [67][PF6]. 
 
The two mononuclear complexes were characterized using a number of spectroscopic and 
analytical techniques. 
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3.6.1 
1
H, 
31
P{
1
H} and 
13
C{
1
H} NMR Spectroscopy 
The 
1
H NMR data of [66][PF6] and [67][PF6] were recorded in deuterated acetone. The 
1
H 
NMR spectrum shows an upfield shift in the proton singlet assigned to the imine proton from 
~8.3 ppm (for 60 & 61) to ~8.1 ppm for [66][PF6] (Figure 3.13) and a downfield shift to ~8.7 
ppm for [67][PF6] (Figure 3.14), suggesting coordination of the ligand to the ruthenium ion. 
Confirmation for the chiral nature of the molecule can be attributed to the appearance of two 
sets of multiplets (integrating for two protons per set) in the range of 2.0 - 2.1 ppm and 3.8 - 
4.6 ppm, and are assigned to the diastereotopic protons on the propyl chain of [66][PF6] and 
[67][PF6]. Furthermore, the loss of 2-fold symmetry around the arene ring results in the 
methyl protons on the isopropyl group of the p-cymene moiety, to resonate as two doublets 
(
3
JHH = 6.9 Hz) in the range of 1.1 - 1.3 ppm for [66][PF6] and [67][PF6]. The two doublets in 
the range of 6.6 - 7.6 ppm, with a coupling constant of 
3
JHH = 16.0 Hz, is assigned to the two 
protons on the alkene moiety. The protons on the un-substituted ferrocenyl ring resonates ~4.2 
ppm as a singlet, whilst the protons on the monosubstituted Cp ring resonate as two doublets 
(
3
JHH = 1.9 Hz) ~4.4 ppm and ~4.7 ppm for [66][PF6] and [67][PF6].  
 
 
Figure 3.13 
1
H NMR spectrum for [CH3CH2CH2-(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA-(5-
ferrocenyl-vinyl)][PF6] [66][PF6] in (CD3)2CO. 
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1
H NMR spectrum of N,O-Ru(II)-arene-PTA mononuclear complex [66][PF6] 
The aromatic protons of [66][PF6] appear as two doublets (
3
JHH = 8.1 Hz) and one singlet, at 
~6.9 ppm and ~7.2 ppm respectively. Due to the loss of two-fold symmetry around the arene 
ring, the four aromatic protons on the arene ring appear as three doublets (5.6 - 6.3 ppm) and 
one multiplet (~6.5 ppm). Similarly observed with the first- and second- generation 
derivatives ([62][PF6]4 & [63][PF6]8), protons on the PTA moiety display an AB-spin system, 
with two doublets and one singlet observed in the range 1.3 - 4.5 ppm. Furthermore, as a 
result of the chirality induced by the ruthenium metal centre, diastereotopic protons on the 
propyl chain are observed in the range of 3.8 - 4.0 ppm and 2.0 - 2.1 ppm. 
 
1
H NMR spectra of N,N-Ru(II)-arene mononuclear complex [67][PF6] 
The pyridyl protons of [67][PF6] appear as two doublets (
3
JHH = 8.3 Hz) and one singlet, at 
~8.1 ppm and ~9.6 ppm respectively. Once again, the diastereotopic protons of the CH2 
groups on the propyl chain are observed in the range of 4.4 - 4.6 ppm and 2.0 - 2.1 ppm. 
 
 
Figure 3.14 
1
H NMR spectrum for [CH3CH2CH2-(η
6
-p-cye)Ru((C6H5N2)-κ
2
-N,N)Cl-(5-ferrocenyl-
vinyl)][PF6] ([67][PF6]) in (CD3)2CO. 
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31
P{
1
H} NMR spectroscopy was used to confirm purity of [66][PF6], as a singlet is observed 
at -33 ppm, suggesting a single coordinated phosphine species (PTA). Furthermore, similar 
values are observed for the first- and second- generation derivatives [62][PF6]4 and 
[63][PF6]8. A septet (
1
JP-F = 707.7 Hz) is observed ~-144 ppm for both complexes and is 
assigned to the phosphine atom on the hexafluorophosphate counter-ion. 
 
13
C{
1
H} NMR spectral data for [66][PF6] and [67][PF6] display the expected number of 
signals for the proposed structure. In particular, the imine carbon signal shifts downfield from 
~164 ppm (for 60) and ~162 ppm (for 61) to ~166 ppm for both [66][PF6] and [67][PF6]. 
 
3.6.2 Infrared Spectroscopy 
The infrared spectrum for [66][PF6] and [67][PF6] displays a stretching vibration for the 
C=Calkene at ~1587 cm
-1
. Similarly observed for the first- and second- generation derivatives 
([62][PF6]4 - [65][PF6]8), the C=Nimine stretching vibration appears ~1619 cm
-1
 and ~1625 cm
-
1
 for [66][PF6] and [67][PF6] respectively. 
 
3.6.3 Mass Spectrometry and HPLC 
The HR-ESI mass spectral data for [66][PF6] (Figure 3.15) and [67][PF6], confirm the 
proposed structures, as both display a base peak for the molecular ion at m/z = 765.1958 and 
at m/z = 629.0955 respectively. 
 
 
Figure 3.15 HR-ESI-TOF mass spectrum for [CH3CH2CH2-(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA-
(5-ferrocenyl-vinyl)][PF6] [66][PF6]. 
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Analytical-HPLC traces were obtained for [66][PF6] and [67][PF6], with single peaks 
observed at tR = ~16 min, and attests to the purity of the mononuclear complexes. 
 
3.6.4 Electrochemistry 
The redox potentials of [66][PF6] and [67][PF6] were measured at a scan rate of 100 mVs
-1
 
and 50 mVs
-1 
respectively, and ferrocene was used as the internal standard. Electrochemical 
data of [66][PF6] and [67][PF6] are listed in Table 3.4. 
 
Table 3.4 Electrochemical data of mononuclear complexes [66][PF6], [67][PF6] and ferrocene 
(Fc). 
 Fe
II
 / Fe
III
  
Compound Epa [V] Epc [V] ΔEp [V]
a
 E1/2 [V]
b
 ΔE1/2 [V]
c
 ipa / ipc Epa (Ru) [V] 
[66][PF6] 0.18 n.o. - - - - 0.97 
[67][PF6] 0.23 0.16 0.07 0.20 0.08 0.98 n.o. 
Fc 0.17 0.07 0.1 0.12 0 0.99 - 
a ΔEp = Epa - Epc, where Epa and Epc are the anodic and cathodic peak potentials vs. Ag/AgCl respectively. 
b 
E1/2 = (Epa + Epc)/2 
c ΔE1/2 = E1/2(Fc-compound) - E1/2(Fc) 
Electrochemical studies were measured in CH3CN at a scan rate of 100 mVs
-1
 ([62][PF6]4 & [63][PF6]8) and  
50 mVs
-1
 ([64][PF6]4 & [65][PF6]8), and referenced to Ag/Ag
+
. 
The E1/2 potentials of [62][PF6]4 - [65][PF6]8 are quoted relative to ferrocene/ferrocenium couple of a sample 
containing only ferrocene. 
n.o. = clear peak not observed. 
[n-Bu4N][ClO4] was used as the background electrolyte. 
 
Cyclic voltammograms of N,O-Ru(II)-arene-PTA mononuclear complex [66][PF6] and N,N-
Ru(II)-arene mononuclear complex [67][PF6] 
The cyclic voltammogram for [66][PF6] (Figure 3.16, bottom) shows two irreversible waves 
at Epa = 0.18 V and 0.97 V for the oxidation of the ferrocenyl moiety and the ruthenium centre 
respectively, and is attributed to the thermodynamic instability of the oxidation products.
68, 69
 
Setting the switching potential just after the first oxidation wave (Epa = 0.18 V) and re-
scanning, results in a reversible one-electron ferrocene/ferrocenium redox potential for 
[66][PF6] (Figure 3.16, top), similarly observed with metallodendrimers [62][PF6]4 and 
[63][PF6]8. Two shoulder peaks are observed in the cyclic voltammogram for [66][PF6], 
which are not assigned, at ~0.88 V (full scan) and at ~0.45 V (partial scan). 
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Figure 3.16 A partial (top) and full (bottom) cyclic voltammogram of [66][PF6] as recorded in 
acetonitrile at a Pt disc-electrode (scan rate:100 mVs
-1
). The partial voltammogram is 
shifted by +12 μA to avoid overlap. [n-Bu4N][ClO4] was used as the background 
electrolyte. 
 
Whilst the cyclic voltammogram for [67][PF6] (Figure 3.17) exhibits one reversible wave 
(E1/2 = 0.20 V) and is assigned to the Fe
II
/Fe
III
 couple.
36, 72
 No oxidation of the ruthenium 
centre was observed in the cyclic voltammogram of [67][PF6]. This is attributed to the 
electron-withdrawing nature of the chlorido ligand, making it difficult to oxidize the metal 
centre. As expected, both [66][PF6] and [67][PF6], exhibit similar cyclic voltammograms and 
wave potentials compared to their dendritic counterparts [62][PF4]4 - [65][PF6]8.  
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Figure 3.17 Full cyclic voltammogram of [67][PF6] as recorded in acetonitrile at a Pt disc-
electrode (scan rate: 50 mVs
-1
). [n-Bu4N][ClO4] was used as the background 
electrolyte. 
 
3.6.5 X-ray Crystallography 
The molecular structure of the mononuclear complex [66][PF6] was elucidated by a single-
crystal X-ray diffraction. Crystals were grown by slow evaporation of a solution of [66][PF6] 
in acetone, and crystallized in the monoclinic space group P 21/c. ORTEP drawing for the 
solvate [66][PF6]
.
H2O is shown in Figure 3.18, with the ferrocene adopting an eclipsed 
confirmation and the E-conformation of the vinylic carbon-carbon double bond is further 
confirmed. The ruthenium atom of [66][PF6] is coordinated to the nitrogen and the oxygen 
atoms of the Schiff base ligand, to the phosphorus atom of the PTA ligand and to the η6-p-
cymene ligand, thus leading to a typical pseudo-tetrahedral or “piano-stool” conformation. 
Crystallographic details can be found in Chapter 6, summarized in Table 6.3. 
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Figure 3.18 ORTEP representations of mononuclear solvate cation [66][PF6]
.
H2O. Thermal 
ellipsoids are drawn at the 50 % probability level. Hydrogen atoms have been omitted 
for clarity. 
 
Selected geometric data for [66][PF6]
.
H2O are listed in Table 3.5. The average distance 
between the ruthenium and carbon atoms of the η6-p-cymene ring is 1.73 Å, comparable to the 
mononuclear ruthenium-arene analogs [38][PF6] and [39][PF6] mentioned in Chapter 2, and 
that of related ruthenium-p-cymene complexes reported in the literature.
74
 The Ru-P distance 
in [66][PF6] is comparable to that observed in analogous ruthenium-arene-PTA compounds.
75, 
76
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Table 3.5 Selected average bond lengths and bond angles in [66][PF6]
.
H2O. 
 [66][PF6]
.
H2O 
 interatomic distances (Å) 
Ru1-N1 2.096(5) 
Ru1-O1 2.068(5) 
Ru1-P1 2.305(2) 
C4-C5 1.46(1) 
C4-N1 1.273(8) 
N1-C3 1.48(1) 
C11-C12 1.33(1) 
Rucentroid ~1.730 
 [66][PF6]
.
H2O 
 angles () 
N1-Ru1-O1 87.5(2) 
N1-Ru1-P1 86.8(1) 
O1-Ru1-P1 80.5(1) 
C5-C4-N1 127.2(6) 
C4-N1-C3 119.2(6) 
C11-C12-C13 125.1(8) 
C8-C11-C12 126.5(7) 
 
A study of their in vitro antitumor activity has been undertaken and the results are discussed 
in Chapter 4. 
 
3.7 Overall Summary 
 
New cationic N,O- and N,N- ferrocenyl-derived ruthenium-arene metallodendrimers have 
been successfully synthesized from new ferrocenyl-derived conjugates. All complexes were 
characterized using an array of spectroscopic and analytical techniques, which confirmed 
formation of the desired compounds. Their mononuclear analogs were prepared and 
characterized. Electrochemical studies were performed, revealing that the N,O-Ru(II)-arene-
PTA complexes result in two irreversible redox processes (oxidation of the Fe
II
 & Ru
II
 
centres), whilst the N,N-Ru(II)-arene complexes display one reversible wave (Fe
II
/Fe
III
- 
couple) in the positive region. Single crystal X-ray diffraction was utilized to further confirm 
the proposed structures and illustrate the mode of coordination, through N,O- and N,N-donor 
atoms. 
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Chapter 4 
Biological Evaluation of Ruthenium, Osmium and  
Ferrocenyl-Derived Metallodendrimers  
 
This chapter forms part of the following publications: 
Preshendren Govender, L. C. Sudding, C. M. Clavel, P. J. Dyson, B. Therrien and G. S. Smith, The Influence 
of RAPTA Moieties on the Antiproliferative Activity of Peripheral-Functionalized Poly(salicylaldiminato) 
Metallodendrimers, Dalton Transactions, 2013, 42, 1267-1277. 
 
Preshendren Govender, F. Edafe, B. C. E. Makhubela, P. J. Dyson, B. Therrien and G. S. Smith, Neutral and 
Cationic Osmium(II)-Arene Metallodendrimers: Synthesis, Characterization and Anticancer Activity, 
Inorganica Chimica Acta, 2014, 409, 112-120. 
 
4.1 Introduction 
 
Drug resistance, side-effects and toxicity are major disadvantages of Pt-based anticancer 
agents, and hence studies towards the use of other platinum-group metals for effective 
therapeutic agents were persued.
1, 2
 Ruthenium(III) complexes, namely NAMI-A 
{H2Im[trans-RuCl4(DMSO)(Him)] (Him = imidazole)}
3 
and KP1019 {H2Ind[trans-
RuCl4(Hind)2] (Hind = indazole),
4, 5
 have shown promise in phase I clinical trials, with the 
former NAMI-A active against solid metastases and currently in a phase II study. The latter, 
KP1019, displays superior activity against metastasis and primary tumors, and in particular 
towards colorectal tumors. However, it has been suggested that the activity of these Ru(III) 
prodrugs is brought about by in vivo reduction into the activated Ru(II) species.
6
 This has 
triggered the development of half-sandwich organometallic ruthenium(II)-arene complexes 
for the exploration as anticancer agents. Furthermore, due to their structural diversity, such as 
the hydrophobic arene ring (which facilitates diffusion of the drug through the cell 
membrane) and the various bonding modes (where the remaining coordination sites are 
usually occupied by mono-, bi-, or tri-dentate ligands) offer these complexes diverse 
biological properties. A host of derivatives have been synthesized which include 
incorporation of paullones,
7, 8
 pyr(id)ones,
9
 ethylenediamine (en),
10, 11
 or 1,3,5-triaza-7-
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phosphatricyclo-[3.3.1.1.]decane (PTA),
12, 13
 to the ruthenium-arene coordination sphere, with 
all the complexes displaying moderate to potent in vitro antitumor activity.  
 
RAPTA compounds of general formula [(η6-arene)Ru(PTA)Cl2] (Figure 4.1), display activity 
against the TS/A mouse adenocarcinoma cancer cell line, and no selectivity towards HBL-100 
human mammary cells.
14
 The RAPTA compounds display moderate activity, but are very 
effective in vivo against metastatic
14
 and primary tumors.
15
 Furthermore, the activity of the 
RAPTA compounds are comparable to the Ru(III)-anticancer drug NAMI-A. Ruthenium-
arene-metronidazole complex [(η6-C6H6)Ru(metronidazole)Cl2] (where metronidazole is used 
in the treatment of rosacea, a dermatological condition), was the first of its kind to combine 
organometallic ruthenium with a bioactive ligand (Figure 4.1).
16
 This type of structure-
activity relationship has been explored by Keppler and co-workers, where paullones, which 
are known inhibitors of cyclin-dependent kinases and glycogen synthase kinase-3, have been 
coupled with organometallic ruthenium (Figure 4.1).
7
 These complexes display high 
antiproliferative activity in three cell lines, making them potential candidates as metal-based 
anticancer drugs.  
 
Figure 4.1 Structures of organometallic ruthenium-arene complexes of interest as anticancer 
agents.
7, 14, 16
 
 
Since the discovery of the trinuclear platinum-based anticancer drug, BBR3464 [trans, trans, 
trans-(NH3)2-Pt(Cl)(CH2)6NH2Pt(NH3)2NH2(CH2)6NH2Pt-(NH3)2(Cl)][NO3]4 (Figure 4.2),
17
 
the concept of multinuclearity has not been extensively explored towards development of new 
anticancer agents.
18, 19
 Remarkably, tethering RAPTA-type complexes to macromolecules 
such as proteins, significantly increases their cytotoxicity.
20, 21
 Consequently, there is growing 
Chapter 4. In Vitro Biological Evaluation 
 
 
 
129 
 
interest in the development of multinuclear ruthenium(II) complexes as potential anticancer 
agents.
18, 19 
 
 
Figure 4.2 Structure of the trinuclear Pt-based anticancer drug BBR3464.
17
 
 
Only recently have metallodendrimers been investigated as potential therapeutic agents.
22
 A 
wide range of functionalities may be introduced onto the periphery of these macromolecules 
allowing them to be modified for specific applications in medicinal chemistry,
23
 host-guest 
chemistry
24
 and catalysis.
25, 26 
Notably, in medicinal chemistry, the concept of multinuclearity 
can be used to improve the potency of chemotherapeutic drugs and the application of 
metallodendrimers can also be used to selectively target tumors by exploiting the enhanced 
permeability and retention (EPR) effect.
27 
The EPR effect results in the passive accumulation 
of macromolecules in cancerous tissues, further increasing the therapeutic index while 
decreasing side effects.
28
 Another utility of metallodendrimers are their multivalency which 
potentially leads to increased interactions between a dendrimer-drug conjugate and a target 
bearing multiple receptors.  
 
Recently, a series of monodentate (N-) and chelating bidentate (N,N- and N,O-) ruthenium-
arene first- and second-generation metallodendrimers based on poly(propyleneimine) 
dendritic scaffolds were prepared.
29, 30
 The chelating bidentate ruthenium-arene 
metallodendrimers show superior in vitro antitumor activity over their monodentate 
counterparts, with the octanuclear cationic N,N-ruthenium-hexamethylbenzene 
metallodendrimer displaying the greatest activity. A clear correlation between the size 
dependency of the metallodendrimer, cytotoxicity and DNA damage was observed. 
 
In this chapter, the in vitro pharmacological evaluation of the neutral and cationic chelating 
bidentate ruthenium- and osmium-arene metallodendrimers, as well as the ferrocenyl-derived 
ruthenium-arene derivatives for antitumor activity will be discussed (Figure 4.3). 
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Figure 4.3 Neutral and cationic chelating bidentate ruthenium- and osmium-arene 
metallodendrimers prepared in this study. 
 
4.2 In vitro Biological Activity of Ruthenium- and Osmium-Arene 
Metallodendrimers 
 
With the established tumor-inhibiting properties of ruthenium-arene-PTA complexes,
31
 and 
the current interest in metallodendrimers for biological applications, the in vitro biological 
activity of the neutral N,O-ruthenium-arene metallodendrimers (25 - 28, Figure 4.3) and 
cationic N,O-ruthenium-arene-PTA metallodendrimers ([29][PF6]4 - [36][PF6]32, Figure 4.3) 
were evaluated against cisplatin-sensitive (A2780) and cisplatin-resistant (A2780cisR) human 
ovarian cancer cell lines, and selected compounds were tested against model human 
embryonic kidney (HEK) cells (Table 4.1 & Table 4.2). 
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Table 4.1 IC50 values of neutral N,O-Ru-arene complexes determined against A2780 and 
A2780cisR human ovarian cancer cells. 
    IC50 [μM]
a
 
Compound Metal n
b
 Arene A2780
c
 A2780cisR
c
 RI
d
 
68 Ru 1 p-cye 49 ± 2.3 47 ± 0.8 1.0 
9 Ru 4 p-cye 50 ± 1.4 52 ± 0.8 1.0 
10 Ru 8 p-cye 22 ± 1.2 15 ± 1.4 0.7 
25 Ru 16 p-cye 6.0 ± 1.0 13.2 ± 1.4 2.2 
26 Ru 32 p-cye 2.9 ± 0.1 9.9 ± 1.2 3.4 
69 Ru 1 HMB 19 ± 1.8 18 ± 0.8 0.9 
11 Ru 4 HMB 27 ± 1.3 25 ± 1.3 0.9 
12 Ru 8 HMB 10 ± 0.3 9 ± 0.2 0.9 
27 Ru 16 HMB 2.1 ± 0.1 2.1 ± 0.1 1.0 
28 Ru 32 HMB 1.6 ± 0.1 2.1 ± 0.1 1.3 
cisplatin Pt 1 - 1.5 25 16.7 
a 
IC50 values of 68, 69, 9 - 12 taken from reference 30, 
b 
n = number of metals present in the complex,  
c 
IC50 value ± standard error, 
d 
RI, resistance index = IC50 of A2780cisR/IC50 of A2780. 
 
 
Table 4.2 IC50 values of cationic N,O-Ru-arene-PTA complexes determined against A2780 and 
A2780cisR human ovarian cancer cells, and healthy HEK cells. 
    IC50 [μM] 
Compound Metal n
a
 Arene A2780
b
 A2780cisR
b
 RI
c
 HEK SIA2780
d
 SIA2780cisR
e
 
[38][PF6] Ru 1 p-cye >200 82.0 ± 6.0 0.4 115.6 0.6 1.4 
[29][PF6]4 Ru 4 p-cye 174.0 ± 40 72.8 ± 1.6 0.4 122.1 0.7 1.7 
[30][PF6]8 Ru 8 p-cye 9.3 ± 0.4 19.3 ± 0.2 2.1 53.2 5.9 2.7 
[31][PF6]16 Ru 16 p-cye 1.4 ± 0.4 3.6 ± 0.2 2.6 12 8.6 3.3 
[32][PF6]32 Ru 32 p-cye 0.8 ± 0.1 2.7 ± 0.1 3.4 2.6 3.3 1.0 
[39][PF6] Ru 1 HMB 38.0 ± 3.4 93.0 ± 7.0 2.4 59.7 1.6 0.6 
[33][PF6]4 Ru 4 HMB 8.9 ± 2.8 25.0 ± 5.0 2.8 89.6 10.1 3.6 
[34][PF6]8 Ru 8 HMB 6.2 ± 0.3 11.8 ± 1.1 1.9 20.9 3.4 1.8 
[35][PF6]16 Ru 16 HMB 2.9 ± 0.1 2.0 ± 0.1 0.7 6.4 2.2 3.2 
[36][PF6]32 Ru 32 HMB 2.0 ± 0.1 1.1 ± 0.1 0.6 2.3 1.2 2.1 
cisplatin Pt 1 - 1.5 25 16.7 - - - 
a 
n = number of metals present in the complex, 
b 
IC50 value ± standard error, 
c 
RI, resistance index = IC50 of 
A2780cisR/IC50 of A2780, 
d 
SIA2780, selectivity index = IC50 of HEK/IC50 of A2780, 
e 
SIA2780cisR, selectivity 
index = IC50 of HEK/IC50 of A2780cisR. 
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To perform an extensive investigation, Chapter 2 described the preparation and 
characterization of neutral and cationic osmium-arene salicylaldiminato derivatives (40 - 
[43][PF6]8, [46][PF6]4, [47][PF6]8, Figure 4.3). Parts of this chapter discuss the 
antiproliferative activity of these osmium derivatives against A2780 and A2780cisR human 
ovarian cancer cells (Table 4.3). 
 
Table 4.3 IC50 values of neutral and cationic osmium-arene complexes determined against 
A2780 and A2780cisR human ovarian cancer cells. 
    IC50 [μM] 
Compound Metal n
a
 Arene A2780
b
 A2780cisR
b
 
48 Os 1 p-cye 58.1 ± 13.3 90.4 ± 11.7 
40 Os 4 p-cye >200 >200 
41 Os 8 p-cye insoluble insoluble 
[49][PF6] Os 1 p-cye >200 >200 
[42][PF6]4 Os 4 p-cye 166.7 ± 12.5 >200 
[43][PF6]8 Os 8 p-cye 16.4 ± 12.5 43.5 ± 2.7 
[51][PF6] Os 1 p-cye 120.7 ± 2.4 65.7 ± 16.3 
[46][PF6]4 Os 4 p-cye 151.5 ± 20.2 >200 
[47][PF6]8 Os 8 p-cye 24.6 ± 4.8 27.5 ± 5.2 
cisplatin Pt 1 - 1.5 25 
a 
n = number of metals present in the complex. 
b 
IC50 value ± standard error. 
 
In order to compare size dependency on the in vitro biological activity, the synthesis and 
characterization of mononuclear analogs of the metallodendrimers were described in Chapter 
2. Furthermore, their antitumor activities were evaluated against A2780 and A2780cisR 
human ovarian cancer cell lines and are described here. The un-complexed N,O-
salicylaldiminato dendritic ligands were not tested. 
 
4.2.1 Influence of the Number of Metal Centres: Mononuclear vs. G1 vs. G2 vs. G3 vs. G4 
Neutral N,O-Ruthenium-Arene Complexes 
The in vitro antitumor activity of the third- and fourth-generation neutral ruthenium-arene 
metallodendrimers 25 - 28 was evaluated against A2780 and A2780cisR human ovarian 
cancer cells, and compared with the activity of the first- and second-generation derivatives (9 
-12) and mononuclear analogs (68 & 69) taken from reference 30 (Figure 2.1 in Chapter 2). 
The general activity of the neutral ruthenium-arene complexes increases when moving from 
the mononuclear analog to the higher dendrimer generations, for both cell lines (A2780 & 
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A2780cisR), and for both the p-cymene (Figure 4.4, left) and hexamethylbenzene (Figure 4.4, 
right) derivatives. The fourth-generation metallodendrimers 26 and 28 display the best 
activity in both the A2780 (IC50 = 2.9 μM and 1.6 μM respectively) and A2780cisR (IC50 = 
9.9 μM and 2.1 μM respectively) cell lines. Furthermore, fourth-generation derivatives 26 and 
28 display higher cytotoxicity compared to structurally similar mononuclear N,O-bidentate 
complexes reported by Grgurić-Šipka and co-workers.32 The correlation between size of the 
metallodendrimer and the increase in antitumor activity, previously observed for 9 - 12,
30
 is 
observed with metallodendrimers 25 - 28.  
 
 
Figure 4.4 Effect of the number of metal centres (Ru-p-cymene complexes - left; Ru-HMB 
complexes - right) on the antitumor activity against A2780 and A2780cisR human 
ovarian cancer cells, with 68, 69, 9 - 12, 25 - 28. IC50 values of 68, 69, 9 - 12 taken 
from reference 30. 
 
Previous work within our research group describes the preparation of a series of first- and 
second-generation monodentate ruthenium(II)-arene (arene = p-cymene or 
hexamethylbenzene) 4-iminopyridyl-based poly(propyleneimine) metallodendrimers (Figure 
4.5), and their in vitro cytotoxicity investigated against A2780 human ovarian cancer cells.
29
 
These complexes showed a lower cytotoxicity compared to cisplatin, however, a clear 
correlation between the size of the compound and the cytotoxicity was similarly observed, 
with the second-generation octanuclear analog displaying the best activity of the series. 
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Figure 4.5 Molecular structure of first- (left) and second-generation (right) monodentate 
ruthenium-arene metallodendrimers based on a 4-iminopyridyl-poly(propyleneimine) 
dendritic scaffold and IC50 values of complexes against A2780 human ovarian cancer 
cells.  
 
Cationic N,O-Ruthenium-Arene-PTA Complexes 
A similar trend observed with the neutral N,O-ruthenium-arene metallodendrimers [25 - 28] is 
observed with the cationic N,O-ruthenium-arene-PTA metallodendrimers [29][PF6]4 - 
[36][PF6]32 (Figure 4.6). Essentially the mononuclear analogs [38][PF6] (Figure 4.6, left) and 
[39][PF6] (Figure 4.6, right) display no activity (IC50 >30 μM) in both the A2780 and 
A2780cisR cell lines. However, the higher generation metallodendrimers display a 
remarkable improvement in activity, in both cell lines, with the fourth-generation 
metallodendrimers [32][PF6]32 and [36][PF6]32 the most active of the series. Metallodendrimer 
[32][PF6]32 (IC50 = 0.8 μM in A2780; 2.7 μM in A2780cisR) shows enhanced cytotoxicity 
compared to the benchmark drug cisplatin (IC50 = 1.5 μM in A2780; 25 μM in A2780cisR).  
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Figure 4.6 Effect of the number of metal centres (Ru-p-cymene complexes - left; Ru-HMB 
complexes - right) on the antitumor activity against A2780 and A2780cisR human 
ovarian cancer cells, with [29][PF6]4 - [36][PF6]32, [38][PF6] and [39][PF6]. 
 
Metallodendrimer [32][PF6]32 shows promising cytotoxicity compared to other multinuclear 
metallodendrimers.
22
 Though not tested in the same cell line, such examples include the 
tetranuclear platinum complex (IC50 = 12.4 μM in L1210/0, mouse leukemia cells) based on 
the butanediamine poly(propyleneimine) dendrimer, functionalized with cisplatin-derived 
moieties (Figure 4.7, left),
33
 and the multinuclear copper complex (IC50 = 8.7 μM in Chang 
liver cells), based on the poly(amidoamine) dendrimer (Figure 4.7, right).
34
 Once again a 
clear correlation between the size dependency of the metallodendrimer and cytotoxicity is 
observed. 
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Figure 4.7  Molecular structure of tetranuclear platinum-based metallodendrimer (left) and 
multinuclear copper-based metallodendrimer (right), and IC50 values of  
compounds.
33, 34
 
  
Neutral and Cationic Osmium-Arene Complexes 
Osmium, found in the same group as ruthenium, is thought to have similar chemical and 
biological properties. Hence, osmium analogs of potent ruthenium(III)-anticancer drugs, 
namely NAMI-A
35
 and KP1019,
36
 were prepared by Sava and Keppler respectively. The 
antiproliferative activity of the osmium-analog of NAMI-A is comparable to its ruthenium 
derivative, with enhanced activity in the human cancer cell line (HT-10) observed, and 
markedly inert towards substitution reactions in the form of hydrolysis and DNA base 
interaction.
35
 Whilst the cytotoxicity of the osmium-analog of KP1019 is inactive in three cell 
lines (i.e. A549, CH1, SW480) and is attributed to their poor solubility in the testing medium 
(1 % dimethylsulfoxide:water).
36
 This is no surprise, with the low-spin d
6
 characteristic of 3
rd
 
row transition metal ions, osmium complexes are usually considered inert in comparison to 
their ruthenium derivatives.
37-42
  
 
Nevertheless, the biological activities of the neutral and cationic osmium-arene complexes 
were evaluated. The cytotoxicity of the neutral N,O-osmium-arene complexes 40, 41 and 48, 
and cationic N,O-osmium-arene-PTA complexes [42][PF6]4, [43][PF6]8 and [49][PF6], and 
cationic N,N-osmium-arene complexes [46][PF6]4, [47][PF6]8 and [51][PF6] were tested in 
vitro against both the A2780 and A2780cisR cell lines (Figure 4.8). Replacing ruthenium with 
osmium results in a drastic decrease in biological activity, as the mononuclear complexes 48, 
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[49][PF6] and [51][PF6], and first-generation derivatives 40, [42][PF6]4 and [46][PF6]4 display 
no activity (IC50 >50 μM) in both cell lines. The cytotoxicity of the second-generation 
metallodendrimer 41 was not obtained due to poor solubility of the complex in the cell 
culture, with the second-generation metallodendrimers [43][PF6]8 (IC50 = 16.4 μM in A2780; 
43.5 μM in A2780cisR) and [47][PF6]8 (IC50 = 24.6 μM in A2780; 27.5 μM in A2780cisR) 
display modest activity compared to cisplatin.  
 
 
 
Figure 4.8 Effect of the number of metal centres (neutral N,O-Os-p-cymene complexes - top left; 
cationic N,O-Os-p-cymene-PTA complexes - top right; cationic N,N-Os-p-cymene 
complexes - bottom centre) on the antitumor activity against A2780 and A2780cisR 
human ovarian cancer cells. ND = Not Done. 
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The pseudo-tetrahedral shape of organometallic ruthenium and osmium derivatives are almost 
identical, which triggered the investigation by Meggers and co-workers on the correlation 
between shape and function of two isostructural ruthenium and osmium complexes (Figure 
4.9).
43
 The two organometallic osmium and ruthenium metal ions functionalized to protein 
kinase inhibitor scaffolds show almost identical biological activities in melanoma cells (1205 
Lu).
43
  
 
Figure 4.9 Molecular structure of the isostructural osmium and ruthenium complex.
43
 
 
Despite the structural similarities between the current series of neutral and cationic osmium-
arene and ruthenium-arene complexes presented in this study, there is no vast improvement in 
the cytotoxicity of the complexes when replacing ruthenium with osmium, in-fact there is a 
drastic decrease in activity. The observed low activity may be attributed to the poor solubility 
in the testing media, similarly observed for the osmium-analog of KP1019.
36
 
 
The neutral and cationic N,O-osmium-arene metallodendrimers presented here are new, and 
following an extensive search of the literature, these osmium-based complexes are the first 
metallodendrimers evaluated as potential anticancer agents. However, multinuclear osmium 
complexes have been reported,
44
 where the authors describe the synthesis of hexanuclear 
osmium-arene metalla-prisms, with focus on encapsulation of inorganic and organic guest 
molecules (Figure 4.10). Similarly observed to their ruthenium metalla-prisms,
45
 the osmium 
analogs enhance the anticancer activities of the encapsulated drug. The improvement in 
activity is attributed to better solubility of the encapsulated drugs, leading to increased cellular 
internalization.  
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Figure 4.10 Molecular structure of hexanuclear osmium-arene metalla-prism.
44
 
 
4.2.2 Influence of the Type of Arene Ring: p-Cymene vs. Hexamethylbenzene 
Neutral N,O-Ruthenium-Arene Complexes 
To investigate whether a structure-activity-relationship exists between the current series of 
metallodendrimers 25 - 28, the p-cymene ligand was replaced with the hexamethylbenzene 
ligand. The arene ring of ruthenium-arene complexes is an important feature in the mode of 
action, in particular towards the inhibition of tumor growth.
46, 47
 IC50 values of the neutral 
third- and fourth-generation metallodendrimers 25 - 28, along with the first- and second-
generation derivatives 9 - 12 and the mononuclear analogs 68 and 69 taken from reference 30 
(Figure 4.11), are compared. 
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Figure 4.11 Effect of the arene ring on the antitumor activity against A2780 (left) and A2780cisR 
(right) human ovarian cancer cells, with neutral N,O-Ru-arene complexes: 
 M (68, 69); G1 (9, 11); G2 (10, 12); G3 (25, 27) and G4 (26, 28). 
 IC50 values for complexes 68, 69 and 9 - 12 are taken from reference 30. 
 
The neutral N,O-ruthenium-hexamethylbenzene metallodendrimers (11, 12, 27, 28) display 
better activity in the A2780 (Figure 4.11, left) and A2780cisR (Figure 4.11, right) cell lines, 
compared to their p-cymene counter-parts (9, 10, 25, 26). It is suggested that the 
hexamethylbenzene ligand improves lipophilicity of the complex, thereby enhancing the 
uptake into cells, and plays a role in biomolecular interactions and recognition processes, such 
as hydrophobic interactions between the arene ring and DNA, specifically in the form of 
strong arene-nucleobase π-π stacking interactions.47 
 
Cationic N,O-Ruthenium-Arene-PTA Complexes 
However, the cationic hexamethylbenzene metallodendrimers [33][PF6]4 - [36][PF6]32 do not 
show an improvement in cytotoxicity in comparison to the p-cymene derivatives [29][PF6]4 - 
[32][PF6]32 in the A2780 cell line (Figure 4.12, left). However, a small improvement in 
cytotoxicity is observed in the cisplatin-resistant cell line (A2780cisR) for the 
hexamethylbenzene analogs (in some cases only) over their p-cymene counterparts (Figure 
4.12, right). 
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Figure 4.12 Effect of the arene ring on the antitumor activity against A2780 (left) and A2780cisR 
(right) human ovarian cancer cells, with cationic N,O-Ru-arene-PTA complexes:  
M ([38][PF6], [39][PF6]); G1 ([29][PF6]4, [33][PF6]4); G2 ([30][PF6]8, 
[34][PF6]8); G3 ([31][PF6]16, [35][PF6]16) and G4 ([32][PF6]32, [36][PF6]32). 
 
The similar trend is observed with reported cationic N,N-ruthenium-arene complexes, 
containing the 2-(pyridine-2-yl)thiazole ligand, with the hexamethylbenzene derivatives 
displaying better activity over the p-cymene derivatives (Figure 4.13, top left).
48
 Furthermore, 
the hexamethylbenzene-octanuclear metallarectangle synthesized by Therrien et al., display 
50 % better activity over its p-cymene derivative (Figure 4.13, top right).
49
 Furthermore, 
Sadler and co-workers reported an increase in cytotoxicity, with an increase in the size of the 
arene ring system in the order, arene = benzene < p-cymene < biphenyl < dihydroanthracene 
< tetrahydroanthracene (Figure 4.13, bottom centre).
50
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Figure 4.13 Molecular structures of ruthenium-arene complexes, with varying arene rings, and 
IC50 values of the compounds in A2780 human ovarian cancer cells.
48-50
 
 
4.2.3 Influence of the Water-Soluble Phosphine Ligand:  
Neutral vs. Cationic (i.e. PTA vs. Chlorido) 
In order to improve interactions between the drug and DNA, it was thought to synthesize 
cationic complexes, to improve simple electrostatic interactions between the cationic complex 
and the negatively charged phosphate groups on the surface of DNA (possible drug target).
51
 
It was thought to abstract the chlorido ligand from the previously reported first- and second-
generation neutral N,O-ruthenium-arene metallodendrimers (9 - 12),
29
 and the newly prepared 
third- and fourth-generation derivatives 25 - 28, and introduce the water-soluble PTA ligand 
into the coordination sphere, in turn generating cationic metallodendrimers [29][PF6]4 - 
[36][PF6]32. Furthermore, with the established tumor inhibiting properties of the RAPTA 
complexes, and the targeting of metastatic tumors in CBA mice,
31, 52
 the introduction of the 
PTA moiety would make for an interesting investigation towards the mode of action of the 
complexes. 
 
In general the cationic metallodendrimers [29][PF6]4 - [36][PF6]32 display a vast improvement 
in biological activity in the A2780 cell line, over their neutral counter-parts 9 - 12 and 25 - 28, 
for both p-cymene (Figure 4.14, left) and hexamethylbenzene (Figure 4.14, right) derivatives. 
The fourth-generation cationic N,O-ruthenium p-cymene metallodendrimer [32][PF6]32 (IC50 = 
0.8 μM in A2780) displays a two-fold increase in activity over its neutral chlorido-derivative 
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26 (IC50 = 2.9 μM in A2780). The hexamethylbenzene metallodendrimer [36][PF6]32 displays 
the same activity to its neutral derivative 28 (IC50 ~ 2 μM in A2780). 
 
 
Figure 4.14 Effect of the charge on the antitumor activity against A2780 human ovarian cancer 
cells (p-cymene derivatives - left; hexamethylbenzene derivatives - right), with neutral 
N,O-Ru-arene complexes and cationic N,O-Ru-arene-PTA complexes. IC50 values of 
neutral complexes 68, 69 and 9 - 12 is taken from reference 30. 
 p-cymene derivatives: M ([38][PF6], 68); G1 ([29][PF6]4, 9); G2 ([30][PF6]8, 10); 
G3 ([31][PF6]16, 25) and G4 ([32][PF6]32, 26). 
 hexamethylbenzene derivatives: M ([39][PF6], 69); G1 ([33][PF6]4, 11); G2 
([34][PF6]8, 12); G3 ([35][PF6]16, 27) and G4 ([36][PF6]32, 28). 
  
Moreover, in the A2780cisR cell line the cationic p-cymene metallodendrimers [29][PF6]4 - 
[32][PF6]32, display better activity than their neutral p-cymene counterparts 9, 10, 25 and 26 
(Figure 4.15, left). In particular the third- and fourth-generation cationic derivatives 
[31][PF6]16 (IC50 = 3.6 μM in A2780cisR) and [32][PF6]32 (IC50 = 2.7 μM in A2780cisR), 
display superior activity over the neutral derivatives 25 (IC50 = 13.2 μM in A2780cisR) and 
26 (IC50 = 9.9 μM in A2780cisR). Whilst the cationic hexamethylbenzene-derived second-, 
third- and fourth-generation metallodendrimers [34][PF6]8 (IC50 = 12 μM in A2780cisR), 
[35][PF6]16 (IC50 = 2.0 μM in A2780cisR) and [36][PF6]32 (IC50 = 1.1 μM in A2780cisR), 
display comparable cytotoxicities to the neutral hexamethylbenzene derivatives 12 (IC50 = 9.0 
μM in A2780cisR), 27 (IC50 = 2.1 μM in A2780cisR) and 28 (IC50 = 2.1 μM in A2780cisR), 
in the A2780cisR cell line. 
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Figure 4.15 Effect of the charge on the antitumor activity against A2780cisR human ovarian 
cancer cells (p-cymene derivatives - left; hexamethylbenzene derivatives - right), with 
neutral N,O-Ru-arene complexes and cationic N,O-Ru-arene-PTA complexes. IC50 
values of neutral complexes 68, 69 and 9 - 12 is taken from reference 30. 
 p-cymene derivatives: M ([38][PF6], 68); G1 ([29][PF6]4, 9); G2 ([30][PF6]8, 10); 
G3 ([31][PF6]16, 25) and G4 ([32][PF6]32, 26). 
 hexamethylbenzene derivatives: M ([39][PF6], 69); G1 ([33][PF6]4, 11); G2 
([34][PF6]8, 12); G3 ([35][PF6]16, 27) and G4 ([36][PF6]32, 28). 
 
It does appear that the PTA ligand improves the pharmacological properties of the 
metallodendrimers, at least in vitro, leading to an improvement in cytotoxicity. The in vitro 
antitumor activity of the above mentioned metallodendrimers is moderate to good compared 
to cisplatin. However, in vitro potency appears not to be a prerequisite in particular for 
ruthenium-arene drugs.
38
 RAPTA complexes exhibit low activity in vitro but possess very 
good antimetastatic activity in vivo.
14, 15
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4.2.4 Resistance 
The mean resistance index (RI) was calculated by the IC50 of A2780cisR cells/IC50 of A2780 
cells for the neutral N,O-ruthenium-arene complexes (Table 4.1) and the cationic N,O-
ruthenium-arene-PTA complexes (Table 4.2). The RI values relate to how resistant the 
compounds are in the cisplatin-sensitive cell line (A2780) compared to the cisplatin-resistant 
cell line (A2780cisR).  
 
Resistance of Neutral N,O-Ruthenium-Arene Complexes 
The neutral N,O-ruthenium-arene complexes display similar activity in both the A2780 and 
A2780cisR cell lines, with RI values approximately equal to 1 (Table 4.1), with the exception 
of metallodendrimers 25 (RI = 2.2) and 26 (RI = 3.4) which display moderate resistance in the 
A2780cisR cells. However, this resistance is modest in comparison to cisplatin-resistance (RI 
= 16.7). In general, the neutral N,O-ruthenium-p-cymene metallodendrimers display an 
increase in resistance with an increase in dendrimer generation, whilst the neutral N,O-
ruthenium-hexamethylbenzene metallodendrimers display no cross-resistance to cisplatin 
(Figure 4.16). 
 
 
Figure 4.16 Effect of changing the arene ligand from p-cymene to hexamethylbenzene on the 
cytotoxicity against A2780 and A2780cisR cells (plotted as a resistance index RI = 
IC50 of A2780 cells / IC50 of A2780cisR cells) for complexes:  
M (68, 69); G1 (9, 11); G2 (10, 12); G3 (25, 27); G4 (26, 28) and cisplatin. 
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Resistance of Cationic N,O-Ruthenium-Arene-PTA Complexes 
The cationic N,O-ruthenium-arene-PTA complexes are active in both the A2780 and 
A2780cisR human ovarian cancer cells, with moderate RI values listed in Table 4.2. There is 
a small increase in resistance of the cationic ruthenium-p-cymene-PTA metallodendrimers 
[29][PF6]4 - [32][PF6]32 with an increase in dendrimer generation (Figure 4.17). However, 
there is a decrease in resistance of the cationic ruthenium-hexamethylbenzene-PTA 
metallodendrimers [33][PF6]4 - [36][PF6]32 with an increase in dendrimer generation towards 
A2780cisR cells. 
 
 
Figure 4.17 Effect of changing the arene ligand from p-cymene to hexamethylbenzene on the 
cytotoxicity against A2780 and A2780cisR cells (plotted as a resistance index RI = 
IC50 of A2780 cells / IC50 of A2780cisR cells) for complexes:  
M ([38][PF6], [39][PF6]); G1 ([29][PF6]4, [33][PF6]4); G2 ([30][PF6]8, 
[34][PF6]8); G3 ([31][PF6]16, [35][PF6]16); G4 ([32][PF6]32, [36][PF6]32) and 
cisplatin. 
 
Generally, both the neutral and cationic ruthenium-arene metallodendrimers display no cross 
resistance to cisplatin, in other words, the cytotoxicities are similar in both cell lines. 
Furthermore, this indicates that these types of systems are markedly less susceptible to the 
same resistance mechanisms that inhibit cisplatin-activity against A2780cisR cells.
53
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4.2.5 Selectivity 
Selectivity of Cationic N,O-Ruthenium-Arene-PTA Complexes 
Before drugs can be considered for biological applications, evaluation of their selectivity for 
cancerous cells over non-tumorigenic cells is extremely important. Hence, the in vitro 
biological activity of the N,O-cationic ruthenium-arene metallodendrimers against model 
human embryonic kidney (HEK) cells was elucidated (Figure 4.18).  
 
 
Figure 4.18 Effect of arene ring (cationic N,O-Ru-p-cymene-PTA complexes - left; cationic N,O-
Ru-hexamethylbenzene-PTA complexes - right) on the selectivity for cancer cells, with 
[29][PF6]4 - [36][PF6]32, [38][PF6] and [39][PF6]. 
 
With the exception of [29][PF6]4, the multinuclear complexes are consistently selective 
towards the cancer cells (A2780 & A2780cisR) over the non-tumorigenic cells. More 
specifically, the first-generation p-cymene metallodendrimer [33][PF6]4 displays good 
selectivity for the A2780 (IC50 = 8.9 μM) and A2780cisR (IC50 = 25 μM) over the HEK cells 
(IC50 = 90 μM). However, the selectivity is not ideal and therefore synthesis of heterometallic 
ferrocenyl-derived ruthenium-arene metallodendrimers were prepared and described in 
Chapter 3. Furthermore, ferrocene is considered non-toxic and its one-electron reversible 
oxidation to the cytotoxic ferrocenium cation makes it a promising candidate in the 
development of therapeutic agents. 
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4.3 Stability of the Cationic N,O-Ruthenium-Arene-PTA Metallodendrimers in 
Solution and Interactions with Nucleotides 
 
4.3.1 Degradation Test 
It is important to understand the stability of drugs in solution before they can be considered 
for any biological applications. Hence, to investigate the influence of the bidentate chelating 
N,O-dendritic ligands on the stability of the cationic N,O-ruthenium-arene metallodendrimers 
in solution, time degradation studies on selected complexes were investigated using 
31
P{
1
H} 
NMR spectroscopy. The hexamethylbenzene derivatives display the best activity, hence first-
generation metallodendrimer [33][PF6]4; and its mononuclear analog [39][PF6] were selected, 
and will be used as a preliminary study to model the behavior of the higher generation 
metallodendrimers in deuterated dimethylsulfoxide. To monitor degradation or the release of 
metallofragments, the complexes were prepared at a concentration of  
0.043 mg.μL-1, and 31P{1H} NMR experiments (Figure 4.19 and 4.20) were performed at  
37 ºC (physiological temperature).  
 
Figure 4.19 
31
P{
1
H} NMR spectra of the mononuclear complex [39][PF6] recorded at 37 ºC in 
(CD3)2SO at different time intervals. 
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Metallodendrimer [33][PF6]4 and mononuclear derivative [39][PF6] displayed good stability in 
deuterated dimethylsulfoxide, with no signs of degradation signals observed in the 
31
P{
1
H} 
NMR spectrum over the 2h period. In addition, this shows that the complexes are stable in 
deuterated dimethylsulfoxide during the time period between preparation of the compound 
stock solutions and dosing of the cancer cells in the assay. 
 
 
Figure 4.20 
31
P{
1
H} NMR spectra of the metallodendrimer [33][PF6]4 recorded at 37 ºC in 
(CD3)2SO at different time intervals. 
 
4.3.2 Aquatic Stability 
It is important to know the identity of the compound that reaches the cell, and accordingly, the 
aqueous chemistry of the complexes is important. Following uptake into the cell, it has been 
reported that ruthenium-arene-PTA complexes are activated via aquation, generating the aqua 
species. This is said to be the ‘active’ form of the complex (Scheme 4.1) and the formation of 
the aqua species can be monitored by NMR spectroscopy.
54, 55
 
 
 
Scheme 4.1 Hydrolysis of RAPTA-C in pure water.
54, 55
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In order to study the influence of the chelating N,O-dendritic ligand on the behavior of the 
N,O-ruthenium-arene complexes in an aqueous solution, the first-generation N,O-ruthenium-
hexamethylbenzene-PTA metallodendrimer [33][PF6]4, used to model the higher generation 
metallodendrimers, was dissolved in D2O:(CD3)2SO (95:5 % v/v) and the complex monitored 
by 
1
H and 
31
P{
1
H}NMR spectroscopy (Figure 4.21).  
 
 
Figure 4.21 
31
P{
1
H} NMR spectra of the metallodendrimer [33][PF6]4 recorded at 37 ºC in 
D2O:(CD3)2SO (95:5) over 14 days. 
 
As expected, introduction of the N,O-chelate ligand resulted in enhanced stability of the 
complex. Metallodendrimer [33][PF6]4 is stable over the 14 days with no side-products or 
aqua-species observed. A similar result was observed by Hanif and co-workers, where a series 
of dichloride carbohydrate-ruthenium-arene derivatives formed mono aqua species within a 
few hours.
56
 However, exchange of the chlorido ligands by O,O-biscarboxylato chelate 
ligands resulted in enhanced stability of the complexes.
57
  
 
Ideally this type of experiment should be performed under biological conditions (in a buffered 
solution, at pH 7.4) and in NaCl solutions representative of blood plasma (100 mM) and 
intracellular (4 mM) concentrations.
14
 Nevertheless, the higher generation cationic ruthenium-
arene metallodendrimers display good cytotoxicity in vitro, and this preliminary investigation 
suggests the activity may not have been brought on by the formation of the aqua-species and 
these complexes operate via a different mode of action to that of the RAPTA series. 
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4.3.3 Nucleotide Binding 
Though the N,O-ruthenium-arene-PTA complexes are inert in water, it has been reported that 
in the presence of other ligands (such as those found in biological media), these reactions may 
occur more readily.
56, 58
 In particular, the binding of ruthenium-arene complexes to 
proteinaceous targets is thought to be an important step in the mechanism of action of these 
complexes,
59-64
 though they also have a strong affinity towards DNA.
64, 65
 Furthermore, 
mechanistic studies on the interaction between RAPTA complexes and DNA suggest that 
these complexes preferentially bind to the purine base, guanine.
66, 67
 Hence, the interaction 
between [39][PF6] (used to model the higher generation metallodendrimers) and nucleotide 
guanosine 5’-monophosphate (5’GMP) in D2O:(CD3)2SO (95:5 % v/v) was monitored by 
1
H 
and 
31
P{
1
H} NMR spectroscopy. Essentially the mixtures were incubated at 37 ºC for 2h 
before preliminary NMR experiments were performed. The 
1
H NMR spectrum (Figure 4.22) 
of the mixture shows a downfield shift in the signal assigned to the H8 atom from 8.22 ppm 
(for free 5’GMP) to 8.64 ppm (for adduct), and is attributed to the formation of the Ru-HMB-
5’GMP adduct. Furthermore, this suggests coordination of the 5’GMP to the ruthenium centre 
via the N7 atom, with similar shifts in signals observed for other Ru(II) complexes.
66
  
 
Figure 4.22 
1
H NMR spectra of [39][PF6] (bottom), 5’GMP (middle), and a mixture of [33][PF6] 
and 5’GMP (ratio 1:1, top) recorded at 37 ºC in D2O:(CD3)2SO (95:5 % v/v) after 2h 
of incubation. The residual water signal is visible ~4.7 ppm. 
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Prior to reaction(s) with biomolecular targets, hydrolysis is considered an essential step in the 
mechanism of action of ruthenium and platinum complexes.
4, 68
 However, for [39][PF6], 
although hydrolysis was not observed, binding of the N7 atom of 5’GMP to the Ru(II) centre 
is observed. This property has been observed for similar chelating bidentate Ru(II) 
complexes,
57
 and hence hydrolysis may not be a prerequisite, as the biological activity may 
appear to be brought on by covalent bonding to biomolecular targets. Using the mononuclear 
complexes [39][PF6] to model the higher generation metallodendrimers, this preliminary 
investigation suggests these types of systems do bind to the N7 atom of the purine base, 
5’GMP, via the ruthenium centre. Therefore, DNA represents a suitable binding partner for 
this class of compounds. 
 
4.4 DNA Binding Study of Neutral and Cationic N,O-Ruthenium-Arene 
Metallodendrimers 
 
DNA is a potential drug target for ruthenium-arene drugs and is an important target in cancer 
therapy.
69
 Furthermore, the most cytotoxic ruthenium drugs act as DNA intercalators upon 
coordination to the suitable ancillary ligand.
70
 In order to correlate the antiproliferative 
activity of the neutral and cationic N,O-ruthenium-arene systems to possible interactions with 
DNA, the compounds were incubated with plasmid DNA for 24 hours and analyzed by gel 
electrophoresis. As mentioned, DNA is a possible biomolecular target for anticancer drugs 
and hence the interactions between both the neutral and cationic ruthenium-arene complexes 
with DNA were investigated. 
Gel electrophoresis was employed for the DNA binding studies and is a technique used to 
separate DNA based on its mobility in an electric field. Mobility of the DNA is primarily 
based on size. Hence, the larger the DNA adducts the slower the migration of the DNA band 
down the gel matrix (agarose gel). Typically, the metal complex is incubated with the plasmid 
DNA and then separated by electrophoresis. This process involves the connection of opposite 
ends of the gel plate to a power source, which in turn is used to initiate migration of the DNA. 
Following electrophoresis, the gel is stained with ethidium bromide (staining agent) and the 
bands analyzed with an UV gel scanner. Incubation of the metal complex with DNA may 
result in DNA damage which will alter the pattern of migration (i.e. retardation of the band).  
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DNA binding studies were performed by incubating plasmid DNA in the presence of the 
ruthenium-arene metallodendrimers (25 - [36][PF6]32), their mononuclear analogs ([38][PF6] 
& [39][PF6]) and cisplatin (cisPt) for 24 h at 37 °C at different metal center/DNA base pair 
ratios (r = 0.25 and 0.5). The entire series was evaluated as this type of experiment can 
accommodate the evaluation of several complexes simultaneously. The resulting mixtures 
were separated by gel electrophoresis and the resulting gels are shown in Figure 4.23. 
 
  
 
 
Figure 4.23  Comparison of DNA damage induced by (from left to right on each gel): (left) the 
neutral N,O-ruthenium-arene-chlorido complexes 25 - 28 and cisplatin (cisPt: 
reference compound), (middle) the cationic N,O-ruthenium-p-cymene-PTA complexes 
[38][PF6], [29][PF6]4 - [32][PF6]32 and cisPt, (right) the cationic N,O-ruthenium-
hexamethylbenzene-PTA complexes [39][PF6], [33][PF6]4 to [36][PF6]32 and cisPt, 
for 24 h at different metal centre:DNA base pair ratios (r = 0.25 and 0.5); visualized 
by electrophoretic DNA migration in an agarose gel. Control is DNA alone. 
 
The cleaving ability of all the compounds was assessed by their efficiency to convert 
supercoiled pBR322 DNA into nicked DNA, while the third form, linear DNA, was not 
observed by gel electrophoresis. Significant differences between the neutral N,O-ruthenium-
arene metallodendrimers (25 - 28) and the cationic N,O-ruthenium-arene-PTA 
metallodendrimers ([29][PF6]4 - [36][PF6]32) were observed. The metallodendrimers bearing 
chlorido ligands do not seem to interact with DNA (with the exception of 25). Whilst the 
metallodendrimers bearing the PTA ligand, which contain eight or more metal centres, 
appears to form extensive DNA aggregates that are unable to migrate in the gel. 
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The reason for ready interaction of the cationic N,O-ruthenium-arene-PTA metallodendrimers 
(G2, G3 & G4) with the plasmid DNA is not known. Three possible reasons for this interaction 
are therefore proposed; firstly there exists negatively charged phosphate groups on the surface 
of the DNA helix, which in turn allows for electrostatic interactions between these negatively 
charged groups and the positive chargers on the cationic complexes (Figure 4.24). 
Furthermore, Eichman and co-workers formed purely organic PAMAM dendrimer-DNA 
adducts, which resulted from ionic interactions between the negatively charged DNA and the 
positively charged dendrimer, that were used for gene transfer.
51
 Kim et al. report the 
synthesis of argentine-rich PAMAM-based dendrimers, which are able to electrostatically 
self-assemble with plasmid DNA, forming nanometer-scale complexes.
71
 
 
 
Figure 4.24 Schematic diagram illustrating the ionic interaction between the positively charged 
metallodendrimer and the negatively charged DNA back-bone.
72
 
 
Secondly, the DAB-dendritic scaffold resembles that of naturally occurring polyamines, 
which are known for their biological activity.
73
 Naturally occurring polyamines such as 
spermidine and putrescine have the ability to interact with nucleic acids of DNA and inhibit 
DNA replication.
74
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Finally, Sadler and co-workers extensively studied the mechanism of action of a series of 
ruthenium-arene complexes bearing substituted arenes or arenes with extended π-systems, 
with particular focus on the interaction between the arene ring and DNA.
70
 Studies showed 
the arene ring provides a hydrophobic face for the complex and enhances π-π stacking 
interactions between the arene ring and DNA bases. Furthermore, the biomolecular 
interactions increased with an increase in size of the coordinated arene. 
 
Moreover, there could be a cooperative effect between these possible modes-of-action, 
resulting in the formation of DNA aggregates and high cytotoxicity of these cationic N,O-
ruthenium-arene metallodendrimers.  
 
4.5 Cell Viability Studies of Ferrocenyl-Derived Metallodendrimers 
 
Research in the medical field is focussed towards the design of new drugs which are active 
against a wide range of cancers and have fewer side-effects than well-established Pt-based 
drugs. Ferrocene has gained considerable attention due to it being neutral, chemically stable 
in an aqueous media and non-toxic. It is easily derivatized and many ferrocenyl-based 
derivatives display cytotoxic,
75, 76
 antitumor,
77, 78
 antimalarial
79
 and antifungal
80
 properties. 
The activity of these complexes are attributed to their favorable electronic properties and ease 
of functionalization.
81, 82
  
 
Ferrocene has been linked with both platinum
83, 84
 and gold
85
 centres, in an attempt to achieve 
a synergistic effect between the two metals and potentially target multiple drug targets. 
Similarly, cationic heterometallic N,O- and N,N-ruthenium-p-cymene metallodendrimers, 
bearing the ferrocene moiety ([62][PF6]4 - [65][PF6]8, Figure 4.3) were synthesized and 
discussed in Chapter 3. Preliminary in vitro cell viability studies of the ligands and their 
complexes were evaluated against A2780 and A2780cisR human ovarian cancer cells and is 
described (Table 4.4). 
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Cell viability studies involve the use of a viability assay which is used to determine the ability 
of cells to maintain or recover its viability. In short, by dosing the cells with the test substance 
at a specific concentration, the cells and the test substance are incubated over a period time 
and the percentage viable cells then measured. The lower the percentage viability value 
obtained the more active the test substances are at the specific test concentration. 
 
Table 4.4 Cell viability values of the ferrocenyl-derived ligands and their heterometallic 
complexes determined against A2780 and A2780cisR human ovarian cancer cells 
after 96 h of exposure to the compound. 
    Cell Viability at 5 μM [%] 
Compound Metal n
a
 Arene A2780
b
 A2780cisR
b
 
60 Fe 1 - 7.8 ± 10.1 18.6 ± 4.7 
56 Fe 4 - 42.3 ± 34.2 37.3 ± 19.5 
57 Fe 8 - 21.1 ± 15.3 36.8 ± 21.7 
61 Fe 1 - 26.0 ± 19.4 24.9 ± 20.6 
58 Fe 4 - 31.3 ± 28.4 29.4 ± 16.5 
59 Fe 8 - 23.0 ± 18.7 30.8 ± 21.5 
[66][PF6] Fe-Ru 1 p-cye 70.3 ± 16.0 54.6 ± 5.8 
[62][PF6]4 Fe-Ru 4 p-cye -2.3 ± 5.6 -4.3 ± 1.5 
[63][PF6]8 Fe-Ru 8 p-cye 5.5 ± 12.6 -1.8 ± 4.2 
[67][PF6] Fe-Ru 1 p-cye 12.0 ± 9.6 25.5 ± 8.9 
[64][PF6]4 Fe-Ru 4 p-cye 86.1 ± 26.3 59.9 ± 12.7 
[65][PF6]8 Fe-Ru 8 p-cye 107.6 ± 97.8 42.5 ±13.1 
a 
n = number of metals present in the complex. 
b 
Cell viability ± standard deviation 
 
The cell viability studies of the ferrocenyl-derived compounds were initially performed at 20 
μM and 10 μM dose concentrations, however many of the compounds displayed potent 
activity, with no structure-activity relationships observed. After lowering the dose 
concentration to 5 μM, generally both the ferrocenyl-derived ligands 56 - 61 and ferrocenyl-
derived ruthenium-p-cymene complexes [62][PF6]4 - [67][PF6] are active in both the A2780 
and A2780cisR cell lines (Figure 4.25), with the A2780 cell line being the most sensitive and 
showing no cross resistance to cisplatin.  
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The moderate results and the large error bars obtained for the ferrocenyl-derived ligands were 
attributed to the poor solubility of the ligands in the culture medium, with precipitation of the 
compounds observed at higher concentrations. Nevertheless, the ferrocenyl-derived N,O- and 
N,N- ligands 56 - 59 and 61 display moderate activity in both cell lines, with the monomeric 
ferrocenyl-derived N,O-salicylaldiminato ligand 60 displaying good activity (Figure 4.25). 
However, there is no correlation between the size of the dendritic ligand and the activity 
observed.  
 
More specifically, it seems the first- and second-generation ferrocenyl-derived N,O-
ruthenium-p-cymene-PTA metallodendrimers [62][PF6]4 and [63][PF6]8 are the most active of 
the heterometallic series (Figure 4.25). There is an increase in activity observed when moving 
from the mononuclear analog [66][PF6] to the higher generation dendritic derivatives 
[62][PF6] and [63][PF6]. Furthermore, introduction of the ruthenium-arene moiety does 
improve the activity in at least two of the metallodendrimers, [62][PF6]4 and [63][PF6]8, and 
can be attributed to possible transmembrane interactions and increased bioavailability brought 
on by the ferrocene moiety.
86
  
 
 
Figure 4.25 Plot of percentage cell viability against A2780 and A2780cisR cells for ferrocenyl-
derived ligands and their complexes: M (60, 61, [66][PF6], [67][PF6]);  
G1 (56, 58, [62][PF6]4, [64][PF6]4) and G2 (57, 59, [63][PF6]8, [65][PF6]8). 
Treated cells that grew slower and/or were less viable than the control cells 
display a negative percent change in cell viability. 
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A similar trend was observed by Auzias et al., where ferrocenyl-derived ruthenium-arene 
complexes displayed improved in vitro antitumor activity against A2780 human ovarian 
cancer cells compared to their ferrocenyl-derived ligands (Figure 4.26).
87
  
 
 
Figure 4.26 Molecular structures of ferrocenyl-derived ligands and ferrocenyl-derived ruthenium-
arene complexes, and IC50 values of the compounds in A2780 human ovarian cancer 
cells.
87
 
 
This improvement in activity is not observed for the ferrocenyl-derived N,N-ruthenium-p-
cymene metallodendrimers [64][PF6]4 and [65][PF6]8 compared to their ferrocenyl-derived 
dendritic ligands 58 and 59, with the mononuclear analog [67][PF6] displaying better activity 
in both cell lines (Figure 4.25). 
 
A direct comparison cannot be made between these heterometallic ferrocenyl-derived 
ruthenium-arene metallodendrimers mentioned and the homometallic ruthenium-arene-PTA 
metallodendrimers discussed in Chapter 2. Hence, the next step in the biological evaluation of 
the heterometallic ferrocenyl-derived ruthenium-arene metallodendrimers is to determine the 
IC50 values of the most active compounds and compare them with the values obtained for the 
homometallic ruthenium-arene-PTA systems. These experiments could not be performed at 
the time of submission and will eventually be performed. 
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4.6 Overall Summary 
 
The neutral N,O-ruthenium-arene metallodendrimers 25 - 28 exhibit moderate to high 
antiproliferative activity against both the A2780 and A2780cisR human ovarian cancer cell 
lines, particularly the second (10, 12), third (25, 27) and fourth (26, 28) generation 
derivatives. The neutral N,O-ruthenium-hexamethylbenzene derivatives (11, 12, 27, 28) 
display better activity, in both the A2780 and A2780cisR cell lines, compared to their p-
cymene counter-parts (9, 10, 25, 26). Furthermore, the neutral N,O-ruthenium-
hexamethylbenzene metallodendrimers display no cross-resistance to cisplatin. All of the 
neutral N,O-ruthenium-arene metallodendrimers demonstrate lower toxicity against human 
embryonic kidney (HEK) cells.  
 
The cationic N,O-ruthenium-arene-PTA metallodendrimers [29][PF6]4 - [36][PF6]32 display a 
similar trend in activity to their neutral derivatives (9 - 12, 25 - 28), with an increase in 
biological activity observed with increase in dendrimer generation. Furthermore, 
incorporation of the PTA moiety resulted in a vast improvement in the biological activity of 
these complexes. With an increase in dendrimer generation, there is a decrease in resistance of 
the cationic ruthenium-hexamethylbenzene-PTA metallodendrimers [33][PF6]4 - [36][PF6]32 
towards A2780cisR cells. These multinuclear complexes are consistently selective for cancer 
cells over the healthy cells.  
 
The introduction of the N,O-chelate ligand resulted in an enhanced stability of the complexes 
in solution, suggesting hydrolysis may not be a prerequisite in the mode of action of these 
complexes. Hence, preliminary NMR experiments confirmed the coordination of the 5’GMP 
to the ruthenium centre via the N7 atom and it appears covalent binding to biomolecules 
might be a prerequisite for these compounds to exhibit their activity. The metallodendrimers 
bearing chlorido ligands do not seem to interact with DNA, whilst the higher generation 
metallodendrimers bearing the PTA ligand, appear to form extensive DNA aggregates that are 
unable to migrate in the gel.  
 
The neutral and cationic osmium-arene complexes (40 - [43][PF6]8, [46][PF6]4, [47][PF6]8), 
displayed no improvement in the cytotoxicity of the complexes when replacing ruthenium 
with osmium.  
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Preliminary cell viability studies performed on the ferrocenyl-derived ligands 56 - 61 and 
ferrocenyl-derived ruthenium-p-cymene-PTA complexes [62][PF6]4 - [67][PF6] are active at 
the 5 μM dose concentration in both the A2780 and A2780cisR cell lines. The complexes 
displayed no cross resistance to cisplatin. The first- and second-generation ferrocenyl-derived 
N,O-ruthenium-p-cymene-PTA metallodendrimers [62][PF6]4 and [63][PF6]8 are the most 
active of the series.  
 
The activity of the neutral and cationic ruthenium-arene metallodendrimers could be 
improved through suitable modification of the ligand structure and/or preparing higher 
dendrimer generations of the active compounds. Modification of the arene ring, with more 
extended arene ring systems, could present an enhanced biological activity. Furthermore, 
though only a handful of these complexes display poor cytotoxicity in vitro, they may display 
effective in vivo activity against metastasis cells, similarly observed for the ruthenium-based 
anticancer drugs RAPTA-C
14, 15
 and NAMI-A.
88, 89
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Chapter 5 
Synthesis, Characterization and CO-Release of  
Polynuclear Tricarbonylmanganese(I)-Polypyridyl Complexes 
Based on Poly(propyleneimine) Dendritic Scaffolds 
 
This chapter forms part of the following publication: 
Preshendren Govender, S. Pai, U. Schatzschneider and G. S. Smith, Next Generation PhotoCORMs: 
Polynuclear Tricarbonylmanganese(I)-Functionalized Polypyridyl Metallodendrimers, Inorganic 
Chemistry, 2013, 52, 5470-5478. 
 
5.1 Introduction 
 
More than half a century ago, it was found that carbon monoxide (CO) is constantly formed in 
small quantities in humans,
1
 and has been viewed as highly toxic due to its deleterious effects 
on the oxygen transport system within the human body.
2
 Over the last 10 years, the interest in 
the biological effects of carbon monoxide has greatly increased, and it is now established in 
the medical literature that CO does have a major role in mammals as a signalling molecule.
3, 4
  
 
There is growing interest in the use of CO-releasing molecules (CORMs) as a stable solid 
storage form of CO,
5
 which is much easier to handle than the toxic gas itself, to eventually 
investigate the potential therapeutic applications and the biological mode of action at a 
molecular level.
6
 Transition-metal carbonyl complexes are a natural choice as CO-prodrugs 
and a number of trigger mechanisms to initiate CO-release from the metal coordination sphere 
have been developed, namely solvent-assisted CO-release and enzyme-triggered CO-release.
7-
11
 Another important technique is light-induced CO-release in photo-activated CORMs 
(PhotoCORMs).
 5, 12-15
 
 
Light has been used to induce a biological response in “caged” complexes (Figure 5.1), as 
well as in the context of photodynamic therapy (PDT), where light is used to initiate the 
production of singlet oxygen by photosensitisers. However, a more well-defined spectrum of 
cellular targets was required in the form a light-activated ‘active’ species. Hence the synthesis 
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of light-activated water-soluble molybdenum-containing CORMs [Mo(C≡CCR1R2OH)(η5-
C5H5)(CO)3] (68, where R = R
1
 = Me or R = Me, R
l
 = Ph) was pursued (Figure 5.1).
16
 The 
light-activated release of carbonyl ligands and the efficient cellular uptake by HT-29 human 
colon cancer cells of a Mn-functionalized CORM, i.e. [Mn(CO)3(tpm)]PF6 (69, where tpm = 
tris(pyrazolyl)methane) (Figure 5.1),
17
 prompted the investigation into the biocompatibility 
and the targeting ability of this CORM. Hence, Schatzschneider and co-workers conjugated 
amino acids and model peptides (70) with the [Mn(CO)3(tpm)]
+ 
via Sonogashira cross-
coupling and “click” reactions, for a more targeted approach (Figure 5.1).18 However, 
incorporation to the bioconjugate did not alter the CO-release properties of the metal carbonyl 
moiety. 
 
 
Figure 5.1 Light-activated CO-releasing molecules.
16-18
 
 
A common problem with all reported CORMs, is the fact that in addition to the CO liberated, 
there is always an inevitable formation of a metal-coligand fragment, which might possess a 
biological activity of its own. One strategy to address this problem is based on systems in 
which the metal-ligand moiety generated after CO-release remains bound to a 
macromolecular carrier. In addition to different polymeric materials,
19
 dendrimers are an 
attractive choice for this purpose due to their monodisperse nature and facile preparation. As 
previously mentioned, such macromolecules are known to passively accumulate in cancerous 
tissue due to the enhanced permeability and retention (EPR) effect.
20
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In this chapter the synthesis and characterization of novel tetranuclear and octanuclear 
Mn(CO)3-functionalized CO-releasing metallodendrimers based on polypyridyl dendritic 
scaffolds is described. The complexes were comprehensively characterized by analytical and 
spectroscopic methods, and are described. The CO-release of the metallodendrimers was 
investigated using the myoglobin assay
21
 and is discussed. In addition, a mononuclear analog 
was synthesized as a model of the larger metallodendrimers in order to study potential size-
dependent scaling effects on the photoactivated CO-release. 
 
5.2 Synthesis and Characterization of Bipyridyl Ligands  
 
The synthesis of the bipyridyl ligands required the preparation of 4’-methyl-2,2’-bipyridine-4-
carboxaldehyde 71 via an oxidation reaction with selenium dioxide in 1,4-dioxane (Scheme 
5.1).
22-24
 Compound 71 was isolated as a white solid in a moderate yield, with the 
experimental data listed in Chapter 6. The appearance of the singlet at ~10 ppm (CHO proton) 
in the 
1
H NMR spectrum and the stretching vibration at ~1700 cm
-1
 (C=O bond) in the 
infrared spectrum, assigned to the aldehyde functionality, confirms the integrity of 71. 
 
 
Scheme 5.1 Synthesis of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde 71. 
 
The N,N-bipyridylimine dendritic ligands 72 and 73 were prepared via a Schiff base 
condensation reaction of 71 with DAB-G1-PPI-(NH2)4 (for 72) or DAB-G2-PPI-(NH2)8 (for 
73) in dichloromethane for 48 h (Scheme 5.2). 72 and 73 were isolated as red-brown oils in 
high yields (89 - 90 %).  
Chapter 5. CO-Releasing Metallodendrimers 
 
 
 
169 
 
 
Scheme 5.2 Synthesis of N,N-bipyridylimine dendritic ligands 72 and 73. 
 
Similarly, the N,N-bipyridylimine monomeric ligand 74 was prepared by reacting n-
propylamine and 71 (Scheme 5.3), to afford 74 as a dark yellow oil in a moderate yield. The 
oils 72 - 74 are soluble in most organic solvents such as dichloromethane, methanol, toluene, 
diethyl ether and dimethylsulfoxide. Spectroscopic (
1
H NMR, 
13
C{
1
H} NMR and IR 
spectroscopy) and analytical data (elemental analysis and mass spectrometry) confirmed the 
integrity of the new ligands. 
 
 
Scheme 5.3 Synthesis of monomeric N,N-bipyridylimine monomeric ligand 74. 
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5.2.1 
1
H and 
13
C{
1
H} NMR Spectroscopy  
The 
1
H and 
13
C{
1
H} NMR data of 72 - 74 was recorded in deuterated chloroform. A broad 
singlet at ~8.3 ppm in the 
1
H NMR spectra for 72 (Figure 5.2) and 73, which integrates for 
four and eight protons respectively, is assigned to the imine proton (Table 5.1) and confirms 
formation of the Schiff base. Additional broad multiplets are observed between 1.4 and 3.7 
ppm in the 
1
H NMR spectra for 72 and 73, are assigned to the aliphatic protons of the core 
and arms of the dendritic ligands. The characteristic sharp singlet at ~2.4 ppm, for 72 and 73, 
is assigned to the protons on the methyl group.  
 
 
Figure 5.2 
1
H NMR spectrum of first-generation N,N-bipyridylimine dendritic ligand 72 in 
CDCl3. 
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Table 5.1 Selected spectroscopic and analytical data for ligands 72 - 74. 
Compound 
1
H NMR  
(imine) [ppm]
a
 
13
C{
1
H} NMR 
(imine) [ppm]
a
 
IR  
(imine) [cm
-1
]
b
 
MS  
([fragment]
+
) 
[m/z]
c
 
72 8.33 159.3 1648 1038.79 [M+H]
+
 
73 8.30 159.2 1648 560.25 [M+4H]
4+
 
74 8.32 159.1 1649 239.28 [M]
+ d
 
a
Recorded in CDCl3 
b
Recorded in NaCl solution cells in CH2Cl2 
c
HR-ESI-TOF-MS 
d
EI-MS 
 
Similar trends and splitting patterns are observed in the 
1
H NMR spectrum of 74 (Figure 5.3, 
Table 5.1). The signals observed for the aliphatic protons on the propyl chain appear upfield, 
with the CH2 protons closest to the imine moiety assigned to the broad triplet observed at ~3.7 
ppm.  
 
Figure 5.3 
1
H NMR spectrum of monomeric N,N-bipyridylimine ligand 74 in CDCl3. 
 
 
 
Chapter 5. CO-Releasing Metallodendrimers 
 
 
 
172 
 
Several peaks are observed in the aromatic region, of the 
1
H NMR spectrum of 72 - 74, 
between 7.0 and 9.0 ppm and are assigned to the protons on the bpy (bipyridyl) moieties. 
With aid of the 2D-COSY NMR spectrum (Figure 5.4) of 74, assignments of the aromatic 
signals of the protons on the bpy moiety and the imine proton are assigned and are listed in 
Chapter 6.  
 
Figure 5.4 2D-COSY NMR spectrum of the N,N-bipyridylimine monomeric ligand 74 in CDCl3. 
 
The 
13
C{
1
H} NMR data of 72 - 74 gave the expected carbon peaks for each compound (Table 
5.1). No significant changes were observed in the chemical shifts of the signals observed 
when moving from the first-generation 72 to the second-generation 73. Signals for the 
aliphatic carbons are observed between 20 - 60 ppm and aromatic carbons seen between 120 - 
160 ppm for 72 - 74. In the 
13
C{
1
H} NMR spectra of 72 - 74, four singlets of medium 
intensity are observed between 144 ppm and 158 ppm and are assigned to the quaternary 
carbons of the bpy moiety (Figure 5.5).  
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Figure 5.5 
13
C{
1
H} NMR spectrum of the first-generation N,N-bipyridylimine dendritic ligand 72 
in CDCl3. 
 
5.2.2 Infrared Spectroscopy 
Along with 
1
H and 
13
C{
1
H} NMR, formation of the imine bond is confirmed by the diagnostic 
C=N absorption band at ~1648 cm
-1
 in the infrared spectrum for ligands 72 - 74 (Table 5.1). 
An absorption band at ~1600 cm
-1
 is observed and was attributed to the C=N bond present in 
the bpy moiety. 
 
5.2.3 Elemental Analysis and Mass Spectrometry 
Elemental analysis and mass spectrometry analysis (Table 5.1) confirmed the integrity of the 
new ligands 72 - 74. Following extensive drying, elemental analysis data were found within 
acceptable limits for 72 - 74, with no solvent inclusion observed. HR-ESI-mass spectrometry 
analysis showed the highest molecular weight fragment of [M+H]
+
 and [M+4H]
4+
 for 72 and 
73 respectively, whilst the EI-MS data for 74 displayed a peak for [M]
+
. 
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5.3 Synthesis and Characterization of Mn(CO)3-Functionalized 
Metallodendrimers 
 
The tricarbonylmanganese(I) functionalized tetranuclear 75, octanuclear 76 and mononuclear 
77 complexes were synthesized via reaction of manganese pentacarbonyl bromide 
[Mn(CO)5Br] and ligands 72, 73 and 74 respectively in dichloromethane at room temperature, 
under the exclusion of light (i.e. in the dark) (Scheme 5.4 and Scheme 5.5).  
 
 
Scheme 5.4 Synthesis of tricarbonylmanganese(I) functionalized tetranuclear (75) and 
octanuclear (76) metallodendrimers. 
 
The workup was performed with minimal exposure to light. Precipitation with diethyl ether, 
afforded the crude products 75 and 76 as yellow-orange solids in moderate yield. Heptane 
was used to precipitate 77 as an orange solid in low yield. Complexes 75 - 77 were purified 
with RP-HPLC using a gradient of 5 - 90 % acetonitrile/water with 0.1 % TFA, and are 
soluble in most polar solvents. 
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Scheme 5.5 Synthesis of tricarbonylmanganese(I) functionalized mononuclear complex 77. 
 
5.3.1 
1
H and 
13
C{
1
H} NMR Spectroscopy  
The 
1
H NMR spectra of complexes 75 - 77 were recorded in deuterated dimethylsulfoxide and 
showed all the relevant peaks for the proposed structures. Broad overlapping signals (possibly 
due to the fact that the Mn(I) centre is paramagnetic) are observed in the 
1
H NMR spectra of 
75 (Figure 5.6) and 76 and are assigned to the aliphatic protons of the dendritic core and arms, 
characteristically seen with other similar metallodendrimers.
25-28
  
 
Figure 5.6 
1
H NMR spectrum of the first-generation tricarbonylmanganese(I) functionalized 
metallodendrimer 75 in (CD3)2SO. 
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There is a small downfield shift in the signal assigned to the imine proton form ~8.3 ppm in 
the ligands 72 - 74 to ~8.5 ppm in the complexes 75 - 77 (Table 5.2). However, the shift is not 
large enough to suggest coordination of the manganese moiety occurs at the imine nitrogen. 
Additionally, there is a downfield shift in the two doublets, assigned to protons adjacent to the 
pyridyl nitrogen, from ~8.5 ppm and ~8.7 ppm in the ligand to ~9.0 ppm and ~9.3 ppm in the 
complexes 75 - 77. The shift in signals suggests coordination occurs in a bidentate manner at 
both the bipyridyl nitrogens, rather than in a monodentate coordination at the imine nitrogen. 
 
Table 5.2 Selected spectroscopic and analytical data for tricarbonylmanganese(I) functionalized 
complexes 75 - 77. 
Compound 
1
H NMR  
(imine) [ppm]
a
 
13
C{
1
H} NMR 
(imine) [ppm]
a
 
IR  
(imine) [cm
-1
]
b
 
MS  
([fragment]
+
) 
[m/z]
c
 
75 8.46 158.0 1644 961.57 [M+2H]
2+
 
76 8.43 157.8 1644 1344.59 [M+3H]
3+
 
77 8.53 158.2 1644 462.02 [M+H]
+
 
a
Recorded in (CD3)2SO 
b
Recorded as pure solids (ATR) 
c
HR-ESI-TOF-MS 
 
13
C{
1
H} NMR spectra for complexes 75 - 77 were recorded in deuterated dimethylsulfoxide 
and gave the expected number of carbon signals for the proposed structures. Similarly, shifts 
in the signals observed in the 
1
H NMR spectra for complexes 75 - 77, were observed in the 
13
C{
1
H} NMR spectra. As expected, the singlet assigned to the carbon atom of the imine 
functionality remains constant at ~158 ppm in both the ligands 72 - 74 and the complexes 75 - 
77 (Table 5.2). Furthermore, three singlets observed in the 
13
C{
1
H} NMR spectrum (Figure 
5.7) at about 220, 221, and 223 ppm also confirm the presence and integrity of the Mn(CO)3 
functionality. 
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Figure 5.7 
13
C{
1
H} NMR spectrum of the first-generation tricarbonylmanganese(I) functionalized 
metallodendrimer 75 in (CD3)2SO, with expansion of three singlets inset. 
 
5.3.2 Infrared Spectroscopy 
The infrared spectrum of complexes 75 - 77 were recorded as pure solids using the ATR 
technique. Three strong stretching vibrations are observed at about 1900 cm
-1
, 1920 cm
-1
 and 
2020 cm
-1
 and are assigned to the C≡O stretching vibrations of the manganese functionality 
(Figure 5.8). These stretching vibrations are comparable with other manganese-tricarbonyl 
mononuclear complexes reported.
29-31
 The shift to higher wavenumbers of the stretching 
vibration assigned to the C=N group of the bpy moiety, from ~1600 cm
-1
 (ligand) to ~1620 
cm
-1 
(complex), indicates that complexation occurred via the two pyridyl nitrogen atoms and 
not via the imine nitrogen atom, as there is no shift in the stretching vibration of the imine 
bond (constant at ~1650 cm
-1
). 
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Figure 5.8 IR (ATR) spectra of tricarbonylmanganese(I) functionalized complexes 75 (black), 76 
(red) and 77 (blue). 
 
5.3.3 Mass Spectrometry and HPLC 
HR-ESI-TOF mass spectrometric data further confirmed the structural integrity of 
metallodendrimers 75 and 76. Mass spectral data of 75 and 76 displayed the highest 
molecular weight fragment of [M+2H]
2+
 and [M+3H]
3+
 respectively, whilst the mass spectral 
data for 77 displayed a peak for [M+H]
+ 
(Table 5.2). Elemental analysis data for 75 - 77 were 
not obtained due to the instability of the complexes (discussed in section 5.4), and hence 
analytical-HPLC traces were obtained of 75 - 77. Single peaks (tR = ~23 min) are observed in 
the analytical-HPLC traces of 75 (Figure 5.9) - 77, and further attests to the purity of the 
metal complexes. The smaller shoulder peak in the analytical-HPLC trace for 75 was 
attributed to trace impurities present in the sample.  
C≡O  
C≡O 
C=Nimine  
C≡O  
C=Nbpy  
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Figure 5.9 Analytical HPLC trace of metallodendrimer 75 with a gradient of acetonitrile/water 5 
- 90 %, over 35 min, flow rate of 0.6 mL/min, showing one major peak at  
tR = 23.1 min. 
 
5.4 Long-Term Stability of Compounds 
 
When compounds 75 - 77 are exposed to natural daylight for an extended period of time, a 
pronounced decrease in the intensity of the signals for the Mn(CO)3 moiety between 2025 cm
-
1
 and 1900 cm
-1
 is observed in the infrared spectra (Figure 5.10). This is indicative of 
significant structural changes in the metal-carbonyl group and a first indicator of the CO-
release from these compounds. In addition, dimethylsulfoxide solutions of the complexes lose 
their bright orange colour and become a dark brown colour with a brown precipitate (possibly 
manganese dioxide), following prolonged exposure to natural daylight (Figure 5.11). The dark 
stability of the compounds 75 - 77 will be discussed in section 5.5.2.  
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Figure 5.10 IR (ATR) spectra of metallodendrimer 75 for a freshly prepared sample (black) and 
after exposure to natural daylight for 1.5 h (blue) and 24 h (red). 
 
 
Figure 5.11 Photograph of metallodendrimer 75 (DMSO solution) following exposure to natural 
daylight for set time intervals. 
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5.5 Electronic Absorption Spectra and CO-Release Properties 
5.5.1 Absorption Maxima and Molar Extinction Coefficients 
The absorbance maxima and molar extinction coefficients of complexes 75 - 77 were 
determined in a mixture of dimethylsulfoxide and water (10:90 % v/v). Two broad bands are 
observed for all compounds 75 - 77 at ~300 nm (λ1) and, at somewhat lower intensity, in the 
range of 370 nm to 450 nm (λ2) (Figure 5.12). Assignments of the bands are based on 
structurally similar mononuclear complexes reported in the literature.
32, 33
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Figure 5.12 Overlay of the electronic absorption spectra of complexes 75 (black), 76 (red), and 77 
(blue) in dimethylsulfoxide/water (10:90 % v/v). 
 
The absorption band at λ1 is assigned to the intraligand charge-transfer (ILCT) band and is 
attributed to the spin allowed intraligand π → π* transitions of the bpy moiety. The absorption 
band at λ2 is assigned to the metal-ligand charge-transfer (MLCT) band. The position of the 
low-energy MLCT transition at λ2 increases slightly upon moving from 75 to 76, by about 10 
nm, while the higher energy ILCT band at λ1 remains unchanged. The absorption maxima and 
the molar extinction coefficients are listed in Table 5.3. The increase in molar extinction 
coefficients for both bands is more pronounced, on moving from the mononuclear compound 
77 to the metallodendrimers 75 and 76. There is an increase in the molar extinction coefficient 
by a factor of ~3.3, on moving from mononuclear 77 to metallodendrimer 76, and the molar 
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extinction coefficient further doubles on moving from 75 to 76, which is expected when 
comparing the increase in the number of manganese-tricarbonyl groups per compound. This 
confirms the linear scaling of the optical properties with increasing dendrimer generation. 
 
Table 5.3 Absorption maxima and molar extinction coefficient of complexes 75 - 77. 
Compound 
Absorption maxima λ1 
[nm] 
ε1  
[M
-1
cm
-1
]
a
 
Absorption maxima 
λ2 [nm] 
ε2 
 [M
-1
cm
-1
]
a
 
75 300 47 717 ± 1413 410 10 371 ± 550 
76 300 91 606 ± 657 420 18 799 ± 818 
77 290 13 278 ± 370 400 3 527 ± 194 
a 
Molar extinction coefficient ± standard error 
 
5.5.2 Dark Stability and CO-Release Properties  
As discussed in Section 5.4, exposure of compounds 75 - 77 to natural daylight resulted in the 
compounds undergoing structural changes (Figure 5.8). Hence, to obtain insight into the 
photoinduced CO-release and the dark stability of compounds 75 - 77, the complexes were 
incubated in a dimethylsulfoxide/water (10:90 % v/v) solution in the absence of light. The 
complexes were incubated for a 16 h (75 (Figure 5.13 and Figure 5.14) and 76 only) and 15 h 
(77 only) period in the dark and the absorbance measured every 30 min. All three compounds 
showed good dark stability in the aqueous solution with only negligible spectral fluctuations 
observed at around 300 and 410 nm. 
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Figure 5.13 UV/Vis spectral traces of metallodendrimer 75 in dimethylsulfoxide/water (10:90 % 
v/v) during incubation in the dark (0 to 16 h, black) followed by photoactivation with a 
LED array at 410 nm for 12 min (red). 
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The compounds were then irradiated with a custom-made LED cluster at 410 nm, coincident 
with the MLCT absorption maximum λ2. Irradiations were interrupted in 1 min intervals to 
measure the absorbance of the compounds 75 - 77. In stark contrast, irradiation at 410 nm 
resulted in a pronounced decrease of the broad band centered at around 400 nm to almost zero 
towards the end of the experiment and a blue-shift of the peak at around 300 nm. Plateau 
values were reached after about 10 - 15 min with no further spectral changes upon extended 
irradiation. 
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Figure 5.14 Change of absorption at selected wavelengths with increasing incubation time in the 
dark (0 to 16 h) and after subsequent photoactivation with a LED array at 410 nm for 
12 min for a solution of dendrimer 75 in dimethylsulfoxide/water (10:90 % v/v), as 
monitored by UV/Vis spectroscopy. 
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5.6 CO-Release Experiments with the Myoglobin Assay 
5.6.1 Myoglobin Assay 
The CO-release from compounds 75 - 77 was studied using the standard myoglobin assay,
21
 
which is based on the UV-Vis spectroscopic detection of the conversion of deoxy-Mb (deoxy-
myoglobin) to Mb-CO (carboxy-myoglobin).
34, 35
 The myoglobin assay is not the only method 
developed for determining the amount and rate of CO-released from compounds, as head 
space analysis by GC is also used.
36, 37
 However, the myoglobin assay remains the principal 
method and was first reported by Motterlini and co-workers in 2002.
21
 The method basically 
involves the release of CO-ligands by the complex into solution, which in-turn binds to the 
deoxy-Mb, instantly converting it into Mb-CO (rate constant, k = 0.38 μMs-1, and binding 
constant = 16.9 μM-1).34 The conversion can be monitored, by observing changes in the Q-
band region, by UV-Vis spectroscopic analysis (Figure 5.15). 
 
Figure 5.15 UV-Vis spectra of the deoxy-Mb and Mb-CO in the Q-band region. 
 
Monitoring spectral changes at 540 nm, the proportion of deoxy-Mb converted to Mb-CO can 
be obtained with the use of the Beer-Lambert law and the overall concentration of deoxy-Mb 
(determined using the known extinction coefficient of ε540 = 15.4 mM
-1
cm
-1
).
38
 Hence, the 
concentration of Mb-CO can be calculated, which represents the quantity of CO-released by 
the complex at each spectral change. 
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5.6.2 Stability in Myoglobin Assay 
Prior to the irradiation experiments (conducted in the dark), the stability of compounds 75 - 
77 in 0.1 M phosphate buffer (PBS, pH 7.4) under the reducing conditions of the myoglobin 
assay was monitored using UV/Vis spectroscopy. Spectral changes were monitored at four 
wavelengths in the Q-band region, over a 16 h period, which include 540 nm and 577 nm 
(formation of Mb-CO), 557 nm (formation of deoxy-Mb) and 510 nm (isobestic point). The 
isobestic point (point of intersection of UV-Vis spectral traces of the two interconverting 
species) should remain constant throughout the experiment (i.e. during the dark and 
irradiation). The two metallodendrimers 75 (Figures 5.16) and 76 showed negligible spectral 
changes over a 16 h period at the four wavelengths. Indicating that no CO-release to 
myoglobin occurs in the dark during this time and is a good indicator of the suitability of 
these compounds as photoactivatable CO-prodrugs. 
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Figure 5.16  Change of absorption at selected wavelengths with increasing incubation time in the 
dark (0 to 16 h) for a solution of metallodendrimer 75 (4 µM) in 0.1 M PBS at pH 7.4 
in the presence of myoglobin (60 µM) and sodium dithionite (10 mM) under a 
dinitrogen atmosphere as monitored by UV/Vis spectroscopy. 
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For the mononulcaer derivative 77, some minor fluctuations were observed in the above 
mentioned spectral regions, in particular during the first few hours of incubation, but since 
these affected all wavelengths monitored to the same degree, they are probably rather 
indicative of some precipitation, due to poor solubility, than a general instability of the 
compound. 
 
5.6.3 Photoactivation of Myoglobin Assay Spiked with the PhotoCORM 
For photoactivation studies, a custom-made LED cluster with an emission wavelength of 410 
nm, matching the MLCT band, was used and setup as in Figure 5.17. The violet light 
photoactivation of the present compounds 75 - 77 is quite an attractive feature, since most 
PhotoCORMs reported to date only show sensitivity to light at shorter wavelengths (315-365 
nm).
16, 29, 30, 39, 40
 For deep tissue penetration, an excitation wavelength of larger than 600-700 
nm would be ideal, which would also minimize potential photodamage to healthy cells.
41
 By 
suitable modification of the substituents in the 4-position of the bpy ligand, it is anticipated 
that the excitation wavelength can be further shifted towards the red.
42
  
 
 
Figure 5.17 Setup of photoactivation experiment (right) and schematic of the setup (left). 
 
A solution of myoglobin in 0.1 M PBS buffer was degassed by bubbling with dinitrogen and 
reduced by addition of sodium dithionite, followed by the addition of a solution of 
compounds 75, 76, or 77 in dimethylsulfoxide/water (10:90 % v/v) was prepared. The 
photoexcitation of the freshly prepared solutions at 410 nm leads to pronounced changes in 
the Q-band region of the Mb absorption. The band at 557 nm slowly decreases in intensity 
while two new bands at 540 and 577 nm slowly increases in intensity for complexes, which is 
characteristic for the conversion of deoxy-Mb to Mb-CO (Figure 5.18).  
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Figure 5.18 Change of absorption in the Q-band region of myoglobin with increasing irradiation 
time at 410 nm for a solution of metallodendrimer 75 (4 µM) in 0.1 M PBS pH 7.4 in 
the presence of myoglobin (60 µM) and sodium dithionite (10 mM) under a dinitrogen 
atmosphere as monitored by UV/Vis spectroscopy. 
 
The concentration of Mb-CO in solution was determined from the absorption data by 
application of the Beer-Lambert law with an assumption that the total concentration of the 
myoglobin remains constant throughout the whole assay and using the molar extinction 
coefficient for Mb-CO of ε540 = 15.4 (mM)
-1
L
-1
.
38
 Since the concentration of deoxy-Mb has to 
be fixed to keep the absorption in the Q-band region <1, an excess of deoxy-Mb over the total 
amount of potentially labile CO in compounds 75 - 77 was always maintained. When 4 µM of 
75 was added to 60 µM of deoxy-Mb, the CO-release profile of complex 75 upon 
photoactivation (Figure 5.18) indicates that approximately eight CO-ligands are released per 
molecule of 75 (Table 5.4).  
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Figure 5.19 Amount of Mb-CO in µM formed with increasing irradiation time at 410 nm for a 
solution of metallodendrimer 75 (4 µM) in 0.1 M PBS pH 7.4 in the presence of 
myoglobin (60 µM) and sodium dithionite (10 mM) under a dinitrogen atmosphere as 
determined from UV/Vis spectroscopy. 
 
Second-generation metallodendrimer 76 (2 µM) released a significantly higher number of 
CO-ligands, about 15 equivalents (Table 5.4). For the mononuclear model complex 77 (10 
µM), about two CO-ligands per molecule were released upon exhaustive photoactivation 
(Table 5.4).  
 
Table 5.4 CO-release data of complexes 75 - 77. 
Compound 
Conc. of MbCO  
[μM]a 
Eq. of CO-
released
b, c
 
Percentage CO-released  
[%]
c
 
75 30.24 ± 0.08 7.56 ± 0.02 63.0 
76 30.47 ± 0.31 15.24 ± 0.15 63.5 
77 20.29 ± 3.03 1.51 ± 0.07 50.5 
a 
Conc. of MbCO ± standard error.  
b 
Eq. of CO-released ± standard error.  
c 
Per molecule 
 
 
Chapter 5. CO-Releasing Metallodendrimers 
 
 
 
189 
 
While the absolute number of CO-ligands liberated from the molecules increases from about 
1.5 to 15.2 when comparing 75 - 77, interestingly, the proportional amount of CO-released 
versus the remaining bound CO stays remarkably constant, with an average value of ~65 % 
for the two metallodendrimers (75, 76) and ~51 % for the mononuclear complex 77 (Table 
5.4). Thus, under the conditions of the myoglobin assay, a maximum of two out of the three 
CO-ligands per metal carbonyl moiety are photolabile. Furthermore, this data indicates that 
the CO-release from each Mn(CO)3 moiety in the metallodendrimers does not seem to be a 
cooperative process due to the linear scaling.  
 
5.7 Kinetics and Quantum Yield Measurements 
 
5.7.1 Rate of CO-Release 
The CO-release studies showed on average the metallodendrimers 75 and 76 released ~65 % 
per molecule, whilst the mononuclear complex 77 released ~51 % of CO per molecule. The 
half-life (t1/2) in this study is defined as the time taken for compounds 75 - 77 to release 50 % 
of the total CO-ligands present per molecule. For an effective CO-releasing molecule the t1/2 
ideally needs to be less than 2 h, as the higher t1/2 is unlikely to result in a high enough CO-
concentration within the cell, due to the CO circulation within the body and insufficient 
binding with heme.
12
 The CO-release profile follows a pseudo first-order behavior and hence 
the t1/2 of each complex 75 - 77 was calculated, by fitting a 1
st
 order exponential growth curve 
(Equation 5.1). 
 
       
 
    Eqn. 5.1 
           
 
       Eqn. 5.2 
  
      
    
  
 
     Eqn. 5.3 
           
   
   
   Eqn. 5.4 
          
   
 
 (1
st
 order) Eqn. 5.5 
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Substitution of the relevant symbols and rearrangement of the equation afforded Equation 5.2. 
Yo is the y-variable where the graph plateaus. Therefore, the concentration of Mb-CO 
(c(MbCO)) at t1/2 is 
Yo
/2, and t = t1/2, to afford Equation 5.3. Rearrangement of Equation 5.3 
and placing t1/2 as the subject of the formula, afforded Equation 5.4. t1, Yo and A1 was obtained 
from the exponential growth curve plot of complexes 75 - 77, and hence t1/2 was calculated 
and listed in Table 5.5. 
 
Table 5.5 Kinetic data of complexes 75 - 77. 
Compound Half-life, t1/2 [min]
a, b
 Rate constant, kCO [s
-1
]
c
 Quantum yield, 410
d
 
75 14.54 ± 0.25 7.9510-4 (2.66 ± 0.16)10-3 
76 16.84 ± 0.56 6.8610-4 (2.71 ± 0.49)10-3 
77 7.41 ± 0.24 1.5610-3 (3.15 ± 0.27)10-3 
a
 Determined under the conditions of the myoglobin assay. 
b
 Half life ± standard error 
c 
Determined from UV/Vis spectral studies in DMSO/water solution . 
d 
Calculated using a photon flux of the LED array determined as (9.9 ± 0.4)10-9 Einsteins-1 
 
Metallodendrimers 75 and 76 displayed a t1/2 of 14.5 min and 16.8 min respectively, whilst the 
mononuclear complex 77 displayed a significantly shortened t1/2 of 7.4 min, way below the 
threshold t1/2 of 2 h. Compared to the tricarbonyl manganese(I)-PTA PhotoCORM (t1/2 = 93.0 
min) synthesized by Mohr et al. the t1/2 of these complexes 75 - 77 is faster.
31
 However, 
compared to one of the first PhotoCORMs reported, [Mn(tpm)(CO)3]
+
 (where tpm = 
tris(pyrazolyl)methane, t1/2 = 10 min), the t1/2 is comparable.
17
 
 
All three compounds follow a pseudo first-order behavior, and hence using Equation 5.5, the 
CO-release rate (kCO) for each complex 75 - 77 was calculated and is listed in Table 5.5. The 
kCO is comparable to [Mn(tpm)(CO)3]
+
,
17 
but is relatively faster than other manganese-
functionalized PhotoCORMs.
29, 43
 CO-release rates are comparable to other metal carbonyl 
complexes such as the iron compound [Fe(CO)(N4Py)](ClO4)2.
44
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5.7.2 Quantum Yield of CO-Release Determined by Ferrioxalate Actionometry  
The quantum yield is defined as the moles of Mb-CO formed by moles of photons produced 
by the light source (i.e. photon flux). As the photons delivered by a light source vary, a large 
photon flux will increase the CO-release rate, whilst a small photon flux will do the reverse. 
To avoid this problem, the quantum yield is measured and is used to compare CO-release of 
PhotoCORMs. The photon flux is defined as the number of quanta (photon flow) passing 
through the cuvette per second, and can be determine by ferrioxalate actinometry.
45, 46
 
Ferrioxalate actinometry involves the photoreduction of potassium ferrioxalate 
K3[Fe(C2O4)3]
.
3H2O (Scheme 5.6). 
 
 
 
Scheme 5.6 Photoreduction of potassium ferrioxalate, K3[Fe(C2O4)3]
.
3H2O. 
 
The quantity of ferrous ions formed during the irradiation period is monitored by the 
conversion to the coloured tris-phenanthroline complex [Fe(phen)3]
2+
 (where phen = 
phenanthroline) (Scheme 5.7).  
 
 
Scheme 5.7 Formation of tris-phenanthroline complex, [Fe(phen)3]
2+
. 
 
With the use of UV/Vis spectroscopy and the molar extinction coefficient of [Fe(phen)3]
2+ 
(11100 Lmol
-1
cm
-1
), the moles of Fe
2+
 ions was determined at λmax = 510 nm.
47
 The photon 
flux was calculated using Equation 5.6, where p is the photon flux (Einstein.s
-1
), t is the 
irradiation time and λ is the quantum yield of ferrous ion production at the irradiation 
wavelength. 
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 Eqn. 5.6 
                   
                   
                       
 Eqn. 5.7 
 
The quantum yield of the complexes could now be calculated using Equation 5.7, where 1 
Einstein = 1 mol of photon, and are listed in Table 5.5. While the values of  are essentially 
identical for metallodendrimers 75 and 76 at about 2.710-3, again indicating that scaling 
effects do not play any role in these systems. For the model compound 77, a slightly larger 
value of 3.210-3 was determined. These values are much lower than reported for other metal 
carbonyl complexes by one to two orders of magnitude.
13, 29, 48
 However, one has to take into 
account the experiments were not carried out in pure solvent, but rather under the conditions 
of the myoglobin assay, using an excitation wavelength of 410 nm, in a spectral region where 
substantial absorption of the heme protein leads to considerable inner filter effects. 
 
5.8 Overall Summary 
 
First- and second-generation polypyridyl metallodendrimers, bearing four and eight 
tricarbonylmanganese(I) end groups, were successfully synthesized and purified using 
preparative HPLC. The complexes were characterized using a series a spectroscopic and 
analytical techniques, namely 
1
H, 
13
C{
1
H} NMR, infrared and mass spectrometry. In addition, 
a mononuclear model complex was prepared for comparison.  
 
All three complexes are stable in solution and in air for an extended period of time in the 
absence of light. However, upon photoactivation at 410 nm using a custom-made LED light 
source, CO-release studies with the myoglobin assay show that at least two of the three 
carbonyl ligands per Mn(CO)3 moiety can be liberated under these conditions. The half-life 
and quantum yield of CO-release are similar for the first- and second-generation 
metallodendrimers, indicating that no scaling effects are operative in these systems and that 
each [Mn(bpy)(CO)3Br] end group behaves independently from the others. Furthermore, the 
total amount of CO-released per molecular unit increases with the dendrimer generation, 
reaching a value of 15 CO per molecule of the second-generation metallodendrimer.  
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Chapter 6 
Experimental Details 
 
6.1 General Remarks 
 
All reactions were performed under an inert atmosphere using a dual vacuum/nitrogen line 
and standard Schlenk-line techniques unless stated otherwise. All reaction solvents were dried 
by heating under reflux and under an inert atmosphere, over the appropriate drying agent and 
all samples were dried under vacuum. 
 
2-pyridinecarboxaldehyde, salicylaldehyde, n-propylamine, DAB-G1-PPI-(NH2)4 (where 
DAB = 1,4-diaminobutane and PPI = poly(propyleneimine), ferrocene carboxaldehyde, 
sodium hexafluorophosphate, hexamethylbenzene, 4,4’-dimethyl-2,2’-bipyridyl, myoglobin 
from horse skeletal muscle and nucleotide guanosine 5’-monophosphate (5’GMP) were 
purchased from Sigma-Aldrich; α-Phellandrene was purchased from Fluka; DAB-G2-PPI-
(NH2)8, DAB-G3-PPI-(NH2)16, DAB-G4-PPI-(NH2)32 was purchased from SyMO-Chem; 
Manganese pentacarbonyl bromide [Mn(CO)5Br] was purchased from Strem Chemicals and 
used without further purification. Ruthenium(III)trichloride trihydrate and 
osmium(III)trichloride trihydrate was obtained as a generous donation from Johnson 
Matthey/Anglo-American Platinum Limited. Deuterated solvents were purchased from 
Sigma-Aldrich. 
 
Reaction progress and product mixtures were monitored by thin-layer chromatography (TLC) 
on precoated silica-gel F254 plates in a suitable solvent system, using the ascending technique; 
the plates were viewed under a UV light. Column chromatography was carried out with 60 Å 
silica-gel (70-230 mesh ASTM). 
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6.2 Instrumentation 
 
Infrared (IR) spectra were measured on a Perkin-Elmer Spectrum 100 FT-IR spectrometer as 
KBr pellets or in NaCl solution cells in DCM or as pure solid samples using a Nicolet 380 
FT-IR-Spectrometer equipped with a SMART iTR ATR unit. Intensity of stretching 
vibrations are marked as strong (s), medium (m) and weak (w). Melting points (MPs) were 
determined using a Büchi Melting Point Machine B -540. 
 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Unity XR400 
spectrometer (
1
H: 399.95 MHz; 
13
C{
1
H}: 100.58 MHz; 
31
P{
1
H}: 161.90 MHz) or Varian 
Mercury XR300 spectrometer (
1
H: 300.08 MHz; 
13
C{
1
H}: 75.46 MHz; 
31
P{
1
H}: 121.47 
MHz) or Bruker Biospin GmbH spectrometer (
1
H: 400.22 MHz; 
13
C{
1
H}: 100.65 MHz; 
31
P{
1
H}: 162.00 MHz) at ambient temperature. Chemical shifts δ in ppm indicate a downfield 
shift relative to tetramethylsilane (TMS) and were referenced relative to the signal of the 
solvent.
1
 Coupling constants J are given in Hz. Individual peaks are marked as singlet (s), 
doublet (d), doublet-of-doublet (dd), triplet (t), or multiplet (m). 
 
Electron impact mass spectrometry (EI-MS) was carried out on a JEOL GCmateII mass 
spectrometer. Electrospray ionisation-mass spectrometry (ESI-MS) was carried out on a 
Waters Synapt mass spectrometer. Data were recorded in positive ion mode. Matrix assisted 
laser desorption time-of-flight (MALDI-TOF) mass spectra were carried out at the Tokyo 
Institute of Technology on a Bruker Daltonics Ultraflex MALDI TOF/TOF mass 
spectrometer using Fluka 87884 trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-
propenylidene]malonitrile (DCTB) as the matrix, equipped with a nitrogen laser and operated 
at an accelerating voltage of 25 kV. 
 
Elemental analysis (C, H, N) was carried out using a Thermo Flash 1112 Series CHNS-O 
Analyser. For certain metallodendrimers, the analyses are outside acceptable limits, and are 
ascribed to the encapsulation of solvent molecules and/or other inorganic salts by the 
dendritic compounds. 
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HPLC analysis was performed on a Dionex Ultimate 3000 instrument equipped with a 
ReproSil 100 column (C18, 5 μm, 4.6 mm or 10 mm diameter, 250 mm length) using a linear 
gradient of 5 - 90 % CH3CN/H2O or MeOH/H2O containing 0.1 % TFA as the eluent over 40 
min at a flow rate of 0.6 mL/min for analytical and 3.0 mL/min for preparative 
chromatography, respectively. 
 
Absorption spectra were measured using an Agilent 8453 UV/Vis diode array 
spectrophotometer in quartz cuvettes (d = 1 cm). 
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6.3 Synthesis of N,O-Salicylaldiminato Ligands  
 
6.3.1 Preparation of 21, 22 and 37 
DAB-G1-PPI-(C7H5NOH)4 (21), DAB-G2-PPI-(C7H5NOH)8 (22) and (E)-2-
((propylimino)methyl)phenol (37) were prepared from known literature reported  
procedures.
2, 3
 
 
6.3.2 General Procedure for the Preparation of 23 and 24 
Salicyldehyde (1.06 mL, 9.94 mmol for 23, 1.07 mL, 10.1 mmol for 24) was added dropwise 
to a solution of DAB-G3-PPI-(NH2)16 (1.04 g, 0.619 mmol for 23) or DAB-G4- PPI-(NH2)32 
(1.10 g, 0.314 mmol for 24) in toluene (20.0 mL). The reaction was stirred for 48 h at room 
temperature. The solvent was removed under vacuum affording a yellow oil. The oil was 
dissolved in DCM (30.0 mL) and washed with distilled H2O (8 × 50 mL). The organic layer 
was dried over anhydrous MgSO4 (~10 g) and filtered. The solvent was removed under 
reduced pressure and the resulting oil dried in vacuo. 
 
6.3.2.1 DAB-G3-(C7H5NOH)16 (23) 
Orange-yellow oil. Yield: 1.47 g, 70.9 %. IR 
(NaCl cells, DCM): ν (cm-1) = 1634 (s, imine, 
C=N); 2950 (s, hydroxyl, O-H).
 1
H NMR 
(CDCl3): δ (ppm) = 1.36, 1.54, 1.77, 2.39, 2.48 
(br m, 144H, NCH2CH2 core, NCH2CH2 core, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 
2nd branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 3rd 
branch, NCH2CH2CH2N 3rd branch), 3.56 (m, 32H, NCH2CH2CH2N 3rd branch), 6.81 (br t, 16H, Ar), 
6.91 (br d, 16H, Ar), 7.17 (br d, 16H, Ar), 7.26 (br t, 16H, Ar), 8.27 (s, 16H, CH imine), 13.50 
(br s, 16H, OH). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 24.5, 24.7, 28.5, 51.5, 52.1, 52.3, 57.4 
(CH2); 116.9, 118.4, 131.1, 132.0 (CH Ar); 118.8, 161.3 (C Ar); 164.9 (CH imine). Elemental 
analysis for C200H272N30O16.3H2O (3406.587): Found C, 70.42; H, 8.21; N, 12.62 %; calcd. 
C, 70.52; H, 8.05; N, 12.34 %. MS (MALDI-TOF, m/z): 3354 [M]
+
. 
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6.3.2.2 DAB-G4-(C7H5NOH)32 (24) 
Orange oil. Yield: 0.858 g, 39.9 %. IR (NaCl 
cells, DCM): ν (cm-1) = 1634 (s, imine, C=N); 
2949 (s, hydroxyl, O-H). 
1
H NMR (CDCl3): δ 
(ppm) = 1.35, 1.52, 1.74, 2.38, 2.45 (br m, 304H, 
NCH2CH2 core, NCH2CH2 core, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 
1st branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 2nd 
branch, NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 
3rd branch, NCH2CH2CH2N 3rd branch, 
NCH2CH2CH2N 4th branch, NCH2CH2CH2N 4th branch), 3.53 (m, 64H, NCH2CH2CH2N 4th branch), 
6.79 (br t, 32H, Ar), 6.89 (br d, 32H, Ar), 7.17 (br d, 32H, Ar), 7.26 (br t, 32H, Ar), 8.27 (s, 
32H, CH imine), 13.48 (br s, 32H, OH). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 24.4, 24.5, 28.5, 
51.4, 52.0, 52.3 (CH2); 116.9, 118.4, 131.1, 132.0 (CH Ar); 118.8, 161.2 (C Ar); 164.8 (CH 
imine). Elemental analysis for C408H558N62O32.1C7H8 (6935.438): Found C, 70.62; H, 8.32; N, 
12.96 %; calcd. C, 70.66; H, 8.11; N, 12.52 %. MS (MALDI-TOF, m/z): 6844 [M]
+
. 
 
6.4 Synthesis of Ru(II)- and Os(II)-Arene Precursors 
 
[Ru(η6-p-PriC6H4Me)Cl2]2, [Ru(η
6
-C6Me6)Cl2]2 and [Os(η
6
-p-Pr
i
C6H4Me)Cl2]2 were prepared 
from known literature reported procedures.
4-6
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6.5 Synthesis of Ru(II)-and Os(II)-Arene Complexes 
 
6.5.1 General Procedure for the Preparation of Neutral N,O-Ru(II)-Arene 
Metallodendrimers (25 - 28) 
Triethylamine (0.0720 mL, 0.519 mmol for 25 - 28) was added dropwise to a stirring solution 
of 23 (0.108 g, 0.0323 mmol for 25 and 27) or 24 (0.109 g, 0.0160 mmol for 26 and 28) in dry 
EtOH (25.0 mL). The yellow suspension was stirred at room temperature for 0.5 h. [Ru(η6-p-
Pr
i
C6H4Me)Cl2]2 (0.158 g, 0.258 mmol for 25 and 26) or [Ru(η
6
-C6Me6)Cl2]2 (0.196 g, 0.289 
mmol for 27 and 28) was added to the reaction mixture and allowed to stir for 48 h at room 
temperature. The reaction mixture was filtered and the solvent removed from the filtrate under 
reduced pressure, yielding a solid. The solid residue was dissolved in a minimum amount of 
DCM and the products were precipitated with hexane. The products were purified by low 
temperature precipitation from DCM with hexane. 
 
6.5.1.1 DAB-G3-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)Cl}16 (25) 
Yellow-brown solid. Yield: 0.233 g, 91.1 %. 
IR (NaCl cells, DCM): ν (cm-1) = 1621 (s, 
imine, C=N).
 1
H NMR (CDCl3): δ (ppm) = 
1.01 & 1.12 (br m, 96H, CH(CH3)2 p-cye), 1.77 - 
2.74 (overlapping m, 240H, NCH2CH2 core, 
NCH2CH2 core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 2nd 
branch, NCH2CH2CH2N 3rd branch, 
NCH2CH2CH2N 3rd branch, CH3 p-cye), 3.11 (br m, 
16H, CH(CH3)2 p-cye), 4.12 & 4.41 (br m, 32H, NCH2CH2CH2N 3rd branch), 5.23 (br d, 32H, Arp-
cye), 5.42 (br d, 32H, Arp-cye), 6.33 (br m, 16H, Ar), 6.81 (br m, 16H, Ar), 7.07 (br m, 32H, 
H16, Ar), 8.05 (br s, 16H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 18.9, 22.3, 22.8 (CH3 
p-cye); 21.7, 22.1, 25.2, 25.6, 30.8, 51.0, 66.9, 67.4 (CH2); 30.5, 80.6, 81.4, 83.3, 87.6 (CH p-
cye); 98.4, 100.2 (C p-cye); 114.0, 121.9, 134.6, 135.4 (CH Ar); 119.2, 164.8 (C Ar), 164.7 (CH 
imine). Elemental analysis for C376H544N30O16Cl16Ru16.8DCM.8Et3NH
+
Cl
-
 (9705.677): Found 
C, 46.14; H, 6.50; N, 3.98 %; calcd. C, 46.53; H, 5.65; N, 4.33 %. MS (HR-ESI-TOF, m/z): 
845.1812 [M-9Cl]
9+
. MP: 62 ºC (decompose without melting). 
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6.5.1.2 DAB-G4-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)Cl}32 (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yellow-brown solid. Yield: 0.227 g, 88.7 %. IR (NaCl cells, DCM): ν (cm-1) = 1621 (s, 
imine, C=N).
 1
H NMR (CDCl3): δ (ppm) = 0.98 & 1.09 (br m, 192H, CH(CH3)2 p-cye), 1.93 - 
2.60 (overlapping m, 400H, NCH2CH2 core, NCH2CH2 core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 
2nd branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 3rd branch, 
NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 4th branch, NCH2CH2CH2N 4th branch, CH3 p-cye), 3.20 
(br m, 32H, CH(CH3)2 p-cye), 4.11 & 4.42 (br m, 64H, NCH2CH2CH2N 4th branch), 5.24 (br d, 
64H, Arp-cye), 5.40 (br d, 64H, Arp-cye), 6.33 (br m, 32H, Ar), 6.80 (br m, 32H, Ar), 7.10 (br m, 
64H, Ar), 8.08 (br s, 32H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 18.9, 22.3, 22.8 (CH3 
p-cye); 21.7, 25.2, 30.8, 50.5, 51.2, 67.0 (CH2); 30.5, 80.6, 81.4, 83.3, 87.6 (CH p-cye); 98.3, 
100.2 (C p-cye); 114.0, 121.8, 134.6, 135.6 (CH Ar); 119.3, 164.6 (C Ar), 164.9 (CH imine). 
Elemental analysis for C760H1104N62O32Cl32Ru32.10DCM.20Et3NH
+
Cl
-
 (19592.596): Found 
C, 46.34; H, 5.22; N, 3.75 %; calcd. C, 46.59; H, 5.68; N, 4.43 %. MS (HR-ESI-TOF, m/z): 
580.9363 [M-26Cl]
26+
. MP: 81 ºC (decompose without melting). 
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6.5.1.3 DAB-G3-PPI-{(η
6
-HMB)Ru((C7H5NO)-κ
2
-N,O)Cl}16 (27) 
Orange solid. Yield: 0.245 g, 84.1 %. IR 
(NaCl cells, DCM): ν (cm-1) = 1617 (s, 
imine, C=N).
 1
H NMR (CDCl3): δ (ppm) = 
1.74 (br m, 4H, NCH2CH2 core), 1.75 - 3.79 
(overlapping br m, 428H, NCH2CH2 core, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 
1st branch, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 
2nd branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 
3rd branch, CH3 HMB), 3.94 & 4.11 (br m, 32H, 
NCH2CH2CH2N 3rd branch), 6.42 (br m, 16H, 
Ar), 6.85 (br m, 16H, Ar), 7.08 (br m, 32H, 
Ar), 8.18 (br s, 16H, CH imine). 
13
C{
1
H} 
NMR (CDCl3): δ (ppm) = 15.8 (CH3 HMB); 16.2, 20.8, 21.3, 25.5, 46.0, 50.0, 50.4, 51.6, 62.3 
(CH2); 89.6 (C HMB); 114.5, 123.5, 133.9, 134.9 (CH Ar); 122.1, 165.0 (C Ar); 165.8 (CH imine). 
Elemental analysis for C392H544N30O16Cl16Ru16.10DCM.4Et3NH
+
Cl
-
 (9517.109): Found C, 
49.00; H, 6.05; N, 3.44 %; calcd. C, 48.47; H, 5.76; N, 4.42 %. MS (MALDI-TOF, m/z): 
8080 [M-Cl]
+
. MP: 179 - 189 ºC. 
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6.5.1.4 DAB-G4-PPI-{(η
6
-HMB)Ru((C7H5NO)-κ
2
-N,O)Cl}32 (28) 
 
Orange solid. Yield: 0.167 g, 68.2 %. IR (NaCl cells, DCM): ν (cm-1) = 1618 (s, imine, C=N). 
1
H NMR (CDCl3): δ (ppm) = 1.85 (br m, 4H, NCH2CH2 core), 1.90 - 3.14 (overlapping br m, 
876H, NCH2CH2 core, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 3rd branch, 
NCH2CH2CH2N 4th branch, NCH2CH2CH2N 4th branch, CH3 HMB), 3.88 & 4.06 (br m, 64H, 
NCH2CH2CH2N 4th branch), 6.38 (br m, 32H, Ar), 6.79 (br m, 32H, Ar), 7.04 (br m, 32H, Ar), 
7.14 (br m, 32H, Ar), 8.16 (br s, 32H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 15.8 (CH3 
HMB); 20.9, 25.6, 35.1, 50.1, 62.3 (CH2); 91.2 (C HMB); 114.3, 123.7, 133.8, 134.8 (CH Ar); 
122.0, 164.8 (C Ar); 166.0 (CH imine). Elemental analysis for 
C792H1104N62Cl32O32Ru32.12DCM.17Et3NH
+
Cl
-
 (19733.856): Found C, 48.34; H, 6.37; N, 
4.14 %; calcd. C, 48.21; H, 5.64; N, 4.40 %. MS (HR-ESI-TOF, m/z): 630.0355 [M+26H]
26+
. 
MP: 183
 
ºC (decompose without melting). 
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6.5.2 General Procedure for the Preparation of Cationic N,O-Ru(II)-Arene-PTA 
Metallodendrimers ([29][PF6]4 - [36][PF6]32) 
Triethylamine (0.083 mL, 0.596 mmol for [29][PF6]4 and [33][PF6]4; 0.075 mL, 0.541 mmol 
for [30][PF6]8 and [34][PF6]8; 0.080 mL, 0.599 mmol for [31][PF6]16 and [35][PF6]16; 0.060 
mL, 0.493 mmol for [32][PF6]32 and [36][PF6]32) was added dropwise to a stirred solution of 
ligand 21 (0.108 g, 0.147 mmol for [29][PF6]4 and [33][PF6]4) or 22 (0.108 g, 0.067 mmol for 
[30][PF6]8 and [34][PF6]8) or 23 (0.125 g, 0.037 mmol for [31][PF6]16 and [35][PF6]16) or 24 
(0.105 g, 0.054 mmol for [32][PF6]32 and [36][PF6]32) in EtOH (50 mL). The resulting yellow 
suspension was allowed to stir at room temperature for 0.5 h. Next, [Ru(η6-p-PriC6H4Me)Cl2]2 
(0.185 g, 0.596 mmol for [29][PF6]4; 0.167 g, 0.272 mmol for [30][PF6]8; 0.183 g, 0.299 
mmol for [31][PF6]16; 0.151 g; 0.246 mmol for [32][PF6]32) or [Ru(η
6
-C6Me6)Cl2]2 (0.215 g, 
0.318 mmol for [33][PF6]4; 0.199 g, 0.294 mmol for [34][PF6]8; 0.172 g, 0.254 mmol for 
[35][PF6]16; 0.161 g, 0.237 mmol for [36][PF6]32) was added to the reaction mixture. The 
reaction mixture was stirred overnight at room temperature and then the reaction mixture was 
filtered and PTA (0.094 g, 0.596 mmol for [29][PF6]4 and [33][PF6]4; 0.085 g, 0.541 mmol for 
[30][PF6]8 and [34][PF6]8; 0.094 g, 0.599 mmol for [31][PF6]16 and [35][PF6]16; 0.078 g, 
0.493 mmol for [32][PF6]32 and [36][PF6]32) was added to the filtrate. The solution was stirred 
for 6 h and filtered by gravity, the filtrate reduced to ~5 mL. NaPF6 (0.100 g, 0.596 mmol for 
[29][PF6]4 and [33][PF6]4; 0.091 g, 0.541 mmol for [30][PF6]8 and [34][PF6]8; 0.101 g, 0.599 
mmol for [31][PF6]16 and [35][PF6]16; 0.083 g, 0.493 mmol for [32][PF6]32 and [36][PF6]32) 
was added and the reaction was stirred at 0 ºC for 1 h, which resulted in the formation of a 
solid. The solid was isolated by filtration, washed with cold EtOH, followed by Et2O and 
dried under reduced pressure. 
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6.5.2.1 [DAB-G1-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA}4][PF6]4 ([29][PF6]4) 
Yellow solid. Yield: 0.400 g, 94.3 %. 
IR (KBr pellets): ν (cm-1) = 1618 (s, 
imine, C=N).
 1
H NMR ((CD3)2CO): δ 
(ppm) = 1.01 & 1.26 (br d, 
3
J = 6.5 
Hz, 24H, CH(CH3)2 p-cye), 1.75 - 1.92 
(overlapping m, 12H, NCH2CH2 core, 
NCH2CH2CH2N branch), 2.22 (s, 12H, 
CH3 p-cye), 2.40 - 2.44 (overlapping m, 
12H, NCH2CH2 core, NCH2CH2CH2N 
branch), 2.61 (br m, 4H, CH(CH3)2 p-cye), 
3.98 & 4.09 (br m, 8H, NCH2CH2CH2N branch), 4.32 (m, 24H, PTA), 4.53 (m, 24H, PTA), 
5.56 (br d, 
3
J = 6.0 Hz, 4H, Ar p-cye), 5.94 (br d, 4H, Ar p-cye), 6.27 (m, 4H, Ar p-cye), 6.42 (m, 
4H, Ar p-cye), 6.49 (t, 
3
J = 6.5 Hz, 4H, Ar), 6.79 (d, 
3
J = 8.3 Hz, 4H, Ar), 7.22 (m, 8H, Ar), 8.20 
(s, 4H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 17.9, 20.8, 21.4 (CH3 p-cye); 21.7, 
53.7, 68.1 (CH2); 51.0, 72.4 (CH2 PTA); 30.6, 83.2, 87.8, 88.8, 91.7 (CH p-cye); 97.2, 121.3 (C 
p-cye); 115.2, 122.1, 135.2, 135.4 (CH Ar); 119.0, 164.2 (C Ar), 166.9 (CH imine). 
31
P{
1
H} NMR 
((CD3)2CO): δ (ppm) = -32.5 (s, PTA), -144.1 (sep, 
1
J = 709.5 Hz, PF6). Elemental analysis 
for C108H156N18O4P8F24Ru4.9EtOH (3293.182): Found C, 38.94; H, 4.93; N, 7.76 %; calcd. C, 
39.39; H, 4.77; N, 7.66 %. MS (HR-ESI-TOF, m/z): 575.6148 [M]
4+
 (where M = [29][PF6]4 - 
4PF6). MP: 272 ºC (decompose without melting). 
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6.5.2.2 [DAB-G2-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA}8][PF6]8 ([30][PF6]8) 
Mustard solid. Yield: 0.363 g, 89.6 %. 
IR (KBr pellets): ν (cm-1) = 1618 (s, 
imine, C=N).
 1
H NMR ((CD3)2CO): δ 
(ppm) = 1.09 & 1.24 (br d, 48H, 
CH(CH3)2 p-cye), 1.96 - 2.78 (overlapping 
m, 64H, NCH2CH2 core, NCH2CH2 core, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 2nd branch), 2.22 (s, 24H, 
CH3 p-cye), 3.57 (br m, 8H, CH(CH3)2 p-cye), 3.92 & 4.08 (br m, 16H, NCH2CH2CH2N 2nd branch), 
4.28 (m, 48H, PTA), 4.55 (m, 48H, PTA), 5.51 (br m, 8H, Ar p-cye), 5.90 (br m, 8H, Ar p-cye), 
6.23 (br m, 8H, Ar p-cye), 6.42 (br m, 8H, Ar p-cye), 6.49 (br t, 8H, Ar), 6.78 (br d, 8H, Ar), 7.23 
(m, 16H, Ar), 8.21 (br s, 8H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 18.0, 20.8, 21.4 
(CH3 p-cye); 52.3, 68.3 (CH2); 51.1, 72.4 (CH2 PTA); 30.6, 82.7, 87.7, 88.8, 92.0 (CH p-cye); 96.8, 
121.4 (C p-cye); 115.1, 122.1, 135.2, 135.4 (CH Ar); 119.1, 164.3 (C Ar); 166.7 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -32.3 (s, PTA), -144.1 (sep, 
1
J = 710.5 Hz, PF6). 
Elemental analysis for C232H360N38O8P16F48Ru8.20EtOH (6993.138): Found C, 39.86; H, 
5.49; N, 7.95 %; calcd. C, 40.11; H, 5.22; N, 7.66 %. MS (HR-ESI-TOF, m/z): 540.1608 
[M+H]
9+
 (where M = [30][PF6]8 - 8PF6). MP: 275 ºC (decompose without melting). 
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6.5.2.3 [DAB-G3-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA}16][PF6]16 ([31][PF6]16) 
Mustard solid. Yield: 0.398 g, 87.5 %. IR 
(KBr pellets): ν (cm-1) = 1618 (s, imine, 
C=N).
 1
H NMR ((CD3)2CO): δ (ppm) = 1.11 
& 1.29 (br d, 96H, CH(CH3)2 p-cye), 1.99 - 
3.16 (overlapping m, 144H, NCH2CH2 core, 
NCH2CH2 core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 
2nd branch, NCH2CH2CH2N 3rd branch, 
NCH2CH2CH2N 3rd branch), 2.22 (s, 48H, CH3 
p-cye), 3.32 (br m, 16H, CH(CH3)2 p-cye), 3.90 
& 4.03 (br m, 32H, NCH2CH2CH2N 3rd 
branch), 4.25 (m, 96H, PTA), 4.56 (m, 96H, PTA), 5.43 (br m, 16H, Ar p-cye), 5.85 (br m, 16H, 
Ar p-cye), 6.15 (br m, 16H, Ar p-cye), 6.26 (br m, 16H, Ar p-cye), 6.59 (br m, 16H, Ar), 6.87 (br 
m, 16H, Ar), 7.34 (br m, 32H, Ar), 8.21 (br s, 16H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ 
(ppm) = 18.1, 20.8, 21.4 (CH3 p-cye); 55.6, 60.8, 67.2, 72.8 (CH2); 50.9, 72.3 (CH2 PTA); 30.6, 
82.6, 87.9, 88.8, 92.0 (CH p-cye); 96.6, 121.4 (C p-cye); 115.2, 122.2, 135.3, 135.3 (CH Ar); 
119.5, 164.3 (C Ar); 167.0 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -26.2 (s, PTA),  
-138.6 (sep, 
1
J = 709.2 Hz, PF6). Elemental analysis for C472H736N78O16P32F96Ru16.55EtOH 
(14725.394): Found C, 38.17; H, 4.09; N, 7.34 %; calcd. C, 38.50; H, 5.04; N, 7.42 %. MS 
(HR-ESI-TOF, m/z): 617.1169 [M]
16+
 (where M = [31][PF6]16 - 16PF6). MP: 259 - 281 ºC. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Experimental 
 
 
 
209 
 
6.5.2.4 [DAB-G4-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA}32][PF6]32 ([32][PF6]32) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mustard solid. Yield: 0.297 g, 78.7 %. IR (KBr pellets): ν (cm-1) = 1618 (s, imine, C=N). 1H 
NMR ((CD3)2CO): δ (ppm) = 1.13 & 1.29 (br d, 192H, CH(CH3)2 p-cye), 1.75 - 3.02 
(overlapping m, 304H, NCH2CH2 core, NCH2CH2 core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 
2nd branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 3rd branch, 
NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 4th branch, NCH2CH2CH2N 4th branch), 2.17 (br s, 96H, 
CH3 p-cye), 3.15 (br m, 32H, CH(CH3)2 p-cye), 3.82 & 3.91 (br m, 64H, NCH2CH2CH2N 4th 
branch), 4.21 (m, 384H, PTA), 4.54 (m, 384H, PTA), 5.42 (br m, 32H, Arp-cye), 5.73 (br m, 32H, 
Arp-cye), 6.12 (br m, 32H, Arp-cye), 6.22 (br s, 32H, Arp-cye), 6.60 (br m, 32H, Ar), 6.89 (br m, 
32H, Ar), 7.29 (br m, 64H, Ar), 8.10 (br s, 32H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ 
(ppm) = 18.0, 20.8, 21.4 (CH3 p-cye); 50.4 52.3, 68.2, 72.8 (CH2); 50.9, 72.3 (CH2 PTA); 30.6, 
82.6, 87.6, 88.9, 92.0 (CH p-cye); 96.7, 121.4 (C p-cye); 115.2, 122.2, 135.3, 135.4 (CH Ar); 
119.3, 164.3 (C Ar); 166.7 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -26.6 (s, PTA), -
144.0 (sep, 
1
J = 711.1 Hz, PF6). Elemental analysis for 
C952H1488N158O32P64F192Ru32.12EtOH.38Et3NH
+
Cl
-
 (30307.105): Found C, 40.48; H, 5.75; N, 
7.45 %; calcd. C, 40.38; H, 5.12; N, 7.56 %. MS (HR-ESI-TOF, m/z): 603.1587 [M]
32+
 
(where M = [32][PF6]32 - 32PF6).
 
MP: 195 - 199 ºC. 
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6.5.2.5 [DAB-G1-PPI-{(η
6
-HMB)Ru((C7H5NO)-κ
2
-N,O)PTA}4][PF6]4 ([33][PF6]4) 
Yellow solid. Yield: 0.422 g, 90.8 %. IR 
(KBr pellets): ν (cm-1) = 1618 (s, imine, 
C=N).
 1
H NMR ((CD3)2CO): δ (ppm) = 
1.75 (overlapping m, 12H, NCH2CH2 core, 
NCH2CH2CH2N branch), 2.07 (br s, 72H, 
CH3 HMB), 2.42 (br m, 4H, NCH2CH2 core), 
2.95 (br m, 8H, NCH2CH2CH2N branch), 
3.49 & 3.85 (br m, 8H, NCH2CH2CH2N 
branch), 4.13 (m, 24H, PTA), 4.45 (m, 24H, 
PTA), 6.51 (t, 
3
J = 7.3 Hz, 4H, Ar), 6.76 (d, 
3
J = 8.4 Hz, 4H, Ar), 7.14 (t, 
3
J = 7.0 Hz, 4H, Ar), 
7.27 (br d, 4H, Ar), 8.02 (s, 4H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 16.3 (CH3 
HMB); 22.3, 26.3, 50.7, 53.0, 64.3 (CH2); 49.5, 73.0 (CH2 PTA); 99.4 (C HMB); 115.9, 123.2, 
134.7, 136.0 (CH Ar); 122.2, 164.3 (C Ar); 165.5 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ 
(ppm) = -41.0 (s, PTA), -144.4 (sep, 
1
J = 714.5 Hz, PF6). Elemental analysis for 
C116H172N18O4P8F24Ru4.10EtOH (3451.465): Found C, 40.29; H, 5.15; N, 7.33 %; calcd. C, 
40.37; H, 5.02; N, 7.30 %. MS (HR-ESI-TOF, m/z) 603.7332 [M]
4+
 (where M = [33][PF6]4 - 
4PF6). MP: 224 ºC (decompose without melting). 
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6.5.2.6 [DAB-G2-PPI-{(η
6
-HMB)Ru((C7H5NO)-κ
2
-N,O)PTA}8][PF6]8 ([34][PF6]8) 
Yellow solid. Yield: 0.413 
g, 92.7 %. IR (KBr pellets): 
ν (cm-1) = 1619 (s, imine, 
C=N).
 1
H NMR 
((CD3)2CO): δ (ppm) = 1.95 
- 3.11 (overlapping m, 64H, 
NCH2CH2 core, NCH2CH2 
core, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 2nd 
branch, NCH2CH2CH2N 2nd 
branch), 2.05 (br s, 144H, 
CH3 HMB), 3.51 & 3.82 (br 
m, 16H, NCH2CH2CH2N 
2nd branch), 4.12 (m, 48H, PTA), 4.45 (m, 48H, PTA), 6.49 (br t, 8H, Ar), 6.76 (d, 
3
J = 8.3 Hz, 
8H, Ar), 7.13 (t, 
3
J = 7.3 Hz, 8H, Ar), 7.25 (br d, 8H, Ar), 8.02 (br s, 8H, CH imine). 
13
C{
1
H} 
NMR ((CD3)2CO): δ (ppm) = 16.3 (CH3 HMB); 18.4, 20.8, 27.2, 29.7, 50.1, 51.0, 58.4, 64.7 
(CH2); 49.4, 72.8 (CH2 PTA); 99.4 (C HMB); 115.8, 123.2, 134.6, 135.9 (CH Ar); 122.2, 164.3 
(C Ar); 165.4 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -40.8 (s, PTA), -144.4 (sep, 
1
J 
= 714.6 Hz, PF6). Elemental analysis for C240H360N38O8P16F48Ru8.20EtOH (7043.158): 
Found C, 40.62; H, 5.76; N, 7.60 %; calcd. C, 40.93; H, 5.15; N, 7.56 %. MS (HR-ESI-TOF, 
m/z): 451.1324 [M+3H]
11+ 
(where M = [34][PF6]8 - 8PF6). MP: 203 ºC (decompose without 
melting). 
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6.5.2.7 [DAB-G3-PPI-{(η
6
-HMB)Ru((C7H5NO)-κ
2
-N,O)PTA}16][PF6]16 ([35][PF6]16) 
Yellow solid. Yield: 0.346 g, 88.1 %. IR 
(KBr pellets): ν (cm-1) = 1618 (s, imine, 
C=N).
 1
H NMR ((CD3)2CO): δ (ppm) = 
1.41 - 3.14 (overlapping m, 144H, 
NCH2CH2 core, NCH2CH2 core, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 
1st branch, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 
2nd branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 
3rd branch), 2.03 (br s, 288H, CH3 HMB), 3.49 
& 3.79 (br m, 32H, NCH2CH2CH2N 3rd 
branch), 4.09 (m, 96H, PTA), 4.42 (m, 96H, 
PTA), 6.46 (br t, 16H, Ar), 6.75 (br d, 
16H, Ar), 7.12 (br t, 16H, Ar), 7.21 (br d, 16H, Ar), 8.00 (br s, 16H, CH imine). 
13
C{
1
H} NMR 
((CD3)2CO): δ (ppm) = 15.7 (CH3 HMB); 21.3, 50.4, 50.9, 64.7 (CH2); 49.3, 72.4 (CH2 PTA); 
99.4 (C HMB); 115.3, 123.6, 134.5, 145.3 (CH Ar); 122.3, 164.8 (C Ar); 165.3 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -40.6 (s, PTA), -144.3 (sep, 
1
J = 714.8 Hz, PF6). 
Elemental analysis for C488H736N78O16P32F96Ru16.37EtOH (14088.339): Found C, 41.31; H, 
5.64; N, 7.67 %; calcd. C, 41.60; H, 5.27; N, 7.75 %. MS (HR-ESI-TOF, m/z): 629.2938 
[M]
16+ 
(where M = [35][PF6]16 - 16PF6). MP: 200
 
ºC (decompose without melting). 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Experimental 
 
 
 
213 
 
6.5.2.8 [DAB-G4-PPI-{(η
6
-HMB)Ru((C7H5NO)-κ
2
-N,O)PTA}32][PF6]32 ([36][PF6]32) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yellow solid. Yield: 0.289 g, 78.3 %. IR (KBr pellets): ν (cm-1) = 1617 (s, imine, C=N). 1H 
NMR (CD3)2CO): δ (ppm) = 2.08 - 3.31 (overlapping br m, 880H, NCH2CH2 core, NCH2CH2 
core, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 3rd branch, NCH2CH2CH2N 3rd branch, 
NCH2CH2CH2N 4th branch, NCH2CH2CH2N 4th branch, CH3 HMB), 3.64 & 4.86 (br m, 64H, 
NCH2CH2CH2N 4th branch), 4.17 (m, 96H, PTA), 4.47 (m, 96H, PTA), 6.48 (br m, 32H, Ar), 
6.82 (br m, 32H, Ar), 7.18 (br m, 32H, Ar), 7.29 (br m, 32H, Ar), 8.16 (br s, 32H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 20.6 (CH3 HMB); 25.9, 55.2, 55.7, 69.6 (CH2); 54.0, 
77.3 (CH2 PTA); 104.3 (C HMB); 120.1, 128.4, 139.3, 140.2 (CH Ar); 127.1, 169.6 (C Ar); 170.2 
(CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -40.4 (s, PTA), -144.0 (sep, 
1
J = 711.2 Hz, 
PF6). Elemental analysis for C984H1488N158O32P64F192Ru32.8EtOH.29Et3NH
+
Cl
-
 (29268.312): 
Found C, 40.48; H, 5.75; N, 7.45 %; calcd. C, 40.38; H, 5.12; N, 7.56 %. MS (HR-ESI-TOF, 
m/z): 596.1664 [M+2H]
34+
 (where M = [36][PF6]32 - 32PF6). MP: 196 ºC (decompose without 
melting). 
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6.5.3 General Procedure for the Preparation of Cationic N,O-Ru(II)-Arene-PTA 
Mononuclear Complexes ([38][PF6] & [39][PF6]) 
To a stirred solution of 37 (0.120 g, 0.736 mmol for [38][PF6] and [39][PF6]) in EtOH (50 
mL), triethylamine (0.108 mL, 0.772 mmol for [38][PF6] and [39][PF6]) was added dropwise. 
The resulting yellow suspension was stirred at room temperature for 0.5 h. [Ru(η6-p-
Pr
i
C6H4Me)Cl2]2 (0.225 g, 0.368 mmol for [38][PF6]) or [Ru(η
6
-C6Me6)Cl2]2 (0.232 g, 0.343 
mmol for [39][PF6]) was added to the reaction mixture and stirred for 0.5 h. The reaction 
mixture was filtered, then PTA (0.121 g, 0.772 mmol for [38][PF6] and [39][PF6]) was added 
to the filtrate and the reaction stirred for 1 h. The orange-yellow solution was filtered and the 
filtrate reduced to ~5 mL. NaPF6 (0.130 g, 0.773 mmol for [38][PF6] and [39][PF6]) was 
added to the filtrate and stirred for 1 h, resulting in the formation of a solid. The product was 
isolated by filtration, washed with cold EtOH, followed by Et2O and dried under vacuum. 
Crystals for X-ray diffraction were obtained by slow diffusion of EtOH (for [38][PF6]) or 
hexane (for [39][PF6]) into a concentrated DCM solution of the complex. 
 
6.5.3.1 [CH3CH2CH2-(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA][PF6] ([38][PF6]) 
Yellow solid. Yield: 0.431 g, 83.7 %. IR 
(KBr pellets): ν (cm-1) = 1619 (s, imine, 
C=N).
 1
H NMR ((CD3)2CO): δ (ppm) = 1.06 
(t, 
3
J = 7.3 Hz, 3H, NCH2CH2CH3), 1.14 & 
1.23 (d, 
3
J = 6.9 Hz, 6H, CH(CH3)2 p-cye), 2.00 
& 2.08 (m, 2H, NCH2CH2CH3), 2.20 (s, 3H, 
CH3 p-cye), 2.64 (m, 1H, CH(CH3)2 p-cye), 3.81 & 3.98 (m, 2H, NCH2CH2CH3), 4.23 and 4.36 
(2d, 6H, PTA), 4.51 (s, 6H, PTA), 5.61 (d, 
3
J = 4.8 Hz, 1H, Arp-cye), 5.85 (d, 
3
J = 5.4 Hz, 1H, 
Arp-cye), 6.32 (d, 
3
J = 4.9 Hz, 1H, Arp-cye), 6.45 (m, 1H, Arp-cye), 6.53 (t, 
3
J = 6.5 Hz, 1H, Ar), 
6.81 (d, 
3
J = 8.3 Hz, 1H, Ar), 7.22 (m, 2H, Ar), 8.13 (s, 1H, CH imine). 
13
C{
1
H} NMR 
((CD3)2CO): δ (ppm) = 10.7 (CH3); 17.9, 21.0, 21.6 (CH3 p-cye); 24.8, 72.3 (CH2); 51.3, 72.6 
(CH2 PTA); 30.8, 83.7, 97.7, 89.1, 91.5 (CH p-cye); 95.6, 121.4 (C p-cye); 115.3, 121.4, 122.6, 
135.6 (CH Ar); 118.4, 164.4 (C Ar); 166.9 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -
33.0 (s, PTA), -144.2 (sep, 
1
J = 707.9 Hz, PF6). Elemental analysis for C26H38N4OP2F6Ru 
(699.619): Found C, 44.69; H, 5.43; N, 7.96 %; calcd. C, 44.64; H, 5.47; N, 8.01 %. MS (ESI, 
m/z): 566 [M-CYE]
+
. MP: 248 ºC (decompose without melting). 
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6.5.3.2 [CH3CH2CH2-(η
6
-HMB)Ru((C7H5NO)-κ
2
-N,O)PTA][PF6] ([39][PF6]) 
Yellow solid. Yield: 0.422 g, 84.6 %. IR (KBr 
pellets): ν (cm-1) = 1618 (s, imine, C=N). 1H 
NMR ((CD3)2CO): δ (ppm) = 1.05 (t, 
3
J = 7.3 Hz, 
3H, NCH2CH2CH3), 2.02 (m, 2H, 
NCH2CH2CH3), 2.06 (s, 18H, CH3 HMB), 3.64 & 
3.81 (m, 2H, NCH2CH2CH3), 4.19 (m, 6H, PTA), 
4.47 (s, 6H, PTA), 6.52 (t, 
3
J = 6.8 Hz, 1H, Ar), 6.87 (d, 
3
J = 9.6 Hz, 1H, Ar), 7.21 (m, 2H, 
Ar), 8.13 (s, 1H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 10.4 (CH3); 15.7 (CH3 HMB); 
23.5, 68.8 (CH2); 49.3, 72.6 (CH2 PTA); 99.5 (C HMB); 115.3, 123.7, 134.6, 135.1 (CH Ar); 
122.1, 164.6 (C Ar); 165.2 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -41.6 (s, PTA), -
148.6 (sep, 
1
J = 707.3 Hz, PF6). Elemental analysis for C28H42N4OP2F6Ru (727.673): Found 
C, 46.19; H, 5.79; N, 7.74 %; calcd. C, 46.22; H, 5.82; N, 7.70 %. MS (ESI, m/z): 283 [M-
PF6]
+
. MP: 248 ºC (decompose without melting). 
 
6.5.4 Synthesis of Neutral N,O-Os(II)-Arene Complexes (40, 41, 48) 
Triethylamine (0.042 mL, 0.303 mmol for 40; 0.032 mL, 0.231 mmol for 41; 0.047 mL, 0.334 
mmol for 48) was added to a stirred solution of 21 (0.055 g, 0.075 mmol for 40) or 22 (0.046 
g, 0.029 mmol for 41) or 37 (0.052 g, 0.318 mmol for 48) in DCM (30 mL). The reaction 
mixture was stirred for 0.5 h. This was followed by the addition of [Os(η6-p-PriC6H4Me)Cl2]2 
(0.121 g, 0.153 mmol for 40; 0.092 g, 0.116 mmol for 41; 0.126 g, 0.159 mmol for 48) and 
the reaction stirred overnight (for 40 and 41) or for 6 h (for 48). The reaction mixture was 
filtered and the filtrate washed with distilled H2O (5 x 50 mL). The organic layer was isolated, 
dried over MgSO4 (~10 g) and filtered. The filtrate was reduced to ~10 mL and the desired 
product precipitated with hexane. The solid was filtered, washed with cold hexane, followed 
by excess Et2O and dried in vacuo. Crystals of complex 48 were obtained by slow evaporation 
of a concentrated DCM solution of this complex. 
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6.5.4.1 [DAB-G1-PPI-{(η
6
-p-cye)Os((C7H5NO)-κ
2
-N,O)Cl}4] (40) 
Mustard-yellow solid. Yield: 0.142 g, 87.5 %. 
IR (NaCl cells, DCM): ν (cm-1) = 1618 (s, 
imine, C=N).
 1
H NMR (CDCl3): δ (ppm) = 
1.08 & 1.21 (br d, 24H, CH(CH3)2 p-cye), 1.47 
- 2.10 (overlapping m, 12H, NCH2CH2 core, 
NCH2CH2CH2N branch), 2.28 (s, 12H, CH3 p-
cye), 2.43 - 3.04 (overlapping m, 16H, 
NCH2CH2 core, NCH2CH2CH2N branch, 
CH(CH3)2 CYE), 4.09 & 4.22 (br m, 8H, NCH2CH2CH2N branch), 5.46 (br m, 8H, Ar p-cye), 5.70 
(br m, 8H, Ar p-cye), 6.44 (br m, 4H, Ar), 6.85 (br m, 4H, Ar), 6.99 (br m, 4H, Ar), 7.20 (br m, 
4H, Ar), 7.75 (br s, 4H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 19.0, 22.2, 23.4 (CH3 p-
cye); 24.4, 25.7, 51.4, 53.4, 69.6 (CH2); 31.1, 71.1, 72.7, 74.1, 80.0 (CH p-cye); 90.0, 90.6 (C p-
cye); 114.7, 121.2, 135.1, 135.5 (CH Ar); 119.4, 163.7 (C Ar), 163.0 (CH imine). Elemental 
analysis for C84H108N6O4Cl4Os4.2Et3NH
+
Cl
-
 (2443.852): Found C, 41.88; H, 6.39; N, 3.47 %; 
calcd. C, 41.28; H, 4.45; N, 3.44 %. MS (HR-ESI-TOF, m/z): 688.3991 [M]
3+
 (where M = 40 
- 3Cl). MP: 151 ºC (decompose without melting). 
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6.5.4.2 [DAB-G2-PPI-{(η
6
-p-cye)Os((C7H5NO)-κ
2
-N,O)Cl}8] (41) 
Mustard-yellow solid. Yield: 0.0662 g, 
51.7 %. IR (NaCl cells, DCM): ν (cm-1) = 
1617 (s, imine, C=N).
 1
H NMR (CDCl3): 
δ (ppm) = 1.05 & 1.17 (br m, 48H, 
CH(CH3)2), 1.59 - 2.82 (overlapping m, 
64H, NCH2CH2 core, NCH2CH2 core, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch, 
NCH2CH2CH2N 2nd branch), 2.30 (br s, 24H, CH3 p-cye), 3.18 (br m, 8H, CH(CH3)2 p-cye), 4.18 & 
4.37 (br m, 16H, NCH2CH2CH2N 2nd branch), 5.61 (br d, 16H, Ar p-cye), 5.72 (br d, 16H, Ar p-cye), 
6.42 (br m, 8H, Ar), 6.82 (br m, 8H, Ar), 7.19 (br m, 16H, Ar), 8.09 (br s, 8H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 19.1, 22.3, 23.8 (CH3 p-cye); 25.2, 49.2, 52.4, 68.7 (CH2); 
31.2, 70.9, 73.0, 73.6, 79.9 (CH p-cye); 90.2, 91.0 (C p-cye); 114.8, 121.2, 135.0, 135.3 (CH Ar); 
119.5, 163.6 (C Ar); 162.7 (CH imine). Elemental analysis for 
C176H232N14O8Cl8Os8.4H2O.5Et3NH
+
Cl
-
 (5237.644): Found C, 40.36; H, 5.68; N, 3.58 %; 
calcd. C, 40.36; H, 4.46; N, 3.74 %. MS (HR-ESI-TOF, m/z): 604.1675 [M]
7+
 (where M = 41 
- 7Cl). MP: 165 ºC (decompose without melting). 
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6.5.4.3 [CH3CH2CH2-(η
6
-p-cye)Os((C7H5NO)-κ
2
-N,O)Cl] (48) 
Orange-yellow solid. Yield: 0.080 g, 48.3 %. IR 
(NaCl cells, DCM): ν (cm-1) = 1617 (s, imine, 
C=N).
 1
H NMR (CDCl3): δ (ppm) = 1.01 (t, 
3
J = 
7.4 Hz, 3H, NCH2CH2CH3), 1.14 & 1.26 (d, 
3
J = 
6.8 Hz, 6H, CH(CH3)2 p-cye), 1.90 & 2.01 (br m, 2H, 
NCH2CH2CH3), 2.30 (s, 3H, CH3 p-cye), 2.65 (m, 1H, CH(CH3)2 p-cye), 3.98 & 4.20 (m, 2H, 
NCH2CH2CH3), 5.40 (d, 
3
J = 5.3 Hz, 2H, Arp-cye), 5.74 (m, 2H, Arp-cye), 6.44 (t, 
3
J = 6.9 Hz, 
1H, Ar), 6.87 (d, 
3
J = 8.5 Hz, 1H, Ar), 6.94 (d, 
3
J = 7.8 Hz, 1H, Ar), 7.22 (m, 1H, Ar), 7.70 (s, 
1H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 11.5 (CH3); 18.7, 22.2, 23.3 (CH3 p-cye); 
24.5, 73.2 (CH2); 31.1, 71.6, 72.2, 74.2, 78.0 (CH p-cye); 89.5, 91.4 (C p-cye); 114.7, 121.4, 
134.2, 135.0 (CH Ar); 119.5, 164.0 (C Ar); 161.6 (CH imine). Elemental analysis for 
C20H26NOClOs (522.114): Found C, 45.98; H, 5.05; N, 2.65 %; calcd. C, 46.01; H, 5.02; N, 
2.68 %. MS (ESI, m/z): 488 [M-Cl]
+
. MP: 226 - 231 ºC. 
 
6.5.5 Synthesis of Cationic N,O-Os(II)-Arene-PTA Complexes ([42][PF6]4, [43][PF6]8, 
[49][PF6]) 
Triethylamine (0.083 mL, 0.596 mmol for [42][PF6]4; 0.042 mL, 0.303 mmol for [43][PF6]8; 
0.077 mL, 0.551 mmol for [49][PF6]) was added to a stirred suspension of 21 (0.108 g, 0.147 
mmol for [42][PF6]4) or 22 (0.060 g, 0.376 mmol for [43][PF6]8) or 37 (0.086 g, 0.524 mmol 
for [49][PF6]) in EtOH (30 mL). The reaction mixture was stirred for 0.5 h. This was followed 
by the addition of [Os(η6-p-PriC6H4Me)Cl2]2 (0.239 g, 0.302 mmol for [42][PF6]4; 0.120 g, 
0.152 mmol for [43][PF6]8; 0.207 g, 0.262 mmol for [49][PF6]) and the reaction stirred 
overnight (for [42][PF6]4 and [43][PF6]8) or for 6 h (for [49][PF6]). The reaction mixture was 
filtered, the filtrate reduced to ~10 mL and PTA (0.094 g, 0.596 mmol for [42][PF6]4; 0.048 g, 
0.303 mmol for [43][PF6]8; 0.087 g, 0.551 mmol for [49][PF6]) was added. The reaction 
mixture was stirred for 6 h, filtered and the filtrate reduced ~5 mL. NaPF6 (0.100 g, 0.596 
mmol for [42][PF6]4; 0.051 g, 0.303 mmol for [43][PF6]8; 0.093 g, 0.551 mmol for [49][PF6]) 
was added to the reaction mixture and stirred for 0.5 h, which resulted in the precipitation of a 
solid. The solid was filtered, washed with cold EtOH and excess Et2O. The solid was 
dissolved in 20 mL acetone. The solution was filtered over Celite
®
 and the filtrate reduced. 
The desired product was precipitated with Et2O and dried under reduced pressure. Crystals of 
complex [49][PF6] were obtained by slow diffusion of hexane into a concentrated DCM 
solution of the complex. 
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6.5.5.1 [DAB-G1-PPI-{(η
6
-p-cye)Os((C7H5NO)-κ
2
-N,O)PTA}4][PF6]4 ([42][PF6]4) 
Yellow solid. Yield: 0.450 g, 94.5 %. 
IR (KBr pellets): ν (cm-1) = 1611 (s, 
imine, C=N).
 1
H NMR ((CD3)2CO): δ 
(ppm) = 0.97 & 1.16 (br d, 
3
J = 6.9 Hz, 
24H, CH(CH3)2 p-cye), 1.48 - 2.11 
(overlapping m, 12H, NCH2CH2 core, 
NCH2CH2CH2N branch), 2.25 (s, 12H, 
CH3 p-cye), 2.39 - 2.97 (overlapping m, 
16H, NCH2CH2 core, NCH2CH2CH2N 
branch, CH(CH3)2 p-cye), 3.99 (br m, 8H, 
NCH2CH2CH2N branch), 4.11 (m, 24H, PTA), 4.34 (m, 24H, PTA), 5.63 (br d, 
3
J = 5.5 Hz, 4H, 
Ar p-cye), 5.94 (br m, 4H, Ar p-cye), 6.08 (m, 4H, Ar p-cye), 6.34 (br m, 4H, Ar p-cye), 6.39 (t, 
3
J = 
7.3 Hz, 4H, Ar), 6.62 (br d, 
3
J = 8.5 Hz, 4H, Ar), 7.18 (br t, 
3
J = 6.8 Hz, 8H, Ar), 8.07 (br s, 
4H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 18.0, 20.7, 21.1 (CH3 p-cye); 52.1, 53.6, 
70.8 (CH2); 50.1, 72.1 (CH2 PTA); 30.1, 73.8, 79.3, 80.0, 82.9 (CH p-cye); 89.5, 121.4 (C p-cye); 
115.7, 120.7, 134.7, 135.2 (CH Ar); 111.7, 164.1 (C Ar), 162.5 (CH imine). 
31
P{
1
H} NMR 
((CD3)2CO): δ (ppm) = -71.2 (s, PTA), -144.1 (sep, 
1
J = 709.8 Hz, PF6). Elemental analysis 
for C108H156N18O4P8F24Os4.EtOH.Et3NH
+
Cl
-
 (3556.580): Found C, 36.21; H, 5.37; N, 7.06 %; 
calcd. C, 36.47; H, 4.42; N, 7.09 %. MS (HR-ESI-TOF, m/z): 632.8656 [M]
4+
 (where M = 
[42][PF6]4 - 4PF6). MP: 185 - 188 ºC. 
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6.5.5.2 [DAB-G2-PPI-{(η
6
-p-cye)Os((C7H5NO)-κ
2
-N,O)PTA}8][PF6]8 ([43][PF6]8) 
Yellow solid. Yield: 0.137 g, 54.0 %. IR 
(KBr pellets): ν (cm-1) = 1614 (s, imine, 
C=N).
 1
H NMR ((CD3)2CO): δ (ppm) = 
0.95 & 1.15 (br d, 48H, CH(CH3)2 p-cye), 
1.74 - 2.17 (overlapping m, 28H, NCH2CH2 
core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch), 2.24 (s, 24H, 
CH3 p-cye), 2.34 - 3.13 (overlapping m, 44H, 
NCH2CH2 core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 
2nd branch, CH(CH3)2 p-cye), 3.92 (br m, 16H, 
NCH2CH2CH2N 2nd branch), 4.09 (m, 48H, PTA), 4.36 (m, 48H, PTA), 5.58 (br m, 8H, Ar p-cye), 
5.89 (br m, 8H, Ar p-cye), 6.04 (br m, 8H, Ar p-cye), 6.33 (br m, 8H, Ar p-cye), 6.38 (br t, 8H, Ar), 
6.61 (br d, 8H, Ar), 7.17 (br m, 16H, Ar), 8.05 (br s, 8H, CH imine). 
13
C{
1
H} NMR 
((CD3)2CO): δ (ppm) = 18.0, 20.7, 21.1 (CH3 p-cye); 50.9, 71.1 (CH2); 50.9, 72.1 (CH2 PTA); 
30.0, 73.4, 79.2, 79.9, 83.2 (CH p-cye); 89.1, 121.5 (C p-cye); 115.7, 120.7, 134.7, 135.1 (CH Ar); 
111.9, 164.0 (C Ar); 162.5 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -70.9 (s, PTA),  
-144.0 (sep, 
1
J = 710.2 Hz, PF6). Elemental analysis for C224H328N38O8P16F48Os8.12EtOH 
(7071.325): Found C, 41.68; H, 5.53; N, 7.30 %; calcd. C, 41.58; H, 5.63; N, 7.43 %. MS 
(HR-ESI-TOF, m/z): 650.3942 [M]
8+
 (where M = [43][PF6]8 - 8PF6). MP: 179 - 182 ºC 
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6.5.5.3 [CH3CH2CH2-(η
6
-p-cye)Os((C7H5NO)-κ
2
-N,O)PTA][PF6] ([49][PF6]) 
Orange-yellow solid. Yield: 0.222 g, 53.8 %. 
IR (KBr pellets): ν (cm-1) = 1613 (s, imine, 
C=N).
 1
H NMR ((CD3)2CO): δ (ppm) = 1.05 
(t, 
3
J = 7.4 Hz, 3H, NCH2CH2CH3), 1.21 & 
1.31 (d, 
3
J = 6.9 Hz, 6H, CH(CH3)2 p-cye), 1.94 
- 2.06 (br m, 2H, NCH2CH2CH3), 2.34 (s, 
3H, CH3 p-cye), 2.58 (m, 1H, CH(CH3)2 p-cye), 3.97 & 4.17 (m, 2H, NCH2CH2CH3), 4.23 (m, 
6H, PTA), 4.45 (m, 6H, PTA), 5.79 (dd, 
3
J = 5.7 Hz, J = 1.2 Hz, 1H, Arp-cye), 5.99 (d, 
3
J = 5.7 
Hz, 1H, Arp-cye), 6.26 (dd, 
3
J = 5.7 Hz, J = 1.1 Hz, 1H, Arp-cye), 6.48 (m, 1H, Arp-cye), 6.55 (t, 
3
J 
= 6.9 Hz, 1H, Ar), 6.77 (d, 
3
J = 8.5 Hz, 1H, Ar), 7.25 (dd, 
3
J = 6.0 Hz, J = 1.8 Hz, 1H, Ar), 
7.32 (t, 
3
J = 6.8 Hz, 1H, Ar), 8.13 (s, 1H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 
10.2 (CH3); 17.9, 21.0, 21.5 (CH3 p-cye); 25.0, 74.9 (CH2); 50.4, 72.4 (CH2 PTA); 30.4, 74.6, 
79.2, 80.4, 82.6 (CH p-cye); 90.7, 121.7 (C p-cye); 116.0, 121.0, 134.8, 135.4 (CH Ar); 111.2, 
162.7 (C Ar); 164.4 (CH imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -71.6 (s, PTA), -148.5 
(sep, 
1
J = 707.6 Hz, PF6). Elemental analysis for C26H38N4OP2F6Os (788.774): Found C, 
39.53; H, 4.94; N, 7.01 %; calcd. C, 39.59; H, 4.86; N, 7.10 %. MS (EI, m/z): 566 [M-PTA-
PF6]
+
. MP: 226 - 231 ºC. 
 
6.5.6 Synthesis of N,N-2-Pyridylimine Ligands (44, 45, 50) 
DAB-G1-PPI-(C6H5N2)4 (44), DAB-G2-PPI-(C6H5N2)8 (45) and (E)-N-(pyridine-2-
ylmethylene)propan-1-amine (50) were prepared from known literature reported procedures.
7-
9
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6.5.7 Synthesis of Cationic N,N-Os(II)-Arene Complexes ([46][PF6]4, [47][PF6]8, 
[51][PF6]) 
Ligand 44 (0.068 g, 0.101 mmol for [26][PF6]4) or 45 (0.066 g, 0.044 mmol for [47][PF6]8) or 
50 (0.154 g, 0.301 mmol for [51][PF6]) was added to a stirred suspension of [Os(η
6
-p-
Pr
i
C6H4Me)Cl2]2 (0.164 g, 0.208 mmol for [46][PF6]4; 0.142 g, 0.180 mmol for [47][PF6]8; 
0.116 g, 0.147 mmol for [51][PF6]) in EtOH (30 mL). The reaction was stirred overnight (for 
[46][PF6]4 and [47][PF6]8) or for 6 h (for [51][PF6]). The reaction mixture was filtered, NaPF6 
(0.069 g, 0.410 mmol for [46][PF6]4; 0.060 g, 0.357 mmol for [47][PF6]8; 0.051 g, 0.301 
mmol for [41][PF6]) was added to the filtrate and the reaction mixture stirred for 0.5 h. This 
resulted in the precipitation of a solid, which was filtered, washed with cold EtOH and excess 
Et2O. The solid was dissolved in 20 mL acetone. The solution was filtered over Celite® and 
the filtrate reduced. The desired product was precipitated with Et2O and dried under vacuum. 
Crystals of complex [51][PF6] were obtained by slow diffusion of Et2O into a concentrated 
acetone solution of the complex. 
 
6.5.7.1 [DAB-G1-PPI-{(η6-p-cye)Os((C6H5N2)-κ
2
-N,N)Cl}4][PF6]4 ([46][PF6]4) 
Dark orange solid. Yield: 0.197 g, 72.4 
%. IR (KBr pellets): ν (cm-1) = 1617 (s, 
imine, C=N), 1598 (s, pyridyl, C=N). 
1
H NMR ((CD3)2CO): δ (ppm) = 1.02 
(br m, 24H, CH(CH3)2 p-cye), 1.29 (br 
m, 4H, NCH2CH2 core,), 1.93 - 2.18 
(overlapping m, 12H, NCH2CH2 core, 
NCH2CH2CH2N branch), 2.39 (s, 12H, 
CH3 p-cye), 2.59 (br m, 4H, CH(CH3)2 p-
cye), 3.39 (br m, 8H, NCH2CH2CH2N branch), 4.70 & 4.81 (br m, 8H, NCH2CH2CH2N branch), 
6.12 (br m, 8H, Ar p-cye), 6.51 (br d, 8H, Ar p-cye), 7.79 (br m, 4H, Pyr), 8.28 (br m, 8H, Pyr), 
9.24 (br s, 4H, CH imine), 9.54 (br m, 4H, Pyr). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 18.3, 
21.6, 22.0 (CH3 p-cye); 24.6, 51.2, 52.8, 65.1 (CH2); 31.2, 75.0, 76.0, 77.3,79.7 (CH p-cye); 97.3, 
97.9 (C p-cye); 129.5, 140.0, 155.5 (CH pyr); 156.1 (C pyr); 169.7 (CH imine). Elemental analysis 
for C80H108N10Cl4P4F24Os4.5EtOH (2922.725): Found C, 36.44; H, 4.69; N, 4.59 %; calcd. C, 
36.99; H, 4.76; N, 4.79 %. MS (HR-ESI-TOF, m/z): 528.1338 [M]
4+
 (where M = [46][PF6]4 -
4PF6). MP: 194 ºC (decompose without melting). 
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6.5.7.2 [DAB-G2-PPI-{(η
6
-p-cye)Os((C6H5N2)-κ
2
-N,N)Cl}8][PF6]8 ([47][PF6]8) 
Yellow -brown solid. Yield: 0.186 g, 75.7 %. 
IR (KBr pellets): ν (cm-1) = 1619 (s, imine, 
C=N), 1596 (s, pyridyl, C=N). 
1
H NMR 
((CD3)2CO): δ (ppm) = 1.01 (br m, 48H, 
CH(CH3)2 p-cye), 1.30 (br m, 4H, NCH2CH2 
core), 1.94 - 2.77 (overlapping m, 56H, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 2nd 
branch, CH(CH3)2 p-cye, CH3 p-cye), 3.26 - 3.61 
(overlapping m, 32H, NCH2CH2 core, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 2nd branch,), 4.80 (br m, 16H, NCH2CH2CH2N 2nd branch), 6.15 & 6.52 (br 
m, 32H, Ar p-cye), 7.77 (br m, 8H, Pyr), 8.24 (br m, 8H, Pyr), 8.32 (br m, 8H, Pyr), 9.33 (br m, 
8H, CH imine), 9.53 (br m, 8H, Pyr). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 18.4, 21.7, 22.1 
(CH3 p-cye); 24.5, 50.9, 53.0, 65.1 (CH2); 31.2, 75.0, 76.0, 77.3,79.7 (CH p-cye); 97.2, 97.8 (C p-
cye); 129.4, 140.0, 155.5 (CH pyr); 156.1 (C pyr); 169.7 (CH imine). Elemental analysis for 
C168H232N22Cl8P8F48Os8.12EtOH (5524.995): Found C, 37.86; H, 5.29; N, 5.95 %; calcd. C, 
37.94; H, 5.04; N, 5.07 %. MS (HR-ESI-TOF, m/z): 545.6624 [M]
8+
 (where M = [47][PF6]8 - 
8PF6). MP: 193 ºC (decompose without melting). 
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6.5.7.3 CH3CH2CH2-(η
6
-p-cye)Os((C6H5N2)-κ
2
-N,N)Cl][PF6] ([51][PF6]) 
Red solid. Yield: 0.120 g, 62.3 %. IR (KBr 
pellets): ν (cm-1) = 1615 (s, imine, C=N), 
1596 (s, pyridyl, C=N).
 1
H NMR 
((CD3)2CO): δ (ppm) = 1.00 (m, 3H, 
NCH2CH2CH3), 1.03 & 1.10 (d, 
3
J = 6.9 
Hz, 6H, CH(CH3)2 p-cye), 1.82 & 1.98 (m, 2H, NCH2CH2CH3), 2.36 (s, 3H, CH3 p-cye), 2.68 (m, 
1H, CH(CH3)2 p-cye), 4.62 (m, 2H, NCH2CH2CH3), 6.12 (d, 
3
J = 6.0 Hz, 1H, Arp-cye), 6.18 (d, 
3
J = 5.9 Hz, 1H, Arp-cye), 6.50 (d, 
3
J = 5.8 Hz, 1H, Arp-cye), 6.63 (d,
 3
J = 5.6 Hz, 1H, Arp-cye), 
7.79 (t, 
3
J = 7.5 Hz, 1H, Pyr), 8.26 (t, 
3
J = 7.5 Hz, 1H, Pyr), 8.45 (d, 
3
J = 7.8 Hz, 1H, Pyr), 
9.39 (s, 1H, CH imine), 9.66 (d, 
3
J = 5.6 Hz, 1H, Pyr). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 
10.8 (CH3); 21.5, 22.0, 22.9 (CH3 p-cye); 17.9, 69.4 (CH2); 31.2, 75.5, 76.0, 76.8, 79.7 (CH p-
cye); 96.7, 97.0 (C p-cye); 128.8, 129.2, 139.7, 155.8 (CH pyr); 156.4 (C pyr); 168.2 (CH imine). 
Elemental analysis for C19H26N2ClPF6Os (653.073): Found C, 34.85; H, 5.98; N, 4.21 %; 
calcd. C, 34.94; H, 4.01; N, 4.29 %. MS (ESI, m/z): 508 [M+H]
+
. MP: 181 ºC (decompose 
without melting). 
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6.6 Synthesis of Ferrocenyl-Derived Conjugates (53 - 55) 
 
6.6.1 Vinyl Ferrocene (53)  
53 was prepared from a known literature reported procedure.
10
 
2.5 M n-BuLi (2.96 mL, 7.40 mmol) was added dropwise to a 
stirred light yellow suspension of methyltriphenylphosphonium 
iodide (2.64 g, 6.53 mmol) in dry THF (100 mL) at -78 ºC. The 
reaction was warmed to RT and stirred for 1.5 h. The light yellow 
suspension turns bright yellow. To this suspension, a solution of 
ferrocene carboxaldehyde 52 (1.03 g, 4.83 mmol) in dry THF (20 mL) was added dropwise at 
-78 ºC. The mixture was warmed to RT and stirred for 20 h. Following stirring, the reaction 
mixture was quenched by slow addition of a saturated solution of NH4Cl (40 mL) at 0 ºC. The 
organic layer was separated and the aqueous layer washed with Et2O (3 x 50 mL). The 
organic fractions were combined, stirred over MgSO4 and filtered. The solvent of the filtrate 
was reduced and excess Et2O added. A brown precipitate was observed and filtered off. The 
solvent of the filtrate was removed to afford the desired product. 
Orange solid. Yield: 0.933 g, 86.0 %. IR (ATR): ν (cm-1) = 1627 (m, alkene, C=C). 1H NMR 
(CDCl3): δ (ppm) = 4.10 (s, 5H, Cp-CH unsubst. ring), 4.20 (t, 
3
J = 1.8 Hz, 2H, Cp-CH), 4.35 (t, 
3
J = 1.9 Hz, 2H, Cp-CH), 5.02 (dd, 
3
J = 10.7 Hz cis & 
2
J = 1.6 Hz geminal, 1H, Cp-CH=CH2), 
5.33 (dd,
 3
J = 17.5 Hz trans &
 2
J = 1.6 Hz geminal, 1H, Cp-CH=CH2), 6.45 (dd, 
3
J = 17.5 Hz trans 
& 
3
J = 10.7 Hz cis, 1H, Cp-CH=CH2). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 66.7, 68.6 (Cp-CH); 
69.2 (Cp-CH unsubst. ring); 83.6 (C Cp); 111.0 (Cp-CH=CH2); 134.7 (Cp-CH=CH2). MP: 48 - 49 
ºC (lit. 48 - 50 ºC).
11
 
Spectroscopic data in agreement with reported literature.
11
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6.6.2 (4E)-(4-ferrocenyl-vinyl)-2-hydroxy-benzaldehyde (54) 
Triethylamine (0.59 mL, 4.25 mmol) was syringed into 
a solution of 53 (0.300 g, 1.42 mmol), 4-bromo-2-
hydroxybenzaldehyde (0.284 g, 1.42 mmol), 
triphenylphosphine (0.0743 g, 0.283 mmol, 20 mol %) 
and palladium acetate (0.0159 g, 0.0708 mmol, 5.0 mol 
% Pd) in 1.4-dioxane (30 mL). The reaction mixture 
was heated under reflux for 3 days. The orange solution 
turned into a dark red solution. The reaction mixture was cooled to RT and filtered over a 
small pad of silica (~2 cm in height). The silica was washed with Et2O, and the solvent of the 
filtrate removed. The crude product was purified by flash column chromatography on silica. 
The column was eluted with a 10:90 (EtOAc/Pet. Ether) solution and the last red band 
collected. The solvent was removed in vacuo to afford the pure product. 
Purple solid. Yield: 0.0614 g, 13.0 %. IR (ATR): ν (cm-1) = 1614 (s, alkene, C=C), 1652 (m, 
carbonyl, C=O). 
1
H NMR (CDCl3): δ (ppm) = 4.16 (s, 5H, Cp-CH unsubst. ring), 4.37 (t, 
3
J = 1.8 
Hz, 2H, Cp-CH), 4.51 (t, 
3
J = 1.8 Hz, 2H, Cp-CH), 6.65 (d, 
3
J = 16.1 Hz trans, 1H, CH alkene), 
7.00 (d, 
4
J = 1.2 Hz, 1H, Ar), 7.06 (dd, 
3
J = 8.0 Hz & 
4
J = 1.5 Hz, 1H, Ar), 7.09 (d,
 3
J = 16.1 
Hz trans, 1H, CH alkene), 7.48 (d, 
3
J = 8.1 Hz, 1H, Ar), 9.83 (s, 1H, CHO), 11.10 (s, 1H, OH). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 67.5, 69.9 (Cp-CH); 69.4 (Cp-CH unsubst. ring); 81.9 (C Cp); 
113.8, 117.6, 134.0 (CH Ar); 119.3, 146.7, 162.2 (C Ar); 124.3, 133.0 (CH alkene); 195.2 
(CHO). HPLC (MeOH/H2O (gradient, 5 - 90 %, flow rate, 0.6 mL/min)): tR = 17.4 min. MS 
(HR-ESI-TOF, m/z): 333.0562 [M+H]
+
. MP: 152 ºC (decompose without melting). 
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6.6.3 (5E)-(5-ferrocenyl-vinyl)-2-pyridinecarboxaldehyde (55) 
Triethylamine (0.70 mL, 5.01 mmol) was syringed into a 
solution of 53 (0.354 g, 1.67 mmol), 5-bromo-2-
pyridinecarboxaldehyde (0.311 g, 1.67 mmol), 
triphenylphosphine (0.0876 g, 0.334 mmol, 20 mol %) 
and palladium acetate (0.0188 g, 0.0835 mmol, 5.0 mol 
% Pd) in 1.4-dioxane (30 mL). The reaction mixture was 
heated under reflux for 3 days. The orange solution turned into a dark red solution. The 
reaction mixture was cooled to RT and filtered over a small pad of silica. The silica was 
washed with Et2O, and the solvent of the filtrate removed. The crude product was purified by 
flash column chromatography on silica (~2 cm in height). The column was eluted with a 
10:90 (EtOAc/Pet. Ether) solution and the last red band collected. The solvent was removed 
in vacuo to afford the pure product. 
Dark purple solid. Yield: 0.1314 g, 24.8 %. IR (ATR): ν (cm-1) = 1575 (s, alkene, C=C), 1629 
(m, pyridyl, C=N), 1703 (m, carbonyl, C=O). 
1
H NMR (CDCl3): δ (ppm) = 4.16 (s, 5H, Cp-
CH unsubst. ring), 4.39 (t, 
3
J = 1.8 Hz, 2H, Cp-CH), 4.50 (t, 
3
J = 1.8 Hz, 2H, Cp-CH), 6.70 (d, 
3
J 
= 16.2 Hz trans, 1H, CH alkene), 7.14 (d,
 3
J = 16.1 Hz trans, 1H, CH alkene), 7.91 (m, 2H, Pyr), 8.77 
(s, 1H, Pyr), 10.05 (s, 1H, CHO). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 67.5, 70.1 (Cp-CH); 
69.5 (Cp-CH unsubst. ring); 81.7 (C Cp); 120.9, 122.0 (CH alkene); 127.9, 135.2 (C Pyr); 132.3, 
133.7, 148.0 (CH Pyr); 192.8 (CHO). HPLC (MeOH/H2O (gradient, 5 - 90 %, flow rate, 0.6 
mL/min)): tR = 15.5 min. MS (HR-ESI-TOF, m/z): 318.0580 [M+H]
+
. MP: 184 - 186 ºC. 
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6.7 General Procedure for the Preparation of Ferrocenyl-Derived N,O-
Salicylaldiminato Dendritic Ligands (56 & 57) 
 
DAB-G1-PPI-(NH2)4 (0.0203 g, 0.0641 mmol for 56) or DAB-G2- PPI-(NH2)8 (0.0249 g, 
0.0322 mmol for 57) in DCM (5.00 mL), was added dropwise to a stirred dark purple solution 
of (4E)-(4-ferrocenyl-vinyl)-2-hydroxy-benzaldehyde (0.0863 g, 0.260 mmol for 56, 0.0861 
g, 0.259 mmol for 57) in 30 mL DCM. Anhydrous MgSO4 (~10 g) was added and the reaction 
mixture stirred overnight at room temperature. The reaction mixture was filtered and the 
solvent removed from the filtrate under reduced pressure, yielding a solid residue. The solid 
residue was dissolved in a minimum amount of DCM and the products were precipitated with 
petroleum ether (40 - 60 ºC). The solid was isolated by filtration, washed with petroleum ether 
(40 - 60 ºC), followed by excess pentane and dried under reduced pressure.  
 
6.7.1 DAB-G1-(4-ferrocenyl-vinyl-C7H5NOH)4 (56) 
Orange solid. Yield: 0.0614 g, 
60.9 %. IR (ATR): ν (cm-1) = 
1614 (s, alkene, C=C & imine, 
C=N). 
1
H NMR (CDCl3): δ 
(ppm) = 1.42 (br m, 4H, 
NCH2CH2 core), 1.82 (br m, 
8H, NCH2CH2CH2N branch), 
2.40 - 2.51 (overlapping m, 
12H, NCH2CH2 core, NCH2CH2CH2N branch), 3.60 (br m, 8H, NCH2CH2CH2N branch), 4.14 (br 
s, 20H, Cp-CH unsubst. ring), 4.30 (br t, 
3
J = 1.7 Hz, 8H, Cp-CH), 4.47 (br t, 
3
J = 1.7 Hz, 8H, Cp-
CH), 6.63 (d, 
3
J = 16.1 Hz trans, 4H, CH alkene), 6.63 (d, 
3
J = 16.1 Hz trans, 4H, CH alkene), 6.90 
(br d, 
3
J = 8.1 Hz, 4H, Ar), 6.94 (d, 
3
J = 16.1 Hz trans, 4H, CH alkene), 7.00 (br s, 4H, Ar), 7.14 
(d,
 3
J = 8.0 Hz, 4H, Ar), 8.27 (br s, 4H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 25.2, 
28.6, 51.5, 54.1, 57.2 (CH2); 67.2, 69.4 (Cp-CH); 69.3 (Cp-CH unsubst. ring); 82.3 (C Cp); 113.8, 
116.3, 131.4 (CH Ar); 117.5, 141.8, 162.1 (C Ar); 125.4, 129.5 (CH alkene); 164.4 (CH imine). 
Elemental analysis for C92H96N6O4Fe4.4DCM (1912.920): Found C, 60.95; H, 5.41; N, 4.61 
%; calcd. C, 60.28; H, 5.48; N, 4.39 %. MS (HR-ESI-TOF, m/z): 525.1727 [M+3H]
3+
. MP: 
87 ºC (decompose without melting). 
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6.7.2 DAB-G2-(4-ferrocenyl-vinyl-C7H5NOH)8 (57) 
Orange solid. Yield: 0.0683 g, 
64.6 %. IR (ATR): ν (cm-1) = 
1613 (s, alkene, C=C & imine, 
C=N). 
1
H NMR (CDCl3): δ 
(ppm) = 1.41 (m, 4H, 
NCH2CH2 core), 1.56 (m, 8H, 
NCH2CH2CH2N 1st branch), 1.79 
(m, 16H, NCH2CH2CH2N 2nd 
branch), 2.41 - 2.50 (overlapping 
m, 32H, NCH2CH2CH2N 1st 
branch, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch), 2.69 (br m, 4H, NCH2CH2 core), 3.57 (br m, 16H, NCH2CH2CH2N 
2nd branch), 4.13 (m, 40H, Cp-CH unsubst. ring), 4.30 (m, 16H, Cp-CH), 4.46 (m, 16H, Cp-CH), 
6.62 (br d, 8H, CH alkene), 6.87 - 6.99 (overlapping m, 24H, 2 x Ar, CH alkene), 7.06 (m, 8H, 
Ar), 8.18 (br s, 8H, CH imine). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 24.7, 25.2, 28.6, 40.8, 51.6, 
52.3, 54.3, 57.3 (CH2); 67.2, 69.4 (Cp-CH); 69.3 (Cp-CH unsubst. ring); 82.8 (C Cp); 113.8, 
116.3, 131.4 (CH Ar); 117.5, 141.8, 161.9 (C Ar); 125.4, 129.5 (CH alkene); 164.4 (CH imine). 
Elemental analysis for C192H208N14O8Fe8.6DCM (3796.202): Found C, 62.73; H, 5.90; N, 
5.50 %; calcd. C, 62.65; H, 5.84; N, 5.17 %. MS (HR-ESI-TOF, m/z): 822.8010 [M+4H]
4+
. 
MP: 285 ºC (decompose without melting).  
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6.8 Synthesis of Ferrocenyl-Derived N,N-Pyridylimine Ligands (58 & 59) 
 
DAB-G1-PPI-(NH2)4 (0.0300 g, 0.0948 mmol for 58) or DAB-G2- PPI-(NH2)8 (0.0606 g, 
0.0784 mmol for 59) in DCM (5.00 mL), was added dropwise to a stirred dark purple solution 
of (5E)-(5-ferrocenyl-vinyl)-2-pyridinecarboxaldehyde (0.122 g, 0.384 mmol for 58, 0.200 g, 
0.631 mmol for 59) in 30 mL DCM. Anhydrous MgSO4 (~10 g) was added and the reaction 
mixture stirred overnight at room temperature. The reaction mixture was filtered and the 
solvent removed from the filtrate under reduced pressure, yielding a solid residue. The solid 
residue was dissolved in a minimum amount of DCM and the products were precipitated with 
petroleum ether (40 - 60 ºC). The solid was isolated by filtration, washed with petroleum ether 
(40 - 60 ºC), followed by excess pentane and dried under reduced pressure.  
 
6.8.1 DAB-G1-(5-ferrocenyl-vinyl-C6H5N2)4 (58) 
Orange solid. Yield: 0.0701 g, 
48.9 %. IR (ATR): ν (cm-1) = 
1579 (m, alkene, C=C), 1628 
(s, pyridyl, C=N), 1640 (m, 
imine, C=N).
 1
H NMR 
(CDCl3): δ (ppm) = 1.45 (br m, 
4H, NCH2CH2 core), 1.88 (br m, 
8H, NCH2CH2CH2N branch), 
2.45 - 2.55 (overlapping m, 12H, NCH2CH2 core, NCH2CH2CH2N branch), 3.69 (br m, 8H, 
NCH2CH2CH2N branch), 4.15 (br s, 20H, Cp-CH unsubst. ring), 4.33 (br m, 8H, Cp-CH), 4.48 (br 
m, 8H, Cp-CH), 6.66 (d, 
3
J = 16.3 Hz trans, 4H, CH alkene), 6.99 (br d, 
3
J = 16.4 Hz trans, 4H, 
CH alkene), 7.77 (br d, 
3
J = 8.3 Hz, 4H, Pyr), 7.92 (br d, 
3
J = 8.1 Hz, 4H, Pyr), 8.37 (br s, 4H, 
CH imine), 8.61 (br s, 4H, Pyr). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 25.2, 28.4, 51.8, 54.1, 59.7 
(CH2); 67.2, 69.5 (Cp-CH); 69.3 (Cp-CH unsubst. ring); 82.4 (C Cp); 121.2, 121.7 (CH alkene); 
130.6, 132.2, 147.4 (CH Pyr); 134.5, 152.7 (C Pyr); 161.7 (CH imine). Elemental analysis for 
C88H92N10Fe4.1.5DCM (1640.544): Found C, 65.54; H, 6.28; N, 8.51 %; calcd. C, 65.53; H, 
5.84; N, 8.54 %. MS (HR-ESI-TOF, m/z): 500.0750 [M+3H]
3+
. MP: 82 ºC (decompose 
without melting). 
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6.8.2 DAB-G2-(5-ferrocenyl-vinyl-C6H5N2)8 (59) 
Orange solid. Yield: 0.125 g, 
50.2 %. IR (ATR): ν (cm-1) = 
1581 (m, alkene, C=C), 1628 
(s, pyridyl, C=N), 1643 (m, 
imine, C=N). 
1
H NMR 
(CDCl3): δ (ppm) = 1.41 (m, 
4H, NCH2CH2 core), 1.58 (m, 
8H, NCH2CH2CH2N 1st 
branch), 1.87 (m, 16H, 
NCH2CH2CH2N 2nd branch), 
2.43 - 2.55 (overlapping m, 
32H, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 2nd branch), 2.72 (br 
m, 4H, NCH2CH2 core), 3.68 (br m, 16H, NCH2CH2CH2N 2nd branch), 4.14 (br s, 40H, Cp-CH 
unsubst. ring), 4.32 (m, 16H, Cp-CH), 4.47 (br m, 16H, Cp-CH), 6.64 (br d, 8H, CH alkene), 6.98 
(br d, 8H, CH alkene), 7.76 (m, 8H, Pyr), 7.90 (m, 8H, Pyr), 8.35 (br s, 8H, CH imine), 8.60 (br s, 
8H, Pyr). 
13
C{
1
H} NMR (CDCl3): δ (ppm) = 24.8, 25.2, 28.4, 40.8, 51.8, 52.4, 54.4, 59.7 
(CH2); 67.2, 69.6 (Cp-CH); 69.3 (Cp-CH unsubst. ring); 82.3 (C Cp); 121.2, 121.7 (CH alkene); 
130.6, 132.2, 147.4 (CH Pyr); 134.5, 152.6 (C Pyr); 161.7 (CH imine). Elemental analysis for 
C184H200N22Fe8.4DCM (3506.249): Found C, 64.33; H, 6.22; N, 8.75 %; calcd. C, 64.40; H, 
5.98; N, 8.79 %. MS (HR-ESI-TOF, m/z): 633.1572 [M+5H]
5+
. MP: 86 - 87 ºC 
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6.9 Synthesis of Ferrocenyl-Derived N,O-Salicylaldiminato Monomeric Ligand 
(60) 
 
n-Propylamine (0.025 mL, 0.303 mmol) was added dropwise to a stirred solution of 54 
(0.0504 g, 0.152 mmol) in DCM (20.0 mL). The reaction mixture was stirred at RT for 2 h. 
The orange reaction mixture was filtered over a small pad of silica (2 cm in height), and 
washed with EtOAc. The solvent was removed from the filtrate under vacuum, to afford the 
desired product without further purification. 
 
6.9.1 (5E, 2E)-(5-ferrocenyl-vinyl)-2-((propylimino)methyl)phenol (60) 
Orange solid. Yield: 0.0316 g, 55.8 %. IR 
(ATR): ν (cm-1) = 1607 (s, alkene, C=C & 
imine, C=N). 
1
H NMR (CDCl3): δ (ppm) = 
0.99 (t, 
3
J = 7.4 Hz, 3H, NCH2CH2CH3), 1.72 
(m, 2H, NCH2CH2CH3), 3.55 (t, 
3
J = 6.8 Hz, 
2H, NCH2CH2CH3), 4.14 (s, 5H, Cp-CH unsubst. ring), 4.30 (d, 
3
J = 1.8 Hz, 2H, Cp-CH), 4.47 
(d, 
3
J = 1.9 Hz, 2H, Cp-CH), 6.64 (d, 
3
J = 16.1 Hz trans, 1H, CH alkene), 6.94 (m, 2H, CH alkene, 
Ar), 7.00 (br s, 1H, Ar), 7.17 (d,
 3
J = 7.9 Hz, 1H, Ar), 8.29 (s, 1H, CH imine). 
13
C{
1
H} NMR 
(CDCl3): δ (ppm) = 11.7 (CH3); 24.1, 61.1 (CH2); 67.2, 69.4 (Cp-CH); 69.3 (Cp-CH unsubst. 
ring); 82.8 (C Cp); 113.8, 116.3, 131.3 (CH Ar); 117.5, 141.8, 162.1 (C Ar); 125.4, 129.5 (CH 
alkene); 164.0 (CH imine). HPLC (MeOH/H2O (gradient, 5 - 90 %, flow rate, 0.6 mL/min)): tR = 
17.5 min. MS (HR-ESI-TOF, m/z): 374.1206 [M+H]
+
. MP: 152 ºC (decompose without 
melting). 
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6.10 Synthesis of Ferrocenyl-Derived N,N-Pyridylimine Monomeric Ligands (61) 
 
n-Propylamine (0.026 mL, 0.316 mmol) was added dropwise to a stirred solution of 55 
(0.0501 g, 0.158 mmol) in DCM (20.0 mL). The reaction mixture was stirred at RT for 2 h. 
The orange reaction mixture was filtered over a small pad of silica, and washed with EtOAc. 
The solvent was removed from the filtrate under vacuum, to afford the desired product 
without further purification. 
 
6.10.1 (5E, 2E)-N-((5-ferrocenyl-vinyl-pyridin-2-yl)methylene)propan-1-amine (61) 
Orange-red solid. Yield: 0.0401 g, 70.9 %. 
IR (ATR): ν (cm-1) = 1579 (s, alkene, C=C), 
1630 (s, pyridyl, C=N), 1643 (m, imine, 
C=N). 
1
H NMR (CDCl3): δ (ppm) = 0.90 (t, 
3
J = 7.4 Hz, 3H, NCH2CH2CH3), 1.68 (m, 
2H, NCH2CH2CH3), 3.55 (m, 2H, 
NCH2CH2CH3), 4.08 (s, 5H, Cp-CH unsubst. ring), 4.27 (m, 2H, Cp-CH), 4.42 (m, 2H, Cp-CH), 
6.61 (d, 
3
J = 16.2 Hz trans, 1H, CH alkene), 6.95 (d, 
3
J = 16.2 Hz trans, 1H, CH alkene), 7.73 (d, 
3
J 
= 8.8 Hz, 1H, Pyr), 7.87 (d, 
3
J = 8.2 Hz, 1H, Pyr), 8.29 (s, 1H, CH imine), 8.57 (s, 1H, Pyr). 
13
C{
1
H} NMR ((CDCl3): δ (ppm) = 12.7 (CH3); 23.9, 63.4 (CH2); 67.2, 69.6 (Cp-CH); 69.4 
(Cp-CH unsubst. ring); 82.3 (C Cp); 121.2, 121.7 (CH alkene); 130.7, 132.2, 147.4 (CH Pyr); 134.6, 
152.7 (C Pyr); 161.6 (CH imine). HPLC (MeOH/H2O (gradient, 5 - 90 %, flow rate, 0.6 
mL/min)): tR = 17.8 min. MS (HR-ESI-TOF, m/z): 359.1208 [M+H]
+
. MP: 184 - 186 ºC. 
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6.11 General Procedure for the Preparation of Ferrocenyl-Derived Cationic N,O-
Ru(II)-Arene-PTA Metallodendrimers ([62][PF6]4 & [63][PF6]8) 
 
Triethylamine (0.017 mL, 0.122 mmol for [62][PF6]4; 0.039 mL, 0.279 mmol for [63][PF6]8) 
was added dropwise to a stirred solution of ligand 56 (0.473 g, 0.0301 mmol for [62][PF6]4) 
or 57 (0.114 g, 0.0347 mmol for [63][PF6]8) in a EtOH:DCM (50:50, 60 mL) solution. The 
resulting orange solution was stirred at room temperature for 0.5 h. Next, [Ru(η6-p-
Pr
i
C6H4Me)Cl2]2 (0.0377 g, 0.0616 mmol for [62][PF6]4; 0.0860 g, 0.140 mmol for 
[63][PF6]8) was added to the reaction mixture. The reaction mixture was stirred overnight at 
room temperature, then the reaction mixture was filtered and PTA (0.0191 g, 0.122 mmol for 
[62][PF6]4; 0.0438 g, 0.279 mmol for [63][PF6]8) was added to the filtrate. The solution was 
stirred for 6 h and filtered. A solution of NaPF6 (0.0205 g, 0.122 mmol for [62][PF6]4; 0.0495 
g, 0.279 mmol for [63][PF6]8) in EtOH (5 mL) was added to the filtrate at 0 ºC and stirred for 
1 h. The DCM was removed from the reaction mixture under reduced pressure, which resulted 
in the precipitation of an orange solid. The solid was isolated by filtration, washed with cold 
EtOH, followed by Et2O and dried in vacuo. 
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6.11.1 [DAB-G1-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA-(5-ferrocenyl-
vinyl)}4][PF6]4 ([62][PF6]4) 
Orange solid. Yield: 0.0807 
g, 72.2 %. IR (ATR): ν (cm-1) 
= 1590 (br s, alkene, C=C & 
imine, C=N). 
1
H NMR 
((CD3)2CO): δ (ppm) = 1.13 
& 1.27 (br m, 24H, 
CH(CH3)2 p-cye), 1.66 (br m, 
4H, NCH2CH2 core), 2.00 (m, 
8H, NCH2CH2CH2N branch), 2.09 (br s, 12H, CH3 p-cye), 2.16 - 2.26 (overlapping m, 12H, 
NCH2CH2 core, NCH2CH2CH2N branch), 2.63 (br m, 4H, CH(CH3)2 p-cye), 3.96 (br m, 8H, 
NCH2CH2CH2N branch), 4.13 (br s, 20H, Cp-CH unsubst. ring), 4.22 - 4.55 (overlapping m, 64H, 
PTA, 2 x Cp-CH), 5.58 (br d, 4H, Ar p-cye), 5.83 (br d, 4H, Ar p-cye), 6.24 (br d, 4H, Ar p-cye), 
6.40 (br d, 4H, Ar p-cye), 6.66 (d, 
3
J = 16.2 Hz trans, 4H, CH alkene), 6.78 (br d, 4H, Ar), 6.85 (br 
s, 4H, Ar), 7.07 (d, 
3
J = 16.0 Hz trans, 4H, CH alkene), 7.17 (m, 4H, Ar), 8.08 (br s, 4H, CH 
imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 17.9, 20.9, 21.5 (CH3 p-cye); 25.0, 53.9, 65.5, 68.3 
(CH2); 51.1, 51.2, 72.4, 72.5 (CH2 PTA); 67.1, 67.3, 69.4 (Cp-CH); 69.1 (Cp-CH unsubst. ring); 
83.2 (C Cp); 30.7, 82.9, 87.5, 88.8, 91.7 (CH p-cye); 97.5, 119.9 (C p-cye); 112.9, 119.3, 135.4 
(CH Ar); 118.5, 145.0, 164.5 (C Ar); 125.4, 130.4 (CH alkene); 165.6 (CH imine). 
31
P{
1
H} NMR 
((CD3)2CO): δ (ppm) = -32.7 (s, PTA), -144.1 (sep, 
1
J = 709.7 Hz, PF6). Elemental analysis 
for C156H196N18O4P8F24Fe4Ru4
.
3DCM (3973.589): Found C, 48.27; H, 5.76; N, 6.44 %; calcd. 
C, 48.06; H, 5.12; N, 6.35 %. MS (HR-ESI-TOF, m/z): 627.7885 [M+2H]
6+
 (where M = 
[62][PF6]4 - 4PF6). MP: 166 ºC (decompose without melting). 
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6.11.2 [DAB-G2-PPI-{(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA-(5-ferrocenyl-
vinyl)}8][PF6]8 ([63][PF6]8) 
Orange solid. Yield: 0.2013 g, 
76.6 %. IR (ATR): ν (cm-1) = 
1590 (br s, alkene, C=C & 
imine, C=N). 
1
H NMR 
((CD3)2CO): δ (ppm) = 1.12 
& 1.26 (br d, 48H, CH(CH3)2 
p-cye), 1.81 - 3.25 (overlapping 
m, 64H, NCH2CH2 core, 
NCH2CH2 core, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 2nd branch, NCH2CH2CH2N 2nd branch), 2.20 (s, 24H, 
CH3 p-cye), 2.60 (br m, 8H, CH(CH3)2 p-cye), 3.89 & 4.00 (br m, 16H, NCH2CH2CH2N 2nd branch), 
4.13 (br s, 40H, Cp-CH unsubst. ring), 4.13 - 4.61 (overlapping m, 128H, PTA, 2 x Cp-CH), 5.52 
(m, 8H, Ar p-cye), 5.82 (m, 8H, Ar p-cye), 6.19 (m, 8H, Ar p-cye), 6.38 (m, 8H, Ar p-cye), 6.65 (br 
d, 8H, CH alkene), 6.71 (m, 8H, Ar), 6.84 (br s, 8H, Ar), 7.05 (br d, 8H, CH alkene), 7.22 (m, 8H, 
Ar), 8.13 (br s, 8H, CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 18.0, 21.0, 21.4 (CH3 p-
cye); 23.5, 43.2, 59.2, 68.2 (CH2); 51.1, 51.2, 72.5 (CH2 PTA); 67.1, 67.4, 69.5 (Cp-CH); 69.2 
(Cp-CH unsubst. ring); 83.0 (C Cp); 30.7, 82.9, 87.6, 88.8, 91.8 (CH p-cye); 97.2, 120.0 (C p-cye); 
112.9, 119.2, 135.5 (CH Ar); 118.6, 145.0, 164.5 (C Ar); 125.5, 130.4 (CH alkene); 165.7 (CH 
imine). 
31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -31.5 (s, PTA), -144.0 (sep, 
1
J = 711.5 Hz, PF6). 
Elemental analysis for C320H414N38O8P16F48Fe8Ru8.9DCM (8348.252): Found C, 47.29; H, 
6.60; N, 6.46 %; calcd. C, 47.33; H, 5.22; N, 6.38 %. MS (HR-ESI-TOF, m/z): 247.1670 
[M+18H]
26+
 (where M = [63][PF6]8 - 8PF6). MP: 285 ºC (decompose without melting). 
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6.12 General Procedure for the Preparation of Ferrocenyl-Derived Cationic N,N-
Ru(II)-Arene Metallodendrimers ([64][PF6]4 & [65][PF6]8) 
 
[Ru(η6-p-PriC6H4Me)Cl2]2 (0.0906 g, 0.148 mmol for [64][PF6]4; 0.0516 g, 0.0843 mmol for 
[65][PF6]8) was added to a stirred orange-red solution of ligand 58 (0.0553 g, 0.0365 mmol 
for [64][PF6]4) or 59 (0.0659 g, 0.0208 mmol for [65][PF6]8) in a EtOH:DCM (50:50, 60 mL) 
solution. The dark purple reaction mixture was stirred overnight at room temperature, and 
then the reaction mixture was filtered. A solution of NaPF6 (0.0249 g, 0.148 mmol for 
[64][PF6]4; 0.0281 g, 0.168 mmol for [65][PF6]8) in EtOH (5 mL) was added to the filtrate at 
0 ºC and stirred for 1 h. The DCM was removed from the reaction mixture under reduced 
pressure, which resulted in the precipitation of a dark purple solid. The solid was isolated by 
filtration, washed with cold EtOH, followed by Et2O and dried in vacuo. 
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6.12.1 [DAB-G1-PPI-{(η
6
-p-cye)Ru((C6H5N2)-κ
2
-N,N)Cl-(5-ferrocenyl-vinyl)}4][PF6]4 
([64][PF6]4)  
Dark-purple solid. Yield: 
0.0983 g, 84.7 %. IR 
(ATR): ν (cm-1) = 1586 (s, 
alkene, C=C), 1623 (s, 
pyridyl & imine, C=N). 
1
H NMR ((CD3)2CO): δ 
(ppm) = 1.09 (br m, 24H, 
CH(CH3)2 p-cye), 1.30 (br 
m, 4H, NCH2CH2 core,), 2.00 (br m, 8H, NCH2CH2CH2N branch), 2.24 (br m, 4H, NCH2CH2 
core,), 2.32 (br d, 12H, CH3 p-cye), 2.62 (br m, 4H, CH(CH3)2 p-cye), 3.26 (br m, 8H, 
NCH2CH2CH2N branch), 4.19 (s, 20H, Cp-CH unsubst. ring), 4.43 - 4.78 (overlapping m, 24H, 
NCH2CH2CH2N branch, 2 x Cp-CH), 6.00 & 6.30 (m, 16H, Ar p-cye), 6.97 & 7.56 (m, 8H, CH 
alkene), 8.10 (m, 4H, Pyr), 8.39 (m, 4H, Pyr), 8.88 (br s, 4H, CH imine), 9.52 (br s, 4H, Pyr). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 18.6, 21.5, 22.0 (CH3 p-cye); 24.5, 25.0, 51.2, 51.8, 
52.7, 64.1 (CH2); 68.0, 69.1, 70.6 (Cp-CH); 69.5 (Cp-CH unsubst. ring); 81.4 (C Cp); 31.1, 83.9, 
85.2, 85.6, 87.5 (CH p-cye); 104.9, 105.3 (C p-cye); 119.1, 137.3 (CH alkene); 129.1, 133.4, 153.7 
(CH Pyr); 139.3, 151.5 (C Pyr); 168.1 (CH imine). Elemental analysis for 
C128H148N10Cl4P4F24Fe4Ru4.4.5DCM (3558.1648): Found C, 44.45; H, 4.68; N, 3.84 %; calcd. 
C, 44.73; H, 4.45; N, 3.94 %. MS (HR-ESI-TOF, m/z): 649.1115 [M+H]
5+
 (where M = 
[64][PF6]4 - 4PF6). MP: 236 ºC (decompose without melting). 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Experimental 
 
 
 
239 
 
6.12.2 [DAB-G2-PPI-{(η
6
-p-cye)Ru((C6H5N2)-κ
2
-N,N)Cl-(5-ferrocenyl-vinyl)}8][PF6]8 
([65][PF6]8)  
Dark-purple solid. Yield: 
0.0985 g, 72.9 %. IR 
(ATR): ν (cm-1) = 1588 (s, 
alkene, C=C), 1625 (s, 
pyridyl & imine, C=N). 
1
H NMR ((CD3)2CO): δ 
(ppm) = 1.06 & 1.11 (br 
m, 48H, CH(CH3)2 p-cye), 
1.28 (br m, 4H, NCH2CH2 
core), 1.86 - 2.30 
(overlapping m, 48H, 
NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch, CH3 p-cye), 2.54 - 3.23 (overlapping m, 44H, NCH2CH2 core, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 2nd branch, CH(CH3)2 p-cye), 
4.19 (br s, 40H, Cp-CH unsubst. ring), 4.43 - 4.71 (overlapping m, 48H, NCH2CH2CH2N 2nd branch, 
2 x Cp-CH), 5.90 & 6.21 (m, 32H, Ar p-cye), 6.98 & 7.55 (m, 16H, CH alkene), 8.06 (m, 8H, 
Pyr), 8.34 (m, 8H, Pyr), 8.73 (br s, 8H, CH imine), 9.50 (br s, 8H, Pyr). 
13
C{
1
H} NMR 
((CD3)2CO): δ (ppm) = 18.5, 21.4, 22.0 (CH3 p-cye); 26.7, 50.8, 51.4, 51.7, 64.9 (CH2); 68.1, 
70.6 (Cp-CH); 69.5 (Cp-CH unsubst. ring); 81.5 (C Cp); 31.1, 84.3, 85.2, 85.3, 87.4 (CH p-cye); 
103.9, 105.4 (C p-cye); 119.0, 137.1 (CH alkene); 128.6, 133.4, 151.7 (CH Pyr); 139.1, 151.7 (C 
Pyr); 166.8(CH imine). Elemental analysis for C264H312N22Cl8P8F48Fe8Ru8.9DCM (7256.558): 
Found C, 45.41; H, 4.11; N, 4.37 %; calcd. C, 45.19; H, 4.58; N, 4.25 %. MS (HR-ESI-TOF, 
m/z): 667.4059 [M]
8+
 (where M = [65][PF6]8 - 8PF6). MP: 203 -204 ºC. 
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6.13 Synthesis of Ferrocenyl-Derived Cationic N,O-Ru(II)-Arene-PTA 
Mononuclear Complex ([66][PF6]) 
 
To a stirred solution of 60 (0.0812 g, 0.218 mmol) in a EtOH:DCM (50:50, 30 mL) solution, 
triethylamine (0.032 mL, 0.228 mmol) was added. The resulting orange solution was stirred at 
room temperature for 0.5 h. Next, [Ru(η6-p-PriC6H4Me)Cl2]2 (0.0666 g, 0.109 mmol) was 
added to the reaction mixture. The reaction mixture was stirred for 2 h at room temperature, 
then the reaction mixture was filtered and PTA (0.0359 g, 0.228 mmol) was added to the red-
orange filtrate. The solution was stirred for 6 h and filtered. A solution of NaPF6 (0.0384 g, 
0.228 mmol) in EtOH (5 mL) was added to the filtrate at 0 ºC and stirred for 0.5 h. The DCM 
was removed from the reaction mixture under reduced pressure, which resulted in the 
precipitation of an orange solid. The solid was isolated by filtration, washed with cold EtOH, 
followed by Et2O and dried under vacuum. Crystals were grown by slow evaporation of a 
solution of [66][PF6] in acetone. 
 
6.13.1 [CH3CH2CH2-(η
6
-p-cye)Ru((C7H5NO)-κ
2
-N,O)PTA-(5-ferrocenyl-vinyl)][PF6] 
([66][PF6]) 
Orange solid. Yield: 0.1033 g, 52.2 
%. IR (ATR): ν (cm-1) = 1587 (s, 
alkene, C=C), 1619 (w, imine, C=N). 
1
H NMR ((CD3)2CO): δ (ppm) = 
1.07 (t, 
3
J = 7.3 Hz, 3H, 
NCH2CH2CH3), 1.17 & 1.30 (d, 
3
J = 
6.9 Hz, 6H, CH(CH3)2 p-cye), 2.02 & 2.06 (m, 2H, NCH2CH2CH3), 2.22 (s, 3H, CH3 p-cye), 2.71 
(m, 1H, CH(CH3)2 p-cye), 3.81 & 3.98 (m, 2H, NCH2CH2CH3), 4.15 (s, 5H, Cp-CH unsubst. ring), 
4.27 & 4.39 (2d, 6H, PTA), 4.34 (t, 
3
J = 1.9 Hz, 2H, Cp-CH), 4.53 (s, 6H, PTA), 4.56 (m, 2H, 
Cp-CH), 5.64 (br d, 1H, Ar p-cye), 5.86 (br d, 1H, Ar p-cye), 6.34 (br d, 1H, Ar p-cye), 6.46 (m, 
1H, Ar p-cye), 6.67 (d, 
3
J = 16.2 Hz trans, 1H, CH alkene), 6.78 (d, 
3
J = 8.1 Hz, 1H, Ar), 6.86 (s, 
1H, Ar), 7.09 (d, 
3
J = 16.2 Hz trans, 1H, CH alkene), 7.16 (d, 
3
J = 8.3 Hz, 1H, Ar), 8.09 (s, 1H, 
CH imine). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 10.5 (CH3); 17.7, 20.8, 21.5 (CH3 p-cye); 
24.7, 72.0 (CH2); 51.1, 51.3, 72.4, 72.5 (CH2 PTA); 67.1, 67.3, 69.4 (Cp-CH); 69.1 (Cp-CH 
unsubst. ring); 82.9 (C Cp); 30.6, 83.9, 87.5, 88.9, 91.1 (CH p-cye); 98.3, 119.9 (C p-cye); 112.8, 
119.2, 135.3 (CH Ar); 117.9, 145.0, 161.1 (C Ar); 125.5, 130.3 (CH alkene); 165.8 (CH imine). 
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31
P{
1
H} NMR ((CD3)2CO): δ (ppm) = -32.7 (s, PTA), -144.2 (sep, 
1
J = 707.7 Hz, PF6). 
HPLC (MeOH/H2O (gradient, 5 - 90 %, flow rate, 0.6 mL/min)): tR = 15.6 min. MS (HR-
ESI-TOF, m/z): [M]
+
 (where M = [66][PF6] - PF6). MP: 198 ºC (decompose without melting). 
 
6.14 Synthesis of Ferrocenyl-Derived Cationic N,N-Ru(II)-Arene Mononuclear 
Complex ([67][PF6]) 
 
[Ru(η6-p-PriC6H4Me)Cl2]2 (0.0489 g, 0.0798 mmol) was added to a stirred orange-red 
solution of ligand 61 (0.0572 g, 0.160 mmol) in a EtOH:DCM (50:50, 20 mL) solution. The 
dark purple reaction mixture was stirred for 1 h at room temperature, and then the reaction 
mixture was filtered. A solution of NaPF6 (0.0282 g, 0.168 mmol) in EtOH (5 mL) was added 
to the filtrate at 0 ºC and stirred for 0.5 h. The DCM was removed from the reaction mixture 
under reduced pressure, which resulted in the precipitation of a dark purple solid. The solid 
was isolated by filtration, washed with cold EtOH, followed by Et2O and dried in vacuo. 
 
6.14.1 [CH3CH2CH2-(η
6
-p-cye)Ru((C6H5N2)-κ
2
-N,N)Cl-(5-ferrocenyl-vinyl)][PF6] 
([67][PF6]) 
Dark purple solid. Yield: 0.0551 g, 96.3 
%. IR (ATR): ν (cm-1) = 1586 (s, alkene, 
C=C), 1625 (s, pyridyl & imine, C=N).
 1
H 
NMR ((CD3)2CO): δ (ppm) = 1.00 (t, 
3
J = 
7.4 Hz, 3H, NCH2CH2CH3), 1.12 & 1.17 
(d, 
3
J = 6.9 Hz, 6H, CH(CH3)2 p-cye), 1.99 
& 2.10 (br m, 2H, NCH2CH2CH3), 2.33 (s, 3H, CH3 p-cye), 2.82 (m, 1H, CH(CH3)2 p-cye), 4.21 
(s, 5H, Cp-CH unsubst. ring), 4.38 & 4.62 (m, 2H, NCH2CH2CH3), 4.50 (m, 2H, Cp-CH), 4.65 
(br d, 2H, Cp-CH), 5.95 & 6.27 (m, 4H, Ar p-cye), 6.98 (d, 
3
J = 16.2 Hz trans, 1H, CH alkene), 
7.59 (d, 
3
J = 16.2 Hz trans, 1H, CH alkene), 8.13 (d, 
3
J = 8.3 Hz, 1H, Pyr), 8.43 (d, 
3
J = 8.2 Hz, 
1H, Pyr), 8.71 (s, 1H, CH imine), 9.56 (s, 1H, Pyr). 
13
C{
1
H} NMR ((CD3)2CO): δ (ppm) = 10.8 
(CH3); 18.1, 67.6 (CH2); 21.2, 21.9, 22.9 (CH3 p-cye); 68.2, 68.4, 70.5 (Cp-CH); 69.5 (Cp-CH 
unsubst. ring); 81.5 (C Cp); 31.1, 84.2, 85.2, 85.3, 87.4 (CH p-cye); 104.0, 105.4 (C p-cye); 119.1, 
136.9 (CH alkene); 128.4, 133.5, 153.6 (CH Pyr); 139.0, 151.9 (C Pyr); 166.1 (CH imine).
 
HPLC 
(MeOH/H2O (gradient, 5 - 90 %, flow rate, 0.6 mL/min)): tR = 15.6 min.
 
MS (HR-ESI-TOF, 
m/z): 629.0955 [M]
+
 (where M = [67][PF6] - PF6). MP: 165 - 166 ºC.
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6.15 Synthesis of Bipyridyl Conjugate (71) 
 
6.15.1 4’-Methyl-2,2’-bipyridine-4-carboxaldehyde (71) 
Selenium dioxide (6.64 g, 59.9 mmol) and 4,4’-dimethyl-2,2’-bipyridyl 
(10.0 g, 54.4 mmol) was dissolved in 1,4-dioxane (40 mL with 4 % H2O) 
and gently heated under reflux for 24 h. The reaction was filtered through 
Celite whilst hot, and washed with 100 mL of EtOH. The filtrate and 
EtOH washings were combined and the solvent removed. The resulting 
residue was suspended in a saturated solution of sodium bicarbonate (50 
mL), stirred for 1 h and extracted with DCM (5 x 50 mL). The organic fractions were 
combined and dried over Na2SO4. The solution was filtered and the solvent removed. The 
resulting orange residue was suspended in a solution of 0.3 M sodium metabisulfite (50 mL) 
and stirred for 1 h. The solution was filtered and the filtered solid suspended in a fresh 
solution of 0.3 M sodium metabisulfite (50 mL) and stirred for 1 h. The solution was filtered 
and the pH of the combined filtrates was adjusted to pH 6 with sodium carbonate (slow 
addition). The aqueous solution was extracted with EtOAc (4 x 100 mL). The organic layers 
were combined, dried over Na2SO4, filtered and solvent removed. 
White solid, Yield: 5.3453 g, 49.6 %. IR (KBr pellets): ν (cm-1) = 1703 (s, carbonyl, C=O), 
1596 (s, bpy C=N). 
1
H NMR (CDCl3):  (ppm) = 2.46 (s, 3H, CH3), 7.18 (m, 1H, CH bpy), 
7.71 (m, 1H, CH bpy), 8.27 (s, 1H, CH bpy), 8.57 (m, 1H, CH bpy), 8.82 (s, 1H, CH bpy), 8.88 
(m, 1H, CH bpy), 10.17 (s, aH, CHO). 
13
C{
1
H} NMR (CDCl3):  (ppm) = 21.2 (CH3); 120.6, 
121.4, 122.1, 125.4, 149.2, 150.3 (CH bpy); 142.7, 148.4, 154.8, 158.4 (C bpy); 191.7 (CHO). 
Spectroscopic data in agreement with reported literature.
12-14
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6.16 Synthesis of Bipyridyl Ligands (72 - 74) 
 
A solution of DAB-G1-PPI-(NH2)4 (0.481 g, 1.51 mmol for 72), DAB-G2-PPI-(NH2)8 (0.822 
g, 1.06 mmol for 73), or n-propylamine (0.360 g, 6.08 mmol for 74) in DCM (10 mL) was 
added dropwise to a stirred solution of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde (71) (1.22 
g, 6.15 mmol for 72; 1.70 g, 8.56 mmol for 73; 1.21 g, 6.39 mmol for 74) in DCM (25 mL) 
and stirred for 48 h (for 72 and 73) or overnight (for 74) at room temperature. The solvent 
was then removed under vacuum to afford a dark yellow oil. This was dissolved in DCM (30 
mL) and washed with copious amounts of ultrapure H2O (15  30 mL). The organic layer was 
separated, dried over sodium sulfate (~10 g), and filtered. The solvent was then removed 
under reduced pressure and the resulting oil dried in vacuo. 
 
6.16.1 DAB-G1-(C12H10N3)4 (72) 
Red-brown oil. Yield: 1.41 g, 89.5 %. IR (NaCl 
cells, DCM): ν (cm-1) = 1648 (s, imine, C=N), 
1596 (s, bpy, C=N).
 1
H NMR (CDCl3):  (ppm) = 
1.45 (br m, 4H, NCH2CH2 core), 1.84 (br m, 8H, 
NCH2CH2CH2N branch), 2.42 (s, 16H, NCH2CH2 
core, CH3), 2.52 (br m, 8H, NCH2CH2CH2N branch), 
3.68 (br m, 8H, NCH2CH2CH2N branch), 7.11 (br d, 
3
J = 4.8 Hz, 4H, CH bpy), 7.64 (br d, 
3
J = 
5.0 Hz, 4H, CH bpy), 8.21 (br s, 4H, CH bpy), 8.33 (br s, 4H, CH imine), 8.51 (br d, 
3
J = 4.9 Hz, 
4H, CH bpy), 8.56 (br s, 4H, CH bpy), 8.67 (br d, 
3
J = 5.0 Hz, 4H, CH bpy). 
13
C{
1
H} NMR 
(CDCl3):  (ppm) = 21.2 (CH3); 25.3, 28.4, 51.7, 54.1, 59.9 (CH2); 120.5, 120.9, 122.0, 
124.9, 149.1, 149.6 (CH bpy); 144.2, 148.1, 155.6, 157.2 (C bpy); 159.3 (CH imine). Elemental 
analysis for C64H72N14 (1037.37): Found C, 73.92; H, 7.11; N, 18.97 %; calcd. C, 74.10; H, 
7.00; N, 18.90 %. MS (HR-ESI-TOF, m/z): 1038.79 [M+H]
+
. 
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6.16.2 DAB-G2-(C12H10N3)8 (73) 
Red-brown oil. Yield: 2.09 g, 88.7 %. IR (NaCl 
cells, DCM): ν (cm-1) = 1648 (s, imine, C=N), 
1596 (s, bpy, C=N).
 1
H NMR (CDCl3):  (ppm) = 
1.39 (br m, 4H, NCH2CH2 core), 1.57 (br m, 8H, 
NCH2CH2CH2N 1st branch), 1.83 (br m, 16H, 
NCH2CH2CH2N 2nd branch), 2.31 - 2.59 (overlapping 
m, 60H, NCH2CH2 core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 1st branch, NCH2CH2CH2N 2nd branch, 
CH3), 3.65 (br m, 16H, NCH2CH2CH2N 2nd branch), 7.09 (br m, 8H, CH bpy), 7.62 (br d, 8H, 
3
J 
= 5.0 Hz, CH bpy), 8.19 (br s, 8H, CH bpy), 8.30 (br s, 8H, CH imine), 8.49 (br d, 
3
J = 4.9 Hz 8H, 
CH bpy), 8.56 (br s, 8H, CH bpy), 8.64 (br d, 
3
J = 5.0 Hz, 8H, CH bpy). 
13
C{
1
H} NMR (CDCl3): 
 (ppm) = 21.1 (CH3); 24.7, 25.2, 28.3, 51.7, 52.3, 53.4, 54.2, 59.9 (CH2); 120.4, 120.9, 
121.9, 124.8, 149.0, 149.5 (CH bpy); 144.2, 148.1, 155.6, 157.2 (C bpy); 159.2 (CH imine). 
Elemental analysis for C136H160N30 (2214.96): Found C, 73.74; H, 7.58; N, 18.68 %; calcd. 
C, 73.75; H, 7.28; N, 18.97 %. MS (HR-ESI-TOF, m/z): 560.25 [M+4H]
4+
.
 
 
6.16.3 (4E)-N-((4'-methyl-[2,2'-bipyridin]-4yl)methylene)propan-1-amine (74) 
Dark yellow oil. Yield: 0.920 g, 63.2 %. IR (NaCl cells, 
DCM): ν (cm-1) = 1649 (s, imine, C=N), 1596 (s, bpy, 
C=N).
 1
H NMR (CDCl3):  (ppm) = 0.94 (t, 
3
J = 7.4 Hz, 
3H, NCH2CH2CH3), 1.73 (m, 2H, NCH2CH2CH3), 2.41 
(s, 3H,CH3 bpy), 4.20 (td, 
3
J = 6.9 Hz, 
4
J = 1.4 Hz, 2H, 
NCH2CH2CH3), 7.11 (d, 
3
J = 2.4 Hz, 1H, CH bpy), 7.67 (dd, 
3
J = 5.0 Hz, 
4
J = 1.6 Hz, 1H, CH 
bpy), 8.22 (s, 1H, CH bpy), 8.32 (s, 1H, CH imine), 8.52 (d, 
3
J = 5.4 Hz, 1H, CH bpy), 8.58 (s, 1H, 
CH bpy), 8.69 (d, 
3
J = 5.26 Hz, 1H, CH bpy). 
13
C{
1
H} NMR (CDCl3):  (ppm) = 11.8, 21.1 
(CH3); 23.8, 63.6 (CH2); 120.5, 120.9, 122.0, 124.9, 149.0, 149.5 (CH bpy); 144.3, 148.1, 
155.6, 157.2 (C bpy); 159.1 (CH imine). Elemental analysis for C15H17N3 (239.32): Found C, 
75.26; H, 7.19; N, 17.55 %; calcd. C, 75.28; H, 7.16; N, 17.56 %. MS (EI, m/z): 239.28 [M]
+
. 
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6.17 Synthesis of Mn(CO)3-Functionalized Complexes (75 - 77) 
 
A solution of ligand 72 (0.112 g, 0.108 mmol for 75), 73 (0.116 g, 0.053 mmol for 76), or 73 
(0.103 g, 0.429 mmol for 77) in DCM (5 mL) was added dropwise to a stirred suspension of 
[Mn(CO)5Br] (0.120 g, 0.439 mmol for 75, 0.116 g, 0.423 mmol for 76, and 0.112 g, 0.408 
mmol for 77) in DCM (30 mL). The reaction mixture was stirred overnight at room 
temperature while protected from light by wrapping in aluminium foil, then filtered by gravity 
and the filtrate reduced to ~5 mL. The addition of Et2O (for 75 and 76) or n-pentane (for 77) 
resulted in the precipitation of the desired product. The solids were filtered, washed with 
copious amounts of Et2O or n-pentane and dried under vacuum. Single crystals of complex 77 
were obtained by slow diffusion of n-pentane into a concentrated DCM solution of the 
compound but did not diffract well enough for a good structure solution due to disorder. 
 
6.17.1 [DAB-G1-PPI-{(CO)3Mn((C12H10N3)-κ
2
-N,N)Br}4] (75) 
Yellow-orange solid. Yield: 
0.165 g, 79.1 %. IR (ATR): ν 
(cm
-1
) = 2022 (s, carbonyl, 
C≡O), 1921 (s, carbonyl, 
C≡O), 1905 (s, carbonyl, 
C≡O), 1644 (m, imine, C=N), 
1618 (m, bpy, C=N). 
1
H NMR 
((CD3)2SO):  (ppm) = 1.39 (overlapping m, 12H, NCH2CH2 core, NCH2CH2CH2N branch), 1.77 
(overlapping m, 12H, NCH2CH2 core, NCH2CH2CH2N branch), 2.36 (br m, 12H, CH3), 3.69 (br 
m, 8H, NCH2CH2CH2N branch), 7.52 (br m, 4H, CH bpy), 7.89 (br m, 4H, CH bpy), 8.46 (br s, 
4H, CH imine), 8.51 (br s, 4H, CH bpy), 8.76 (br s, 4H, CH bpy), 8.98 (br m, 4H, CH bpy), 9.19 
(br m, 4H, CH bpy). 
13
C{
1
H} NMR ((CD3)2SO):  (ppm) = 20.6 (CH3); 24.7, 27.8, 50.9, 53.4, 
58.9 (CH2); 121.0, 123.5, 124.2, 127.8, 153.9, 154.3 (CH bpy); 145.2, 151.2, 152.8, 156.0 
(Cbpyr); 158.0 (CH imine); 221.0, 221.7, 222.0 (CO). HPLC (CH3CN/H2O (gradient, 5 - 90 
%, flow rate, 0.6 mL/min)): tR = 23.1 min. MS (HR-ESI-TOF, m/z): 961.57 [M+2H]
2+
. 
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6.17.2 [DAB-G2-PPI-{(CO)3Mn((C12H10N3)-κ
2
-N,N)Br}8] (76) 
Yellow-orange solid. Yield: 0.139 
g, 65.4 %. IR (ATR): ν (cm-1) = 
2022 (s, carbonyl, C≡O), 1920 (s, 
carbonyl, C≡O), 1904 (s, carbonyl, 
C≡O), 1644 (m, imine, C=N), 1619 
(m, bpy, C=N). 
1
H NMR 
((CD3)2SO):  (ppm) = 1.23 
(overlapping m, 28H, NCH2CH2 
core, NCH2CH2CH2N 1st branch, 
NCH2CH2CH2N 2nd branch), 1.38 
(overlapping m, 20H, NCH2CH2 core, NCH2CH2CH2N 1st branch, NCH2CH2CH2N 1st branch), 1.71 
(br m, 16H, NCH2CH2CH2N 2nd branch), 2.42 (br m, 24H, CH3), 3.63 (br m, 16H, 
NCH2CH2CH2N 2nd branch), 7.48 (br m, 8H, CH bpy), 7.84 (br m, 8H, CH bpy), 8.43 (br m, 16H, 
CH imine, CH bpy), 8.69 (br s, 8H, CH bpy), 8.95 (br m, 8H, CH bpy), 9.14 (br m, 8H, CH bpy). 
13
C{
1
H} NMR ((CD3)2SO):  (ppm) = 20.6 (CH3); 24.2, 24.9, 27.8, 51.0, 51.5, 53.8, 54.7, 
58.9 (CH2); 121.0, 123.4, 124.1, 127.8, 153.8, 154.3 (CH bpy); 145.2, 151.1, 152.8, 156.0 (C 
bpy); 157.8 (CH imine); 220.9, 221.6, 222.9 (CO). HPLC (CH3CN/H2O (gradient, 5 - 90 %, 
flow rate, 0.6 mL/min)): tR = 23.1 min. MS (HR-ESI-TOF, m/z): 1344.59 [M+3H]
3+
. 
 
6.17.3 [CH3CH2CH2-(CO)3Mn((C12H10N3)-κ
2
-N,N)Br] (77) 
Orange solid. Yield: 0.0731 g, 39.1 %. IR 
(ATR): ν (cm-1) = 2021 (s, carbonyl, C≡O), 
1928 (s, carbonyl, C≡O), 1899 (s, carbonyl, 
C≡O), 1644 (m, imine, C=N), 1616 (m, bpy, 
C=N). 
1
H NMR ((CD3)2SO):  (ppm) = 0.93 
(br t, 
3
J = 6.85 Hz, 3H, NCH2CH2CH3), 1.72 (br m, 2H, NCH2CH2CH3), 2.55 (br s, 3H, CH3 
bpy), 3.69 (br t, 
3
J = 6.23 Hz, 2H, NCH2CH2CH3), 7.58 (br m, 1H, CH bpy), 7.97 (br m, 1H, CH 
bpy), 8.53 (br s, 1H, CH imine), 8.59 (br s, 1H, CH bpy), 8.82 (br s, 1H, CH bpy), 9.02 (br m, 1H, 
CH bpy), 9.25 (br m, 1H, CH bpy). 
13
C{
1
H} NMR ((CD3)2SO):  (ppm) = 11.7, 20.6 (CH3); 
23.3, 62.5 (CH2); 120.9, 124.0, 124.3, 127.9, 154.1, 154.4 (CH bpy); 145.4, 151.3, 152.8, 
158.1 (C bpy); 158.2 (CH imine); 221.0, 221.7, 222.0 (CO). HPLC (CH3CN/H2O (gradient, 5 - 
90 %, flow rate, 0.6 mL/min)): tR = 22.9 min. MS (HR-ESI-TOF, m/z): 462.02 [M+H]
+
. 
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6.18 Electrochemical Studies 
 
Electrochemical studies were not performed on the ferrocenyl-derived ligands 56 - 61, as the 
focus of this study was on the ferrocenyl-derived complexes [62][PF6]4 - [67][PF6]. Cyclic 
voltammetric studies were performed at ambient temperature using a Bioanalytical Systems 
Inc. BAS 100W Electrochemical Analyser with a one-compartment three-electrode system 
comprising of a Pt disk working electrode, a platinum wire auxiliary electrode and a Ag/Ag
+ 
reference electrode (0.01 M AgNO3 and 0.1 M [n-Bu4N][ClO4] in anhydrous CH3CN). The 
reported electrochemical potentials (listed in Tables 3.3 & 3.4 of Chapter 3) are with 
reference to this electrode. Measurements were made on anhydrous CH3CN solutions which 
were 2 mM in sample and contained 0.1 M [n-Bu4N][ClO4] as the background electrolyte. 
San rates were optimised in an effort to obtain a smoother voltammogram. Unless otherwise 
stated, the scan rate used was 100 mV.s
-1
.
 
Under these conditions the ferrocene/ferrocenium 
couple, which was used as a reference, had an E1/2 of +0.12 V and ∆Ep = 0.10 V. All solutions 
were purged with argon and voltammograms were recorded under a blanket of argon. The 
platinum working electrode was polished between runs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Experimental 
 
 
 
248 
 
6.19 X-ray Crystallography 
 
Crystals of mononuclear complexes [38][PF6], [39][PF6], [49][PF6], [51][PF6] and [66][PF6] 
were mounted on a STOE Image Plate Diffraction system equipped with a ϕ circle 
goniometer, using Mo-Kα graphite monochromated radiation (λ = 0.71073 Å) with ϕ range 0-
200
º
. The structures were solved by direct methods using the program SHELXS-97, while the 
refinement and all further calculations were carried out using SHELXL-97.
15
 The H-atoms 
were found on Fourier difference map or included in calculated positions and treated as riding 
atoms using the SHELXL default parameters. The non-H atoms were refined anisotropically, 
using weighted fullmatrix least-square on F
2
.  
 
Single-crystal X-ray diffraction data of 48 were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data 
collection was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream 
cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using 
the program SAINT.
16
 The data were scaled and absorption correction performed using 
SADABS.
17
 The structure was solved by direct methods using SHELXS-97 and refined by 
full-matrix least-squares methods based on F
2
 using SHELXL-97.
15
  
 
Crystallographic details are summarized in Tables 6.1, 6.2 and 6.3. Figures 2.8, 2.10, 2.11 and 
3.18 were drawn with ORTEP.
18
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Table 6.1 Crystallographic and selected experimental data for mononuclear complexes 
[38][PF6] and [39][PF6]. 
 [38][PF6] [39][PF6] 
Chemical formula C26H38F6N4OP2Ru C28H42F6N4OP2Ru 
Formula weight 699.61 727.67 
Crystal system  Triclinic Orthorhombic 
Space group P -1 (no. 2) P bca (no. 61) 
Crystal colour and shape  orange block Yellow plate 
Crystal size 0.17 x 0.15 x 0.09 0.22 x 0.18 x 0.16 
a (Å) 9.2116(5) 14.364(3) 
b (Å) 11.0549(6) 15.552(3) 
c (Å) 15.4803(8) 28.435(6) 
α (°) 102.868(4) 90 
β (°) 97.444(4) 90 
γ (°) 102.792(4) 90 
V (Å
3
) 1471.91(14) 6352(2) 
Z 2 8 
T (K) 173(2) 293(2) 
Dc (g·cm
-3
) 1.579 1.522 
μ (mm-1) 0.707 0.658 
Scan range (°) 3.19 < 2θ < 55.71 4.04 < 2θ < 52.16 
Unique reflections 7938 5901 
Reflections used [I>2σ(I)] 6403 1639 
Rint 0.0879 0.0836 
Final R indices [I>2σ(I)]a R1 0.0998, wR2 0.2413 R1 0.0451, wR2 0.0870 
R indices (all data) R1 0.1209, wR2 0.2491 R1 0.1792, wR2 0.1061 
Goodness-of-fit 1.217 0.642 
Max, Min Δρ (e Å-3) 3.733, -2.034 0.588, -0.653 
a 
Structures were refined on F0
2
: wR2 = [Σ[w(F0
2
 - Fc
2
)
2] / Σ w(F0
2
)
2
]
1/2
,  
where w
-1
 = [Σ (F0
2
) + (aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3 
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Table 6.2 Crystallographic and selected experimental data for mononuclear complexes 48, 
[49][PF6] and [51][PF6]. 
 48 [49][PF6] [51][PF6] 
Chemical formula C20H26ClNOOs C26H38F6N4OP2Os C19H26ClF6N2POs 
Formula weight 522.07 788.74 653.04 
Crystal system  Orthorhombic Triclinic Triclinic 
Space group Pbca P -1 P -1 
Crystal colour and shape  Yellow needles Orange block Red block 
Crystal size 0.15 x 0.13 x 0.08 0.22 x 0.19 x 0.18 0.17 x 0.16 x 0.13 
a (Å) 12.8543(7) 9.2386(4) 9.2552(11) 
b (Å) 18.2467(9) 11.0355(5) 9.8786(11) 
c (Å) 32.5773(15) 15.4940(7) 12.2867(16) 
α (°) 90.00 103.275(4) 82.159(15) 
β (°) 90.00 97.262(4) 80.047(14) 
γ (°) 90.00 102.771(4) 84.028(14) 
V (Å
3
) 7641.0(7) 1473.06(11) 1092.4(2) 
Z 16 2 2 
T (K) 173(2) 173(2) 173(2) 
Dc (g·cm
-3
) 1.815 1.778 1.985 
μ (mm-1) 6.821 
 
4.503 6.092 
Scan range (°) 5.04 < 2θ < 51.02 4.50 < 2θ < 55.55 4.10 < 2θ < 52.00 
Unique reflections 7862 7950 4029 
Reflections used [I>2σ(I)] 5977 6973 3263 
Rint 0.0599 0.0590 0.0705 
Final R indices [I>2σ(I)]a R1 0.0289, wR2 0.0504 R1 0.0366, wR2 0.0758 R1 0.0503, wR2 0.1184 
R indices (all data) R1 0.0487, wR2 0.0556 R1 0.0467, wR2 0.0780 R1 0.0633, wR2 0.1238 
Goodness-of-fit 1.004 1.128 1.001 
 Max, Min Δρ (e Å
-3
) 0.758, -0.779 1.496, -2.190 3.053, -4.257 
a 
Structures were refined on F0
2
: wR2 = [Σ[w(F0
2
 - Fc
2
)
2] / Σ w(F0
2
)
2
]
1/2
,  
where w
-1
 = [Σ (F0
2
) + (aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3 
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Table 6.3 Crystallographic and selected experimental data for mononuclear complexes 
[66][PF6]. 
 [66][PF6]
.
H2O 
Chemical formula C38H48F6N4OP2RuFe 
Formula weight 909.68 
Crystal system  Monoclinic 
Space group P 21/c 
Crystal colour and shape  Red block 
Crystal size 0.25 x 0.22 x 0.20 
a (Å) 11.0255(8) 
b (Å) 8.6471(5) 
c (Å) 41.358(3) 
α (°) 90.00 
β (°) 98.991(6) 
γ (°) 90.00 
V (Å
3
) 3894.6(5) 
Z 1 
T (K) 293(2) 
Dc (g·cm
-3
) 1.577 
μ (mm-1) 0.911 
Scan range (°) 1.87 < 2θ < 29.32 
Unique reflections 10516 
Reflections used [I>2σ(I)] 4523 
Rint 0.2698 
Final R indices [I>2σ(I)]a R1 0.0736, wR2 0.1298 
R indices (all data) R1 0.1895, wR2 0.1686 
Goodness-of-fit 0.883 
 Max, Min Δρ (e Å
-3
) 0.733, -1.666 
a 
Structures were refined on F0
2
: wR2 = [Σ[w(F0
2
 - Fc
2
)
2] / Σ w(F0
2
)
2
]
1/2
,  
where w
-1
 = [Σ (F0
2
) + (aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3 
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6.20 NMR Experiments 
 
6.20.1 Degradation Test 
The first-generation metallodendrimer [33][PF6]4 (~0.1 mg/mL) and its mononuclear analog 
[39][PF6] (~0.1 mg/mL) were dissolved in (CD3)2SO. 
31
P{
1
H} NMR experiments were 
performed at 37 ºC, at 15 min intervals over a 2h period. The 
31
P{
1
H} NMR spectra were 
recorded on a Bruker Biospin GmbH spectrometer at 162.00 MHz. 
 
6.20.2 Aquatic Stability 
For the hydrolysis studies first-generation metallodendrimer [33][PF6]4 (~0.1 mg/mL) was 
dissolved in D2O:(CD3)2SO (95:5 % v/v) because of limited solubility, and the sample was 
analyzed using 
1
H and 
31
P{
1
H}NMR experiments at 37 ºC over 14 days. 
1
H and 
31
P{
1
H} 
NMR spectra were recorded daily on a Bruker Biospin GmbH spectrometer (
1
H: 400.22 MHz, 
31
P{
1
H}: 162.00 MHz). 
 
6.20.3 Interactions with 5’GMP 
For the 5’GMP binding studies, the mononuclear complex [39][PF6] (used to model the 
higher generation metallodendrimers) was dissolved in a solution of 5’GMP (10 mg/mL) in 
D2O:(CD3)2SO (95:5 % v/v, because of limited solubility). The mixtures were incubated at 37 
ºC for 2h before 
1
H NMR experiments were performed. 
1
H NMR spectra were recorded on a 
Bruker Biospin GmbH spectrometer (
1
H: 400.22 MHz). 
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6.21 Biological Studies 
 
6.21.1 Cell Culture and Inhibition of Cell Growth 
The human A2780 and A2780cisR ovarian carcinoma cell lines were obtained from the 
European Collection of Cell Cultures (Salisbury, UK). Cells were grown routinely in RPMI-
1640 medium with 10 % fetal calf serum (FCS) and antibiotics at 37 ºC and 5 % CO2. 
Cytotoxicity was determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide) (in triplicate).
19
 Cells were seeded in 96-well plates as 
monolayers with 100 mL of cell solution (approximately 20,000 cells) per well and pre-
incubated for 24 h in medium supplemented with 10 % FCS. Compounds were prepared as 
DMSO stock solutions, then immediately dissolved in the culture medium and serially diluted 
to the appropriate concentration, to give a final DMSO concentration of 0.5 %. Thus, the 
probability of DMSO-mediated ligand dissociation occurring is low. A 100 mL portion of 
drug solution was added to each well and the plates were incubated for another 72 h. 
Subsequently, MTT (5 mg/mL solution) was added to the cells and the plates were incubated 
for a further 2 h. The culture medium was aspirated, and the purple formazan crystals formed 
by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO. The 
optical density, directly proportional to the number of surviving cells, was quantified at 590 
nm using a multiwell plate reader and the fraction of surviving cells was calculated from the 
absorbance of untreated control cells. Evaluation is based on means from two independent 
experiments, each comprising three microcultures per concentration level. 
 
6.21.2 DNA Binding Study 
Samples were prepared by mixing a solution of 75 ng/mL pBR322 plasmid DNA with the 
appropriate complex at the appropriate concentration to give the required r value (0.5 and 
0.25, r being the ratio of the metal centre to DNA base pairs). The samples were incubated 
for 24 h at 37 °C. The mobility of the plasmid DNA was analyzed by gel electrophoresis 
on 0.8 % at a constant voltage of 100 V for 1 h in tris-acetate-EDTA buffer. The gel was 
stained for 30 min in 0.5 mg/mL (w/v) ethidium bromide and the bands were then 
analyzed with an UVP gel scanner. 
 
 
 
 
Chapter 6. Experimental 
 
 
 
254 
 
6.21.3 Cell Viability Study 
Testing is done with cells growing in 96 well microtiter plates at 37 °C with 5 % CO2/air. 
Shortly before confluency, cells are trypsinized and a single cell suspension is prepared. Cells 
are then plated out at a density of 250-2000 cells/well in 100 μL medium, depending on the 
cell line. Plates returned to the incubator and cells allowed to attach and begin growing for 24 
h before adding test substances. On the day of testing, one untreated plate for each cell line is 
removed, fixed with glutaraldehyde and stored in the refrigerator; this plate serves later as the 
control. To prepare stock dilutions of test substances, five serial dilutions of substance in 
DMF or DMSO at 1000-fold the target concentration are performed. Next, these solutions are 
diluted 500-fold into culture medium to give five dilutions of test substance at 2-fold the 
target concentration. Then, 100 μL of medium containing test substance is added to each well, 
which already contains 100 μL of medium. The final solvent concentration (i.e. DMF or 
DMSO) in each well is 0.1 %. Plates are returned to the back of the incubator for 96 h. The 
method for quantifying growth inhibition is based on staining cells with crystal violet. After 96 h 
incubation with substance, culture medium is discarded and replace with 100 μL/well of a 1 % 
glutaraldehyde-buffer solution for 20 min to fix the cells. The fixing solution is discarded and the 
cells stored under 100 μl/well PBS at 4 °C until staining. Before staining, PBS medium is 
removed from all plates. Staining is done for 30 min with 100 μL/well of a 0.02 % solution of 
crystal violet dissolved in PBS buffer solution. After discarding the excess dye and washing the 
cells for 30 min in clear water, the cell bound dye is re-dissolved in 100 μL/well 70 % 
ethanol/water and the optical densities of the wells are measured at λ = 570 nm with a microtiter 
plate reader. 
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6.21.4 Myoglobin Assay 
A solution of horse skeletal muscle myoglobin in phosphate buffer (PBS, 0.1 M, pH 7.4) was 
degassed by bubbling with dinitrogen and reduced by addition of sodium dithionite (100 mM, 
100 µL) in PBS buffer (0.1 M, pH 7.4). The PBS buffer solution was prepared according to 
literature methods.
20
 A concentrated stock solution of metal compounds 75, 76, or 77 in 
DMSO/H2O (10:90, v/v) was added, followed by PBS to give a total volume of 1000 µL and 
final concentrations of 60 µM of myoglobin, 10 mM of sodium dithionite and 4 µM of 75, 2 
µM of 76, or 10 µM of 77. Solutions were freshly prepared for the dark stability and 
photoactivation experiments. Irradiations were carried out under dinitrogen with a custom-
built LED setup at 410 nm (5 mm round type UV-LEDs, wavelength range 407-412 nm, 
model YDG-504VC, Kingbright Elec. Co., Taipei, Taiwan, http://www.kingbright.com, part 
no. 181000-05), positioned perpendicular to the cuvette at a distance of 5 cm (Figure 5.17, 
Chapter 5). The irradiation was interrupted in 1 min intervals during the initial 10 min, 
followed by 2 min intervals for the next 10 min, and then 5 min intervals to collect UV/Vis 
spectra on an Agilent 8453 UV/Vis diode array spectrophotometer until no more spectral 
changes were observed in the Q-band region of myoglobin. Dark control spectra were 
automatically collected for an extended period of time set by the spectrometer software. All 
irradiation experiments were carried out in triplicate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Experimental 
 
 
 
256 
 
6.22 Ferrioxalate Actinometry 
 
Ferrioxalate actinometry was used to determine the photon flux of the 410 nm LED array 
because of its sensitivity, wide spectral range including ultraviolet, and the ease of use.
21, 22
 
The entire ferrioxalate actinometry procedure including the preparation of solutions was 
carried out under dim red light. The moles of ferrous iron formed were determined 
spectrophotometrically by complexation with 1,10-phenanthroline (phen) to give the coloured 
tris-phenanthroline complex, [Fe(phen)3]
2+
 with max = 510 nm. In a 1 cm quartz cell, 0.006 M 
(3 ml) of potassium ferrioxalate in 0.05 M sulfuric acid as the chemical actinometer was 
irradiated with a 410 nm LED array under efficient stirring. 1 ml of this irradiated solution 
was mixed with 0.1 % 1,10-phenanthroline in H2O and 0.5 ml of sodium acetate buffer in 
H2O (1 M, pH 3.5) and further diluted to 10 ml by H2O. A reference was prepared in the same 
way except that it has not been irradiated. Both solutions were placed in the dark (about an 
hour) to allow the complexation to complete. The absorbance was then measured at 510 nm ( 
= 11.100 M
-1
cm
-1
). The absorbance (A510) was kept within the range of 0.4 - 1.0. The photon 
flux of the 410 nm LED array was then calculated by using 410 nm = 1.14 following the 
equation:
23
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Chapter 7 
Overall Summary, Conclusions and Future Outlook 
 
7.1 Conclusions 
 
The main objectives of this study were to prepare new bioorganometallic metallodendrimers 
as potential metal-based therapeutic agents. These would contribute towards the development 
of the field of bioorganometallics.  
 
7.1.1 Synthesis of Ruthenium-Arene and Osmium-Arene Metallodendrimers 
A series of new ruthenium-arene and osmium-arene metallodendrimers were prepared and 
characterized using an array of spectroscopic and analytical techniques. The complexes were 
based on four generations of the 1,4-diaminobutane-poly(propylene) dendritic scaffold. 
 
Two new third- and fourth-generation N,O-salicylaldiminato dendritic ligands 23 and 24 were 
prepared via Schiff base condensation between salicylaldehyde and the appropriate dendritic 
scaffold. Four new third- and fourth-generation neutral N,O-ruthenium-arene (arene = p-
cymene or hexamethylbenzene) metallodendrimers 25 - 28 were prepared by coupling the 
appropriate ruthenium precursor (i.e. [Ru(η6-p-PriC6H4Me)Cl2]2 or [Ru(η
6
-C6Me6)Cl2]2) and 
the appropriate N,O-salicylaldiminato dendritic ligand 23 or 24. All these compounds (ligands 
and complexes) were characterized with 
1
H, 
13
C{
1
H} NMR and FT-IR spectroscopy, 
MALDI-TOF or HR-ESI mass spectrometry, and elemental analysis.  
 
Eight new first-, second-, third- and fourth-generation cationic N,O-ruthenium-arene-PTA 
(arene = p-cymene or hexamethylbenzene) metallodendrimers [29][PF6]4 - [36][PF6]32 were 
synthesized via a bridge-splitting reaction of the appropriate metal dimer (i.e. [Ru(η6-p-
Pr
i
C6H4Me)Cl2]2 or [Ru(η
6
-C6Me6)Cl2]2) and the N,O-salicylaldiminato dendritic ligand 21 -
24. This was followed by the displacement of the chlorido ligand with PTA, to afford cationic 
compounds that were isolated as hexafluorophosphate salts in good yields. The cationic 
metallodendrimers were characterized with 
1
H, 
13
C{
1
H}, 
31
P{
1
H} NMR and FT-IR 
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spectroscopy, MALDI-TOF or HR-ESI mass spectrometry, and elemental analysis. Two new 
mononuclear complexes [38][PF6] and [39][PF6] were synthesized as models of the larger 
metallodendrimers [29][PF6]4 - [36][PF6]32, in order to compare size dependency on the 
antiproliferative activity. Single-crystal X-ray diffraction of [38][PF6] and [39][PF6] 
confirmed the expected pseudo-tetrahedral geometry around the Ru(II) ion and the 
coordination of the monomeric salicylaldiminato ligand 37, in a bidentate-chelating manner 
through its phenolic oxygen and imine nitrogen. 
 
To investigate whether the type of metal has influence on the biological activity, six new 
neutral and cationic osmium-arene complexes (40 - [43][PF6]8, [46][PF6]4, [47][PF6]8) of their 
ruthenium analogs were prepared, by reacting the osmium-arene dimer [Os(η6-p-
Pr
i
C6H4Me)Cl2]2 and the appropriate dendritic ligand (21, 22, 44, 45). These 
metallodendrimers were characterized with 
1
H, 
13
C{
1
H}, 
31
P{
1
H} NMR and FT-IR 
spectroscopy, HR-ESI mass spectrometry, and elemental analysis. The molecular structure of 
three new mononuclear osmium-arene complexes (48, [49][PF6] & [51][PF6]) were 
unambiguously determined by single-crystal X-ray diffraction and showed the expected 
pseudo-tetrahedral geometry around the osmium center.  
 
7.1.2 Synthesis of Heterometallic Ferrocenyl-Derived Ruthenium-Arene 
Metallodendrimers 
Two new N,O- and N,N- ferrocenyl-derived conjugates 54 and 55, were prepared via a Heck 
coupling reaction of vinyl ferrocene 53 and the appropriate aryl-bromide. These conjugates 
were subsequently reacted with the appropriate dendritic scaffold, via a Schiff base 
condensation reaction, to afford four new N,O- and N,N- ferrocenyl-derived dendritic ligands 
56 - 59.  
 
Four new heterometallic first- and second-generation cationic N,O- and N,N- ferrocenyl-
derived ruthenium-p-cymene metallodendrimers [62][PF6]4 - [65][PF6]8 were synthesized via 
a bridge-splitting reaction between [Ru(η6-p-PriC6H4Me)Cl2]2 and the appropriate dendritic 
ligand 56 - 59. All of the compounds were characterized using various analytical and 
spectroscopic techniques including FT-IR solid state, 
1
H, 
13
C{
1
H} and 
31
P{
1
H} NMR 
spectroscopy, elemental analysis and HR-ESI mass spectrometry. 
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Two new N,O- and N,N- monomeric ligands 60 and 61, were prepared via similar methods to 
the dendritic ligands 56 - 59, with subsequent complexation to the ruthenium-p-cymene dimer 
[Ru(η6-p-PriC6H4Me)Cl2]2, afforded mononuclear derivatives [66][PF6] and [67][PF6]. The 
molecular structure of [66][PF6] was elucidated by a single-crystal X-ray diffraction. 
 
7.1.3 In Vitro Biological Activity 
A series of new neutral and cationic ruthenium-arene metallodendrimers were evaluated for in 
vitro antitumor activity. Essentially the mononuclear analogs are inactive, whilst, the neutral 
N,O-ruthenium-arene metallodendrimers 25 - 28 exhibited moderate to high antiproliferative 
activity against both the A2780 and A2780cisR human ovarian cancer cell lines. Furthermore, 
the fourth-generation neutral N,O-ruthenium-arene metallodendrimers 26 and 28 displayed 
potent activity compared to cisplatin. The neutral N,O-ruthenium-hexamethylbenzene 
derivatives (27, 28) displayed better activity, in both the A2780 and A2780cisR cell lines, 
compared to their p-cymene counter-parts (25, 26), and was attributed to the improvement of 
the lipophilicity and improved hydrophobic interactions between the arene ring and DNA. 
The neutral N,O-ruthenium-p-cymene metallodendrimers (25, 26) displayed an increase in 
resistance with an increase in dendrimer generation, whilst the neutral N,O-ruthenium-
hexamethylbenzene metallodendrimers (27, 28) displayed no cross-resistance to cisplatin. 
Furthermore, the neutral N,O-ruthenium-arene metallodendrimers 25 - 28 demonstrated lower 
toxicity against human embryonic kidney (HEK) cells.  
 
The cationic N,O-ruthenium-arene-PTA metallodendrimers [29][PF6]4 - [36][PF6]32 displayed 
a similar trend in activity to their neutral derivatives 25 - 28, with an excellent increase in 
cytotoxicity observed with an increase in dendrimer generation. Furthermore, incorporation of 
the PTA moiety does appear to improve the pharmacological properties of the dendritic 
systems. The fourth-generation cationic ruthenium-p-cymene metallodendrimer [32][PF6]32 
displayed the highest activity in the high nanomolar range, with a two-fold increase in activity 
over the neutral chlorido-derivative 26. The cationic N,O-ruthenium-hexamethylbenzene 
metallodendrimers [29][PF6]4 - [32][PF6]32 displayed a modest improvement in activity 
compared to their p-cymene counter-parts [33][PF6]4 - [36][PF6]32. With an increase in 
dendrimer generation, there was a decrease in resistance of the cationic ruthenium-
hexamethylbenzene-PTA metallodendrimers [33][PF6]4 - [36][PF6]32 towards A2780cisR 
cells. These multinuclear complexes were consistently selective for cancer cells over the 
healthy cells.  
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First-generation cationic ruthenium-hexamethylbenzene metallodendrimer [33][PF6]4 and 
mononuclear derivative [39][PF6] demonstrated good stability in DMSO-d6 over a 2h period. 
The first-generation cationic ruthenium-hexamethylbenzene metallodendrimer [33][PF6]4 was 
stable in D2O for 14 days with no side-products or aqua-species observed. The introduction of 
the N,O-chelate ligand resulted in enhanced stability of the complexes, and appeared that 
covalent binding to biomolecules might be a prerequisite for the compounds to exhibit such 
activity. Hence, preliminary 
1
H and 
31
P{
1
H} NMR experiments used to monitor interactions 
between [39][PF6] and nucleotide guanosine 5’-monophosphate (5’GMP), confirmed the 
coordination of the 5’GMP to the ruthenium centre via the N7 atom, and suggest that 
hydrolysis may not be a prerequisite in the mode of action of these complexes. 
 
The metallodendrimers bearing chlorido ligands do not seem to interact with DNA. Whilst the 
metallodendrimers bearing the PTA ligand, that contained eight or more metal centres, 
appeared to form extensive DNA aggregates that was unable to migrate in the gel.  
 
The antiproliferative activity of the neutral and cationic osmium-arene complexes (40 - 
[43][PF6]8, [46][PF6]4, [47][PF6]8) presented in this study, were investigated in vitro. The 
neutral metallodendrimers showed no activity, whilst the cationic metallodendrimers 
displayed moderate activity in both cell lines (A2780 & A2780cisR). Once again, the PTA 
ligand improved biological properties of the dendritic systems, leading to improved antitumor 
activity. However, replacing ruthenium with osmium did not show vast improvement in the 
cytotoxicity of these complexes compared to their ruthenium analogs. Nevertheless, these 
were the first osmium-based metallodendrimers investigated as anticancer agents. 
 
Preliminary cell viability studies performed on the ferrocenyl-derived ligands 56 - 61 and 
ferrocenyl-derived ruthenium-p-cymene complexes [62][PF6]4 - [67][PF6] displayed activity 
at the 5 μM dose concentration in both the A2780 and A2780cisR cell lines, with no cross 
resistance to cisplatin observed. The data for the first- and second-generation ferrocenyl-
derived N,O-ruthenium-p-cymene-PTA metallodendrimers [62][PF6]4 and [63][PF6]8 are the 
most active of the series. It does seem preparation of the mixed heterometallic ferrocenyl-
derived ruthenium-arene systems do show better activity than the ferrocenyl-derived ligands, 
for at least two of the metallodendrimers. 
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Though a select number of complexes displayed low to moderate in vitro cytotoxicity 
compared to the benchmark drug cisplatin, they may display effective in vivo activity against 
metastasis cells, similarly observed for the ruthenium-based drugs RAPTA-C
1, 2
 and NAMI-
A.
3, 4
 
 
7.1.4 Synthesis and CO-Release Properties of Mn(CO)3-Functionalized 
Metallodendrimers  
Two new N,N-bipyridylimine dendritic ligands 72 and 73 were prepared via a Schiff base 
condensation reaction of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde 71 with the appropriate 
first- and second- generation DAB poly(propelene) dendritic scaffold. 
 
Two new tetranuclear and octanuclear Mn(CO)3-functionalized CO-releasing 
metallodendrimers 75 and 76, based on first- and second-generation polypyridyl dendritic 
scaffolds, were prepared and comprehensively characterized by analytical and spectroscopic 
methods, such as 
1
H, 
31
C{
1
H} NMR, FT-IR and UV/Vis spectroscopy and ESI-mass 
spectrometry. In addition, a new mononuclear analog 77 was synthesized as a model of the 
larger metallodendrimers in order to study potential size-dependent scaling effects on the 
photoactivated CO-release.  
 
All three complexes are stable in solution and in air for an extended period of time in the 
absence of light. The CO-release of the metallodendrimers 75, 76 and closest mononuclear 
analog 77 was investigated using the myoglobin assay, which showed that at least two of the 
three carbonyl ligands per Mn(CO)3 moiety can be liberated under these conditions. The total 
amount of CO-released per molecular unit increases with the dendrimer generation, reaching a 
value of 15 CO per molecule of the second-generation metallodendrimer 76. Furthermore, 
these peripherally functionalized dendritic systems were the first of its kind to contain CO-
releasing moieties. 
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To conclude, although no exhaustive aspects of medicinal chemistry are given in this thesis, 
there are several key properties that should be addressed, such as tolerability, 
biocompatibility, pharmacokinetics and stability under physiological conditions. Exhaustive 
testing in the form of toxicity studies and biodistribution is required, as well as an 
examination of in vivo applications. Nevertheless, research highlighted in this thesis 
represents exciting developments in the medicinal applications of metallodendrimers that 
show potential and warrant further exploration in multinuclear metal-based drug discovery.  
 
7.2 Future Outlook 
 
7.2.1 Investigating Higher Dendrimer Generations and Alternative Dendritic Scaffolds 
The present study has shown great scope of ruthenium-arene functionalized 
metallodendrimers as potential biological agents. Improved cytotoxicities may be possible by 
preparation of higher generation dendritic systems (higher than the 4
th
 generation), in turn 
exploiting the enhanced permeability and retention (EPR) effect. Generally, all the complexes 
presented in this study may be structurally modified by replacing the DAB-dendritic scaffold 
with the highly water-soluble PAMAM dendritic scaffold, in an effort to increase the 
hydrophilicity of the complexes.
5, 6
 
 
Anionic water-soluble metallodendrimers (bearing sulfonate groups) have been investigated 
as aqueous biphasic hydroformylation catalysts.
7
 By applying this strategy and 
functionalizing the metallodendrimers with water-soluble sulfonate end-groups, may improve 
the lipophilicity and anticancer activity of these metallodendrimers presented in this study. 
 
Furthermore, the disulfide bond (-S-S-) is a valuable functional group in a variety of chemical 
and biological agents that display potent reactivity or biological activities.
8
 The disulfide bond 
has already been found in proteins, oxidized glutathione, and even in numerous natural 
products including some drugs.
8
 Hence, the incorporation of the disulfide bond into the 
dendritic scaffold may influence the biological activity of these metallodendrimers and thus 
should be explored.  
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7.2.2 Exploring Covalently Bound Dendrimer-Drug Conjugates 
Extended Ruthenium-Arene Systems 
Mononuclear ruthenium-arene systems functionalized with an extended arene ring, such as 
tetrahydroanthracene, have shown good antiproliferative activity, whilst the biphenyl ring has 
shown to improve lipophilicity.
9
 Hence, preparing ruthenium-arene metallodendrimers which 
include the extended arene system may improve selectivity and cell-uptake of these 
complexes presented in this study. 
 
Cyclodextrin Derivatized Metallodendrimers 
The regular and highly branched structure of metallodendrimers allows for the placement of 
repeating moieties on their surface. Terminally functionalized ferrocenyl-derived 
metallodendrimers have been reported, and each ferrocene moiety encapsulated with β-
cyclodextrin.
10
 The hydrophobic interior cavity and the hydrophilic exterior surface, makes 
cyclodextrins very attractive.
11
 Hence, encapsulation of the ferrocenyl-derived ruthenium-
arene moiety with such molecular hosts may afford improved lipophilicity and improved 
solubility in aqueous buffer solutions, which in turn may result in enhanced biological 
activities of the presented metallodendrimers. 
 
Improved Heck Reaction 
Chapter 3 discussed the preparation of ferrocenyl-derived ruthenium-arene complexes, where 
the key step in these reactions was to incorporate the ferrocenyl moiety via the Heck reaction. 
These reactions were successful; however the yields were low. Improvement on the reaction 
conditions may afford better yields, such as changing the reaction solvent to DMF or DMSO, 
to ascertain higher boiling temperatures. One could use the more reactive aryl-iodide as a 
substrate, utilize a different base such as Cs2CO3, changing the Pd-catalyst to the bulkier 
Pd2(dba)3 and/or varying the phosphine ligand to the bulkier P(t-Bu)3. A number of alterations 
to the reaction conditions can be attempted in an effort to maximize the yield of the Heck 
reaction used in the preparation of these compounds. 
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Tagged Metallodendrimers  
By functionalizing the arene ring with a fluorescent tag, a series of metallodendrimers can be 
prepared, and with the use of fluorescence microscopy the cell uptake of the drugs can be 
monitored. Furthermore, with this technique possible drug targets may be identified. 
Radiolabelled metallodendrimers, bearing the ruthenium isotope 
106
Ru, can be prepared in an 
effort to show the biodistribution of the compounds within the cell, similarly observed by 
Sadler and co-workers.
12
 
 
7.2.3 Exploring the Biology 
Further Biological Studies 
In order to make a comparison, further in vitro experiments to calculate the IC50 values of the 
heterometallic ferrocenyl-derived ruthenium-arene metallodendrimers described in Chapter 3 
should be performed, in both the A2780 and A2780cisR human ovarian cancer cell lines.  
 
A series of biological experiments can be employed such as, screening across several cell 
lines to show selectivity, in vivo experiments, DNA binding experiments, circular dichroism 
experiments, reactive-oxygen species (ROS) studies and atomic force microscopy (AFM) 
studies. These are just some of the biological studies and experiments that may assist in 
elucidating the mode of action of these potential therapeutic agents. 
 
In Vitro Testing of CO-Releasing Metallodendrimers 
The next step in the discovery of new CO-realising agents, involves investigating the in vitro 
photoactivity of these metallodendrimers presented here, against cancer cells, more 
specifically against adherent HT29 human colon cancer cells, in the form of cell viability 
studies. Variation of the bidentate ligand, will allow for the discovery of new CO-releasing 
molecules with varying CO-release and biological activities. 
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